1: Sipuleucel-T (Provenge). Urol Nurs. 2012 Mar-Apr;32(2):99. PubMed PMID:
22690467.


2: David Urdal. Interview with Asher Mullard. Nat Rev Drug Discov. 2011 Oct
31;10(11):806-7. doi: 10.1038/nrd3584. PubMed PMID: 22037031.


3: New treatments for metastic prostate cancer. Med Lett Drugs Ther. 2010 Sep
6;52(1346):69-70. PubMed PMID: 20814400.


4: Immunotherapy: a new option for advanced prostate cancer. Harv Mens Health
Watch. 2010 Sep;15(2):1-2. PubMed PMID: 20941869.


5: Current world literature. Curr Opin Urol. 2010 May;20(3):253-67. doi:
10.1097/MOU.0b013e32833970be. PubMed PMID: 20393297.


6: An empiric victory. Nat Biotechnol. 2010 Jun;28(6):529. doi:
10.1038/nbt0610-529. PubMed PMID: 20531311.


7: Vaccine approved for prostate cancer. The vaccine, which harnesses the immune 
system, may provide more treatment options for all cancers. Duke Med Health News.
2010 Jul;16(7):3. PubMed PMID: 20662142.


8: Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R
D. 2006;7(3):197-201. Review. PubMed PMID: 16752945.


9: Radiolabeled J591 antibody delivers lethal hit to advance prostate cancers in 
a phase I trail. Cancer Biol Ther. 2004 Aug;3(8):699-700. PubMed PMID: 15754442.


10: Bibliography. Current world literature. Oncology: prostate and renal. Curr
Opin Urol. 2000 Sep;10(5):508-28. PubMed PMID: 11005456.


11: General discussion: treatment of prostatic cancer. Cancer Chemother Rep. 1975
Jan-Feb;59(1):251-4. PubMed PMID: 1131805.


12: Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR,
Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates
Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer. Hum Gene Ther.
2014 May 5. [Epub ahead of print] PubMed PMID: 24694017.


13: Abate-Daga D, Rosenberg SA, Morgan RA. Pancreatic cancer: Hurdles in the
engineering of CAR-based immunotherapies. Oncoimmunology. 2014 Jun 18;3:e29194.
eCollection 2014. PubMed PMID: 25083334; PubMed Central PMCID: PMC4108460.


14: Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg 
SA, Morgan RA. Development of a T cell receptor targeting an HLA-A*0201
restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy
of cancer. PLoS One. 2014 Mar 28;9(3):e93321. doi: 10.1371/journal.pone.0093321. 
eCollection 2014. PubMed PMID: 24681846; PubMed Central PMCID: PMC3969312.


15: Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, Begun FP,
Tyson I, Heal A, Mitchell E, et al. Monoclonal antibodies and
radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin
Urol. 1992 Feb;10(1):45-54. Erratum in: Semin Urol 1992 May;10(2):138. PubMed
PMID: 1565904.


16: Abern M, Kaufman HL, Latchamsetty K. An update on TroVax for the treatment of
progressive castration-resistant prostate cancer. Onco Targets Ther.
2011;4:33-41. doi: 10.2147/OTT.S14271. Epub 2011 May 24. PubMed PMID: 21691576;
PubMed Central PMCID: PMC3116792.


17: Ablin RJ. The need for personalized therapy and companion diagnostics in
prostate cancer. Biomark Med. 2011 Jun;5(3):281-3. doi: 10.2217/bmm.11.42. PubMed
PMID: 21657837.


18: Ablin RJ. A retrospective and prospective overview of prostate-specific
antigen. J Cancer Res Clin Oncol. 1997;123(11-12):583-94. Review. PubMed PMID:
9620215.


19: Ablin RJ, Gonder MJ. Immunological aspects of benign and malignant tumors of 
the prostate. Contrib Gynecol Obstet. 1985;14:185-98. Review. PubMed PMID:
2415296.


20: Ablin RJ. Immunomodulatory effects of oestrogen in prostatic cancer: update
and further consideration. Allergol Immunopathol (Madr). 1981 Jan-Feb;9(1):63-70.
PubMed PMID: 7258047.


21: Ablin RJ. Modulatory effects of estrogen on immunologic responsiveness. III. 
Effect of hormonal versus nonhormonal therapy on tumor-associated immunity in
prostatic cancer. Am J Reprod Immunol. 1981 Aug;1(4):206-9. PubMed PMID: 7337156.


22: Ablin RJ, Fontana G. Cryoimmunotherapy: continuing studies toward determining
a rational approach for assessing the candidacy of the prostatic cancer patient
for cryoimmunotherapy and postoperative responsiveness. An interim report.
Cryobiology. 1980 Apr;17(2):170-7. Review. PubMed PMID: 6995026.


23: Ablin RJ, Bhatti RA, Bush IM, Guinan PD. Suppression of tumor-associated
immunity by human seminal plasma and its possible role in the natural history of 
prostatic cancer. Eur Urol. 1980;6(4):225-8. PubMed PMID: 7389776.


24: Ablin RJ, Fontana G, Sesia G. [Immunological response to cryonecrosis of
prostatic carcinoma. Preliminary evaluation of patient candidates for
cryosurgery]. Minerva Urol. 1979 Oct-Dec;31(4):223-8. Italian. PubMed PMID:
542195.


25: Ablin RJ, Bhatti RA, Guinan PD, Bush IM. Effect of human seminal plasma on
tumour-associated immunity in prostatic cancer. A preliminary report.
Experientia. 1979 Nov 15;35(11):1510-11. PubMed PMID: 510506.


26: Ablin RJ, Fontana G. Cryoimmunotherapy: continuing studies toward determining
a rational approach for assessing the candidacy of the prostatic cancer patient
for cryoimmunotherapy and postoperative responsiveness. An interim report. Eur
Surg Res. 1979;11(4):223-33. PubMed PMID: 527611.


27: Ablin RJ, Bruns GR, Guinan PD, Al Sheik H, Bush IM. Modulatory effects of
oestrogen on immunologic responsiveness. I. Inhibition of DNA synthesis in
peripheral blood lymphocytes from patients with Peyronie's disease, prostatic
cancer and transsexuals and a commentary. Eur Urol. 1979;5(6):359-68. PubMed
PMID: 467472.


28: Ablin RJ, Bhatti RA, Guinan PD. Effect of estrogen on tumor-associated
immunity in patients with adenocarcinoma of the prostate. Cancer Res. 1978
Nov;38(11 Pt 1):3702-6. PubMed PMID: 698929.


29: Ablin RJ, Bruns GR, Guinan PD, Sadoughi N, Sheik HA, Bush IM. Alterations in 
host responsiveness in patients with prostatic cancer following cryosurgery or
transurethral resection. Am Surg. 1977 Mar;43(3):144-50. PubMed PMID: 320926.


30: Ablin RJ. Serum proteins in prostatic cancer VI. Reduction of the suppressive
("blocking"?) properties of serum on in vitro parameters of cell-mediated
immunologic responsiveness following cryosurgery. Urol Int. 1977;32(1):65-73.
PubMed PMID: 70099.


31: Ablin RJ. Possible suppression of host resistance by estrogen therapy for
prostatic cancer. Can Med Assoc J. 1976 Dec 4;115(11):1082-4. PubMed PMID:
1000436; PubMed Central PMCID: PMC1878895.


32: Ablin RJ, Guinan PD, Bruns GR, Sheik HI, Sadoughi N, Bush IM. Evaluation of
cellular immunologic responsiveness in the clinical management of patients with
prostatic cancer. II. Effect of oestrogen, cryosurgery and transurethral
resection on thymic-dependent lymphocytic blastogenesis. Urol Int.
1976;31(5):383-400. PubMed PMID: 1087494.


33: Ablin RJ. A rational approach toward determining the candidacy of the
prostatic cancer patient for cryoimmunotherapy: an interim report. Eur Surg Res. 
1976;8(6):481-4. PubMed PMID: 1017432.


34: Ablin RJ. Cryosensitivity. Factors influencing development of immunologic
response following cyrosurgery of prostate. Urology. 1975 Mar;05(3):317-21.
PubMed PMID: 1118992.


35: Ablin RJ. Immunotherapy for prostatic cancer. Previous and prospective
considerations. Oncology. 1975;31(3-4):177-202. Review. PubMed PMID: 1105280.


36: Ablin RJ, Burns GR, Guinan P, Bush IM. Antiandrogenic suppression of
lymphocytic blastogenesis: in vitro and in vivo observations. Experientia. 1974
Nov 15;30(11):1351-3. PubMed PMID: 4435189.


37: Ablin RJ. Interference of immunologic surveillance by immunoregulatory alpha 
globulin--a hypothesis. Neoplasma. 1973;20(2):159-62. PubMed PMID: 4122507.


38: Abouharb S, Corn PG. Optimal therapy sequencing in metastatic
castration-resistant prostate cancer. Curr Oncol Rep. 2013 Jun;15(3):217-23. doi:
10.1007/s11912-013-0311-y. Review. PubMed PMID: 23568599.


39: Abubakr YA, Redman BG. The role of immunotherapy in urologic malignancies.
Cancer Treat Res. 1996;88:235-48. Review. PubMed PMID: 9239484.


40: Acar O, Esen T, Lack NA. New therapeutics to treat castrate-resistant
prostate cancer. ScientificWorldJournal. 2013 May 27;2013:379641. doi:
10.1155/2013/379641. Print 2013. Review. PubMed PMID: 23781155; PubMed Central
PMCID: PMC3678432.


41: Acres B. Cancer immunotherapy: phase II clinical studies with TG4010
(MVA-MUC1-IL2). J BUON. 2007 Sep;12 Suppl 1:S71-5. PubMed PMID: 17935281.


42: Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, Caristi N. 
Emerging targeted therapies for castration-resistant prostate cancer. Front
Endocrinol (Lausanne). 2012 May 31;3:73. doi: 10.3389/fendo.2012.00073.
eCollection 2012. PubMed PMID: 22666217; PubMed Central PMCID: PMC3364443.


43: Adler AJ. Mechanisms of T cell tolerance and suppression in cancer mediated
by tumor-associated antigens and hormones. Curr Cancer Drug Targets. 2007
Feb;7(1):3-14. Review. PubMed PMID: 17305474.


44: Afrin LB, Ergul SM. Medical therapy of prostate cancer: 1999. J S C Med
Assoc. 2000 Feb;96(2):77-84. Review. PubMed PMID: 10710906.


45: Agah R, Malloy B, Kerner M, Mazumder A. Generation and characterization of
IL-2-activated bone marrow cells as a potent graft vs tumor effector in
transplantation. J Immunol. 1989 Nov 1;143(9):3093-9. PubMed PMID: 2809219.


46: Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New agents for prostate
cancer. Ann Oncol. 2014 Sep;25(9):1700-9. doi: 10.1093/annonc/mdu038. Epub 2014
Mar 20. PubMed PMID: 24658665.


47: Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy 
of castration-resistant prostate cancer. Eur Urol. 2012 May;61(5):950-60. doi:
10.1016/j.eururo.2011.12.028. Epub 2011 Dec 22. Review. PubMed PMID: 22209376.


48: Agarwal N, Padmanabh S, Vogelzang NJ. Development of novel immune
interventions for prostate cancer. Clin Genitourin Cancer. 2012 Jun;10(2):84-92. 
doi: 10.1016/j.clgc.2012.01.012. Epub 2012 Mar 10. Review. PubMed PMID: 22409862.


49: Aguilar FF, Barranco JJ, Fuentes EB, Aguilera LC, Sáez YL, Santana MD,
Vázquez EP, Baker RB, Acosta OR, Pérez HG, Nieto GG. Very small size
proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno
response in a GnRH based vaccine directed to prostate cancer. Vaccine. 2012 Oct
12;30(46):6595-9. doi: 10.1016/j.vaccine.2012.08.020. Epub 2012 Aug 23. PubMed
PMID: 22921738.


50: Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies
for cancer: mechanisms and clinical development. J Cell Biochem. 2011
Aug;112(8):1969-77. doi: 10.1002/jcb.23126. Review. PubMed PMID: 21465529.


51: Ahmad S, Sweeney P, Sullivan GC, Tangney M. DNA vaccination for prostate
cancer, from preclinical to clinical trials - where we stand? Genet Vaccines
Ther. 2012 Oct 9;10(1):9. doi: 10.1186/1479-0556-10-9. PubMed PMID: 23046944;
PubMed Central PMCID: PMC3502114.


52: Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell
antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate
cancer growth. Mol Ther. 2009 Jun;17(6):1101-8. doi: 10.1038/mt.2009.66. Epub
2009 Mar 31. PubMed PMID: 19337234; PubMed Central PMCID: PMC2835175.


53: Ahmed H, Elsamra S, Sigman M. Case of malignant priapism and review of the
literature. Med Health R I. 2012 Jan;95(1):14-5. Review. PubMed PMID: 22439456.


54: Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial
chemistry to cancer-targeting peptides. Mol Pharm. 2007 Sep-Oct;4(5):631-51. Epub
2007 Sep 20. Review. PubMed PMID: 17880166.


55: Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specific membrane
antigen-based therapeutics. Adv Urol. 2012;2012:973820. doi: 10.1155/2012/973820.
Epub 2011 Jul 17. PubMed PMID: 21811498; PubMed Central PMCID: PMC3145341.


56: Alam S, McNeel DG. DNA vaccines for the treatment of prostate cancer. Expert 
Rev Vaccines. 2010 Jul;9(7):731-45. doi: 10.1586/erv.10.64. Review. PubMed PMID: 
20624047.


57: Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier
B, Massard C, Fizazi K. [New drugs in metastatic castration-resistant prostate
cancer]. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. French. 
PubMed PMID: 20022854.


58: Alblin RJ, Soanes WA, Gonder MJ. Prospects for cryo-immunotherapy in cases of
metastasizing carcinoma of the prostate. Cryobiology. 1971 Jun;8(3):271-9. PubMed
PMID: 5570410.


59: Albrecht H, Denardo GL, Denardo SJ. Development of anti-MUC1 di-scFvs for
molecular targeting of epithelial cancers, such as breast and prostate cancers. Q
J Nucl Med Mol Imaging. 2007 Dec;51(4):304-13. Epub 2007 May 1. Review. PubMed
PMID: 17464275.


60: Alexander RB. CD8-based T cell vaccination and CD4 T cell responses in
prostate cancer. J Immunother. 2005 Jul-Aug;28(4):295-6. PubMed PMID: 16000946.


61: Allen BJ, Li Y, Rizvi SM, Russell PJ. Targeted alpha therapy of prostate
cancer. Methods Mol Med. 2003;81:333-57. PubMed PMID: 12725130.


62: Allen BJ, Rizvi S, Li Y, Tian Z, Ranson M. In vitro and preclinical targeted 
alpha therapy for melanoma, breast, prostate and colorectal cancers. Crit Rev
Oncol Hematol. 2001 Jul-Aug;39(1-2):139-46. PubMed PMID: 11418311.


63: Alsøe L, Stacy JE, Fosså A, Funderud S, Brekke OH, Gaudernack G.
Identification of prostate cancer antigens by automated high-throughput filter
immunoscreening. J Immunol Methods. 2008 Jan 31;330(1-2):12-23. Epub 2007 Nov 20.
PubMed PMID: 18045611.


64: Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campennì GM, Palazzo
A, Cortesi E. Medical strategies for treatment of castration resistant prostate
cancer (CRPC) docetaxel resistant. Cancer Biol Ther. 2012 Sep;13(11):1001-8. doi:
10.4161/cbt.21188. Epub 2012 Jul 24. Review. PubMed PMID: 22825325; PubMed
Central PMCID: PMC3461806.


65: Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013 May
28;332(2):225-8. doi: 10.1016/j.canlet.2012.03.005. Epub 2012 Mar 9. Review.
PubMed PMID: 22410464; PubMed Central PMCID: PMC3695618.


66: Alvarez-Breckenridge C, Chiocca EA. A viral strategy to ambush tumors. Nat
Med. 2011 Jul 7;17(7):784-5. doi: 10.1038/nm0711-784. PubMed PMID: 21738155.


67: Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet 
I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K. STEAP, a
prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol
Immunother. 2006 Dec;55(12):1515-23. Epub 2006 Apr 19. PubMed PMID: 16622681.


68: Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I,
Lemonnier FA, Kosmatopoulos K. EphA2 as target of anticancer immunotherapy:
identification of HLA-A*0201-restricted epitopes. Cancer Res. 2003 Dec
1;63(23):8476-80. PubMed PMID: 14679012.


69: Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, Said J, Reiter
RE. Prostate stem cell antigen is overexpressed in human transitional cell
carcinoma. Cancer Res. 2001 Jun 15;61(12):4660-5. PubMed PMID: 11406532.


70: Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate
cancer: mechanisms, targets, and treatment. Prostate Cancer. 2012;2012:327253.
doi: 10.1155/2012/327253. Epub 2012 Mar 5. PubMed PMID: 22530130; PubMed Central 
PMCID: PMC3316959.


71: Amato RJ, Stepankiw M. Evaluation of MVA-5T4 as a novel immunotherapeutic
vaccine in colorectal, renal and prostate cancer. Future Oncol. 2012
Mar;8(3):231-7. doi: 10.2217/fon.12.7. Review. PubMed PMID: 22409460.


72: Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated
antigen-based immunotherapy. Expert Opin Biol Ther. 2010 Feb;10(2):281-7. doi:
10.1517/14712590903586213. Review. PubMed PMID: 20088718.


73: Amato RJ, Drury N, Naylor S, Jac J, Saxena S, Cao A, Hernandez-McClain J,
Harrop R. Vaccination of prostate cancer patients with modified vaccinia ankara
delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother. 2008
Jul-Aug;31(6):577-85. doi: 10.1097/CJI.0b013e31817deafd. PubMed PMID: 18528296.


74: Amato RJ, Hernandez-McClain J. Phase II Clinical Trial of GM-CSF Treatment in
Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate.
Clin Med Oncol. 2008;2:471-5. Epub 2008 Jul 8. PubMed PMID: 21892320; PubMed
Central PMCID: PMC3161657.


75: Amato RJ. 5T4-modified vaccinia ankara: progress in tumor-associated
antigen-based immunotherapy. Expert Opin Biol Ther. 2007 Sep;7(9):1463-9. Review.
PubMed PMID: 17727334.


76: Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first
immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T. 2011
Apr;36(4):197-202. PubMed PMID: 21572775; PubMed Central PMCID: PMC3086121.


77: Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA. Tolerization of
tumor-specific T cells despite efficient initial priming in a primary murine
model of prostate cancer. J Immunol. 2007 Feb 1;178(3):1268-76. Erratum in: J
Immunol. 2007 Nov 15;179(10):7184. PubMed PMID: 17237372.


78: Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of
dendritic cells for cancer therapy. Lancet Oncol. 2014 Jun;15(7):e257-67. doi:
10.1016/S1470-2045(13)70585-0. Review. PubMed PMID: 24872109.


79: Anilkumar G, Barwe SP, Christiansen JJ, Rajasekaran SA, Kohn DB, Rajasekaran 
AK. Association of prostate-specific membrane antigen with caveolin-1 and its
caveolae-dependent internalization in microvascular endothelial cells:
implications for targeting to tumor vasculature. Microvasc Res. 2006
Jul-Sep;72(1-2):54-61. Epub 2006 May 19. PubMed PMID: 16713605.


80: Anisimova NY, Sosnov AV, Ustyuzhanina NE, Baronzio G, Kiselevsky MV.
Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by
Interleukin-2/β-Cyclodextrin Nanocomposition against Androgen Receptor-Negative
Prostate Cancers. ISRN Oncol. 2011;2011:405656. doi: 10.5402/2011/405656. Epub
2011 Aug 17. PubMed PMID: 22084730; PubMed Central PMCID: PMC3196213.


81: Antonarakis ES, Drake CG. Combining immunological and androgen-directed
approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin
Oncol. 2012 May;24(3):258-65. doi: 10.1097/CCO.0b013e32835205a0. Review. PubMed
PMID: 22410456; PubMed Central PMCID: PMC3444804.


82: Antonarakis ES. Combining active immunotherapy with immune checkpoint
blockade for the treatment of advanced prostate cancer. Asian J Androl. 2012
Jul;14(4):520-1. doi: 10.1038/aja.2012.45. Epub 2012 May 14. Erratum in: Asian J 
Androl. 2012 Jul;14(4):655. PubMed PMID: 22580638; PubMed Central PMCID:
PMC3720070.


83: Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of
docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer
Prostatic Dis. 2011 Sep;14(3):192-205. doi: 10.1038/pcan.2011.23. Epub 2011 May
17. Review. PubMed PMID: 21577234; PubMed Central PMCID: PMC3444817.


84: Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for 
metastatic castration-resistant prostate cancer. Cancer Lett. 2010 May
1;291(1):1-13. doi: 10.1016/j.canlet.2009.08.012. Epub 2009 Aug 29. Review.
PubMed PMID: 19717225; PubMed Central PMCID: PMC4029098.


85: Antonarakis ES, Drake CG. Current status of immunological therapies for
prostate cancer. Curr Opin Urol. 2010 May;20(3):241-6. doi:
10.1097/MOU.0b013e3283381793. Review. PubMed PMID: 20179598; PubMed Central
PMCID: PMC4124631.


86: Antonarakis ES, Carducci MA. Combining low-dose cyclophosphamide with
GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects.
Expert Opin Investig Drugs. 2010 Feb;19(2):311-4. doi: 10.1517/13543780903530678.
PubMed PMID: 20047504; PubMed Central PMCID: PMC4124637.


87: Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation
therapy on the immune system: implications for combination therapy of prostate
cancer. Front Biosci. 2007 Sep 1;12:4957-71. Review. PubMed PMID: 17569623.


88: Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, Apelian D, Hodge 
JW. Combination therapy with a second-generation androgen receptor antagonist and
a metastasis vaccine improves survival in a spontaneous prostate cancer model.
Clin Cancer Res. 2013 Nov 15;19(22):6205-18. doi: 10.1158/1078-0432.CCR-13-1026. 
Epub 2013 Sep 18. PubMed PMID: 24048332; PubMed Central PMCID: PMC3833876.


89: Arija JA, Beca RG, López CL, Domínguez PS, Lovelle AS, Gilarranz YJ.
[Treatment of the patient with castration-resistant biochemical progression of
prostate cancer]. Arch Esp Urol. 2012 Jan-Feb;65(1):185-92. Review. Spanish.
PubMed PMID: 22318189.


90: Arlen PM. Prostate cancer vaccines: an old yet novel target, the androgen
receptor. Expert Rev Vaccines. 2013 Mar;12(3):249-51. doi: 10.1586/erv.13.17.
PubMed PMID: 23496664.


91: Arlen PM, Wood LV. Prostate cancer vaccines: moving therapeutic vaccination
forward in the post-Provenge era. Expert Rev Vaccines. 2012 Mar;11(3):287-302.
doi: 10.1586/erv.11.183. Review. PubMed PMID: 22380822.


92: Arlen PM. Prostate cancer immunotherapy: the role for sipuleucel-T and other 
immunologic approaches. Oncology (Williston Park). 2011 Mar;25(3):261-2. Review. 
PubMed PMID: 21548469.


93: Arlen PM, Mohebtash M, Madan RA, Gulley JL. Promising novel immunotherapies
and combinations for prostate cancer. Future Oncol. 2009 Mar;5(2):187-96. doi:
10.2217/14796694.5.2.187. Review. PubMed PMID: 19284377; PubMed Central PMCID:
PMC2705770.


94: Arlen PM, Gulley JL. Current perspectives in prostate cancer vaccines.
Anticancer Agents Med Chem. 2009 Dec;9(10):1052-7. Review. PubMed PMID: 19719454;
PubMed Central PMCID: PMC3471219.


95: Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman 
J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H,
Wright J, Dahut W, Schlom J, Gulley JL. Clinical safety of a viral vector based
prostate cancer vaccine strategy. J Urol. 2007 Oct;178(4 Pt 1):1515-20. Epub 2007
Aug 16. PubMed PMID: 17707059.


96: Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P,
Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J,
Schlom J, Dahut W. A randomized phase II study of concurrent docetaxel plus
vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. 
Clin Cancer Res. 2006 Feb 15;12(4):1260-9. PubMed PMID: 16489082; PubMed Central 
PMCID: PMC1526707.


97: Arlen PM, Dahut WL, Gulley JL. Immunotherapy for prostate cancer: what's the 
future? Hematol Oncol Clin North Am. 2006 Aug;20(4):965-83, xi. Review. PubMed
PMID: 16861126.


98: Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer: a review of
clinical data. Curr Opin Investig Drugs. 2005 Jun;6(6):592-6. Review. PubMed
PMID: 15988910.


99: Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches. Semin Oncol. 
2005 Dec;32(6):549-55. Review. PubMed PMID: 16338420.


100: Arlen PM, Gulley JL, Dahut W. Vaccine therapy for a patient with
androgen-insensitive prostate cancer without evidence of measurable disease on
scans. Am J Ther. 2004 May-Jun;11(3):238-41. PubMed PMID: 15133542.


101: Armstrong AJ. New treatments for men with castration-resistant prostate
cancer: can we move from small steps to giant leaps? Eur Urol. 2014
Feb;65(2):300-2. doi: 10.1016/j.eururo.2013.08.059. Epub 2013 Sep 10. PubMed
PMID: 24054873.


102: Armstrong AJ, Ferrari AC, Quinn DI. The role of surrogate markers in the
management of men with metastatic castration-resistant prostate cancer. Clin Adv 
Hematol Oncol. 2011 Dec;9(12 Suppl 28):1-14; quiz 15-6. Review. PubMed PMID:
22407145.


103: Armstrong AJ, George DJ. New drug development in metastatic prostate cancer.
Urol Oncol. 2008 Jul-Aug;26(4):430-7. doi: 10.1016/j.urolonc.2007.11.006. Review.
PubMed PMID: 18593623.


104: Armstrong AJ, Febbo PG, George DJ, Moul J. Systemic strategies for prostate 
cancer. Minerva Urol Nefrol. 2007 Mar;59(1):11-25. Review. PubMed PMID: 17431367.


105: Armstrong AJ, Carducci MA. Advanced prostate cancer: the future. Can J Urol.
2005 Jun;12 Suppl 2:42-7. Review. PubMed PMID: 16018833.


106: Armstrong AJ, Carducci MA. Novel therapeutic approaches to advanced prostate
cancer. Clin Adv Hematol Oncol. 2005 Apr;3(4):271-82. Review. PubMed PMID:
16167000.


107: Arndt C, Feldmann A, Töpfer K, Koristka S, Cartellieri M, Temme A, Ehninger 
A, Ehninger G, Bachmann M. Redirection of CD4+ and CD8+ T lymphocytes via a novel
antibody-based modular targeting system triggers efficient killing of PSCA+
prostate tumor cells. Prostate. 2014 Sep;74(13):1347-58. doi: 10.1002/pros.22851.
Epub 2014 Jul 22. PubMed PMID: 25053504.


108: Arndt C, Feldmann A, Koristka S, Cartellieri M, Dimmel M, Ehninger A,
Ehninger G, Bachmann M. Simultaneous targeting of prostate stem cell antigen and 
prostate-specific membrane antigen improves the killing of prostate cancer cells 
using a novel modular T cell-retargeting system. Prostate. 2014
Sep;74(13):1335-46. doi: 10.1002/pros.22850. Epub 2014 Jul 22. PubMed PMID:
25053443.


109: Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, Galili R,
Cerwenka A, Benharroch D, Sion-Vardy N, Porgador A, Mandelboim O. Harnessing
soluble NK cell killer receptors for the generation of novel cancer immune
therapy. PLoS One. 2008 May 14;3(5):e2150. doi: 10.1371/journal.pone.0002150.
Erratum in: PLoS ONE. 2008;3(5). doi:
10.1371/annotation/eaf9794a-9325-4977-952d-51285c3f6c6a. PubMed PMID: 18478075;
PubMed Central PMCID: PMC2364651.


110: Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, Escara-Wilke J, Leander KR,
Defeo-Jones D, Hwang C, Sanda MG. Androgen ablation augments human
HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.
Prostate. 2010 Jun 15;70(9):1002-11. doi: 10.1002/pros.21134. PubMed PMID:
20209643; PubMed Central PMCID: PMC2875372.


111: Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li 
V, Rubin MA, Libermann TA, Sanda MG. Identification of the transcription factor
single-minded homologue 2 as a potential biomarker and immunotherapy target in
prostate cancer. Clin Cancer Res. 2009 Sep 15;15(18):5794-802. doi:
10.1158/1078-0432.CCR-09-0911. Epub 2009 Sep 8. PubMed PMID: 19737960.


112: Ascierto PA, Addeo R, Cartenì G, Daniele B, De Laurentis M, Ianniello G,
Morabito A, Palmieri G, Pepe S, Perrone F, Pignata S, Montesarchio V. The role of
immunotherapy in solid tumors: report from the Campania Society of Oncology
Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med. 2014 Oct 21;12(1):291. 
[Epub ahead of print] PubMed PMID: 25331657; PubMed Central PMCID: PMC4209076.


113: Aso Y. [Treatment of genitourinary malignancy--present concept and
controversy]. Gan To Kagaku Ryoho. 1988 Feb;15(2):192-4. Japanese. PubMed PMID:
2449133.


114: Asselah J, Sperlich C. Post-docetaxel options for further survival benefit
in metastatic castration-resistant prostate cancer: Questions of choice. Can Urol
Assoc J. 2013 Jan-Feb;7(1-2 Suppl 1):S11-7. PubMed PMID: 23682301; PubMed Central
PMCID: PMC3652214.


115: Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-independent
prostate cancer: an update. Semin Oncol. 2004 Apr;31(2 Suppl 4):26-32. Review.
PubMed PMID: 15124131.


116: Attard G, de Bono JS. Translating scientific advancement into clinical
benefit for castration-resistant prostate cancer patients. Clin Cancer Res. 2011 
Jun 15;17(12):3867-75. doi: 10.1158/1078-0432.CCR-11-0943. Review. PubMed PMID:
21680542.


117: Aust TR, Massey JA. Tubercular prostatic abscess as a complication of
intravesical bacillus Calmette-Guérin immunotherapy. Int J Urol. 2005
Oct;12(10):920-1. PubMed PMID: 16323989.


118: Awwad M, Strome PG, Gilman SC, Axelrod HR. Modification of monoclonal
antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not
interfere with antibody effector functions. Cancer Immunol Immunother. 1994
Jan;38(1):23-30. PubMed PMID: 8299115.


119: Azuma K, Shichijo S, Shomura H, Matsueda S, Fujii T, Itoh K. Identification 
of HER2/ neu-derived peptides capable of inducing both cellular and humoral
immune responses in HLA-A24 positive breast cancer patients. Breast Cancer Res
Treat. 2004 Jul;86(1):19-29. PubMed PMID: 15218358.


120: Azumi M, Kobayashi H, Aoki N, Sato K, Kimura S, Kakizaki H, Tateno M.
Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic
target for renal cell and bladder cancer. J Urol. 2010 May;183(5):2036-44. doi:
10.1016/j.juro.2009.12.094. Epub 2010 Mar 19. PubMed PMID: 20303532.


121: Badalament RA, Burgers JK, Petty LR, Mojzisik CM, Berens A, Marsh W, Hinkle 
GH, Martin EW Jr. Radioimmunoguided radical prostatectomy and lymphadenectomy.
Cancer. 1993 Apr 1;71(7):2268-75. PubMed PMID: 8453548.


122: Bagi CM. Targeting of therapeutic agents to bone to treat metastatic cancer.
Adv Drug Deliv Rev. 2005 May 25;57(7):995-1010. Epub 2005 Apr 13. Review. PubMed 
PMID: 15876400.


123: Bahl A. Metastatic castration-resistant prostate cancer. Part 1: the
challenges of the disease and its treatment. Eur J Oncol Nurs. 2013 Sep;17 Suppl 
1:S1-6. doi: 10.1016/S1462-3889(14)70002-X. Review. PubMed PMID: 24461207.


124: Bai A, Higham E, Eisen HN, Wittrup KD, Chen J. Rapid tolerization of
virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8. doi:
10.1073/pnas.0805599105. Epub 2008 Aug 22. PubMed PMID: 18723683; PubMed Central 
PMCID: PMC2519043.


125: Bak SP, Barnkob MS, Wittrup KD, Chen J. CD8+ T-cell responses rapidly select
for antigen-negative tumor cells in the prostate. Cancer Immunol Res. 2013
Dec;1(6):393-401. doi: 10.1158/2326-6066.CIR-13-0109. Epub 2013 Sep 20. PubMed
PMID: 24778132; PubMed Central PMCID: PMC4106291.


126: Bak SP, Barnkob MS, Bai A, Higham EM, Wittrup KD, Chen J. Differential
requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of
tumor-tolerized CD8 T cells. J Immunol. 2012 Aug 15;189(4):1708-16. doi:
10.4049/jimmunol.1201271. Epub 2012 Jul 13. PubMed PMID: 22798683; PubMed Central
PMCID: PMC4060810.


127: Balasar M, Doğan M, Kandemir A, Taskapu HH, Cicekci F, Toy H, Gurbuz R.
Investigation of granulomatous prostatitis incidence following intravesical BCG
therapy. Int J Clin Exp Med. 2014 Jun 15;7(6):1554-7. eCollection 2014. PubMed
PMID: 25035779; PubMed Central PMCID: PMC4100965.


128: Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, 
Ma D, Bander NH, Scheinberg DA, Sgouros G. Response of LNCaP spheroids after
treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific
membrane antigen antibody (J591). Cancer Res. 2001 Mar 1;61(5):2008-14. PubMed
PMID: 11280760.


129: Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R,
Ménard S, Pratesi G. Combination of a CpG-oligodeoxynucleotide and a
topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J
Cancer. 2004 May;40(8):1275-81. PubMed PMID: 15110894.


130: Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P. MHC class I
and II expression in prostate carcinoma and modulation by interferon-alpha and
-gamma. Prostate. 1997 Dec 1;33(4):233-9. PubMed PMID: 9397194.


131: Bander NH. Current status of monoclonal antibodies for imaging and therapy
of prostate cancer. Semin Oncol. 1994 Oct;21(5):607-12. Review. PubMed PMID:
7939751.


132: Barnea E, Beer I, Patoka R, Ziv T, Kessler O, Tzehoval E, Eisenbach L,
Zavazava N, Admon A. Analysis of endogenous peptides bound by soluble MHC class I
molecules: a novel approach for identifying tumor-specific antigens. Eur J
Immunol. 2002 Jan;32(1):213-22. PubMed PMID: 11782012.


133: Barqawi AB, Crawford ED. The current use and future trends of focal surgical
therapy in the management of localized prostate cancer. Cancer J. 2007
Sep-Oct;13(5):313-7. Review. PubMed PMID: 17921730.


134: Barrou B, Benoît G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S, Massicard 
S, Bercovici N, Ericson ML, Thiounn N. Vaccination of prostatectomized prostate
cancer patients in biochemical relapse, with autologous dendritic cells pulsed
with recombinant human PSA. Cancer Immunol Immunother. 2004 May;53(5):453-60.
Epub 2004 Feb 4. PubMed PMID: 14760510.


135: Bartholeyns J, Bardot V, Chokri M, Romet-Lemonne JL. [Adoptive
immunotherapy: evaluation and perspectives in the treatment of certain cancers]. 
Rev Med Interne. 2000 Oct;21(10):863-71. Review. French. PubMed PMID: 11075395.


136: Bartholeyns J, Romet-Lemonne JL, Chokri M, Buyse M, Velu T, Bruyns C, Van de
Winkel JJ, Heeney J, Koopman G, Malmsten M, De Groote D, Monsigny M, Midoux P,
Alarcon B. Cellular vaccines. Res Immunol. 1998 Sep-Oct;149(7-8):647-9. PubMed
PMID: 9851517.


137: Baselga J, Albanell J. Epithelial growth factor receptor interacting agents.
Hematol Oncol Clin North Am. 2002 Oct;16(5):1041-63. Review. PubMed PMID:
12512382.


138: Basler M, Groettrup M. Advances in prostate cancer immunotherapies. Drugs
Aging. 2007;24(3):197-221. Review. PubMed PMID: 17362049.


139: Basset V, Flamand V, Crouzet S, Ploussard G. [Choice of new drugs in
castration-resistant prostate cancer: predictive factors and effectiveness
assessment]. Prog Urol. 2013 Oct;23 Suppl 1:S44-8. doi:
10.1016/S1166-7087(13)70045-9. Review. French. PubMed PMID: 24314738.


140: Bastos DA, Dzik C, Rathkopf D, Scher HI. Expanding androgen- and androgen
receptor signaling-directed therapies for castration-resistant prostate cancer.
Oncology (Williston Park). 2014 Aug;28(8):693-9. Review. PubMed PMID: 25140626.


141: Batiuk TD, Barry JM, Bennett WM, Meyer MM, Tolzman D, Norman DJ. Incidence
and type of cancer following the use of OKT3: a single center experience with 557
organ transplants. Transplant Proc. 1993 Feb;25(1 Pt 2):1391. PubMed PMID:
8382860.


142: Baum V, Bühler P, Gierschner D, Herchenbach D, Fiala GJ, Schamel WW, Wolf P,
Elsässer-Beile U. Antitumor activities of PSMA×CD3 diabodies by redirected T-cell
lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38. doi:
10.2217/imt.12.136. Erratum in: Immunotherapy. 2014 Mar;6(3):362. PubMed PMID:
23256796.


143: Baxevanis CN, Papamichail M, Perez SA. Immunologic biomarkers in prostate
cancer: the AE37 paradigm. Hum Vaccin Immunother. 2014 May;10(5):1244-7. doi:
10.4161/hv.28032. Epub 2014 Feb 19. PubMed PMID: 24552987.


144: Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu
as a target for cancer vaccines. Immunotherapy. 2010 Mar;2(2):213-26. doi:
10.2217/imt.09.89. Review. PubMed PMID: 20635929.


145: Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA,
Cacoullos NT, Papamichail M. Immunogenic HER-2/neu peptides as tumor vaccines.
Cancer Immunol Immunother. 2006 Jan;55(1):85-95. Epub 2005 Oct 27. Review. PubMed
PMID: 15948002.


146: Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring
efficacy of therapeutics in cancer patients: an update. Cancer Immunol
Immunother. 2008 Jun;57(6):759-75. doi: 10.1007/s00262-007-0445-6. Epub 2008 Jan 
10. Review. PubMed PMID: 18188561.


147: Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA
vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell
responses in patients with recurrent prostate cancer. J Immunother. 2010
Jul-Aug;33(6):639-47. doi: 10.1097/CJI.0b013e3181dda23e. PubMed PMID: 20551832;
PubMed Central PMCID: PMC3045767.


148: Bedke J, Gouttefangeas C, Stenzl A. [Prostate carcinoma: vaccination as a
new option for treatment]. Urologe A. 2012 Jan;51(1):44-9. doi:
10.1007/s00120-011-2712-6. Review. German. PubMed PMID: 21989588.


149: Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer
PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW. Randomized trial of autologous
cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Clin Cancer Res. 2011 Jul 1;17(13):4558-67. doi: 10.1158/1078-0432.CCR-10-3223.
Epub 2011 May 10. PubMed PMID: 21558406.


150: Behe M, Alt K, Deininger F, Bühler P, Wetterauer U, Weber WA, Elsässer-Beile
U, Wolf P. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new
radioimmunotherapeutic agent against prostate cancer. In Vivo. 2011
Jan-Feb;25(1):55-9. PubMed PMID: 21282735.


151: Bei R, Paranavitana C, Milenic D, Kashmiri SV, Schlom J. Generation,
purification, and characterization of a recombinant source of human
prostate-specific antigen. J Clin Lab Anal. 1995;9(4):261-8. PubMed PMID:
7562244.


152: Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015
(Provenge) in patients with androgen-dependent, biochemically relapsed prostate
cancer. Clin Prostate Cancer. 2005 Jun;4(1):55-60. PubMed PMID: 15992463.


153: Beleva B. [Neoplasms following kidney transplantation]. Khirurgiia (Sofiia).
1991;44(1):38-41. Bulgarian. PubMed PMID: 1942901.


154: Belldegrun A, Bander NH, Lerner SP, Wood DP, Pantuck AJ. Society of Urologic
Oncology Biotechnology Forum: new approaches and targets for advanced prostate
cancer. J Urol. 2001 Oct;166(4):1316-21. Review. PubMed PMID: 11547065.


155: Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A,
deKernion J, Figlin R. Interleukin 2 gene therapy for prostate cancer: phase I
clinical trial and basic biology. Hum Gene Ther. 2001 May 20;12(8):883-92. PubMed
PMID: 11387054.


156: Bellmunt J, Oh WK. Castration-resistant prostate cancer: new science and
therapeutic prospects. Ther Adv Med Oncol. 2010 May;2(3):189-207. doi:
10.1177/1758834009359769. PubMed PMID: 21789134; PubMed Central PMCID:
PMC3126017.


157: Bellone M, Calcinotto A, Filipazzi P, De Milito A, Fais S, Rivoltini L. The 
acidity of the tumor microenvironment is a mechanism of immune escape that can be
overcome by proton pump inhibitors. Oncoimmunology. 2013 Jan 1;2(1):e22058.
PubMed PMID: 23483769; PubMed Central PMCID: PMC3583905.


158: Bellone M, Rigamonti N. Vitamin D-binding protein-derived
macrophage-activating factor, GcMAF, and prostate cancer. Cancer Immunol
Immunother. 2012 Dec;61(12):2377-8. doi: 10.1007/s00262-012-1310-9. Epub 2012 Jun
28. PubMed PMID: 22740161.


159: Bellone M, Mondino A, Corti A. Vascular targeting, chemotherapy and active
immunotherapy: teaming up to attack cancer. Trends Immunol. 2008
May;29(5):235-41. doi: 10.1016/j.it.2008.02.003. Epub 2008 Mar 28. Review. PubMed
PMID: 18375183.


160: Beltrami P, Ruggera L, Cazzoletti L, Schiavone D, Zattoni F. Are prostate
biopsies mandatory in patients with prostate-specific antigen increase during
intravesical immuno- or chemotherapy for superficial bladder cancer? Prostate.
2008 Aug 1;68(11):1241-7. doi: 10.1002/pros.20790. PubMed PMID: 18484098.


161: Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK,
Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for
castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011
Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Review.
PubMed PMID: 21592649.


162: Bendle GM, Linnemann C, Bies L, Song JY, Schumacher TN. Blockade of TGF-β
signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol.
2013 Sep 15;191(6):3232-9. doi: 10.4049/jimmunol.1301270. Epub 2013 Aug 12.
PubMed PMID: 23940272.


163: Benson MC, Coffey DS. New concepts and controversies concerning prostate
cancer. Prog Clin Biol Res. 1984;153:547-62. Review. PubMed PMID: 6382287.


164: Bera TK, Saint Fleur A, Lee Y, Kydd A, Hahn Y, Popescu NC, Zimonjic DB, Lee 
B, Pastan I. POTE paralogs are induced and differentially expressed in many
cancers. Cancer Res. 2006 Jan 1;66(1):52-6. PubMed PMID: 16397215.


165: Bera TK, Maitra R, Iavarone C, Salvatore G, Kumar V, Vincent JJ,
Sathyanarayana BK, Duray P, Lee BK, Pastan I. PATE, a gene expressed in prostate 
cancer, normal prostate, and testis, identified by a functional genomic approach.
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3058-63. PubMed PMID: 11880645; PubMed
Central PMCID: PMC122472.


166: Bera TK, Zimonjic DB, Popescu NC, Sathyanarayana BK, Kumar V, Lee B, Pastan 
I. POTE, a highly homologous gene family located on numerous chromosomes and
expressed in prostate, ovary, testis, placenta, and prostate cancer. Proc Natl
Acad Sci U S A. 2002 Dec 24;99(26):16975-80. Epub 2002 Dec 10. Erratum in: Proc
Natl Acad Sci U S A. 2003 Feb 4;100(3):1462. PubMed PMID: 12475935; PubMed
Central PMCID: PMC139254.


167: Berenguer M, Prieto M, Bustamante M, Carrasco D, López-Andújar R, Mir J,
Berenguer J. [Incidence of de novo neoplasms after liver transplantation]. Med
Clin (Barc). 1998 Oct 24;111(13):481-4. Spanish. PubMed PMID: 9859063.


168: Berger M, Kreutz FT, Horst JL, Baldi AC, Koff WJ. Phase I study with an
autologous tumor cell vaccine for locally advanced or metastatic prostate cancer.
J Pharm Pharm Sci. 2007;10(2):144-52. PubMed PMID: 17706173.


169: Berlyn KA, Ponniah S, Stass SA, Malone JG, Hamlin-Green G, Lim JK,
Cottler-Fox M, Tricot G, Alexander RB, Mann DL, Malone RW. Developing dendritic
cell polynucleotide vaccination for prostate cancer immunotherapy. J Biotechnol. 
1999 Aug 20;73(2-3):155-79. Review. PubMed PMID: 10486925.


170: Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis
ML. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer.
2002 Mar;9(1):33-44. Review. PubMed PMID: 11914181.


171: Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR,
Kalnicki S, Hodge JW, Guha C. Radiation-induced modulation of costimulatory and
coinhibitory T-cell signaling molecules on human prostate carcinoma cells
promotes productive antitumor immune interactions. Cancer Biother Radiopharm.
2014 May;29(4):153-61. doi: 10.1089/cbr.2013.1578. Epub 2014 Apr 2. PubMed PMID: 
24693958; PubMed Central PMCID: PMC4024843.


172: Bertilaccio MT, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M,
Jachetti E, Greenberg NM, Corti A, Bellone M. Vasculature-targeted tumor necrosis
factor-alpha increases the therapeutic index of doxorubicin against prostate
cancer. Prostate. 2008 Jul 1;68(10):1105-15. doi: 10.1002/pros.20775. PubMed
PMID: 18437689.


173: Besse B, Soria JC. [Treatment of cancer: surgery, radiotherapy,
chemotherapy, hormonal therapy. Multidisciplinary therapeutic decision making and
informing the patient]. Rev Prat. 2007 Feb 28;57(4):429-40; quiz 440. Review.
French. PubMed PMID: 17455746.


174: Bessede T, Bigot P, Neuzillet Y, Pignot G, Patard JJ, Pfister Ch, Rigaud J, 
Salomon L, Soulié M. [The 2010 news: highlights of the ASCO-GU, UAE, ASCO, AUA
congress…]. Prog Urol. 2011 Mar;21 Suppl 2:S16-22. doi:
10.1016/S1166-7087(11)70004-5. French. PubMed PMID: 21397822.


175: Biagini C. [Oncologic radiotherapy: state of the art]. Radiol Med. 1995
Nov;90(5):616-9. Italian. PubMed PMID: 8685434.


176: Bielat KL, Halpern J, Simich JP, Huben RP, Ambrus JL. A morphological
analysis of an in vitro model of cytotoxic antitumor activity. Cancer Detect
Prev. 1988;12(1-6):1-7. PubMed PMID: 3052828.


177: Bilusic M, Heery C, Madan RA. Immunotherapy in prostate cancer: emerging
strategies against a formidable foe. Vaccine. 2011 Sep 2;29(38):6485-97. doi:
10.1016/j.vaccine.2011.06.088. Epub 2011 Jul 7. Review. PubMed PMID: 21741424;
PubMed Central PMCID: PMC3605720.


178: Binsaleh S. Diagnosis and treatment of prostate cancer in renal-transplant
recipients. Int Urol Nephrol. 2012 Feb;44(1):149-55. doi:
10.1007/s11255-011-9988-8. Epub 2011 May 26. PubMed PMID: 21614508.


179: Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A. PD-L1 
is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2014
Nov 6. [Epub ahead of print] PubMed PMID: 25428917.


180: Bishr M, Lattouf JB, Gannon PO, Saad F. Updates on therapeutic targets and
agents in castration-resistant prostate cancer. Minerva Urol Nefrol. 2011
Jun;63(2):131-43. Review. PubMed PMID: 21623331.


181: Bitting RL, Armstrong AJ. Potential predictive biomarkers for
individualizing treatment for men with castration-resistant prostate cancer.
Cancer J. 2013 Jan-Feb;19(1):25-33. doi: 10.1097/PPO.0b013e31827e0b9c. Review.
PubMed PMID: 23337754.


182: Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class 
I expression in prostate cancer: implications for immunotherapy. Urology. 1995
Nov;46(5):681-6; discussion 686-7. PubMed PMID: 7495121.


183: Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer. 2003 Oct
6;89(7):1147-51. Review. PubMed PMID: 14520435; PubMed Central PMCID: PMC2394286.


184: Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome 
inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005 Jun 1;5(1):18.
PubMed PMID: 15929791; PubMed Central PMCID: PMC1164423.


185: Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G,
Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S. Antitumor
vaccination: where we stand. Haematologica. 2000 Nov;85(11):1172-206. Review.
PubMed PMID: 11074658.


186: Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Fas (APO-1, CD95) receptor
expression and new options for immunotherapy in childhood medulloblastomas.
Anticancer Res. 1999 Jul-Aug;19(4B):3293-314. PubMed PMID: 10652626.


187: Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate
specific antigen expression in human breast carcinoma cells. Anticancer Res. 1997
Jul-Aug;17(4A):2577-81. PubMed PMID: 9252683.


188: Bogden AE, Esber HJ. Predictive experimental animal tumor models: a concept.
Natl Cancer Inst Monogr. 1978 Dec;(49):263-7. PubMed PMID: 758024.


189: Boghaert ER, Sridharan L, Armellino DC, Khandke KM, DiJoseph JF, Kunz A,
Dougher MM, Jiang F, Kalyandrug LB, Hamann PR, Frost P, Damle NK.
Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl 
gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates
Lewisy-positive human carcinoma cells and xenografts. Clin Cancer Res. 2004 Jul
1;10(13):4538-49. PubMed PMID: 15240546.


190: Boikos SA, Antonarakis ES. Immunotherapy for prostate cancer enters its
golden age. Clin Med Insights Oncol. 2012;6:263-73. doi: 10.4137/CMO.S7475. Epub 
2012 Jul 10. PubMed PMID: 22844202; PubMed Central PMCID: PMC3403579.


191: Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol 
D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile
R. Functional cloning of recurrence-specific antigens identifies molecular
targets to treat tumor relapse. Mol Ther. 2013 Aug;21(8):1507-16. doi:
10.1038/mt.2013.116. Epub 2013 Jun 11. PubMed PMID: 23752316; PubMed Central
PMCID: PMC3734666.


192: Bok RA. Treatment of prostate cancer: therapeutic potential of targeted
immunotherapy with APC8015. Ther Clin Risk Manag. 2008 Feb;4(1):79-85. PubMed
PMID: 18728723; PubMed Central PMCID: PMC2503669.


193: Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Reis RB.
Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic
castration-refractory prostate cancer (mCRPC): a systematic review and
meta-analysis. Int Braz J Urol. 2012 Nov-Dec;38(6):717-27. Review. PubMed PMID:
23302410.


194: Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P.
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med. 2011
Jan;41(1):29-44. doi: 10.1053/j.semnuclmed.2010.08.005. Review. PubMed PMID:
21111858; PubMed Central PMCID: PMC3392994.


195: Bouchelouche K, Capala J. 'Image and treat': an individualized approach to
urological tumors. Curr Opin Oncol. 2010 May;22(3):274-80. doi:
10.1097/CCO.0b013e3283373d5c. Review. PubMed PMID: 20150811; PubMed Central
PMCID: PMC2855391.


196: Bouchelouche K, Capala J, Oehr P. Positron emission tomography/computed
tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol. 2009
Sep;21(5):469-74. doi: 10.1097/CCO.0b013e32832d56e4. Review. PubMed PMID:
19535981; PubMed Central PMCID: PMC2788311.


197: Bouffioux C. [Cancer of the prostate]. Acta Urol Belg. 1979
Apr;47(2):189-470. Review. French. PubMed PMID: 90455.


198: Bover Fuentes E, Fuentes Aguilar F, Junco Barranco J, Zaldivar Merino I,
Arteaga Moré N, Calzada Aguilera L, López Sáez Y, Pimentel Vázquez E, Basulto
Baker R. Active component of a GnRH based vaccine binds to natural GnRH receptors
in Dunning R3327-G cell line and human prostate carcinoma vesicles. J Exp Ther
Oncol. 2007;6(4):279-84. PubMed PMID: 18038761.


199: Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging
treatment modalities for metastatic castration-resistant prostate cancer. BJU
Int. 2011 Apr;107 Suppl 2:13-20. doi: 10.1111/j.1464-410X.2010.10036.x. PubMed
PMID: 21382150.


200: Braillon A. Re: Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, et al.
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur 
urol 2011;60:279-90. Eur Urol. 2011 Oct;60(4):e33. doi:
10.1016/j.eururo.2011.06.054. Epub 2011 Jul 13. PubMed PMID: 21767907.


201: Brand TC, Tolcher AW. Management of high risk metastatic prostate cancer:
the case for novel therapies. J Urol. 2006 Dec;176(6 Pt 2):S76-80; discussion
S81-2. Review. PubMed PMID: 17084174.


202: Brannen GE, Gomolka DM, Coffey DS. Specificity of cell membrane antigens in 
prostatic cancer. Cancer Chemother Rep. 1975 Jan-Feb;59(1):127-38. PubMed PMID:
1131799.


203: Braun S, Pantel K. Micrometastatic bone marrow involvement: detection and
prognostic significance. Med Oncol. 1999 Sep;16(3):154-65. Review. PubMed PMID:
10523795.


204: Brausi M, Olaru V. Management of high-risk non-muscle invasive bladder
cancer. Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Review. PubMed PMID:
23288212.


205: Bregni M, Ueno NT, Childs R. The second international meeting on allogeneic 
transplantation in solid tumors. Bone Marrow Transplant. 2006 Oct;38(8):527-37.
Epub 2006 Sep 4. PubMed PMID: 16953213.


206: Brennen WN, Drake CG, Isaacs JT. Enhancement of the T-cell armamentarium as 
a cell-based therapy for prostate cancer. Cancer Res. 2014 Jul 1;74(13):3390-5.
doi: 10.1158/0008-5472.CAN-14-0249. Epub 2014 Apr 18. PubMed PMID: 24747912;
PubMed Central PMCID: PMC4079728.


207: Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair
WR, Garin-Chesa P. TAG-72 expression in primary, metastatic and hormonally
treated prostate cancer as defined by monoclonal antibody CC49. J Urol. 1995
May;153(5):1575-9. PubMed PMID: 7536270.


208: Brill TH, Kübler HR, Pohla H, Buchner A, Fend F, Schuster T, van Randenborgh
H, Paul R, Kummer T, Plank C, Eisele B, Breul J, Hartung R, Schendel DJ,
Gansbacher B. Therapeutic vaccination with an
interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients
with progressive castration-resistant prostate cancer: a phase I/II trial. Hum
Gene Ther. 2009 Dec;20(12):1641-51. doi: 10.1089/hum.2009.101. PubMed PMID:
19671000.


209: Brill TH, Kübler HR, von Randenborgh H, Fend F, Pohla H, Breul J, Hartung R,
Paul R, Schendel DJ, Gansbacher B. Allogeneic retrovirally transduced, IL-2- and 
IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory
prostate cancer--a phase I clinical trial. J Gene Med. 2007 Jul;9(7):547-60.
PubMed PMID: 17514769.


210: Brodin P, Gilg S, Lundell L, Mattsson J. Major surgery in a neutropenic
patient undergoing allogeneic stem cell transplantation for high risk
myelofibrosis. Int J Hematol. 2012 Dec;96(6):798-800. doi:
10.1007/s12185-012-1178-7. Epub 2012 Sep 29. PubMed PMID: 23054643.


211: Broghammer EL, Ratliff TL. Immunotherapy of urologic tumors: principles and 
progress. Urol Oncol. 2002 Mar-Apr;7(2):45-56. Review. PubMed PMID: 12474522.


212: Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L,
Iafrate M, Prayer-Galetti T, Pagano F, Viola A. Boosting antitumor responses of T
lymphocytes infiltrating human prostate cancers. J Exp Med. 2005 Apr
18;201(8):1257-68. Epub 2005 Apr 11. PubMed PMID: 15824085; PubMed Central PMCID:
PMC2213151.


213: Brossart P. Dendritic cells in vaccination therapies of malignant diseases. 
Transfus Apher Sci. 2002 Oct;27(2):183-6. Review. Erratum in: Transfus Apheresis 
Sci. 2003 Feb;28(1):103. Brossart M D, Peter [corrected to Brossart, Peter].
PubMed PMID: 12350054.


214: Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, 
McCarter MD, Waziri A, Slansky JE. Influence of human immune cells on cancer:
studies at the University of Colorado. Immunol Res. 2013 Mar;55(1-3):22-33. doi: 
10.1007/s12026-012-8346-y. Review. PubMed PMID: 22941561; PubMed Central PMCID:
PMC3984131.


215: Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM, Netto G,
Pardoll DM, Drake CG. Anti-tumor effects of endogenous prostate cancer-specific
CD8 T cells in a murine TCR transgenic model. Prostate. 2012 Apr;72(5):514-22.
doi: 10.1002/pros.21453. Epub 2011 Jul 14. PubMed PMID: 21761425; PubMed Central 
PMCID: PMC3248615.


216: Brünisholz M, Hodel K, Brunner FP, Harder F, Torhorst J, Thiel G. [Tumors
and kidney transplantation]. Schweiz Med Wochenschr. 1984 Dec 22;114(51):1915-24.
Review. German. PubMed PMID: 6395328.


217: Buchsbaum S, Barnea E, Dassau L, Beer I, Milner E, Admon A. Large-scale
analysis of HLA peptides presented by HLA-Cw4. Immunogenetics. 2003
Jun;55(3):172-6. Epub 2003 May 16. PubMed PMID: 12750860.


218: Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor
antigens into cancer vaccines. Clin Vaccine Immunol. 2011 Jan;18(1):23-34. doi:
10.1128/CVI.00286-10. Epub 2010 Nov 3. Review. PubMed PMID: 21048000; PubMed
Central PMCID: PMC3019775.


219: Buonerba C, Ferro M, Di Lorenzo G. Sipuleucel-T for prostate cancer: the
immunotherapy era has commenced. Expert Rev Anticancer Ther. 2011 Jan;11(1):25-8.
doi: 10.1586/era.10.180. Review. PubMed PMID: 21166508.


220: Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW,
Richardson RL, Valone FH, Vuk-Pavlović S. Immunotherapy (APC8015, Provenge)
targeting prostatic acid phosphatase can induce durable remission of metastatic
androgen-independent prostate cancer: a Phase 2 trial. Prostate. 2004 Aug
1;60(3):197-204. PubMed PMID: 15176049.


221: Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ,
Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH,
Vuk-Pavlović S. Priming tissue-specific cellular immunity in a phase I trial of
autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000
Jun;6(6):2175-82. PubMed PMID: 10873066.


222: Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, Alitalo
K, Wu L. Suppression of prostate cancer nodal and systemic metastasis by blockade
of the lymphangiogenic axis. Cancer Res. 2008 Oct 1;68(19):7828-37. doi:
10.1158/0008-5472.CAN-08-1488. PubMed PMID: 18829538; PubMed Central PMCID:
PMC2800077.


223: Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory
cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res.
1990;16(7):361-9. PubMed PMID: 2152694.


224: Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E,
Tzakos AG, Jaeger W, Thalhammer T. Tumor-specific expression of organic
anion-transporting polypeptides: transporters as novel targets for cancer
therapy. J Drug Deliv. 2013;2013:863539. doi: 10.1155/2013/863539. Epub 2013 Feb 
3. PubMed PMID: 23431456; PubMed Central PMCID: PMC3574750.


225: Bühler P, Wolf P, Elsässer-Beile U. Targeting the prostate-specific membrane
antigen for prostate cancer therapy. Immunotherapy. 2009 May;1(3):471-81. doi:
10.2217/imt.09.17. Review. PubMed PMID: 20635963.


226: Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann
W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U. A bispecific
diabody directed against prostate-specific membrane antigen and CD3 induces
T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother. 2008
Jan;57(1):43-52. Epub 2007 Jun 20. PubMed PMID: 17579857; PubMed Central PMCID:
PMC2755730.


227: Camarero J, Ruiz S. Cancer immunotherapy products: regulatory aspects in the
European Union. Hum Vaccin Immunother. 2012 Sep;8(9):1354-9. doi:
10.4161/hv.21142. Epub 2012 Aug 6. PubMed PMID: 22863755; PubMed Central PMCID:
PMC3579920.


228: Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc 
Natl Acad Sci U S A. 2014 Apr 29;111(17):E1749-58. doi: 10.1073/pnas.1314722111. 
Epub 2014 Apr 14. PubMed PMID: 24733910; PubMed Central PMCID: PMC4035954.


229: Campbell I, Magliocco A, Moyana T, Zheng C, Xiang J. Adenovirus-mediated
p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer
Gene Ther. 2000 Sep;7(9):1270-8. PubMed PMID: 11023200.


230: Carballido E, Fishman M. Sipuleucel-T: Prototype for development of
anti-tumor vaccines. Curr Oncol Rep. 2011 Apr;13(2):112-9. doi:
10.1007/s11912-011-0152-5. Review. PubMed PMID: 21243538.


231: Carducci MA, DeWeese TL, Nelson WG, Simons JW, Sinibaldi V, Eisenberger MA. 
Prostate cancer treatment strategies based on tumor-specific biological
principles: future directions. Semin Oncol. 1996 Dec;23(6 Suppl 14):56-62.
Review. PubMed PMID: 8996587.


232: Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of
the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 2002 May 
15;62(10):2840-7. PubMed PMID: 12019162.


233: Carlsson B, Forsberg O, Bengtsson M, Tötterman TH, Essand M.
Characterization of human prostate and breast cancer cell lines for experimental 
T cell-based immunotherapy. Prostate. 2007 Mar 1;67(4):389-95. PubMed PMID:
17219382.


234: Carlsson B, Tötterman TH, Essand M. Generation of cytotoxic T lymphocytes
specific for the prostate and breast tissue antigen TARP. Prostate. 2004 Oct
1;61(2):161-70. PubMed PMID: 15305339.


235: Carpenter EL, Vonderheide RH. Telomerase-based immunotherapy of cancer.
Expert Opin Biol Ther. 2006 Oct;6(10):1031-9. Review. PubMed PMID: 16989585.


236: Carretero R, Gil-Julio H, Vázquez-Alonso F, Garrido F, Castiñeiras J, Cózar 
JM. Involvement of HLA class I molecules in the immune escape of urologic tumors.
Actas Urol Esp. 2014 Apr;38(3):192-9. doi: 10.1016/j.acuro.2013.06.006. Epub 2013
Dec 7. English, Spanish. PubMed PMID: 24315763.


237: Casati A, Zimmermann VS, Benigni F, Bertilaccio MT, Bellone M, Mondino A.
The immunogenicity of dendritic cell-based vaccines is not hampered by
doxorubicin and melphalan administration. J Immunol. 2005 Mar 15;174(6):3317-25. 
PubMed PMID: 15749863.


238: Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C,
Rabkin SD, Martuza RL. Oncolytic herpes simplex virus armed with xenogeneic
homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate
cancer. Gene Ther. 2010 Jun;17(6):805-10. doi: 10.1038/gt.2010.20. Epub 2010 Mar 
11. PubMed PMID: 20220784; PubMed Central PMCID: PMC3243306.


239: Castro JE. Immunological effect of hormones: a review. J R Soc Med. 1978
Feb;71(2):123-5. PubMed PMID: 633259; PubMed Central PMCID: PMC1436373.


240: Castro JE, Cass W. Maintenance of human tumours and tissues in
immunosuppressed mice. Br J Surg. 1974 Jun;61(6):421-6. PubMed PMID: 4134862.


241: Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X,
Bigliari A, Williams JC, Hu J, Lowenstein PR. Current and future strategies for
the treatment of malignant brain tumors. Pharmacol Ther. 2003 Apr;98(1):71-108.
Review. PubMed PMID: 12667889.


242: Catalona WJ. Immunobiology of carcinoma of the prostate. Invest Urol. 1980
Mar;17(5):373-7. Review. PubMed PMID: 6987190.


243: Cathomas R. [Integration of drug treatment in the management concept of
prostate cancer]. Internist (Berl). 2013 Oct;54(10):1262-70. doi:
10.1007/s00108-013-3334-4. Review. German. PubMed PMID: 23896735.


244: Cavacini LA, Duval M, Eder JP, Posner MR. Evidence of determinant spreading 
in the antibody responses to prostate cell surface antigens in patients immunized
with prostate-specific antigen. Clin Cancer Res. 2002 Feb;8(2):368-73. PubMed
PMID: 11839651.


245: Cavallo F, Forni G. Recent advances in cancer immunotherapy with an emphasis
on vaccines. Expert Rev Vaccines. 2009 Jan;8(1):25-8. doi:
10.1586/14760584.8.1.25. PubMed PMID: 19093768.


246: Centers for Disease Control and Prevention (CDC). Transfusion-related
transmission of yellow fever vaccine virus--California, 2009. MMWR Morb Mortal
Wkly Rep. 2010 Jan 22;59(2):34-7. PubMed PMID: 20094025.


247: Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M. Targeting
metastatic castration-resistant prostate cancer: mechanisms of progression and
novel early therapeutic approaches. Expert Opin Investig Drugs. 2014
Apr;23(4):469-87. doi: 10.1517/13543784.2014.885950. Epub 2014 Feb 3. Review.
PubMed PMID: 24490883.


248: Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, Gulley JL, Arlen
PM, Yokokawa J, Pastan I, Schlom J, Tsang KY. New gene expressed in prostate: a
potential target for T cell-mediated prostate cancer immunotherapy. Cancer
Immunol Immunother. 2010 Jan;59(1):63-71. doi: 10.1007/s00262-009-0723-6. Epub
2009 Jun 4. PubMed PMID: 19495750; PubMed Central PMCID: PMC2782544.


249: Cersosimo RJ. New agents for the management of castration-resistant prostate
cancer. Ann Pharmacother. 2012 Nov;46(11):1518-28. doi: 10.1345/aph.1R169. Epub
2012 Nov 7. Review. PubMed PMID: 23136351.


250: Cesano A, Visonneau S, Santoli D. TALL-104 cell therapy of human solid
tumors implanted in immunodeficient (SCID) mice. Anticancer Res. 1998
Jul-Aug;18(4A):2289-95. PubMed PMID: 9703868.


251: Cha E, Small EJ. Is there a role for immune checkpoint blockade with
ipilimumab in prostate cancer? Cancer Med. 2013 Apr;2(2):243-52. doi:
10.1002/cam4.64. Epub 2013 Feb 24. Review. PubMed PMID: 23634292; PubMed Central 
PMCID: PMC3639663.


252: Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic
approaches. J Clin Oncol. 2011 Sep 20;29(27):3677-85. doi:
10.1200/JCO.2010.34.5025. Epub 2011 Aug 8. Review. PubMed PMID: 21825260; PubMed 
Central PMCID: PMC3675707.


253: Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther.
2010 Feb;12(1):77-85. Review. PubMed PMID: 20140819.


254: Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K,
Becker MD, Goeckeler WF, Schlom J, Hodge JW. The use of chelated radionuclide
(samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of 
tumor cells and enhance T cell-mediated killing. Clin Cancer Res. 2008 Jul
1;14(13):4241-9. doi: 10.1158/1078-0432.CCR-08-0335. PubMed PMID: 18594006;
PubMed Central PMCID: PMC3407883.


255: Chakŭrov S, Minchev M. [Active specific immune therapy of prostate gland
cancer]. Khirurgiia (Sofiia). 2002;58(1):32-8. Review. Bulgarian. PubMed PMID:
12515033.


256: Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in
regulation of T cell responses: mechanisms and manipulation in tumor
immunotherapy. Annu Rev Immunol. 2001;19:565-94. Review. PubMed PMID: 11244047.


257: Chang CH, Hsu WC, Wang CY, Jan ML, Tsai TH, Lee TW, Lynn SG, Yeh CH, Chang
TJ. Longitudinal microSPECt/CT imaging and pharmacokinetics of synthetic
luteinizing hormone-releasing hormone (LHRH) vaccine in rats. Anticancer Res.
2007 Sep-Oct;27(5A):3251-8. PubMed PMID: 17970068.


258: Chang SS, Kibel AS. The role of systemic cytotoxic therapy for prostate
cancer. BJU Int. 2009 Jan;103(1):8-17. doi: 10.1111/j.1464-410X.2008.08256.x.
Epub 2008 Nov 25. Review. PubMed PMID: 19040524.


259: Chaturvedi S, Garcia JA. Novel agents in the management of castration
resistant prostate cancer. J Carcinog. 2014 Mar 5;13:5. doi:
10.4103/1477-3163.128185. eCollection 2014. Review. PubMed PMID: 24799832; PubMed
Central PMCID: PMC4007389.


260: Cheema Z, Hari-Gupta Y, Kita GX, Farrar D, Seddon I, Corr J, Klenova E.
Expression of the cancer-testis antigen BORIS correlates with prostate cancer.
Prostate. 2014 Feb;74(2):164-76. doi: 10.1002/pros.22738. Epub 2013 Oct 4. PubMed
PMID: 24123052.


261: Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first
FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011 Jun
1;17(11):3520-6. doi: 10.1158/1078-0432.CCR-10-3126. Epub 2011 Apr 6. PubMed
PMID: 21471425.


262: Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer
Immunol Immunother. 2013 Feb;62(2):203-16. doi: 10.1007/s00262-012-1388-0. Epub
2013 Feb 7. Review. PubMed PMID: 23389507; PubMed Central PMCID: PMC3608094.


263: Chen WR, Liu H, Ritchey JW, Bartels KE, Lucroy MD, Nordquist RE. Effect of
different components of laser immunotherapy in treatment of metastatic tumors in 
rats. Cancer Res. 2002 Aug 1;62(15):4295-9. PubMed PMID: 12154032.


264: Cheng J, Li L, Liu Y, Wang Z, Zhu X, Bai X. Interleukin-1α induces
immunosuppression by mesenchymal stem cells promoting the growth of prostate
cancer cells. Mol Med Rep. 2012 Nov;6(5):955-60. doi: 10.3892/mmr.2012.1019. Epub
2012 Aug 7. PubMed PMID: 22895682.


265: Cheng ML, Fong L. Beyond sipuleucel-T: immune approaches to treating
prostate cancer. Curr Treat Options Oncol. 2014 Mar;15(1):115-26. doi:
10.1007/s11864-013-0267-z. Review. PubMed PMID: 24402184.


266: Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a
consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin
Oncol. 1999 Aug;17(8):2454-60. PubMed PMID: 10561309.


267: Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B,
Visakorpi T. Castration-resistant prostate cancer: from new pathophysiology to
new treatment targets. Eur Urol. 2009 Oct;56(4):594-605. doi:
10.1016/j.eururo.2009.06.027. Epub 2009 Jun 24. Review. PubMed PMID: 19560857.


268: Chiacchio S, Mazzarri S, Lorenzoni A, Nyakale N, Boni G, Borsò E, Alsharif
A, Grosso M, Manca G, Greco C, Volterrani D, Mariani G. Radionuclide therapy and 
integrated protocols for bone metastases. Q J Nucl Med Mol Imaging. 2011
Aug;55(4):431-47. Review. PubMed PMID: 21738116.


269: Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW, Cheng G.
Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the
critical role of type I interferons in tumor immune surveillance. Cancer Res.
2010 Apr 1;70(7):2595-603. doi: 10.1158/0008-5472.CAN-09-1162. Epub 2010 Mar 16. 
PubMed PMID: 20233880; PubMed Central PMCID: PMC2995454.


270: Chiriva-Internati M, Mirandola L, Figueroa JA, Yu Y, Grizzi F, Kim M,
Jenkins M, Cobos E, Jumper C, Alalawi R. Selective expression and immunogenicity 
of the cancer/testis antigens SP17, AKAP4 and PTTG1 in non-small cell lung
cancer: new candidates for active immunotherapy. Chest. 2014 May 8. doi:
10.1378/chest.13-0770. [Epub ahead of print] PubMed PMID: 24811938.


271: Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ,
Cobos E, Kast WM. Identification of AKAP-4 as a new cancer/testis antigen for
detection and immunotherapy of prostate cancer. Prostate. 2012 Jan;72(1):12-23.
doi: 10.1002/pros.21400. Epub 2011 Apr 25. PubMed PMID: 21520158.


272: Chisholm GD, Pavone-Macaluso M. Cancer of the prostate: advances in
diagnosis and treatment. Report of a round table discussion held at the Third
Congress of the European Association of Urology, Monte Carlo, June 16, 1978. Eur 
Urol. 1980;6(4):197-205. PubMed PMID: 7389772.


273: Chopra A. (99m)Tc/(111)In-Labeled DTPA-succinyl polylysine. 2012 Oct 16
[updated 2012 Nov 21]. Molecular Imaging and Contrast Agent Database (MICAD)
[Internet]. Bethesda (MD): National Center for Biotechnology Information (US);
2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK114337/
PubMed PMID: 23193620.


274: Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL,
Greenberg NM, Greenberg PD. Cell-intrinsic abrogation of TGF-β signaling delays
but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine
model of autochthonous prostate cancer. J Immunol. 2012 Oct 15;189(8):3936-46.
doi: 10.4049/jimmunol.1201415. Epub 2012 Sep 14. PubMed PMID: 22984076; PubMed
Central PMCID: PMC3466379.


275: Choudhury A, Mosolits S, Kokhaei P, Hansson L, Palma M, Mellstedt H.
Clinical results of vaccine therapy for cancer: learning from history for
improving the future. Adv Cancer Res. 2006;95:147-202. Review. PubMed PMID:
16860658.


276: Choudhury AD, Kantoff PW. New agents in metastatic prostate cancer. J Natl
Compr Canc Netw. 2012 Nov 1;10(11):1403-9. PubMed PMID: 23138168.


277: Christiansen JJ, Weimbs T, Bander N, Rajasekaran AK. Differing effects of
microtubule depolymerizing and stabilizing chemotherapeutic agents on
t-SNARE-mediated apical targeting of prostate-specific membrane antigen. Mol
Cancer Ther. 2006 Oct;5(10):2468-73. PubMed PMID: 17041090.


278: Christiansen JJ, Rajasekaran SA, Inge L, Cheng L, Anilkumar G, Bander NH,
Rajasekaran AK. N-glycosylation and microtubule integrity are involved in apical 
targeting of prostate-specific membrane antigen: implications for immunotherapy. 
Mol Cancer Ther. 2005 May;4(5):704-14. PubMed PMID: 15897234.


279: Chu TM. Potential applications of monoclonal antibodies in cancer diagnosis 
and therapy. Cancer Invest. 1985;3(6):565-84. Review. PubMed PMID: 2417671.


280: Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr,
Schellhammer PF, Glass WF, Somers KD. Prostate tumor microenvironment alters
immune cells and prevents long-term survival in an orthotopic mouse model
following flt3-ligand/CD40-ligand immunotherapy. J Immunother. 2004
Jan-Feb;27(1):13-26. PubMed PMID: 14676630.


281: Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, 
Schellhammer PF, Somers KD. Impact of the tumor microenvironment on host
infiltrating cells and the efficacy of flt3-ligand combination immunotherapy
evaluated in a treatment model of mouse prostate cancer. Cancer Immunol
Immunother. 2003 Sep;52(9):535-45. PubMed PMID: 14627125.


282: Ciavarra RP, Somers KD, Brown RR, Glass WF, Consolvo PJ, Wright GL,
Schellhammer PF. Flt3-ligand induces transient tumor regression in an ectopic
treatment model of major histocompatibility complex-negative prostate cancer.
Cancer Res. 2000 Apr 15;60(8):2081-4. PubMed PMID: 10786663.


283: Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Dendritic cell-based
vaccines: barriers and opportunities. Future Oncol. 2012 Oct;8(10):1273-99. doi: 
10.2217/fon.12.125. Review. PubMed PMID: 23130928.


284: Clarke JM, Armstrong AJ. Novel therapies for the treatment of advanced
prostate cancer. Curr Treat Options Oncol. 2013 Mar;14(1):109-26. doi:
10.1007/s11864-012-0222-4. Review. PubMed PMID: 23322116; PubMed Central PMCID:
PMC3591460.


285: Clarke NW. Landmarks in non-hormonal pharmacological therapies for
castration-resistant prostate cancer. BJU Int. 2012 Oct;110 Suppl 1:14-22. doi:
10.1111/j.1464-410X.2012.11430.x. Review. PubMed PMID: 23046036.


286: Clarke RA, Allen BJ. Next-generation therapy for residual prostate cancer.
Immunotherapy. 2013 Nov;5(11):1235-41. doi: 10.2217/imt.13.127. Review. PubMed
PMID: 24188677.


287: Clavel B. [Medical treatment of malignant bone tumors (carcinolytics,
hormonotherapy, immunotherapy)]. Sem Hop. 1974 Jan 20;50(4):287-95. Review.
French. PubMed PMID: 4368180.


288: Cleton FJ. [Corticosteroids in oncology]. Ned Tijdschr Geneeskd. 1977 Oct
22;121(43):1715-20. Dutch. PubMed PMID: 270013.


289: Clines GA, Guise TA. Mechanisms and treatment for bone metastases. Clin Adv 
Hematol Oncol. 2004 May;2(5):295-302. Review. PubMed PMID: 16163196.


290: Coeffic D, Noël G. [Cancer facts in 1997. Treatments and perspectives].
Soins. 1997 May;(615):12-23. French. PubMed PMID: 9239093.


291: Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics--theory.
Urology. 1981 Mar;17(Suppl 3):40-53. Review. PubMed PMID: 7010755.


292: Coffey RN, Watson RW, Hegarty PK, Watson CL, Wolohan L, Brady HR, O'Keane C,
Fitzpatrick JM. Priming prostate carcinoma cells for increased apoptosis is
associated with up-regulation of the caspases. Cancer. 2001 Nov 1;92(9):2297-308.
PubMed PMID: 11745284.


293: Compérat E, Egevad L, Camparo P, Roupret M, Vaessen C, Valdman A, Jonmarker 
S, Capron F, Cussenot O, Charlotte F. Clinical significance of intratumoral CD8+ 
regulatory T cells in prostate carcinoma. Anal Quant Cytol Histol. 2010
Feb;32(1):39-44. PubMed PMID: 20701086.


294: Conrad R, Remberger M, Cederlund K, Barkholt L. Cytokine expression in
tumors treated with donor lymphocyte infusions after allogeneic hematopoietic
stem cell transplantation. Immunotherapy. 2011 Mar;3(3):443-51. doi:
10.2217/imt.10.116. PubMed PMID: 21395385.


295: Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW,
Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Castration-resistant prostate 
cancer: AUA Guideline. J Urol. 2013 Aug;190(2):429-38. doi:
10.1016/j.juro.2013.05.005. Epub 2013 May 9. PubMed PMID: 23665272.


296: Copier J, Ward S, Dalgleish A. Cell based cancer vaccines: regulatory and
commercial development. Vaccine. 2007 Sep 27;25 Suppl 2:B35-46. Review. PubMed
PMID: 17916462.


297: Copier J, Whelan M, Dalgleish A. Biomarkers for the development of cancer
vaccines: current status. Mol Diagn Ther. 2006;10(6):337-43. Review. PubMed PMID:
17154650.


298: Cormier L, Lechevallier E, Barrou B, Benoit G, Bensadoun H, Boudjema K,
Descottes JL, Doré B, Guy L, Malavaud B, Martin X, Patard JJ, Petit J, Salomon L.
Diagnosis and treatment of prostate cancers in renal-transplant recipients.
Transplantation. 2003 Jan 27;75(2):237-9. PubMed PMID: 12548131.


299: Corrado F, Pizza G, de Vinci C, Corrado G. [Immunotherapy with transfer
factor in hormone-resistant metastasized carcinoma of the prostate]. Arch Esp
Urol. 1989;42 Suppl 2:191-6. Spanish. PubMed PMID: 2639623.


300: Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D,
Marsili S, Giorgi G, Lozzi L, Neri P, Francini G. A
parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response
induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from
prostate cancer metastases, with epitope peptide-loaded autologous dendritic
cells and low-dose IL-2. Br J Cancer. 2001 Nov 30;85(11):1722-30. PubMed PMID:
11742494; PubMed Central PMCID: PMC2363980.


301: Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of 
human cytolytic T lymphocyte lines directed against prostate-specific antigen
(PSA) employing a PSA oligoepitope peptide. J Immunol. 1998 Sep
15;161(6):3186-94. PubMed PMID: 9743387.


302: Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In 
vitro generation of human cytotoxic T lymphocytes specific for peptides derived
from prostate-specific antigen. J Natl Cancer Inst. 1997 Feb 19;89(4):293-300.
PubMed PMID: 9048833.


303: Cracco CM, Terrone C, Porpiglia F, Scarpa RM. Immune response in prostate
cancer. Minerva Urol Nefrol. 2005 Dec;57(4):301-11. Review. PubMed PMID:
16247351.


304: Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT. Honokiol-mediated
inhibition of PI3K/mTOR pathway: a potential strategy to overcome
immunoresistance in glioma, breast, and prostate carcinoma without impacting T
cell function. J Immunother. 2009 Jul-Aug;32(6):585-92. doi:
10.1097/CJI.0b013e3181a8efe6. PubMed PMID: 19483651; PubMed Central PMCID:
PMC3795513.


305: Cress AE, Mohla S. Therapeutic targeting of prostate cancer. Cancer Biol
Ther. 2004 Oct;3(10):1028-30. Epub 2004 Oct 15. PubMed PMID: 15539935.


306: Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and 
future. Clin Med Res. 2006 Sep;4(3):218-27. Review. PubMed PMID: 16988102; PubMed
Central PMCID: PMC1570487.


307: Cruz LJ, Rueda F, Cordobilla B, Simón L, Hosta L, Albericio F, Domingo JC.
Targeting nanosystems to human DCs via Fc receptor as an effective strategy to
deliver antigen for immunotherapy. Mol Pharm. 2011 Feb 7;8(1):104-16. doi:
10.1021/mp100178k. Epub 2010 Dec 20. PubMed PMID: 21121669.


308: Culine S. [Update on the medical treatment of urologic tumors]. Bull Cancer.
2000 Jan;87(1):71-5. Review. French. PubMed PMID: 10673634.


309: Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity
of prostate specific antigens: comparative analysis of transcript levels in
prostate and non-prostatic tissues. Cancer Lett. 2006 May 18;236(2):229-38. Epub 
2005 Jul 19. PubMed PMID: 16046056.


310: Curiel TJ, Curiel DT. Tumor immunotherapy: inching toward the finish line. J
Clin Invest. 2002 Feb;109(3):311-2. PubMed PMID: 11827989; PubMed Central PMCID: 
PMC150867.


311: Curigliano G, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M,
Minchella I, Goldhirsch A. Developing an effective breast cancer vaccine:
challenges to achieving sterile immunity versus resetting equilibrium. Breast.
2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. Review. PubMed
PMID: 24074802.


312: Curnow RT. Clinical experience with CD64-directed immunotherapy. An
overview. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5. Review. PubMed
PMID: 9435876.


313: Dalgleish A, Whelan M. Novel immunotherapeutic approaches to prostate
cancer. Curr Opin Mol Ther. 2005 Feb;7(1):30-4. Review. PubMed PMID: 15732527.


314: Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III
studies reflect the initial optimism of phase II studies. Vaccine. 2011 Nov
3;29(47):8501-5. doi: 10.1016/j.vaccine.2011.09.012. Epub 2011 Sep 18. Review.
PubMed PMID: 21933695.


315: Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: The long
trek. Cancer Immunol Immunother. 2006 Aug;55(8):1025-32. Epub 2006 Feb 28.
Review. PubMed PMID: 16506069.


316: Dalgleish AG. Cancer vaccines as a therapeutic strategy. Expert Rev
Vaccines. 2004 Dec;3(6):665-8. PubMed PMID: 15606350.


317: Dalgleish AG, Perry MJ, Eaton JD, Hrouda D, Todryk SM, Kirby RS. The
immunotherapy of prostate cancer. Prostate Cancer Prostatic Dis. 2000
Dec;3(4):303-307. PubMed PMID: 12497083.


318: Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domchek SM, Vonderheide RH.
Telomerase vaccination has no detectable effect on SCID-repopulating and
colony-forming activities in the bone marrow of cancer patients. Exp Hematol.
2005 Nov;33(11):1275-80. PubMed PMID: 16263411.


319: Dangles V, Halberstam I, Scardino A, Choppin J, Wertheimer M, Richon S,
Quelvennec E, Moirand R, Guillet JG, Kosmatopoulos K, Bellet D, Zeliszewski D.
Tumor-associated antigen human chorionic gonadotropin beta contains numerous
antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T
lymphocytes. Cancer Immunol Immunother. 2002 Feb;50(12):673-81. Epub 2001 Dec 12.
PubMed PMID: 11862419.


320: Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodríguez
JA, Ortiz-Sánchez E, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. A
novel IgE antibody targeting the prostate-specific antigen as a potential
prostate cancer therapy. BMC Cancer. 2013 Apr 17;13:195. doi:
10.1186/1471-2407-13-195. PubMed PMID: 23594731; PubMed Central PMCID:
PMC3651304.


321: Dannull J, Diener PA, Prikler L, Fürstenberger G, Cerny T, Schmid U,
Ackermann DK, Groettrup M. Prostate stem cell antigen is a promising candidate
for immunotherapy of advanced prostate cancer. Cancer Res. 2000 Oct
1;60(19):5522-8. PubMed PMID: 11034097.


322: Das S, Hahn Y, Walker DA, Nagata S, Willingham MC, Peehl DM, Bera TK, Lee B,
Pastan I. Topology of NGEP, a prostate-specific cell:cell junction protein widely
expressed in many cancers of different grade level. Cancer Res. 2008 Aug
1;68(15):6306-12. doi: 10.1158/0008-5472.CAN-08-0870. PubMed PMID: 18676855;
PubMed Central PMCID: PMC2562772.


323: Das S, Hahn Y, Nagata S, Willingham MC, Bera TK, Lee B, Pastan I. NGEP, a
prostate-specific plasma membrane protein that promotes the association of LNCaP 
cells. Cancer Res. 2007 Feb 15;67(4):1594-601. PubMed PMID: 17308099.


324: David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus
DM, Bander NH. Clinical utility of radiolabeled monoclonal antibodies in prostate
cancer. Clin Genitourin Cancer. 2006 Mar;4(4):249-56. Review. PubMed PMID:
16729907.


325: Davol PA, Smith JA, Kouttab N, Elfenbein GJ, Lum LG. Anti-CD3 x anti-HER2
bispecific antibody effectively redirects armed T cells to inhibit tumor
development and growth in hormone-refractory prostate cancer-bearing severe
combined immunodeficient beige mice. Clin Prostate Cancer. 2004 Sep;3(2):112-21. 
PubMed PMID: 15479495.


326: Dawson N. Immunotherapeutic approaches in prostate cancer: PROVENGE. Clin
Adv Hematol Oncol. 2010 Jun;8(6):419-21. PubMed PMID: 20733552.


327: Dawson NA, Roesch EE. Sipuleucel-T and immunotherapy in the treatment of
prostate cancer. Expert Opin Biol Ther. 2014 May;14(5):709-19. doi:
10.1517/14712598.2014.896897. Epub 2014 Mar 12. PubMed PMID: 24620782.


328: Dawson NA. New molecular targets in advanced prostate cancer. Expert Rev
Anticancer Ther. 2006 Jul;6(7):993-1002. Review. PubMed PMID: 16831072.


329: Dawson NA, Slovin SF. Novel approaches to treat asymptomatic, hormone-naive 
patients with rising prostate-specific antigen after primary treatment for
prostate cancer. Urology. 2003 Dec 29;62 Suppl 1:102-18. Review. PubMed PMID:
14747048.


330: Day CH, Fanger GR, Retter MW, Hylander BL, Penetrante RB, Houghton RL, Zhang
X, McNeill PD, Filho AM, Nolasco M, Badaro R, Cheever MA, Reed SG, Dillon DC,
Watanabe Y. Characterization of KLK4 expression and detection of KLK4-specific
antibody in prostate cancer patient sera. Oncogene. 2002 Oct 10;21(46):7114-20.
PubMed PMID: 12370833.


331: Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel therapies for
metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011 Nov
16;103(22):1665-75. doi: 10.1093/jnci/djr362. Epub 2011 Sep 13. Review. PubMed
PMID: 21917607; PubMed Central PMCID: PMC4176261.


332: De Bari B, Fiorentino A, Greto D, Ciammella P, Arcangeli S, Avuzzi B,
D'Angelillo RM, Desideri I, Kirienko M, Marchiori D, Massari F, Fundoni C, Franco
P, Filippi AR, Alongi F. Prostate cancer as a paradigm of multidisciplinary
approach? Highlights from the Italian young radiation oncologist meeting. Tumori.
2013 Nov-Dec;99(6):637-49. doi: 10.1700/1390.15450. PubMed PMID: 24503785.


333: De Mulder PH, Schalken JA, Sternberg CN. Treatment options in hormone
resistant prostate cancer. Ann Oncol. 2002;13 Suppl 4:95-102. Review. PubMed
PMID: 12401673.


334: De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, van
der Zanden HG, Masucci G. Correlation between HLA-A2 gene frequency, latitude,
ovarian and prostate cancer mortality rates. Med Oncol. 2004;21(1):49-52. PubMed 
PMID: 15034213.


335: De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong
TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van
den Eertwegh AJ, Le DT, Caturegli P. Development of thyroglobulin antibodies
after GVAX immunotherapy is associated with prolonged survival. Int J Cancer.
2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973. Epub 2014 May 28. PubMed PMID: 
24832153; PubMed Central PMCID: PMC4199892.


336: de Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS,
van Tinteren H, Mesman EM, Song JY, Schumacher TN. TCR gene therapy of
spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol.
2008 Aug 15;181(4):2563-71. PubMed PMID: 18684947; PubMed Central PMCID:
PMC2587021.


337: Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, Becker M, Marquez C,
Knox S. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356
monoclonal antibody. Clin Cancer Res. 1996 Aug;2(8):1289-97. PubMed PMID:
9816299.


338: Decenzo JM, Allison R, Leadbetter GW Jr. Skin testing in genitourinary
carcinoma: 2-year followup. J Urol. 1975 Aug;114(2):271-3. PubMed PMID: 1171996.


339: Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, Gautam SC.
Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol
Cancer Ther. 2003 Jan;2(1):95-103. PubMed PMID: 12533677.


340: Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC.
Chemosensitization of hormone-refractory prostate cancer cells by curcumin to
TRAIL-induced apoptosis. J Exp Ther Oncol. 2005;5(2):81-91. PubMed PMID:
16471035.


341: DeFrancesco L. Landmark approval for Dendreon's cancer vaccine. Nat
Biotechnol. 2010 Jun;28(6):531-2. doi: 10.1038/nbt0610-531. PubMed PMID:
20531312.


342: Degl'Innocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio
MT, Hess-Michelini R, Doglioni C, Bellone M. Peripheral T-cell tolerance
associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Cancer Res. 2008 Jan 1;68(1):292-300. doi: 10.1158/0008-5472.CAN-07-2429. PubMed 
PMID: 18172322.


343: Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M,
Monno A, Arcelloni C, Greenberg NM, Bellone M. Peripheral T cell tolerance occurs
early during spontaneous prostate cancer development and can be rescued by
dendritic cell immunization. Eur J Immunol. 2005 Jan;35(1):66-75. PubMed PMID:
15597325.


344: del Campo AB, Aptsiauri N, Méndez R, Zinchenko S, Vales A, Paschen A, Ward
S, Ruiz-Cabello F, González-Aseguinolaza G, Garrido F. Efficient recovery of HLA 
class I expression in human tumor cells after beta2-microglobulin gene transfer
using adenoviral vector: implications for cancer immunotherapy. Scand J Immunol. 
2009 Aug;70(2):125-35. doi: 10.1111/j.1365-3083.2009.02276.x. PubMed PMID:
19630918.


345: DeNardo GL, DeNardo SJ, Kukis DL, O'Donnell RT, Shen S, Mirick GR, Meares
CF. Metabolite production in patients with lymphoma after radiometal-labeled
antibody administration. J Nucl Med. 2001 Sep;42(9):1324-33. PubMed PMID:
11535720.


346: DeNardo SJ, Denardo GL. Targeted radionuclide therapy for solid tumors: an
overview. Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S89-95. Review. PubMed
PMID: 16979448.


347: DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP,
O'Donnell RT, DeNardo GL. Enhancement of the therapeutic index: from
nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for
metastatic prostate cancer. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s. 
PubMed PMID: 16203820.


348: DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL,
Natarajan A, Lamborn KR, Jacobs F, Siantar CL. Enhanced therapeutic index of
radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation
dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid
(DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer
Res. 2003 Sep 1;9(10 Pt 2):3938S-44S. PubMed PMID: 14506192.


349: Denies S, Sanders NN. Recent progress in canine tumor vaccination: potential
applications for human tumor vaccines. Expert Rev Vaccines. 2012
Nov;11(11):1375-86. doi: 10.1586/erv.12.104. Review. PubMed PMID: 23249236.


350: Derhovanessian E, Adams V, Hähnel K, Groeger A, Pandha H, Ward S, Pawelec G.
Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs,
correlates with clinical response to whole-cell vaccination in prostate cancer
patients. Int J Cancer. 2009 Sep 15;125(6):1372-9. doi: 10.1002/ijc.24497. PubMed
PMID: 19533748.


351: Desai P, Jiménez JA, Kao C, Gardner TA. Future innovations in treating
advanced prostate cancer. Urol Clin North Am. 2006 May;33(2):247-72, viii.
Review. PubMed PMID: 16631463.


352: Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong
CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ,
Darcy PK, Kershaw MH. Tissues in different anatomical sites can sculpt and vary
the tumor microenvironment to affect responses to therapy. Mol Ther. 2014
Jan;22(1):18-27. doi: 10.1038/mt.2013.219. Epub 2013 Sep 19. PubMed PMID:
24048441; PubMed Central PMCID: PMC3978809.


353: di Capua Sacoto C, Luján Marco S, Bahilo Mateu P, Budía Alba A, Pontones
Moreno JL, Jiménez Cruz JF. [De novo urological neoplasms in kidney transplant
patients: experience in 1,751 patients]. Actas Urol Esp. 2010 Jan;34(1):88-94.
Spanish. PubMed PMID: 20223138.


354: Di Carlo E. [Neoplastic pathology of the prostate: perspectives].
Pathologica. 2005 Aug;97(4):165-6. Italian. PubMed PMID: 16440631.


355: Di Lorenzo G, Ferro M, Buonerba C. Sipuleucel-T (Provenge®) for
castration-resistant prostate cancer. BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi:
10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16. Review. PubMed PMID:
22177289.


356: Di Lorenzo G, Buonerba C, Kantoff PW. Immunotherapy for the treatment of
prostate cancer. Nat Rev Clin Oncol. 2011 May 24;8(9):551-61. doi:
10.1038/nrclinonc.2011.72. Review. PubMed PMID: 21606971.


357: Di Lorenzo G, Autorino R, Figg WD, De Placido S. Hormone-refractory prostate
cancer: where are we going? Drugs. 2007;67(8):1109-24. Review. PubMed PMID:
17521214.


358: Dickerson JB. Provenge: revolutionary technology or ethical bust? Hum
Vaccin. 2011 Apr;7(4):477-80. Epub 2011 Apr 1. Review. PubMed PMID: 21451262.


359: Dieli F, Caccamo N, Meraviglia S. Advances in immunotherapy of
castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more. 
Curr Opin Investig Drugs. 2008 Oct;9(10):1089-94. Review. PubMed PMID: 18821471.


360: Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts 
A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC. Targeting
human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy 
of hormone-refractory prostate cancer. Cancer Res. 2007 Aug 1;67(15):7450-7.
PubMed PMID: 17671215; PubMed Central PMCID: PMC3915341.


361: Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD. Transforming growth
factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific
immunity and early prostate tumor progression. Lab Invest. 2009 Feb;89(2):142-51.
doi: 10.1038/labinvest.2008.123. Epub 2008 Dec 15. PubMed PMID: 19079323.


362: Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm. 2011
Feb;26(1):1-64. doi: 10.1089/cbr.2010.0902. Review. PubMed PMID: 21355777.


363: Dillman RO, Soori G, DePriest C, Nayak SK, Beutel LD, Schiltz PM, de Leon C,
O'Connor AA. Treatment of human solid malignancies with autologous activated
lymphocytes and cimetidine: a phase II trial of the cancer biotherapy research
group. Cancer Biother Radiopharm. 2003 Oct;18(5):727-33. PubMed PMID: 14629821.


364: DiPaola RS, Kumar P, Hait WN, Weiss RE. State-of-the-art prostate cancer
treatment and research. A report from the Cancer Institute of New Jersey. N J
Med. 2001 Feb;98(2):23-33. Review. PubMed PMID: 11221439.


365: Disis ML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic
protein. Semin Oncol. 2001 Dec;28(6 Suppl 18):12-20. Review. PubMed PMID:
11774201.


366: Djavan B, Nelson K, Kazzazi A, Bruhn A, Sadri H, Gomez-Pinillos A, Ferrari
AC. Immunotherapy in the treatment of advanced prostate cancer. Can J Urol. 2011 
Oct;18(5):5865-74. Review. PubMed PMID: 22018147.


367: Djavan B. Editorial - immunotherapy for prostate cancer. Can J Urol. 2011
Aug;18(4):5763. PubMed PMID: 21854706.


368: Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, Pillarsetty
N, Hricak H, Sadelain M, Ponomarev V. Monitoring the efficacy of adoptively
transferred prostate cancer-targeted human T lymphocytes with PET and
bioluminescence imaging. J Nucl Med. 2008 Jul;49(7):1162-70. doi:
10.2967/jnumed.107.047324. Epub 2008 Jun 13. PubMed PMID: 18552144; PubMed
Central PMCID: PMC2756034.


369: Doehn C. Immunotherapy of prostate cancer. Eur Urol. 2008 Apr;53(4):681-3;
discussion 684-5. doi: 10.1016/j.eururo.2007.12.038. Epub 2008 Jan 3. Erratum in:
Eur Urol. 2008 Jun;53(6):1321. PubMed PMID: 18248878.


370: Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D. Prostate cancer
vaccines: current status and future potential. BioDrugs. 2008;22(2):71-84.
Review. PubMed PMID: 18345705.


371: Doehn C, Böhmer T, Sommerauer M, Kausch I, Jocham D. [Vaccine therapy of
prostate cancer]. Aktuelle Urol. 2005 Sep;36(5):407-16. Review. German. PubMed
PMID: 16163603.


372: Doehn C, Jocham D. Technology evaluation: TG-1031, Transgene SA. Curr Opin
Mol Ther. 2000 Feb;2(1):106-11. Review. PubMed PMID: 11249647.


373: Dong B, Minze LJ, Xue W, Chen W. Molecular insights into the development of 
T cell-based immunotherapy for prostate cancer. Expert Rev Clin Immunol. 2014
Nov;10(11):1547-57. doi: 10.1586/1744666X.2014.962515. Epub 2014 Sep 26. PubMed
PMID: 25259804.


374: Dong J, Luo J, Yan J, Zhang L, Gao J, Yu J. [Prokaryotic expression,
purification and antigenicity identification of mouse prostate stem cell
antigen]. Nan Fang Yi Ke Da Xue Xue Bao. 2012 Apr;32(4):502-6. Chinese. PubMed
PMID: 22543130.


375: Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z.
Complement resistance of human carcinoma cells depends on membrane regulatory
proteins, protein kinases and sialic acid. Clin Exp Immunol. 2003
Feb;131(2):254-63. PubMed PMID: 12562385; PubMed Central PMCID: PMC1808622.


376: Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA,
Allison JP, Li MO. T cell surveillance of oncogene-induced prostate cancer is
impeded by T cell-derived TGF-β1 cytokine. Immunity. 2011 Jul 22;35(1):123-34.
doi: 10.1016/j.immuni.2011.04.019. Epub 2011 Jul 14. PubMed PMID: 21757379;
PubMed Central PMCID: PMC3430371.


377: Donn F, Bruns T, von Meyerrinck L, Augustin C, Schulz M, Klosterhalfen H,
Schmoldt A. Monoclonal antibody to the prostate specific antigen. Andrologia.
1990;22 Suppl 1:44-55. PubMed PMID: 1720289.


378: Doo SW, Kim JH, Yang WJ, Kim SI, Lee DW, Hong SS, Song YS. A case of
tuberculous prostatitis with abscess. World J Mens Health. 2012 Aug;30(2):138-40.
doi: 10.5534/wjmh.2012.30.2.138. Epub 2012 Aug 31. PubMed PMID: 23596601; PubMed 
Central PMCID: PMC3623522.


379: Doonan BP, Haque A. HLA Class II Antigen Presentation in Prostate Cancer
Cells: A Novel Approach to Prostate Tumor Immunotherapy. Open Cancer Immunol J.
2010 Jan 1;3:1-7. PubMed PMID: 24163711; PubMed Central PMCID: PMC3807132.


380: Dorff TB, Wilkins C, Hepgur M, Quinn DI. Durable complete remission from
castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
Clin Genitourin Cancer. 2014 Apr;12(2):e55-8. doi: 10.1016/j.clgc.2013.11.006.
Epub 2013 Nov 14. PubMed PMID: 24331572.


381: Dorff TB, Crawford ED. Management and challenges of corticosteroid therapy
in men with metastatic castrate-resistant prostate cancer. Ann Oncol. 2013
Jan;24(1):31-8. doi: 10.1093/annonc/mds216. Epub 2012 Jul 24. Review. PubMed
PMID: 22831986.


382: Dovedi SJ, Davies BR. Emerging targeted therapies for bladder cancer: a
disease waiting for a drug. Cancer Metastasis Rev. 2009 Dec;28(3-4):355-67. doi: 
10.1007/s10555-009-9192-9. Review. PubMed PMID: 19997963.


383: Doyle PJ. Primary treatment of prostatic cancer. Br Med J. 1977 Nov
5;2(6096):1224. PubMed PMID: 563273; PubMed Central PMCID: PMC1632142.


384: Drachenberg D, Childs RW. Allogeneic stem cell transplantation as
immunotherapy for renal cell carcinoma: from immune enhancement to immune
replacement. Urol Clin North Am. 2003 Aug;30(3):611-22. Review. PubMed PMID:
12953759.


385: Drakaki A, McDermott DF. Novel immunotherapies in GU malignancies. Curr
Oncol Rep. 2013 Jun;15(3):224-31. doi: 10.1007/s11912-013-0306-8. Review. PubMed 
PMID: 23519772.


386: Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate
cancer: new therapies, novel combination strategies and implications for
immunotherapy. Oncogene. 2014 Oct 23;33(43):5053-5064. doi: 10.1038/onc.2013.497.
Epub 2013 Nov 25. Review. PubMed PMID: 24276248.


387: Drake CG. Visceral Metastases and Prostate Cancer Treatment: 'Die Hard,'
'Tough Neighborhoods,' or 'Evil Humors'? Oncology (Williston Park). 2014 Nov
15;28(11). pii: 202395. Review. PubMed PMID: 25403629.


388: Drake CG. The potential role of antigen spread in immunotherapy for prostate
cancer. Clin Adv Hematol Oncol. 2014 May;12(5):332-4. PubMed PMID: 25003491.


389: Drake CG. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in
castration-resistant prostate cancer. J Natl Cancer Inst. 2012 Sep
19;104(18):1422; author reply 1422-3. Epub 2012 Aug 21. PubMed PMID: 22911668.


390: Drake CG, Antonarakis ES. Current status of immunological approaches for the
treatment of prostate cancer. Curr Opin Urol. 2012 May;22(3):197-202. doi:
10.1097/MOU.0b013e3283519ad5. Review. PubMed PMID: 22328018; PubMed Central
PMCID: PMC3444809.


391: Drake CG. Update on prostate cancer vaccines. Cancer J. 2011
Sep-Oct;17(5):294-9. doi: 10.1097/PPO.0b013e3182325e78. Review. PubMed PMID:
21952278; PubMed Central PMCID: PMC3420819.


392: Drake CG, Antonarakis ES. Update: immunological strategies for prostate
cancer. Curr Urol Rep. 2010 May;11(3):202-7. doi: 10.1007/s11934-010-0106-8.
Review. PubMed PMID: 20425628; PubMed Central PMCID: PMC4020436.


393: Drake CG. Immunotherapy for prostate cancer: an emerging treatment modality.
Urol Clin North Am. 2010 Feb;37(1):121-9, Table of Contents. doi:
10.1016/j.ucl.2009.11.001. Review. PubMed PMID: 20152525.


394: Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev
Immunol. 2010 Aug;10(8):580-93. doi: 10.1038/nri2817. Review. PubMed PMID:
20651745; PubMed Central PMCID: PMC3082366.


395: Drake CG. Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol. 
2009 Sep 1;27(25):4035-7. doi: 10.1200/JCO.2009.22.2299. Epub 2009 Jul 27. PubMed
PMID: 19635998.


396: Drake CG. Immunotherapy for metastatic prostate cancer. Urol Oncol. 2008
Jul-Aug;26(4):438-44. doi: 10.1016/j.urolonc.2007.03.029. Epub 2007 Dec 21.
Review. PubMed PMID: 18593624.


397: Drake CG. Basic overview of current immunotherapy approaches in urologic
malignancy. Urol Oncol. 2006 Sep-Oct;24(5):413-8. PubMed PMID: 16962493.


398: Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL,
Flies DB, Kennedy EP, Long M, McGary PW, Coryell L, Nelson WG, Pardoll DM, Adler 
AJ. Androgen ablation mitigates tolerance to a prostate/prostate
cancer-restricted antigen. Cancer Cell. 2005 Mar;7(3):239-49. PubMed PMID:
15766662; PubMed Central PMCID: PMC2846360.


399: Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A,
von Bergwelt-Baildon M. Dendritic cell based tumor vaccination in prostate and
renal cell cancer: a systematic review and meta-analysis. PLoS One. 2011 Apr
20;6(4):e18801. doi: 10.1371/journal.pone.0018801. Review. PubMed PMID: 21533099;
PubMed Central PMCID: PMC3080391.


400: Dreicer R. How to approach sequencing therapy in patients with metastatic
castration resistant prostate cancer. Can J Urol. 2014 Apr;21(2 Supp 1):93-7.
PubMed PMID: 24775730.


401: Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B,
Limacher JM, Squiban P, Pantuck A. MVA-MUC1-IL2 vaccine immunotherapy (TG4010)
improves PSA doubling time in patients with prostate cancer with biochemical
failure. Invest New Drugs. 2009 Aug;27(4):379-86. doi: 10.1007/s10637-008-9187-3.
Epub 2008 Oct 18. PubMed PMID: 18931824.


402: Dreicer R, Klein EA, Elson P, Peereboom D, Byzova T, Plow EF. Phase II trial
of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate
cancer. Urol Oncol. 2005 Mar-Apr;23(2):82-6. PubMed PMID: 15869991.


403: Dubensky TW Jr, Skoble J, Lauer P, Brockstedt DG. Killed but metabolically
active vaccines. Curr Opin Biotechnol. 2012 Dec;23(6):917-23. doi:
10.1016/j.copbio.2012.04.005. Epub 2012 May 18. Review. PubMed PMID: 22608846.


404: Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. Semin Immunol. 2010 
Jun;22(3):155-61. doi: 10.1016/j.smim.2010.04.007. Epub 2010 May 21. Review.
PubMed PMID: 20488726.


405: Dunning NL, Laversin SA, Miles AK, Rees RC. Immunotherapy of prostate
cancer: should we be targeting stem cells and EMT? Cancer Immunol Immunother.
2011 Aug;60(8):1181-93. doi: 10.1007/s00262-011-1065-8. Epub 2011 Jun 19. Review.
PubMed PMID: 21688178.


406: Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR,
Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC. A
novel alphavirus vaccine encoding prostate-specific membrane antigen elicits
potent cellular and humoral immune responses. Clin Cancer Res. 2007 Jul
1;13(13):3999-4008. PubMed PMID: 17606734.


407: Díaz B, Sanjuan I, Gambón F, Loureiro C, Magadán S, González-Fernández A.
Generation of a human IgM monoclonal antibody directed against HLA class II
molecules: a potential agent in the treatment of haematological malignancies.
Cancer Immunol Immunother. 2009 Mar;58(3):351-60. doi: 10.1007/s00262-008-0558-6.
Epub 2008 Aug 2. PubMed PMID: 18677479.


408: Eaton JD, Perry MJ, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS.
Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory 
prostate cancer. BJU Int. 2002 Jan;89(1):19-26. PubMed PMID: 11849155.


409: Eaton JD, Perry MJ, Todryk SM, Mazucco RA, Kirby RS, Griffiths JR, Dalgleish
AG. Genetic prodrug activation therapy (GPAT) in two rat prostate models
generates an immune bystander effect and can be monitored by magnetic resonance
techniques. Gene Ther. 2001 Apr;8(7):557-67. PubMed PMID: 11319623.


410: Eggermont AM. Can immuno-oncology offer a truly pan-tumour approach to
therapy? Ann Oncol. 2012 Sep;23 Suppl 8:viii53-7. doi: 10.1093/annonc/mds264.
Review. PubMed PMID: 22918930.


411: Egland KA, Kumar V, Duray P, Pastan I. Characterization of overlapping
XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast,
and other types of cancers. Mol Cancer Ther. 2002 May;1(7):441-50. PubMed PMID:
12479262.


412: El-Hamamsy I, Stevens LM, Carrier M, Pelletier G, White M, Tremblay F,
Perrault LP. Incidence and prognosis of cancer following heart transplantation
using RATG induction therapy. Transpl Int. 2005 Nov;18(11):1280-5. PubMed PMID:
16221159.


413: Elkord E. Immunology and immunotherapy approaches for prostate cancer.
Prostate Cancer Prostatic Dis. 2007;10(3):224-36. Epub 2007 Apr 10. Review.
PubMed PMID: 17420764.


414: Elsässer-Beile U, Bühler P, Wolf P. Targeted therapies for prostate cancer
against the prostate specific membrane antigen. Curr Drug Targets. 2009
Feb;10(2):118-25. Review. PubMed PMID: 19199907.


415: Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W,
Wetterauer U. A new generation of monoclonal and recombinant antibodies against
cell-adherent prostate specific membrane antigen for diagnostic and therapeutic
targeting of prostate cancer. Prostate. 2006 Sep 15;66(13):1359-70. PubMed PMID: 
16894535.


416: Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5
adenovirus recombinant for a tumor antigen in combination with recombinant
canarypox virus (ALVAC) cytokine gene delivery induces destruction of established
prostate tumors. Int J Cancer. 2001 Dec 15;94(6):842-9. PubMed PMID: 11745487.


417: Emens LA. Re-purposing cancer therapeutics for breast cancer immunotherapy. 
Cancer Immunol Immunother. 2012 Aug;61(8):1299-305. doi:
10.1007/s00262-012-1247-z. Epub 2012 Mar 28. Review. PubMed PMID: 22454154;
PubMed Central PMCID: PMC3582212.


418: Enatsu N, Ota T, Ochi A. Prostatorectal fistula following intravesical
bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the urinary
bladder. Int J Urol. 2010 Sep;17(9):822-3. doi: 10.1111/j.1442-2042.2010.02597.x.
PubMed PMID: 20727055.


419: Engeler D, Ludewig B, Schmid HP. [Uro-oncological research from the
laboratory and clinical practice]. Urologe A. 2008 Aug;47(8):978-81. doi:
10.1007/s00120-008-1779-1. Review. German. PubMed PMID: 18521561.


420: Engleman EG. Dendritic cell-based cancer immunotherapy. Semin Oncol. 2003
Jun;30(3 Suppl 8):23-9. Review. PubMed PMID: 12881809.


421: Erdman SE, Sohn JJ, Rao VP, Nambiar PR, Ge Z, Fox JG, Schauer DB. CD4+CD25+ 
regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.
Cancer Res. 2005 May 15;65(10):3998-4004. PubMed PMID: 15899788.


422: Eriksson F, Tötterman T, Maltais AK, Pisa P, Yachnin J. DNA vaccine coding
for the rhesus prostate specific antigen delivered by intradermal electroporation
in patients with relapsed prostate cancer. Vaccine. 2013 Aug 20;31(37):3843-8.
doi: 10.1016/j.vaccine.2013.06.063. Epub 2013 Jul 2. PubMed PMID: 23831327.


423: Eriksson M, Andreasson K, Weidmann J, Lundberg K, Tegerstedt K, Dalianis T, 
Ramqvist T. Murine polyomavirus virus-like particles carrying full-length human
PSA protect BALB/c mice from outgrowth of a PSA expressing tumor. PLoS One.
2011;6(8):e23828. doi: 10.1371/journal.pone.0023828. Epub 2011 Aug 17. PubMed
PMID: 21858228; PubMed Central PMCID: PMC3157473.


424: Esber HJ, Menninger FF Jr, Taylor DJ, Bogden AE. Nonspecific stimulation of 
tumor-associated immunity by methanol-soluble fraction of Mycobacterium
butyricum. Cancer Res. 1972 Apr;32(4):795-803. PubMed PMID: 4501928.


425: Eshhar Z, Waks T, Pinthus J. Redirecting immune cells against bone
metastases: Immunotherapy of prostate cancer metastases using genetically
programmed immune effector cells. Discov Med. 2005 Jun;5(27):259-64. PubMed PMID:
20704885.


426: Esplugues E, Vega-Ramos J, Cartoixà D, Vazquez BN, Salaet I, Engel P,
Lauzurica P. Induction of tumor NK-cell immunity by anti-CD69 antibody therapy.
Blood. 2005 Jun 1;105(11):4399-406. Epub 2005 Feb 3. PubMed PMID: 15692061.


427: Essand M. Gene therapy and immunotherapy of prostate cancer:
adenoviral-based strategies. Acta Oncol. 2005;44(6):610-27. Review. PubMed PMID: 
16165921.


428: Essand M, Grönvik C, Hartman T, Carlsson J. Radioimmunotherapy of prostatic 
adenocarcinomas: effects of 131I-labelled E4 antibodies on cells at different
depth in DU 145 spheroids. Int J Cancer. 1995 Nov 3;63(3):387-94. PubMed PMID:
7591237.


429: Eymard JC, Gervais A, Jarcau R, Bernard J. [State of the art about new
therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells 
and recombinant virus]. Bull Cancer. 2007 Jul;94(7 Suppl):F69-76. Review. French.
PubMed PMID: 17845996.


430: Eymard JC, Bernard J. [Cell therapy and prostate cancer]. Bull Cancer. 2003 
Aug-Sep;90(8-9):734-43. Review. French. PubMed PMID: 14609763.


431: Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the
ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer
immunotherapy. J Exp Med. 2014 Apr 7;211(4):715-25. doi: 10.1084/jem.20130590.
Epub 2014 Mar 31. PubMed PMID: 24687957; PubMed Central PMCID: PMC3978270.


432: Farooqi AA, Fayyaz S, Qureshi MZ, Rashid S. Prostate cancer and
immunoproteome: awakening and reprogramming the guardian angels. Arch Immunol
Ther Exp (Warsz). 2012 Jun;60(3):191-8. doi: 10.1007/s00005-012-0169-y. Epub 2012
Apr 8. Review. PubMed PMID: 22484802.


433: Farr A, Herout R, Margreiter M, Tosev G, Djavan B. New findings in bladder
and prostate cancer: highlights from the 26th annual congress of the European
Association of Urology, March 18-22, 2011, Vienna, Austria. Can J Urol. 2011
Apr;18(2):5601-7. PubMed PMID: 21504647.


434: Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP.
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A
prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A.
2008 Mar 4;105(9):3509-14. doi: 10.1073/pnas.0712269105. Epub 2008 Feb 26. PubMed
PMID: 18303116; PubMed Central PMCID: PMC2265147.


435: Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson
JH. The history, evolution, and clinical use of dendritic cell-based immunization
strategies in the therapy of brain tumors. J Neurooncol. 2003
Aug-Sep;64(1-2):161-76. Review. PubMed PMID: 12952297.


436: Fehervari ZT. Unraveling immunology. Genome Biol. 2001;2(10):REPORTS4024.
Epub 2001 Sep 26. PubMed PMID: 11597331; PubMed Central PMCID: PMC138969.


437: Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M, Koristka
S, Michalk I, Lindemann D, Schmitz M, Temme A, Bornhäuser M, Ehninger G, Bachmann
M. Novel humanized and highly efficient bispecific antibodies mediate killing of 
prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J
Immunol. 2012 Sep 15;189(6):3249-59. doi: 10.4049/jimmunol.1200341. Epub 2012 Aug
8. PubMed PMID: 22875801.


438: Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, Temme A,
Cartellieri M, Bachmann M. Retargeting of T cells to prostate stem cell antigen
expressing tumor cells: comparison of different antibody formats. Prostate. 2011 
Jun 15;71(9):998-1011. doi: 10.1002/pros.21315. Epub 2010 Dec 28. PubMed PMID:
21541976.


439: Fenner A. Prostate cancer: Targeting SSX cancer-testis antigens for
immunotherapy. Nat Rev Urol. 2011 Nov 22;8(12):647. doi: 10.1038/nrurol.2011.181.
PubMed PMID: 22105319.


440: Fensterle J, Bergmann B, Yone CL, Hotz C, Meyer SR, Spreng S, Goebel W, Rapp
UR, Gentschev I. Cancer immunotherapy based on recombinant Salmonella enterica
serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera 
toxin subunit B. Cancer Gene Ther. 2008 Feb;15(2):85-93. Epub 2007 Dec 14. PubMed
PMID: 18084243.


441: Ferguson K, Yadav A, Morey S, Abdullah J, Hrysenko G, Eng JY, Sajjad M,
Koury S, Rittenhouse-Olson K. Preclinical studies with JAA-F11
anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer. Future
Oncol. 2014 Feb;10(3):385-99. doi: 10.2217/fon.13.209. PubMed PMID: 24559446.


442: Ferraro B, Cisper NJ, Talbott KT, Philipson-Weiner L, Lucke CE, Khan AS,
Sardesai NY, Weiner DB. Co-delivery of PSA and PSMA DNA vaccines with
electroporation induces potent immune responses. Hum Vaccin. 2011 Jan-Feb;7
Suppl:120-7. Epub 2011 Jan 1. PubMed PMID: 21266849.


443: Ferrer FA, Rodriguez R. Prostate cancer gene therapy. Hematol Oncol Clin
North Am. 2001 Jun;15(3):497-508. Review. PubMed PMID: 11525293.


444: Fiedler U, Wirth MP. [Gene therapy and immunotherapy in prostatic
carcinoma]. Urologe A. 2001 May;40(3):207-16. Review. German. PubMed PMID:
11405130.


445: Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D, Negrini S,
Ferrera F, Romagnoli A, Basso M, Contini P, Rizzi M, Ghio M, Benatti U, Damonte
G, Ravetti JL, Carmignani G, Zanetti M, Indiveri F. Frequency of
telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood. 2006 Feb
15;107(4):1505-12. Epub 2005 Oct 25. PubMed PMID: 16249379.


446: Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang 
L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar
R, Scott J, Antonia S, Gabrilovich D, Fishman M. Serial assessment of lymphocytes
and apoptosis in the prostate during coordinated intraprostatic dendritic cell
injection and radiotherapy. Immunotherapy. 2012 Apr;4(4):373-82. doi:
10.2217/imt.12.24. PubMed PMID: 22512631; PubMed Central PMCID: PMC4241355.


447: Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy
with radiation therapy. Front Oncol. 2012 Nov 26;2:169. doi:
10.3389/fonc.2012.00169. eCollection 2012. PubMed PMID: 23233905; PubMed Central 
PMCID: PMC3515996.


448: Finley DS, Pouliot F, Shuch B, Chin A, Pantuck A, Dekernion JB, Belldegrun
AS. Ultrasound-based combination therapy: potential in urologic cancer. Expert
Rev Anticancer Ther. 2011 Jan;11(1):107-13. doi: 10.1586/era.10.174. Review.
PubMed PMID: 21166515.


449: Finley DS, Pouliot F, Pantuck A. Words of wisdom. Re: Overall survival
analysis of a phase II randomized controlled trial of a poxviral-based
PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Eur Urol. 2010 Sep;58(3):466.
PubMed PMID: 20845530.


450: Finocchiaro G, Pellegatta S. Immunotherapy for glioma: getting closer to the
clinical arena? Curr Opin Neurol. 2011 Dec;24(6):641-7. doi:
10.1097/WCO.0b013e32834cbb17. Review. PubMed PMID: 22027543.


451: Finstad CL, Wang CY, Kowalski J, Zhang M, Li ML, Li XM, Xia WG, Bosland MC, 
Murthy KK, Walfield AM, Koff WC, Zamb TJ. Synthetic luteinizing hormone releasing
hormone (LHRH) vaccine for effective androgen deprivation and its application to 
prostate cancer immunotherapy. Vaccine. 2004 Mar 12;22(9-10):1300-13. PubMed
PMID: 15003660.


452: Finter F, Rinnab L, Gust K, Küfer R. [Palliative systemic therapy of
castration-resistant prostate cancer: current developments]. Urologe A. 2009
Nov;48(11):1295-301. doi: 10.1007/s00120-009-2111-4. Review. German. PubMed PMID:
19847385.


453: Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. γδ T cells for
cancer immunotherapy: A systematic review of clinical trials. Oncoimmunology.
2014 Jan 1;3(1):e27572. Epub 2014 Jan 17. Review. PubMed PMID: 24734216; PubMed
Central PMCID: PMC3984269.


454: Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne
PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG. Generation of
monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing 
tumors. Prostate. 2002 May 15;51(3):153-65. PubMed PMID: 11967950.


455: Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic
cell vaccine for prostate cancer. Expert Opin Biol Ther. 2009 Dec;9(12):1565-75. 
doi: 10.1517/14712590903446921. Review. PubMed PMID: 19916735.


456: Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B,
Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S,
Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson 
CN, De Santis M, Seruga B, de Wit R. Optimal management of metastatic
castration-resistant prostate cancer: highlights from a European Expert Consensus
Panel. Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010.
Epub 2014 Apr 3. PubMed PMID: 24703899.


457: Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M. Role of
targeted therapy in the treatment of advanced prostate cancer. BJU Int. 2010
Mar;105(6):748-67. doi: 10.1111/j.1464-410X.2010.09236.x. Review. PubMed PMID:
20353536.


458: Flanigan RC, Polcari AJ, Shore ND, Price TH, Sims RB, Maher JC, Whitmore JB,
Corman JM. An analysis of leukapheresis and central venous catheter use in the
randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for
metastatic castrate resistant prostate cancer. J Urol. 2013 Feb;189(2):521-6.
doi: 10.1016/j.juro.2012.09.029. Epub 2012 Dec 14. PubMed PMID: 23253957.


459: Flemming A. Immunotherapy: A vaccine for prostate cancer? Nat Rev Cancer.
2011 Jul 22;11(8):539. doi: 10.1038/nrc3117. PubMed PMID: 21779008.


460: Florczyk SJ, Liu G, Kievit FM, Lewis AM, Wu JD, Zhang M. 3D porous
chitosan-alginate scaffolds: a new matrix for studying prostate cancer
cell-lymphocyte interactions in vitro. Adv Healthc Mater. 2012 Sep;1(5):590-9.
doi: 10.1002/adhm.201100054. Epub 2012 Jul 6. PubMed PMID: 23184794; PubMed
Central PMCID: PMC3682216.


461: Foggi P. [23rd Congress of the European Society for Medical Oncology, 6-10
November 1998, Athens, Greece]. Clin Ter. 1998 Nov-Dec;149(6):401-7. Italian.
PubMed PMID: 10100400.


462: Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL,
Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated
lymphocyte recruitment into the tumor microenvironment following preoperative
sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Sep
24;106(11). pii: dju268. doi: 10.1093/jnci/dju268. Print 2014 Nov. PubMed PMID:
25255802; PubMed Central PMCID: PMC4241888.


463: Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM,
Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor
immunity to prostate cancer through combination immunotherapy with CTLA4 blockade
and GM-CSF. Cancer Res. 2009 Jan 15;69(2):609-15. doi:
10.1158/0008-5472.CAN-08-3529. PubMed PMID: 19147575.


464: Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep. 2007
May;9(3):226-33. Review. PubMed PMID: 17430695.


465: Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep. 2006
May;7(3):239-46. Review. PubMed PMID: 16630528.


466: Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol. 2003
Oct;30(5):649-58. Review. PubMed PMID: 14571412.


467: Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG.
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J
Immunol. 2001 Dec 15;167(12):7150-6. PubMed PMID: 11739538.


468: Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev
Immunol. 2000;18:245-73. Review. PubMed PMID: 10837059.


469: Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of
tissue-specific autoimmune prostatitis with prostatic acid phosphatase
immunization: implications for immunotherapy of prostate cancer. J Immunol. 1997 
Oct 1;159(7):3113-7. PubMed PMID: 9317107.


470: Forde PM, Reiss KA, Zeidan AM, Brahmer JR. What lies within: novel
strategies in immunotherapy for non-small cell lung cancer. Oncologist.
2013;18(11):1203-13. doi: 10.1634/theoncologist.2013-0171. Epub 2013 Oct 8.
Review. PubMed PMID: 24105749; PubMed Central PMCID: PMC3825306.


471: Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, 
Tanguay S, Lapointe R. The Wnt pathway regulator DKK1 is preferentially expressed
in hormone-resistant breast tumours and in some common cancer types. Br J Cancer.
2007 Feb 26;96(4):646-53. Epub 2007 Jan 23. PubMed PMID: 17245340; PubMed Central
PMCID: PMC2360041.


472: Forsberg O, Carlsson B, Malmström PU, Ullenhag G, Tötterman TH, Essand M.
High frequency of prostate antigen-directed T cells in cancer patients compared
to healthy age-matched individuals. Prostate. 2009 Jan 1;69(1):70-81. doi:
10.1002/pros.20858. PubMed PMID: 18814178.


473: Fortmüller K, Alt K, Gierschner D, Wolf P, Baum V, Freudenberg N, Wetterauer
U, Elsässer-Beile U, Bühler P. Effective targeting of prostate cancer by
lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody. Prostate.
2011 May;71(6):588-96. doi: 10.1002/pros.21274. Epub 2010 Oct 13. PubMed PMID:
20945402.


474: Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB. NY-ESO-1
protein expression and humoral immune responses in prostate cancer. Prostate.
2004 Jun 1;59(4):440-7. PubMed PMID: 15065093.


475: Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of
prostatic epithelial cell lines derived from transgenic adenocarcinoma of the
mouse prostate (TRAMP) model. Cancer Res. 1997 Aug 15;57(16):3325-30. PubMed
PMID: 9269988.


476: Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM,
Kallen KJ. Highly potent mRNA based cancer vaccines represent an attractive
platform for combination therapies supporting an improved therapeutic effect. J
Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605. PubMed PMID: 22262664.


477: Fournié JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, 
Laurent G. What lessons can be learned from γδ T cell-based cancer immunotherapy 
trials? Cell Mol Immunol. 2013 Jan;10(1):35-41. doi: 10.1038/cmi.2012.39. Epub
2012 Dec 17. Review. PubMed PMID: 23241899; PubMed Central PMCID: PMC4003170.


478: Fox SB, Launchbury R, Bates GJ, Han C, Shaida N, Malone PR, Harris AL,
Banham AH. The number of regulatory T cells in prostate cancer is associated with
the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not
HIF-1alpha. Prostate. 2007 May 1;67(6):623-9. PubMed PMID: 17328069.


479: Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T,
Pagano F, Tridente G, Colombatti M. Anti-tumor effects of toxins targeted to the 
prostate specific membrane antigen. Prostate. 2002 Sep 15;53(1):9-23. PubMed
PMID: 12210476.


480: Fraley EE, Ecker S. Tumor production in immune-suppressed hamsters by
spontaneously transformed humann prostatic epithelium. J Urol. 1971
Jul;106(1):95-9. PubMed PMID: 4105136.


481: Francini G, Scardino A, Kosmatopoulos K, Lemonnier FA, Campoccia G, Sabatino
M, Pozzessere D, Petrioli R, Lozzi L, Neri P, Fanetti G, Cusi MG, Correale P.
High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein
generate in vitro and in vivo antitumor CTL response without autoimmune side
effects. J Immunol. 2002 Nov 1;169(9):4840-9. PubMed PMID: 12391194.


482: Frank MO, Kaufman J, Tian S, Suárez-Fariñas M, Parveen S, Blachère NE,
Morris MJ, Slovin S, Scher HI, Albert ML, Darnell RB. Harnessing naturally
occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One. 
2010 Sep 1;5(9). pii: e12367. doi: 10.1371/journal.pone.0012367. PubMed PMID:
20824184; PubMed Central PMCID: PMC2931687.


483: Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, Quezado M,
Rosenberg SA, Royal RE. Identification and characterization of a tumor
infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and 
prostate cancer cell lines. Cancer Immunol Immunother. 2010 Dec;59(12):1757-69.
doi: 10.1007/s00262-010-0897-y. Epub 2010 Aug 24. PubMed PMID: 20734041.


484: Fransson J, Ek S, Ellmark P, Söderlind E, Borrebaeck CA, Furebring C.
Profiling of internalizing tumor-associated antigens on breast and pancreatic
cancer cells by reversed genomics. Cancer Lett. 2004 May 28;208(2):235-42. PubMed
PMID: 15142683.


485: Freedland SJ, Pantuck AJ, Weider J, Zisman A, Belldegrun AS. Immunotherapy
of prostate cancer. Curr Urol Rep. 2001 Jun;2(3):242-7. Review. PubMed PMID:
12084272.


486: Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, Groshen S, 
Lieskovsky G, Boyd SD, Skinner DG. Radical cystectomy for high risk patients with
superficial bladder cancer in the era of orthotopic urinary reconstruction.
Cancer. 1995 Sep 1;76(5):833-9. PubMed PMID: 8625187.


487: Fried TR, Rosenberg RR, Lipsitz LA. Older community-dwelling adults'
attitudes toward and practices of health promotion and advance planning
activities. J Am Geriatr Soc. 1995 Jun;43(6):645-9. PubMed PMID: 7775723.


488: Friedman AL. Cautious renal transplantation for the elderly is realistic.
Nephron Clin Pract. 2011;119 Suppl 1:c14-8. doi: 10.1159/000328020. Epub 2011 Aug
10. Review. PubMed PMID: 21832851.


489: Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R,
Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D,
Slootstra JW, Baeuerle PA, Rattel B, Kufer P. Regression of human prostate cancer
xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE
antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012
Dec;11(12):2664-73. doi: 10.1158/1535-7163.MCT-12-0042. Epub 2012 Oct 5. PubMed
PMID: 23041545.


490: Frohlich MW. Sipuleucel-T for the treatment of advanced prostate cancer.
Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004.
Review. PubMed PMID: 22595047.


491: Fromm PD, Gottlieb D, Bradstock KF, Hart DN. Cellular therapy to treat
haematological and other malignancies: progress and pitfalls. Pathology. 2011
Oct;43(6):605-15. doi: 10.1097/PAT.0b013e32834b6b24. Review. PubMed PMID:
21897329.


492: Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of
resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Int J Oncol. 2003 Feb;22(2):431-7. PubMed PMID: 12527945.


493: Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitization of prostate
carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the
Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol. 1997 Aug 25;180(1):70-83.
PubMed PMID: 9316641.


494: Frost P, Rose NR, Choe BK. Immunology of prostatic carcinoma-an overview.
Semin Oncol. 1976 Jun;3(2):107-13. PubMed PMID: 935881.


495: Frost PJ, Butterfield LH, Dissette VB, Economou JS, Bonavida B.
Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by
MART-1-specific CTL cultures. J Immunol. 2001 Mar 1;166(5):3564-73. PubMed PMID: 
11207317.


496: Frunza A, Slavescu D, Lascar I. Perineural invasion in head and neck cancers
- a review. J Med Life. 2014 Jun 15;7(2):121-3. Epub 2014 Jun 25. PubMed PMID:
25408713; PubMed Central PMCID: PMC4197494.


497: Fu X, Meng Z, Liang W, Tian Y, Wang X, Han W, Lou G, Wang X, Lou F, Yen Y,
Yu H, Jove R, Huang W. miR-26a enhances miRNA biogenesis by targeting Lin28B and 
Zcchc11 to suppress tumor growth and metastasis. Oncogene. 2014 Aug
21;33(34):4296-306. doi: 10.1038/onc.2013.385. Epub 2013 Sep 23. PubMed PMID:
24056962.


498: Fuerst J, Fiebiger E, Jungwirth A, Mack D, Talwar PG, Frick J, Rovan E.
Effect of active immunization against luteinizing hormone-releasing hormone on
the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning
R3327-AT2.1 prostate cancer sublines. Prostate. 1997 Jul 1;32(2):77-84. PubMed
PMID: 9215394.


499: Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B,
Hakenberg OW, Hoelig K, Rieber EP, Wirth MP. Vaccination of hormone-refractory
prostate cancer patients with peptide cocktail-loaded dendritic cells: results of
a phase I clinical trial. Prostate. 2006 Jun 1;66(8):811-21. PubMed PMID:
16482569.


500: Fujii R, Iwahashi M, Kikkawa K, Inagaki T, Kohjimoto Y, Ojima T, Mori T,
Kuramoto T, Nishizawa S, Azuma I, Yamaue H, Shinka T, Hara I. Bacillus
Calmette-Guérin cell-wall skeleton enhances the killing activity of cytotoxic
lymphocyte-activated human dendritic cells transduced with the prostate-specific 
antigen gene. BJU Int. 2009 Dec;104(11):1766-73. PubMed PMID: 20063450.


501: Fukao T. Dendritic-cell-based anticancer vaccination: has it matured? Trends
Immunol. 2002 May;23(5):231-2. PubMed PMID: 12102734.


502: Fukuchi K, Steiniger SC, Deryugina E, Liu Y, Lowery CA, Gloeckner C, Zhou B,
Kaufmann GF, Quigley JP, Janda KD. Inhibition of tumor metastasis: functional
immune modulation of the CUB domain containing protein 1. Mol Pharm. 2010 Feb
1;7(1):245-53. doi: 10.1021/mp900236t. PubMed PMID: 19916495; PubMed Central
PMCID: PMC2815031.


503: Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R,
Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ,
Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M. Targeted elimination of
prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005 Oct
1;65(19):9080-8. PubMed PMID: 16204083.


504: Gaines KK. Sipuleucel-T (Provenge): immunotherapy for metastatic prostate
cancer. Urol Nurs. 2012 Mar-Apr;32(2):95-8. PubMed PMID: 22690466.


505: Gaines KK. News briefs on prostate cancer, alcoholism, osteoporosis, and
drug updates. Urol Nurs. 2005 Dec;25(6):481-2. PubMed PMID: 16438256.


506: Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J,
Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic
cell-based interventions for cancer therapy. Oncoimmunology. 2012 Oct
1;1(7):1111-1134. PubMed PMID: 23170259; PubMed Central PMCID: PMC3494625.


507: Galustian C, Vyakarnam A, Elhage O, Hickman O, Dasgupta P, Smith RA.
Immunotherapy of prostate cancer: identification of new treatments and targets
for therapy, and role of WAP domain-containing proteins. Biochem Soc Trans. 2011 
Oct;39(5):1433-6. doi: 10.1042/BST0391433. Review. PubMed PMID: 21936828.


508: Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.
Radiation-induced immunogenic modulation of tumor enhances antigen processing and
calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014 Jan
30;5(2):403-16. PubMed PMID: 24480782; PubMed Central PMCID: PMC3964216.


509: Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R. Sargramostim (GM-CSF) and
lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase
I-II clinical trial. Urol Oncol. 2014 Jan;32(1):33.e11-7. doi:
10.1016/j.urolonc.2012.12.004. Epub 2013 Mar 17. PubMed PMID: 23510862.


510: Garcia JA, Rini BI. Castration-resistant prostate cancer: many treatments,
many options, many challenges ahead. Cancer. 2012 May 15;118(10):2583-93. doi:
10.1002/cncr.26582. Epub 2011 Oct 28. Review. PubMed PMID: 22038761.


511: Garcia JA. Sipuleucel-T in patients with metastatic castration-resistant
prostate cancer: an insight for oncologists. Ther Adv Med Oncol. 2011
Mar;3(2):101-8. doi: 10.1177/1758834010397692. PubMed PMID: 21789160; PubMed
Central PMCID: PMC3126040.


512: Garcia JA, Dreicer R. Immunotherapy in castration-resistant prostate cancer:
integrating sipuleucel-T into our current treatment paradigm. Oncology (Williston
Park). 2011 Mar;25(3):242-9. PubMed PMID: 21548467.


513: Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM. In vivo effects of
vaccination with six-transmembrane epithelial antigen of the prostate: a
candidate antigen for treating prostate cancer. Cancer Res. 2007 Feb
1;67(3):1344-51. PubMed PMID: 17283172.


514: Gardner TA, Elzey BD, Hahn NM. Sipuleucel-T (Provenge) autologous vaccine
approved for treatment of men with asymptomatic or minimally symptomatic
castrate-resistant metastatic prostate cancer. Hum Vaccin Immunother. 2012
Apr;8(4):534-9. doi: 10.4161/hv.19795. Review. PubMed PMID: 22832254.


515: Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal
irradiation of human tumor cells modulates phenotype resulting in enhanced
killing by cytotoxic T lymphocytes. Cancer Res. 2004 Nov 1;64(21):7985-94.
Erratum in: Cancer Res. 2005 Jan 1;65(1):374. Chakarborty, Mala [corrected to
Chakraborty, Mala]. PubMed PMID: 15520206.


516: Gaston KE, Ornstein DK. Pharmacotherapy for biochemical recurrences after
therapy for localised prostate cancer. Expert Opin Pharmacother. 2002
Jun;3(6):657-69. Review. PubMed PMID: 12036405.


517: Gati A, Lajmi N, Derouiche A, Marrakchi R, Chebil M, Benammar-Elgaaied A.
NY-ESO-1 expression and immunogenicity in prostate cancer patients. Tunis Med.
2011 Oct;89(10):779-83. PubMed PMID: 22076902.


518: Gatti G, Nuñez NG, Nocera DA, Dejager L, Libert C, Giraudo C, Maccioni M.
Direct effect of dsRNA mimetics on cancer cells induces endogenous IFN-β
production capable of improving dendritic cell function. Eur J Immunol. 2013
Jul;43(7):1849-61. doi: 10.1002/eji.201242902. Epub 2013 May 28. PubMed PMID:
23636788.


519: Geary SM, Salem AK. Prostate cancer vaccines: Update on clinical
development. Oncoimmunology. 2013 May 1;2(5):e24523. Epub 2013 Apr 29. PubMed
PMID: 23762812; PubMed Central PMCID: PMC3667918.


520: Geiger KD, Hendruschk S, Rieber EP, Morgenroth A, Weigle B, Juratli T,
Senner V, Schackert G, Temme A. The prostate stem cell antigen represents a novel
glioma-associated antigen. Oncol Rep. 2011 Jul;26(1):13-21. doi:
10.3892/or.2011.1265. Epub 2011 Apr 15. PubMed PMID: 21503583.


521: Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, Schultz S, Kirschfink M.
Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by
siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug
Targets. 2010 Dec;10(8):922-31. PubMed PMID: 20879979.


522: Gendler SJ, Mukherjee P. Spontaneous adenocarcinoma mouse models for
immunotherapy. Trends Mol Med. 2001 Oct;7(10):471-5. Review. PubMed PMID:
11597523.


523: George D, Moul JW. Emerging treatment options for patients with
castration-resistant prostate cancer. Prostate. 2012 Feb;72(3):338-49. doi:
10.1002/pros.21435. Epub 2011 Jul 11. Review. PubMed PMID: 21748753.


524: George D. How does sipuleucel-T alter our clinical practice? BJU Int. 2010
Oct;106(7):945-6. PubMed PMID: 20931691.


525: George DJ, Kantoff PW, Lin DW. New and emerging treatments for advanced
prostate cancer. Clin Adv Hematol Oncol. 2011 Jun;9(6 Suppl 12):1-15. Review.
PubMed PMID: 22361744.


526: Gerritsen WR. The evolving role of immunotherapy in prostate cancer. Ann
Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review. PubMed
PMID: 22918924.


527: Gerritsen WR, Sharma P. Current and emerging treatment options for
castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol.
2012 Feb;32(1):25-35. doi: 10.1007/s10875-011-9595-6. Epub 2011 Nov 4. Review.
PubMed PMID: 22048979; PubMed Central PMCID: PMC3276755.


528: Ghafouri-Fard S, Ousati Ashtiani Z, Sabah Golian B, Hasheminasab SM,
Modarressi MH. Expression of two testis-specific genes, SPATA19 and LEMD1, in
prostate cancer. Arch Med Res. 2010 Apr;41(3):195-200. doi:
10.1016/j.arcmed.2010.04.003. PubMed PMID: 20682177.


529: Ghanei M, Shohrati M, Saburi A. The new aspects of immunotherapy in prostate
cancer. Cancer Immunol Immunother. 2012 Dec;61(12):2375-6. doi:
10.1007/s00262-012-1309-2. Epub 2012 Jun 27. PubMed PMID: 22736256.


530: Ghosh A. Different approaches of gene therapy used in prostate cancer. Cell 
Mol Biol (Noisy-le-grand). 2005 Sep 2;51(1):103-11. Review. PubMed PMID:
16171569.


531: Giarelli E. Cancer vaccines: a new frontier in prevention and treatment.
Oncology (Williston Park). 2007 Oct;21(11 Suppl Nurse Ed):11-7; discussion 18.
Review. PubMed PMID: 18154203.


532: Gilboa E, McNamara J 2nd, Pastor F. Use of oligonucleotide aptamer ligands
to modulate the function of immune receptors. Clin Cancer Res. 2013 Mar
1;19(5):1054-62. doi: 10.1158/1078-0432.CCR-12-2067. PubMed PMID: 23460536.


533: Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic
cells. Immunol Rev. 2004 Jun;199:251-63. Review. PubMed PMID: 15233739.


534: Gillies SD, Lan Y, Wesolowski JS, Qian X, Reisfeld RA, Holden S, Super M, Lo
KM. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate
and colon carcinoma metastases. J Immunol. 1998 Jun 15;160(12):6195-203. PubMed
PMID: 9637539.


535: Gingrich JR, Chauhan RD, Steiner MS. Gene therapy for prostate cancer. Curr 
Oncol Rep. 2001 Sep;3(5):438-47. Review. PubMed PMID: 11489246.


536: Girard MP. [Vaccines for the future]. Ann Pharm Fr. 2009 May;67(3):203-12.
doi: 10.1016/j.pharma.2009.02.004. Epub 2009 Mar 27. Review. French. PubMed PMID:
19446671.


537: Goethuys H, Baert L, Van Poppel H, Lieskovsky G, Brady LW, Petrovich Z.
Treatment of metastatic carcinoma of the prostate. Am J Clin Oncol. 1997
Feb;20(1):40-5. Review. PubMed PMID: 9020286.


538: Goetz D. New options for the management of castration-resistant prostate
cancer: a case perspective. J Natl Compr Canc Netw. 2011 Feb;9 Suppl 3:S13-23;
quiz S24. Review. Erratum in: J Natl Compr Canc Netw. 2011 May;9(5):xxx. PubMed
PMID: 21357663.


539: Gofrit ON, Pode D, Pizov G, Zorn KC, Katz R, Shapiro A. Prostatic urothelial
carcinoma: is transurethral prostatectomy necessary before bacillus
Calmette-Guérin immunotherapy? BJU Int. 2009 Apr;103(7):905-8. doi:
10.1111/j.1464-410X.2008.08210.x. Epub 2008 Nov 19. PubMed PMID: 19021623.


540: Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer
chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug
delivery. J Pharm Pharmacol. 2002 Feb;54(2):159-80. Review. PubMed PMID:
11848280.


541: Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J
Nucl Med. 2002 May;43(5):693-713. Review. PubMed PMID: 11994535.


542: Gomella LG, Gelpi-Hammerschmidt F, Kundavram C. Practical guide to
immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T
immunotherapy. Can J Urol. 2014 Apr;21(2 Supp 1):48-56. PubMed PMID: 24775724.


543: Gomella LG, Petrylak DP, Shayegan B. Current management of advanced and
castration resistant prostate cancer. Can J Urol. 2014 Apr;21(2 Supp 1):1-6.
PubMed PMID: 24775717.


544: Gomella LG, Gelpi F, Kelly WK. New treatment options for castrate-resistant 
prostate cancer: a urology perspective. Can J Urol. 2011 Aug;18(4):5767-77.
Review. PubMed PMID: 21854708.


545: Gonzalez Marinello GM, Santos ES, Raez LE. Epidermal growth factor vaccine
in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2012 Apr;12(4):439-45.
doi: 10.1586/era.12.24. Review. PubMed PMID: 22500681.


546: González G, Crombet T, Catalá M, Mirabal V, Hernández JC, González Y,
Marinello P, Guillén G, Lage A. A novel cancer vaccine composed of
human-recombinant epidermal growth factor linked to a carrier protein: report of 
a pilot clinical trial. Ann Oncol. 1998 Apr;9(4):431-5. PubMed PMID: 9636835.


547: Gotoh M, Takasu H, Harada K, Yamaoka T. Development of HLA-A2402/K(b)
transgenic mice. Int J Cancer. 2002 Aug 10;100(5):565-70. PubMed PMID: 12124806.


548: Gould P. Sipuleucel-T shows partial advantage in prostate cancer. Lancet
Oncol. 2006 Sep;7(9):710. PubMed PMID: 16981300.


549: Govindan SV, Stein R, Qu Z, Chen S, Andrews P, Ma H, Hansen HJ, Griffiths
GL, Horak ID, Goldenberg DM. Preclinical therapy of breast cancer with a
radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a
residualizing iodine radiolabel. Breast Cancer Res Treat. 2004 Mar;84(2):173-82. 
PubMed PMID: 14999147.


550: Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid
phosphatase expression in human tissues. Int J Clin Exp Pathol. 2011
Mar;4(3):295-306. Epub 2011 Mar 22. PubMed PMID: 21487525; PubMed Central PMCID: 
PMC3071662.


551: Graddis TJ, Diegel ML, McMahan CJ, Tsavler L, Laus R, Vidovic D. Tumor
immunotherapy with alternative reading frame peptide antigens. Immunobiology.
2004;209(7):535-44. Erratum in: Immunobiology. 2005;209(10):753. Graddis, Thomas 
J [added]; Diegel, Michael L [added]; McMahan, Catherine J [added]; Tsavler,
Larisa [added]; Laus, Reiner [added]. PubMed PMID: 15568617.


552: Granziero L, Krajewski S, Farness P, Yuan L, Courtney MK, Jackson MR,
Peterson PA, Vitiello A. Adoptive immunotherapy prevents prostate cancer in a
transgenic animal model. Eur J Immunol. 1999 Apr;29(4):1127-38. PubMed PMID:
10229079.


553: Gray A, de la Luz Garcia-Hernandez M, van West M, Kanodia S, Hubby B, Kast
WM. Prostate cancer immunotherapy yields superior long-term survival in TRAMP
mice when administered at an early stage of carcinogenesis prior to the
establishment of tumor-associated immunosuppression at later stages. Vaccine.
2009 Dec 30;27 Suppl 6:G52-9. doi: 10.1016/j.vaccine.2009.09.106. PubMed PMID:
20006141; PubMed Central PMCID: PMC2810316.


554: Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in 
therapeutic vaccination of cancer patients: the need to apply therapeutic
vaccination strategies in the preventive setting. Immunol Rev. 2008
Apr;222:316-27. doi: 10.1111/j.1600-065X.2008.00605.x. Review. PubMed PMID:
18364011.


555: Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, 
Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C. The
C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial 
cell targeting with multistage progression to carcinoma. Oncogene. 2000 Feb
21;19(8):1020-7. Review. PubMed PMID: 10713685.


556: Gregor P, Huang QD, Gallardo HF, Rasalan TS, Morris MJ. A case report of
putative autoimmunity to prostate cancer after immune-mediated rejection of
melanoma through a shared tumor antigen. Clin Genitourin Cancer. 2012
Jun;10(2):126-9. doi: 10.1016/j.clgc.2011.12.002. Epub 2012 Jan 27. PubMed PMID: 
22284755; PubMed Central PMCID: PMC3358358.


557: Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D, Heston
WD, Houghton AN, Scher HI. Induction of autoantibodies to syngeneic
prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer. 2005 
Sep 1;116(3):415-21. PubMed PMID: 15800947; PubMed Central PMCID: PMC1951508.


558: Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales 
MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher
HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines
enhances T-cell responses, tumor immunity and autoimmunity to self antigens in
animal and cellular model systems. Vaccine. 2004 Apr 16;22(13-14):1700-8. PubMed 
PMID: 15068853.


559: Gregorakis AK, Holmes EH, Murphy GP. Prostate-specific membrane antigen:
current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. Review. PubMed
PMID: 9508077.


560: Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson 
TC, Zhao W, Ratliff TL. Inhibition of murine prostate tumor growth and activation
of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst.
2001 Jul 4;93(13):998-1007. PubMed PMID: 11438565.


561: Gross-Goupil M, Roca S, Pasticier G, Ravaud A. [Strategy in advanced
castration-resistant prostate cancer]. Bull Cancer. 2012 Jul;99 Suppl 1:S37-45.
doi: 10.1684/bdc.2012.1562. Review. French. PubMed PMID: 22522582.


562: Grossmann ME, Wood M, Celis E. Expression, specificity and immunotherapy
potential of prostate-associated genes in murine cell lines. World J Urol. 2001
Nov;19(5):365-70. PubMed PMID: 11760786.


563: Grossmann ME, Davila T, Celis T. Avoiding tolerance against prostatic
antigens with subdominant peptide epitopes. J Immunother. 2001
May-Jun;24(3):237-41. PubMed PMID: 11394501.


564: Grossmann ME, Davila E, Celis E. Avoiding Tolerance Against Prostatic
Antigens With Subdominant Peptide Epitopes. J Immunother (1991). 2001
May;24(3):237-241. PubMed PMID: 11395639.


565: Grosso JF, Drake CG. Current immunotherapeutic strategies in prostate
cancer. Surg Oncol Clin N Am. 2007 Oct;16(4):861-71, x. Review. PubMed PMID:
18022549.


566: Groth A, Salnikov AV, Ottinger S, Gladkich J, Liu L, Kallifatidis G,
Salnikova O, Ryschich E, Giese N, Giese T, Momburg F, Büchler MW, Moldenhauer G, 
Herr I. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3
Bispecific antibody for tumor targeting. Clin Cancer Res. 2012 Feb
15;18(4):1028-38. doi: 10.1158/1078-0432.CCR-11-2767. Epub 2012 Jan 6. PubMed
PMID: 22228630.


567: Groth C, Fortini ME. Therapeutic approaches to modulating Notch signaling:
current challenges and future prospects. Semin Cell Dev Biol. 2012
Jun;23(4):465-72. doi: 10.1016/j.semcdb.2012.01.016. Epub 2012 Jan 30. Review.
PubMed PMID: 22309842; PubMed Central PMCID: PMC3372654.


568: Groves-Kirkby N. Prostate cancer. Immunotherapy and combined chemotherapy
for castration-resistant and metastatic disease. Nat Rev Urol. 2010 Sep;7(9):472.
doi: 10.1038/nrurol.2010.124. PubMed PMID: 20839381.


569: Grunewald TG, Bach H, Cossarizza A, Matsumoto I. The STEAP protein family:
versatile oxidoreductases and targets for cancer immunotherapy with overlapping
and distinct cellular functions. Biol Cell. 2012 Nov;104(11):641-57. doi:
10.1111/boc.201200027. Epub 2012 Sep 24. PubMed PMID: 22804687.


570: Grupp K, Ospina-Klinck D, Tsourlakis MC, Koop C, Wilczak W, Adam M, Simon R,
Sauter G, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas 
A. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate
cancer. Prostate. 2014 Jul;74(10):1012-22. doi: 10.1002/pros.22816. Epub 2014 May
1. PubMed PMID: 24789172.


571: Gschwend JE, Hautmann RE. [Is gene therapy of advanced prostatic carcinoma
on the verge of clinical application?]. Urologe A. 1998 Mar;37(2):172-4. Review. 
German. PubMed PMID: 9563131.


572: Guinan P, Ray P, Shaw M. Immunotherapy of prostate cancer: a review.
Prostate. 1984;5(2):221-30. Review. PubMed PMID: 6369279.


573: Guinan P, Toronchi E, Shaw M, Crispin R, Sharifi R. Bacillus calmette-guerin
(BCG) adjuvant therapy in stage D prostate cancer. Urology. 1982 Oct;20(4):401-3.
PubMed PMID: 6755855.


574: Guinan P, Crispen R, Baumgartner G, Rao R, Totonchi E, Ablin R, John T.
Adjuvant immunotherapy with bacillus Calmette-Guérin in prostatic cancer.
Urology. 1979 Dec;14(6):561-5. PubMed PMID: 390811.


575: Guinan P, Bush IM, Sadoughi N, Mallick K, Ablin RJ. Immunologic
considerations of carcinoma of the prostate. Prog Exp Tumor Res. 1974;19:353-68. 
Review. PubMed PMID: 4216041.


576: Guinan P, Sadoughi N, Bush IM, John T, Eghrari F, Ablin RJ. Immunology of
genitourinary tumors. Urology. 1973 Nov;2(5):493-9. Review. PubMed PMID: 4131868.


577: Guinan P, Bush IM, John T, Sadoughi N, Ablin RJ. B.C.G. immunotherapy in
carcinoma of prostate. Lancet. 1973 Aug 25;2(7826):443-4. PubMed PMID: 4124919.


578: Guinan PD, John T, Baumgartner G, Sundar B, Ablin RJ. Adjuvant immunotherapy
(BCG) in stage D prostate cancer. Am J Clin Oncol. 1982 Feb;5(1):65-8. PubMed
PMID: 7081139.


579: Guinan PD, John T, Nagale V, Ablin RJ. BCG adjuvant immunotherapy in
carcinoma of the prostate: an interim report. Allergol Immunopathol (Madr). 1978 
Jul-Aug;6(4):293-6. PubMed PMID: 735980.


580: Guinan PD, John T, Sahadevan V, Crispen R, Nagale V, McKiel C, Ablin RJ.
Prostate carcinoma: immunostaging and adjuvant immunotherapy with BCG. Natl
Cancer Inst Monogr. 1978 Dec;(49):355-60. PubMed PMID: 748793.


581: Guinan PD, Ablin RJ, Rios ER, Sheik HA, Bush IM. Immunostaging in carcinoma 
of prostate. Urology. 1976 Feb;7(2):178-80. PubMed PMID: 1108352.


582: Guiter J. [Monoclonal antibodies in urology. Basic theories and clinical
applications]. Ann Urol (Paris). 1985;19(1):7-12. Review. French. PubMed PMID:
3885840.


583: Gulley J, Dahut WL. Chemotherapy for prostate cancer: finally an advance! Am
J Ther. 2004 Jul-Aug;11(4):288-94. Review. PubMed PMID: 15266221.


584: Gulley J, Dahut WL. Novel approaches to treating the asymptomatic
hormone-refractory prostate cancer patient. Urology. 2003 Dec 29;62 Suppl
1:147-54. Review. PubMed PMID: 14747053.


585: Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K,
Panicali D, Poole D, Schlom J, Michael Hamilton J. Phase I study of a vaccine
using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with
metastatic androgen-independent prostate cancer. Prostate. 2002 Oct
1;53(2):109-17. PubMed PMID: 12242725.


586: Gulley JL, Madan RA, Heery CR. Therapeutic vaccines and immunotherapy in
castration-resistant prostate cancer: current progress and clinical applications.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e166. PubMed
PMID: 23714490.


587: Gulley JL, Leitman SF, Dahut W, Schlom J. Re: interdisciplinary critique of 
sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl
Cancer Inst. 2012 Jul 18;104(14):1106; author reply 1109-12. doi:
10.1093/jnci/djs280. PubMed PMID: 22825555.


588: Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances,
lessons learned, and areas for further research. Clin Cancer Res. 2011 Jun
15;17(12):3884-91. doi: 10.1158/1078-0432.CCR-10-2656. Review. PubMed PMID:
21680544; PubMed Central PMCID: PMC3471147.


589: Gulley JL, Dahut WL. Future directions in tumor immunotherapy: CTLA4
blockade. Nat Clin Pract Oncol. 2007 Mar;4(3):136-7. PubMed PMID: 17327854.


590: Gunby P. Rapid research response emphasized in unique prostate cancer
program. JAMA. 1997 Mar 26;277(12):945-8. PubMed PMID: 9091653.


591: Guo C, Yi H, Yu X, Zuo D, Qian J, Yang G, Foster BA, Subjeck JR, Sun X,
Mikkelsen RB, Fisher PB, Wang XY. In situ vaccination with CD204 gene-silenced
dendritic cell, not unmodified dendritic cell, enhances radiation therapy of
prostate cancer. Mol Cancer Ther. 2012 Nov;11(11):2331-41. doi:
10.1158/1535-7163.MCT-12-0164. Epub 2012 Aug 15. PubMed PMID: 22896667; PubMed
Central PMCID: PMC3496075.


592: Guo C, Yi H, Yu X, Hu F, Zuo D, Subjeck JR, Wang XY. Absence of scavenger
receptor A promotes dendritic cell-mediated cross-presentation of cell-associated
antigen and antitumor immune response. Immunol Cell Biol. 2012 Jan;90(1):101-8.
doi: 10.1038/icb.2011.10. Epub 2011 Mar 8. PubMed PMID: 21383767; PubMed Central 
PMCID: PMC3134534.


593: Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH.
HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel
targets for prostate cancer immunotherapy. Scand J Immunol. 2013
Sep;78(3):248-57. doi: 10.1111/sji.12083. PubMed PMID: 23721092.


594: Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, Nitta RT, Wong AJ.
Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol. 2010
Oct 7;10:72. doi: 10.1186/1472-6750-10-72. PubMed PMID: 20925961; PubMed Central 
PMCID: PMC2959087.


595: Gupta S, Carballido E, Fishman M. Sipuleucel-T for therapy of asymptomatic
or minimally symptomatic, castrate-refractory prostate cancer: an update and
perspective among other treatments. Onco Targets Ther. 2011;4:79-96. doi:
10.2147/OTT.S14107. Epub 2011 Jun 29. PubMed PMID: 21792315; PubMed Central
PMCID: PMC3143908.


596: Gururajan M, Posadas EM, Chung LW. Future perspectives of prostate cancer
therapy. Transl Androl Urol. 2012 Jan 3;1(1):19-32. PubMed PMID: 22773967; PubMed
Central PMCID: PMC3389805.


597: Gutschank S, Rothauge CF, Kraushaar J, Gutschank W, Sedlacek KH. [The
metastatic prostate cancer. Effectiveness of a combination of female hormones and
specific immune-stimulating therapy]. MMW Munch Med Wochenschr. 1981 Jan
23;123(4):133-4. German. PubMed PMID: 6261127.


598: Haas GP, Solomon D, Rosenberg SA. Tumor-infiltrating lymphocytes from
nonrenal urological malignancies. Cancer Immunol Immunother. 1990;30(6):342-50.
PubMed PMID: 2105845.


599: Hadaschik B, Su Y, Huter E, Ge Y, Hohenfellner M, Beckhove P. Antigen
specific T-cell responses against tumor antigens are controlled by regulatory T
cells in patients with prostate cancer. J Urol. 2012 Apr;187(4):1458-65. doi:
10.1016/j.juro.2011.11.083. Epub 2012 Feb 16. PubMed PMID: 22341271.


600: Hadaschik BA, Zhang K, So AI, Bell JC, Thüroff JW, Rennie PS, Gleave ME.
[Oncolytic vesicular stomatitis viruses as intravesical agents against
non-muscle-invasive bladder cancer]. Urologe A. 2008 Sep;47(9):1145-51. doi:
10.1007/s00120-008-1827-x. German. PubMed PMID: 18670747.


601: Haddad H, Garcia JA. Novel agents for the management of castration-resistant
prostate cancer. Curr Opin Urol. 2012 May;22(3):175-82. doi:
10.1097/MOU.0b013e3283523ba0. Review. PubMed PMID: 22472509.


602: Haga K, Tomioka A, Liao CP, Kimura T, Matsumoto H, Ohno I, Hermann K, Logg
CR, Jiao J, Tanaka M, Hirao Y, Wu H, Kruse CA, Roy-Burman P, Kasahara N. PTEN
knockout prostate cancer as a model for experimental immunotherapy. J Urol. 2009 
Jan;181(1):354-62. doi: 10.1016/j.juro.2008.08.124. Epub 2008 Nov 17. PubMed
PMID: 19010487; PubMed Central PMCID: PMC2838731.


603: Hakimi R. [Treatment of a questionable prostate carcinoma recurrence with
oncolytic viruses, dendritic cells and heat shock proteins in established
naturopathy practice]. Versicherungsmedizin. 2012 Jun 1;64(2):87-8. German.
PubMed PMID: 22808649.


604: Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free
survival as a predictor of overall survival in men with castrate-resistant
prostate cancer. J Clin Oncol. 2009 Jun 10;27(17):2766-71. doi:
10.1200/JCO.2008.18.9159. Epub 2009 Apr 20. PubMed PMID: 19380448; PubMed Central
PMCID: PMC2698015.


605: Halder S, Hardie DL, Scheel-Toellner D, Salmon M, Buckley CD. Generation and
characterization of novel stromal specific antibodies. Cell Res. 2005
Sep;15(9):739-44. PubMed PMID: 16212881; PubMed Central PMCID: PMC3119635.


606: Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. 
Integrated safety data from 4 randomized, double-blind, controlled trials of
autologous cellular immunotherapy with sipuleucel-T in patients with prostate
cancer. J Urol. 2011 Sep;186(3):877-81. doi: 10.1016/j.juro.2011.04.070. Epub
2011 Jul 23. PubMed PMID: 21788048.


607: Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy:
sipuleucel-T and beyond. Pharmacotherapy. 2011 Aug;31(8):813-28. doi:
10.1592/phco.31.8.813. Review. PubMed PMID: 21923608; PubMed Central PMCID:
PMC4159742.


608: Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC.
Identification of fibroblast growth factor-5 as an overexpressed antigen in
multiple human adenocarcinomas. Cancer Res. 2001 Jul 15;61(14):5511-6. PubMed
PMID: 11454700.


609: Hanahan D, Lanzavecchia A, Mihich E. Fourteenth Annual Pezcoller Symposium: 
the novel dichotomy of immune interactions with tumors. Cancer Res. 2003 Jun
1;63(11):3005-8. PubMed PMID: 12782611.


610: Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman
J, Guha C. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine
and radiation therapy leads to a therapeutic response in a murine model of
prostate cancer. Cancer Immunol Immunother. 2012 Dec;61(12):2227-38. doi:
10.1007/s00262-012-1257-x. Epub 2012 May 27. PubMed PMID: 22644735.


611: Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y. CD147/EMMPRIN and CD44 are
potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug
Targets. 2010 May;10(3):287-306. Review. PubMed PMID: 20370680.


612: Harada M, Matsueda S, Yao A, Noguchi M, Itoh K. Vaccination of cytotoxic T
lymphocyte-directed peptides elicited and spread humoral and Th1-type immune
responses to prostate-specific antigen protein in a prostate cancer patient. J
Immunother. 2005 Jul-Aug;28(4):368-75. PubMed PMID: 16000955.


613: Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Prostate-related
antigen-derived new peptides having the capacity of inducing prostate
cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncol Rep. 2004
Sep;12(3):601-7. PubMed PMID: 15289844.


614: Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K.
Prostate-specific antigen-derived epitopes capable of inducing cellular and
humoral responses in HLA-A24+ prostate cancer patients. Prostate. 2003 Oct
1;57(2):152-9. PubMed PMID: 12949939.


615: Harada M, Noguchi M, Itoh K. Target molecules in specific immunotherapy
against prostate cancer. Int J Clin Oncol. 2003 Aug;8(4):193-9. Review. PubMed
PMID: 12955573.


616: Hardy B, Raiter A, Rubin M, Sprecher E, Sella A, Flex D, Lelcuk S, Bsharah
B, Mishaeli M, Niv Y. Cancer disease predictive diagnosis: BAT/CD3-positive
lymphocytes in cancer patients. Int J Oncol. 2005 Apr;26(4):971-5. PubMed PMID:
15753991.


617: Harrington JA, Jones RJ. Management of metastatic castration-resistant
prostate cancer after first-line docetaxel. Eur J Cancer. 2011
Sep;47(14):2133-42. doi: 10.1016/j.ejca.2011.04.036. Epub 2011 Jun 12. Review.
PubMed PMID: 21658937.


618: Harris DT, Matyas GR, Gomella LG, Talor E, Winship MD, Spitler LE,
Mastrangelo MJ. Immunologic approaches to the treatment of prostate cancer. Semin
Oncol. 1999 Aug;26(4):439-47. Review. PubMed PMID: 10482186.


619: Harris KA, Reese DM. Treatment options in hormone-refractory prostate
cancer: current and future approaches. Drugs. 2001;61(15):2177-92. Review. PubMed
PMID: 11772129.


620: Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, Getnet D,
Bruno TC, Goldberg MV, Pardoll DM, DeWeese TL, Drake CG. Radiotherapy augments
the immune response to prostate cancer in a time-dependent manner. Prostate. 2008
Sep 1;68(12):1319-29. doi: 10.1002/pros.20794. PubMed PMID: 18561247; PubMed
Central PMCID: PMC2710770.


621: Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, Kaufman
HL, de Belin J, Kelleher M, Goonewardena M, Naylor S. MVA-5T4-induced immune
responses are an early marker of efficacy in renal cancer patients. Cancer
Immunol Immunother. 2011 Jun;60(6):829-37. doi: 10.1007/s00262-011-0993-7. Epub
2011 Mar 9. PubMed PMID: 21387109.


622: Harrop R, Shingler W, Kelleher M, de Belin J, Treasure P. Cross-trial
analysis of immunologic and clinical data resulting from phase I and II trials of
MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J
Immunother. 2010 Nov-Dec;33(9):999-1005. doi: 10.1097/CJI.0b013e3181f5dac7.
PubMed PMID: 20948436.


623: Harrop R, Carroll MW. Viral vectors for cancer immunotherapy. Front Biosci. 
2006 Jan 1;11:804-17. Review. PubMed PMID: 16146772.


624: Harzstark AL, Small EJ. Castrate-resistant prostate cancer: therapeutic
strategies. Expert Opin Pharmacother. 2010 Apr;11(6):937-45. doi:
10.1517/14656561003677382. Review. PubMed PMID: 20307219.


625: Harzstark AL, Small EJ. Immunotherapeutics in development for prostate
cancer. Oncologist. 2009 Apr;14(4):391-8. doi: 10.1634/theoncologist.2008-0240.
Epub 2009 Apr 2. Review. PubMed PMID: 19342474.


626: Harzstark AL, Ryan CJ. Therapies in development for castrate-resistant
prostate cancer. Expert Rev Anticancer Ther. 2008 Feb;8(2):259-68. doi:
10.1586/14737140.8.2.259. Review. PubMed PMID: 18279066.


627: Harzstark AL, Small EJ. Immunotherapy for prostate cancer using
antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol
Ther. 2007 Aug;7(8):1275-80. Review. PubMed PMID: 17696825.


628: Hassan W, Sanford MA, Woo SL, Chen SH, Hall SJ. Prospects for
herpes-simplex-virus thymidine-kinase and cytokine gene transduction as
immunomodulatory gene therapy for prostate cancer. World J Urol. 2000
Apr;18(2):130-5. Review. PubMed PMID: 10854148.


629: Hautmann S, Huland E, Huland H. Intratumoral depot interleukin-2 therapy
inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted
subcutaneously in rats. J Cancer Res Clin Oncol. 1997;123(11-12):614-8. PubMed
PMID: 9620219.


630: Hautmann SH, Huland E, Huland H. Local intratumor immunotherapy of prostate 
cancer with interleukin-2 reduces tumor growth. Anticancer Res. 1999
Jul-Aug;19(4A):2661-3. PubMed PMID: 10470215.


631: Havranek EG, Whelan MA, Greenhalgh R, Dalgleish AG, Pandha H. Advances in
prostate cancer immunotherapy. Surg Oncol. 2002 Jun;11(1-2):35-45. Review. PubMed
PMID: 12031866.


632: Hay RV, Cao B, Skinner RS, Su Y, Zhao P, Gustafson MF, Qian CN, Teh BT,
Knudsen BS, Resau JH, Shen S, Waters DJ, Gross MD, Vande Woude GF. Nuclear
imaging of Met-expressing human and canine cancer xenografts with radiolabeled
monoclonal antibodies (MetSeek). Clin Cancer Res. 2005 Oct 1;11(19 Pt
2):7064s-7069s. PubMed PMID: 16203803.


633: Hayakawa M, Marumo K, Nagakura K, Hata M, Fujioka T, Nakamura H, Murai M.
[Studies on human natural killer (NK) cell activity against cell lines derived
from malignant urinary tract tumors. Part 3: Effects of OK432 on human NK cell
activity and proliferation of tumor cells]. Nihon Hinyokika Gakkai Zasshi. 1984
Jul;75(7):1124-33. Japanese. PubMed PMID: 6542157.


634: Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M,
Celis E, Kobayashi H. Six-transmembrane epithelial antigen of the prostate and
enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J
Transl Med. 2011 Nov 5;9:191. doi: 10.1186/1479-5876-9-191. PubMed PMID:
22053850; PubMed Central PMCID: PMC3219573.


635: Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, Bolton 
WE. Impaired expression and function of signal-transducing zeta chains in
peripheral T cells and natural killer cells in patients with prostate cancer.
Cytometry. 1998 Jun 1;32(2):109-19. PubMed PMID: 9627224.


636: Heath EI, Carducci MA. New targets in the management of prostate cancer.
Hematol Oncol Clin North Am. 2006 Aug;20(4):985-99, xi. Review. PubMed PMID:
16861127.


637: Hechter O. Susceptibility of the prostate cancer cell to different physical,
hormonal, and chemical agents: present status and theoretical prospects for
improved prostate cancer therapy. Prostate. 1984;5(2):159-80. PubMed PMID:
6709520.


638: Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell
immunotherapies: of mice and men. Int Rev Immunol. 2006 Sep-Dec;25(5-6):321-52.
Review. PubMed PMID: 17169779.


639: Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, 
Horninger W, Klocker H. Novel therapeutic approaches for the treatment of
castration-resistant prostate cancer. J Steroid Biochem Mol Biol. 2013
Nov;138:248-56. doi: 10.1016/j.jsbmb.2013.06.002. Epub 2013 Jun 20. Review.
PubMed PMID: 23792785; PubMed Central PMCID: PMC3834152.


640: Heidenreich A. [Immunotherapy for metastatic prostate cancer: do we really
need this?]. Urologe A. 2012 Jan;51(1):32-8. doi: 10.1007/s00120-011-2740-2.
German. PubMed PMID: 22258374.


641: Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to
make it standard of care for glioblastoma? Neuro Oncol. 2011 Jan;13(1):3-13. doi:
10.1093/neuonc/noq169. Epub 2010 Dec 10. Review. PubMed PMID: 21149252; PubMed
Central PMCID: PMC3018912.


642: Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, 
Glinsky VV, Rittenhouse-Olson K. Inhibition of spontaneous breast cancer
metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11.
Neoplasia. 2006 Nov;8(11):939-48. PubMed PMID: 17132226; PubMed Central PMCID:
PMC1716011.


643: Heinemann V, Moosmann N. [Neoadjuvant and adjuvant therapies for solid
tumours]. MMW Fortschr Med. 2007 Sep 6;149(35-36):27-30. Review. German. PubMed
PMID: 17944281.


644: Heinrich JE, Pollard M, Wolter WA, Liang Z, Song H, Rosen ED, Suckow MA.
Vaccination against prostate cancer using a live tissue factor deficient cell
line in Lobund-Wistar rats. Cancer Immunol Immunother. 2007 May;56(5):725-30.
Epub 2006 Sep 5. PubMed PMID: 16953436.


645: Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P,
Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with
prostate-specific antigen RNA stimulate CTL responses against metastatic prostate
tumors. J Clin Invest. 2002 Feb;109(3):409-17. PubMed PMID: 11828001; PubMed
Central PMCID: PMC150859.


646: Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H,
Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, Kiessling R,
Masucci GV. The common Scandinavian human leucocyte antigen ancestral haplotype
62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer
Immunol Immunother. 2009 Oct;58(10):1599-608. doi: 10.1007/s00262-009-0669-8.
Epub 2009 Feb 13. PubMed PMID: 19214504.


647: Hellman M, Tossavainen H, Rappu P, Heino J, Permi P. Characterization of
intrinsically disordered prostate associated gene (PAGE5) at single residue
resolution by NMR spectroscopy. PLoS One. 2011;6(11):e26633. doi:
10.1371/journal.pone.0026633. Epub 2011 Nov 2. PubMed PMID: 22073178; PubMed
Central PMCID: PMC3206799.


648: Hemstreet GP 3rd, Rossi GR, Pisarev VM, Enke CA, Helfner L, Hauke RJ,
Tennant L, Ramsey WJ, Vahanian NN, Link CJ. Cellular immunotherapy study of
prostate cancer patients and resulting IgG responses to peptide epitopes
predicted from prostate tumor-associated autoantigens. J Immunother. 2013
Jan;36(1):57-65. doi: 10.1097/CJI.0b013e3182780abc. PubMed PMID: 23211622.


649: Henry CJ, Buss MS, Hellström I, Hellström KE, Brewer WG, Bryan JN, Siegall
CB. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of 
spontaneously occurring invasive carcinoma. Clin Cancer Res. 2005 Jan 15;11(2 Pt 
1):751-5. PubMed PMID: 15701865.


650: Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen
P, Zanetti M. Identification of a human telomerase reverse transcriptase peptide 
of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates
lysis of tumor cells. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12275-80. Epub
2002 Sep 6. PubMed PMID: 12218171; PubMed Central PMCID: PMC129435.


651: Hernando JJ, Park TW, Kuhn WC. Dendritic cell-based vaccines in breast and
gynaecologic cancer. Anticancer Res. 2003 Sep-Oct;23(5b):4293-303. Review. PubMed
PMID: 14666641.


652: Hernando JJ, Park TW, Kübler K, Offergeld R, Schlebusch H, Bauknecht T.
Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced
gynaecological malignancies: clinical and immunological evaluation of a phase I
trial. Cancer Immunol Immunother. 2002 Mar;51(1):45-52. Epub 2002 Jan 10. PubMed 
PMID: 11845259.


653: Herr HW. Strategies for the management of recurrent and advanced urologic
cancers. Quality of life. Cancer. 1987 Aug 1;60(3 Suppl):623-30. PubMed PMID:
3297289.


654: Herr HW. Suppressor cells in immunodepressed bladder and prostate cancer
patients. J Urol. 1980 May;123(5):635-9. PubMed PMID: 6448304.


655: Herrero JI. De novo malignancies following liver transplantation: impact and
recommendations. Liver Transpl. 2009 Nov;15 Suppl 2:S90-4. doi: 10.1002/lt.21898.
PubMed PMID: 19877025.


656: Hess Michelini R, Freschi M, Manzo T, Jachetti E, Degl'Innocenti E, Grioni
M, Basso V, Bonini C, Simpson E, Mondino A, Bellone M. Concomitant tumor and
minor histocompatibility antigen-specific immunity initiate rejection and
maintain remission from established spontaneous solid tumors. Cancer Res. 2010
May 1;70(9):3505-14. doi: 10.1158/0008-5472.CAN-09-4253. Epub 2010 Apr 13. PubMed
PMID: 20388780.


657: Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs
encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating 
factor efficiently primes CTL responses, but is insufficient to overcome
tolerance to a model tumor/self antigen. Cancer Immunol Immunother. 2006
Jun;55(6):672-83. Epub 2005 Aug 20. PubMed PMID: 16133108.


658: Higano CS. New developments in the treatment of castration-resistant
prostate cancer. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):773-6. PubMed PMID:
24853214.


659: Higano CS. Potential use of custirsen to treat prostate cancer. Onco Targets
Ther. 2013 Jun 25;6:785-97. doi: 10.2147/OTT.S33077. Print 2013. PubMed PMID:
23836992; PubMed Central PMCID: PMC3699352.


660: Higano CS, Crawford ED. New and emerging agents for the treatment of
castration-resistant prostate cancer. Urol Oncol. 2011 Nov-Dec;29(6 Suppl):S1-8. 
doi: 10.1016/j.urolonc.2011.08.013. Review. PubMed PMID: 22074657.


661: Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P,
Kantoff PW. Sipuleucel-T. Nat Rev Drug Discov. 2010 Jul;9(7):513-4. doi:
10.1038/nrd3220. PubMed PMID: 20592741.


662: Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost
N, Frohlich MW. Integrated data from 2 randomized, double-blind,
placebo-controlled, phase 3 trials of active cellular immunotherapy with
sipuleucel-T in advanced prostate cancer. Cancer. 2009 Aug 15;115(16):3670-9.
doi: 10.1002/cncr.24429. PubMed PMID: 19536890.


663: Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons 
JW, Sacks N, Aimi J, Small EJ. Phase 1/2 dose-escalation study of a
GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic
hormone-refractory prostate cancer. Cancer. 2008 Sep 1;113(5):975-84. doi:
10.1002/cncr.23669. PubMed PMID: 18646045.


664: Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. Safety and
biological activity of repeated doses of recombinant human Flt3 ligand in
patients with bone scan-negative hormone-refractory prostate cancer. Clin Cancer 
Res. 2004 Feb 15;10(4):1219-25. PubMed PMID: 14977818.


665: Higham EM, Shen CH, Wittrup KD, Chen J. Cutting edge: delay and reversal of 
T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in
an autochthonous tumor model. J Immunol. 2010 Jun 1;184(11):5954-8. doi:
10.4049/jimmunol.1000265. Epub 2010 Apr 28. PubMed PMID: 20427765; PubMed Central
PMCID: PMC3061230.


666: Higham EM, Wittrup KD, Chen J. Activation of tolerogenic dendritic cells in 
the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand.
J Immunol. 2010 Apr 1;184(7):3394-400. doi: 10.4049/jimmunol.0903111. Epub 2010
Mar 3. PubMed PMID: 20200275; PubMed Central PMCID: PMC2843821.


667: Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G,
Giesler JM, Jüttner E, Peters JH, Häring B, Leo R, Unger C, Azemar M.
Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated 
with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic
cells--a pilot study. Prostate. 2007 Apr 1;67(5):500-8. PubMed PMID: 17262804.


668: Hill RE, de Avila DM, Bertrand KP, Greenberg NM, Reeves JJ. Immunization
against luteinizing hormone-releasing hormone fusion proteins does not decrease
prostate cancer in the transgenic adenocarcinoma mouse prostate model. Exp Biol
Med (Maywood). 2003 Jul;228(7):818-22. PubMed PMID: 12876301.


669: Hillerdal V, Ramachandran M, Leja J, Essand M. Systemic treatment with
CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs
survival of mice. BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.
PubMed PMID: 24438073; PubMed Central PMCID: PMC3899402.


670: Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M. T cells engineered
with a T cell receptor against the prostate antigen TARP specifically kill
HLA-A2+ prostate and breast cancer cells. Proc Natl Acad Sci U S A. 2012 Sep
25;109(39):15877-81. Epub 2012 Sep 10. PubMed PMID: 23019373; PubMed Central
PMCID: PMC3465394.


671: Hillman GG, Kallinteris NL, Lu X, Wang Y, Wright JL, Li Y, Wu S, Forman JD, 
Gulfo JV, Humphreys RE, Xu M. Turning tumor cells in situ into T-helper
cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and
immuno-consolidation. Cancer Treat Rev. 2004 May;30(3):281-90. Review. PubMed
PMID: 15059651.


672: Hillman GG, Triest JA, Cher ML, Kocheril SV, Talati BR. Prospects of
immunotherapy for the treatment of prostate carcinoma--a review. Cancer Detect
Prev. 1999;23(4):333-42. Review. PubMed PMID: 10403905.


673: Hirohashi Y, Sato N. Tumor-associated dendritic cells: molecular mechanisms 
to suppress antitumor immunity. Immunotherapy. 2011 Aug;3(8):945-7. doi:
10.2217/imt.11.94. PubMed PMID: 21843082.


674: Hoag N, Pommerville PJ, Kibsey PC, Cavers DJ, Eddy RJ. Tuberculous
epididymitis following intravesical Bacillus Calmette-Guérin immunotherapy. Can J
Urol. 2009 Apr;16(2):4589-91. PubMed PMID: 19364433.


675: Hoda MR, Hamza A, Greco F, Wagner S, Reichelt O, Heynemann H, Fischer K,
Fornara P. Management of localized prostate cancer by retropubic radical
prostatectomy in patients after renal transplantation. Nephrol Dial Transplant.
2010 Oct;25(10):3416-20. doi: 10.1093/ndt/gfq193. Epub 2010 Apr 12. PubMed PMID: 
20388632.


676: Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. 
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by
cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J
Cancer. 2013 Aug 1;133(3):624-36. doi: 10.1002/ijc.28070. Epub 2013 Mar 16.
PubMed PMID: 23364915; PubMed Central PMCID: PMC3663913.


677: Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz
L, Panicali D, Kantor JA. A recombinant vaccinia virus expressing human
prostate-specific antigen (PSA): safety and immunogenicity in a non-human
primate. Int J Cancer. 1995 Oct 9;63(2):231-7. PubMed PMID: 7591210.


678: Hodges CV, Pearse HD, Stille L. Radical prostatectomy for carcinoma: 30-year
experience and 15-year survivals. J Urol. 1979 Aug;122(2):180-2. PubMed PMID:
459011.


679: Hoffman RM. Orthotopic metastatic (MetaMouse) models for discovery and
development of novel chemotherapy. Methods Mol Med. 2005;111:297-322. PubMed
PMID: 15911987.


680: Hohenfellner M. [Prostate cancer: an update]. Urologe A. 2010 Sep;49 Suppl
1:169-71. doi: 10.1007/s00120-010-2376-7. Review. German. PubMed PMID: 20812046.


681: Holko P, Kawalec P. Economic evaluation of sipuleucel-T immunotherapy in
castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2014
Jan;14(1):63-73. doi: 10.1586/14737140.2014.856270. Review. PubMed PMID:
24224852.


682: Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic
use. Expert Opin Investig Drugs. 2001 Mar;10(3):511-9. Review. PubMed PMID:
11227049.


683: Honma I, Torigoe T, Hirohashi Y, Kitamura H, Sato E, Masumori N, Tamura Y,
Tsukamoto T, Sato N. Aberrant expression and potency as a cancer immunotherapy
target of alpha-methylacyl-coenzyme A racemase in prostate cancer. J Transl Med. 
2009 Dec 9;7:103. doi: 10.1186/1479-5876-7-103. PubMed PMID: 20003233; PubMed
Central PMCID: PMC2797764.


684: Hood BL, Malehorn DE, Conrads TP, Bigbee WL. Serum proteomics using mass
spectrometry. Methods Mol Biol. 2009;520:107-28. doi:
10.1007/978-1-60327-811-9_8. PubMed PMID: 19381950.


685: Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana
M, Takesako K, Murai M. Screening of HLA-A24-restricted epitope peptides from
prostate-specific membrane antigen that induce specific antitumor cytotoxic T
lymphocytes. Clin Cancer Res. 2002 Dec;8(12):3885-92. PubMed PMID: 12473604.


686: Horne CH, McLay AL, Tavadia HB, Carmichael I, Mallinson AC, Laiwah AA,
Thomas MA, MacSween RN. Studies on pregnancy-associated globulin. Clin Exp
Immunol. 1973 Apr;13(4):603-11. PubMed PMID: 4123823; PubMed Central PMCID:
PMC1553736.


687: Hou LH, Du Y, Zhang XP, An XP, Chen W. [Expression of prostate stem cell
antigen (PSCA) and selection of its specific binding peptide]. Sheng Wu Gong
Cheng Xue Bao. 2004 Sep;20(5):694-8. Chinese. PubMed PMID: 15973992.


688: Houston SJ, Rubens RD. The systemic treatment of bone metastases. Clin
Orthop Relat Res. 1995 Mar;(312):95-104. Review. PubMed PMID: 7543393.


689: Hrouda D, Todryk SM, Perry MJ, Souberbielle BE, Kayaga J, Kirby RS,
Dalgleish AG. Allogeneic whole-tumour cell vaccination in the rat model of
prostate cancer. BJU Int. 2000 Oct;86(6):742-8. PubMed PMID: 11069388.


690: Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of
advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172).
Br J Urol. 1998 Oct;82(4):568-73. PubMed PMID: 9806190.


691: Hrouda D, Muir GH, Dalgleish AG. The role of immunotherapy for urological
tumours. Br J Urol. 1997 Mar;79(3):307-16. Review. PubMed PMID: 9117206.


692: Hrubá E, Vondráček J, Líbalová H, Topinka J, Bryja V, Souček K, Machala M.
Gene expression changes in human prostate carcinoma cells exposed to genotoxic
and nongenotoxic aryl hydrocarbon receptor ligands. Toxicol Lett. 2011 Oct
10;206(2):178-88. doi: 10.1016/j.toxlet.2011.07.011. Epub 2011 Jul 23. PubMed
PMID: 21802500.


693: Hsieh CL, Chung LW. New prospectives of prostate cancer gene therapy:
molecular targets and animal models. Crit Rev Eukaryot Gene Expr.
2001;11(1-3):77-120. Review. PubMed PMID: 11693967.


694: Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX. PIM-1-specific mAb 
suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt 
phosphorylation, and activating apoptosis. J Clin Invest. 2009 Feb;119(2):362-75.
doi: 10.1172/JCI33216. Epub 2009 Jan 19. PubMed PMID: 19147983; PubMed Central
PMCID: PMC2631288.


695: Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells
and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl 
Acad Sci U S A. 2001 Oct 9;98(21):12180-5. Epub 2001 Oct 2. PubMed PMID:
11593034; PubMed Central PMCID: PMC59788.


696: Huang HY. [Role of TROP2 in cancer and as potential therapeutic target].
Zhonghua Bing Li Xue Za Zhi. 2013 Dec;42(12):860-3. Review. Chinese. PubMed PMID:
24507116.


697: Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW,
Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. Soluble CD27-pool in
humans may contribute to T cell activation and tumor immunity. J Immunol. 2013
Jun 15;190(12):6250-8. doi: 10.4049/jimmunol.1300022. Epub 2013 May 15. PubMed
PMID: 23677477; PubMed Central PMCID: PMC4084782.


698: Huang X, Raskovalova T, Lokshin A, Krasinskas A, Devlin J, Watkins S, Wolf
SF, Gorelik E. Combined antiangiogenic and immune therapy of prostate cancer.
Angiogenesis. 2005;8(1):13-23. PubMed PMID: 16132614.


699: Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso
M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG,
Fukumura D, Jain RK, Poznansky MC. Vascular normalizing doses of antiangiogenic
treatment reprogram the immunosuppressive tumor microenvironment and enhance
immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. doi:
10.1073/pnas.1215397109. Epub 2012 Oct 8. PubMed PMID: 23045683; PubMed Central
PMCID: PMC3491458.


700: Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of
sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl
Cancer Inst. 2012 Feb 22;104(4):273-9. doi: 10.1093/jnci/djr514. Epub 2012 Jan 9.
PubMed PMID: 22232132; PubMed Central PMCID: PMC3283534.


701: Humphreys RE, Hillman GG, von Hofe E, Xu M. Forcing tumor cells to present
their own tumor antigens to the immune system: a necessary design for an
efficient tumor immunotherapy. Cell Mol Immunol. 2004 Jun;1(3):180-5. Review.
PubMed PMID: 16219165.


702: Huo W, Ye J, Liu R, Chen J, Li Q. Vaccination with a chaperone complex based
on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor
growth in mice. Vaccine. 2010 Aug 31;28(38):6333-7. doi:
10.1016/j.vaccine.2010.06.093. Epub 2010 Jul 14. PubMed PMID: 20637304.


703: Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer:
advances in immunotherapy. BioDrugs. 2003;17(2):131-8. Review. PubMed PMID:
12641491.


704: Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB,
Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic 
mouse model using CTLA-4 blockade. Cancer Res. 2000 May 1;60(9):2444-8. PubMed
PMID: 10811122.


705: Hurwitz M, Petrylak DP. Sequencing of agents for castration-resistant
prostate cancer. Oncology (Williston Park). 2013 Nov;27(11):1144-9, 1154-8.
Review. PubMed PMID: 24575543.


706: Huus JC, Kursh ED, Poor P, Persky L. Delayed cutaneous hypersensitivity in
patients with prostatic adenocarcinoma. J Urol. 1975 Jul;114(1):86-7. PubMed
PMID: 1142506.


707: Hwang C, Sanda MG. Prospects and limitations of recombinant poxviruses for
prostate cancer immunotherapy. Curr Opin Mol Ther. 1999 Aug;1(4):471-9. Review.
PubMed PMID: 11713762.


708: Hwang EC, Lim MS, Im CM, Kwon DD, Lee HJ, Nguyen-Pham TN, Lee YK, Lee JJ.
Generation of potent cytotoxic T lymphocytes against castration-resistant
prostate cancer cells by dendritic cells loaded with dying allogeneic prostate
cancer cells. Scand J Immunol. 2013 Feb;77(2):117-24. doi: 10.1111/sji.12007.
PubMed PMID: 23126536.


709: Hwang LC, Fein S, Levitsky H, Nelson WG. Prostate cancer vaccines: current
status. Semin Oncol. 1999 Apr;26(2):192-201. Review. PubMed PMID: 10597730.


710: Hörig H, Lee CS, Kaufman HL. Prostate-specific antigen vaccines for prostate
cancer. Expert Opin Biol Ther. 2002 Apr;2(4):395-408. Review. PubMed PMID:
11955277.


711: Ibrahiem EH, Nigam VN, Brailovsky CA, Backman BD, Elhilali MM. Combined
cyclophosphamide chemotherapy and maltose tetrapalmitate immunotherapy in the
treatment of transplanted bladder and prostate carcinoma of the rat. Cancer Res. 
1984 Feb;44(2):536-42. PubMed PMID: 6537897.


712: Ikeda K. [Experimental study of the effects of hormonal therapy and
intralesional injections of interleukin 2, activated macrophages on mouse
prostate cancer models]. Nihon Ika Daigaku Zasshi. 1994 Aug;61(4):278-85.
Japanese. PubMed PMID: 8083332.


713: Imai M, Ohta R, Varela JC, Song H, Tomlinson S. Enhancement of
antibody-dependent mechanisms of tumor cell lysis by a targeted activator of
complement. Cancer Res. 2007 Oct 1;67(19):9535-41. PubMed PMID: 17909064.


714: Imai M, Hwang HY, Norris JS, Tomlinson S. The effect of dexamethasone on
human mucin 1 expression and antibody-dependent complement sensitivity in a
prostate cancer cell line in vitro and in vivo. Immunology. 2004
Mar;111(3):291-7. PubMed PMID: 15009429; PubMed Central PMCID: PMC1782423.


715: Ingram M, Bishai MB, Techy GB, Narayan KS, Saroufeem R, Yazan O, Marshall
CE. Lymphocytic infiltration of bladder after local cellular immunotherapy.
Cytotherapy. 2000;2(4):297-301. PubMed PMID: 12042039.


716: Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y,
Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the
bladder and BCG-induced granulomata: associations with localized stage
progression. Cancer. 2007 Apr 15;109(8):1499-505. PubMed PMID: 17340590.


717: Inoue Y, Takaue Y, Takei M, Kato K, Kanai S, Harada Y, Tobisu K, Noguchi M, 
Kakizoe T, Itoh K, Wakasugi H. Induction of tumor specific cytotoxic T
lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402
binding peptide. J Urol. 2001 Oct;166(4):1508-13. Erratum in: J Urol 2002
May;167(5):2146. PubMed PMID: 11547122.


718: Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, Sakamoto N. Clinical
experience of integrative cancer immunotherapy with GcMAF. Anticancer Res. 2013
Jul;33(7):2917-9. PubMed PMID: 23780980.


719: Itoh K, Takahashi R, Yoshitomi M, Terasaki M, Noguchi M. [Personalized
peptide vaccination]. Nihon Rinsho. 2012 Dec;70(12):2118-23. Review. Japanese.
PubMed PMID: 23259383.


720: Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada 
M. New peptides of the polycomb group protein enhancer of zeste homolog 2 with
the potential to induce cancer-reactive cytotoxic T lymphocytes in human
leukocyte antigen-A2+ prostate cancer patients. Oncol Rep. 2007 Nov;18(5):1231-7.
PubMed PMID: 17914578.


721: Iversen TZ, Andersen MH, Svane IM. The Targeting of Indoleamine 2,3
Dioxygenase -Mediated Immune Escape in Cancer. Basic Clin Pharmacol Toxicol. 2014
Sep 10. doi: 10.1111/bcpt.12320. [Epub ahead of print] PubMed PMID: 25207460.


722: Ivshina AV, Zhumagazin ZhD, Zabotina TN, Matveev BP, Kadagidze ZG. [Effect
of the spread of the process and treatment on the phenotype of peripheral blood
lymphocytes in patients with prostatic cancer]. Urol Nefrol (Mosk). 1995
Nov-Dec;(6):36-8. Russian. PubMed PMID: 8686123.


723: Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P.
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration 
of CTLA-4 blocking antibody. Sci Transl Med. 2014 Apr 2;6(230):230ra45. doi:
10.1126/scitranslmed.3008002. PubMed PMID: 24695685.


724: Jackson CM, Lim M, Drake CG. Immunotherapy for brain cancer: recent progress
and future promise. Clin Cancer Res. 2014 Jul 15;20(14):3651-9. doi:
10.1158/1078-0432.CCR-13-2057. Epub 2014 Apr 25. PubMed PMID: 24771646.


725: Jacobs JJ, Snackey C, Geldof AA, Characiejus D, Van Moorselaar RJ, Den Otter
W. Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of 
prostate cancer. Anticancer Res. 2014 Jun;34(6):2689-700. Review. PubMed PMID:
24922629.


726: Jacobs SC, McLaughlin AP 3rd, Gittes RF. Effects of immunosuppression on the
rejection of methylcholanthrene tumor isografts. J Surg Oncol. 1977;9(4):353-7.
PubMed PMID: 895157.


727: Jadus MR, Natividad J, Mai A, Ouyang Y, Lambrecht N, Szabo S, Ge L, Hoa N,
Dacosta-Iyer MG. Lung cancer: a classic example of tumor escape and progression
while providing opportunities for immunological intervention. Clin Dev Immunol.
2012;2012:160724. doi: 10.1155/2012/160724. Epub 2012 Jul 29. Review. PubMed
PMID: 22899945; PubMed Central PMCID: PMC3414063.


728: Jadvar H, Quinn DI. Targeted α-particle therapy of bone metastases in
prostate cancer. Clin Nucl Med. 2013 Dec;38(12):966-71. doi:
10.1097/RLU.0000000000000290. Review. PubMed PMID: 24212441; PubMed Central
PMCID: PMC3874447.


729: Jalali SA, Parmiani G. Pre-clinical and clinical aspects of peptide-based
vaccine against human solid tumors. Recent Pat Biotechnol. 2011 Aug;5(2):108-17. 
PubMed PMID: 21707528.


730: Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer 
research. Curr Opin Urol. 2002 Sep;12(5):401-6. Review. PubMed PMID: 12172427.


731: Jankun J. Protein-based nanotechnology: antibody conjugated with
photosensitizer in targeted anticancer photoimmunotherapy. Int J Oncol. 2011
Oct;39(4):949-53. doi: 10.3892/ijo.2011.1110. Epub 2011 Jul 1. PubMed PMID:
21725592.


732: Jarosz M, Szala S. [Endoglin as a target of antitumor therapy]. Postepy Hig 
Med Dosw (Online). 2013 Feb 19;67:79-89. Review. Polish. PubMed PMID: 23475485.


733: Javadpour N. Immunologic features of genitourinary cancer. Urology. 1973
Aug;2(2):103-8. Review. PubMed PMID: 4129366.


734: Jeet V, Russell PJ, Khatri A. Modeling prostate cancer: a perspective on
transgenic mouse models. Cancer Metastasis Rev. 2010 Mar;29(1):123-42. doi:
10.1007/s10555-010-9212-9. Review. PubMed PMID: 20143131.


735: Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR.
Repertoire enhancement with adoptively transferred female lymphocytes controls
the growth of pre-implanted murine prostate cancer. PLoS One. 2012;7(4):e35222.
doi: 10.1371/journal.pone.0035222. Epub 2012 Apr 6. PubMed PMID: 22493742; PubMed
Central PMCID: PMC3320876.


736: Jiang ZK, Johnson M, Moughon DL, Kuo J, Sato M, Wu L. Rapamycin enhances
adenovirus-mediated cancer imaging and therapy in pre-immunized murine hosts.
PLoS One. 2013 Sep 2;8(9):e73650. doi: 10.1371/journal.pone.0073650. eCollection 
2013. PubMed PMID: 24023896; PubMed Central PMCID: PMC3759448.


737: Jindal PK, Hota D, Prasad KV, Nijhawan R, Vaidyanathan S. Advanced prostatic
carcinoma in a 19-year-old male. Urol Int. 1994;52(4):225-7. PubMed PMID:
8030173.


738: Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg
SM, Gulley JL, Schlom J. A combination trial of vaccine plus ipilimumab in
metastatic castration-resistant prostate cancer patients: immune correlates.
Cancer Immunol Immunother. 2014 Apr;63(4):407-18. doi: 10.1007/s00262-014-1524-0.
Epub 2014 Feb 11. PubMed PMID: 24514956.


739: Johnson LE, Becker JT, Dubovsky JA, Olson BM, McNeel DG. Prostate carcinoma 
in transgenic Lewis rats - a tumor model for evaluation of immunological
treatments. Chin Clin Oncol. 2013 Mar 1;2(1). doi:
10.3978/j.issn.2304-3865.2012.11.06. PubMed PMID: 24324949; PubMed Central PMCID:
PMC3855422.


740: Johnson LE, McNeel DG. Identification of prostatic acid phosphatase (PAP)
specific HLA-DR1-restricted T-cell epitopes. Prostate. 2012 May 15;72(7):730-40. 
doi: 10.1002/pros.21477. Epub 2011 Aug 30. PubMed PMID: 22529020.


741: Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P,
Vogelzang NJ, Wirth M, Van Poppel H, Osanto S. Current vaccination strategies for
prostate cancer. Eur Urol. 2012 Feb;61(2):290-306. doi:
10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3. Review. PubMed PMID: 22001436.


742: Jorcyk CL, Liu ML, Shibata MA, Maroulakou IG, Komschlies KL, McPhaul MJ,
Resau JH, Green JE. Development and characterization of a mouse prostate
adenocarcinoma cell line: ductal formation determined by extracellular matrix.
Prostate. 1998 Jan 1;34(1):10-22. PubMed PMID: 9428383.


743: Junco JA, Basalto R, Fuentes F, Bover E, Reyes O, Pimentel E, Calzada L,
Castro MD, Arteaga N, López Y, Hernández H, Bringas R, Garay H, Peschke P, Bertot
J, Guillén G. Gonadotrophin releasing hormone-based vaccine, an effective
candidate for prostate cancer and other hormone-sensitive neoplasms. Adv Exp Med 
Biol. 2008;617:581-7. doi: 10.1007/978-0-387-69080-3_60. PubMed PMID: 18497085.


744: Junco JA, Peschke P, Zuna I, Ehemann V, Fuentes F, Bover E, Pimentel E,
Basulto R, Reyes O, Calzada L, Castro MD, Arteaga N, López Y, Garay H, Hernández 
H, Bringas R, Guillén GE. Immunotherapy of prostate cancer in a murine model
using a novel GnRH based vaccine candidate. Vaccine. 2007 Dec 5;25(50):8460-8.
Epub 2007 Oct 4. PubMed PMID: 18022737.


745: Jung V, Fischer E, Imig J, Kleber S, Nuber N, Reinshagen F, Kamradt J,
Grobholz R, Knuth A, Renner C, Wadle A. Yeast-based identification of prostate
tumor antigens provides an effective vaccine platform. Anticancer Res. 2010
Mar;30(3):895-902. PubMed PMID: 20393012.


746: Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC,
Old LJ. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer.
2000 Feb 15;85(4):460-5. PubMed PMID: 10699915.


747: Jursik C, Prchal M, Grillari-Voglauer R, Drbal K, Fuertbauer E, Jungfer H,
Albert WH, Steinhuber E, Hemetsberger T, Grillari J, Stockinger H, Katinger H.
Large-scale production and characterization of novel CD4+ cytotoxic T cells with 
broad tumor specificity for immunotherapy. Mol Cancer Res. 2009 Mar;7(3):339-53. 
doi: 10.1158/1541-7786.MCR-07-2208. Epub 2009 Feb 24. PubMed PMID: 19240181.


748: Jäger D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A,
Jäger E. Humoral and cellular immune responses against the breast cancer antigen 
NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun. 2005
Dec 12;5:11. PubMed PMID: 16335914.


749: Jäger D, Zippelius A, Knuth A. [Identification of tumor antigens: strategies
and perspectives]. Praxis (Bern 1994). 2004 Sep 22;93(39):1584-8. Review. German.
PubMed PMID: 15500242.


750: Jäger D, Unkelbach M, Frei C, Bert F, Scanlan MJ, Jäger E, Old LJ, Chen YT, 
Knuth A. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new
cancer/testis-like antigen NW-BR-3 by serological screening of a testicular
library with breast cancer serum. Cancer Immun. 2002 Jun 28;2:5. PubMed PMID:
12747750.


751: Jähnisch H, Füssel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, Rieber
EP, Wirth MP, Schmitz M. Dendritic cell-based immunotherapy for prostate cancer. 
Clin Dev Immunol. 2010;2010:517493. doi: 10.1155/2010/517493. Epub 2010 Nov 4.
Review. PubMed PMID: 21076523; PubMed Central PMCID: PMC2975068.


752: Jönsson B, Wilking N. Cancer vaccines and immunotherapeutics: challenges for
pricing, reimbursement and market access. Hum Vaccin Immunother. 2012
Sep;8(9):1360-3. doi: 10.4161/hv.21921. Epub 2012 Aug 24. PubMed PMID: 22922209; 
PubMed Central PMCID: PMC3579921.


753: Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS,
McBride WH, Schaue D. Radiation enhances regulatory T cell representation. Int J 
Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1128-35. doi:
10.1016/j.ijrobp.2010.09.034. Epub 2010 Nov 17. PubMed PMID: 21093169; PubMed
Central PMCID: PMC3117954.


754: Kamata Y, Kuhara A, Iwamoto T, Hayashi K, Koido S, Kimura T, Egawa S, Homma 
S. Identification of HLA class I-binding peptides derived from unique
cancer-associated proteins by mass spectrometric analysis. Anticancer Res. 2013
May;33(5):1853-9. PubMed PMID: 23645730.


755: Kaminski JM, Summers JB, Ward MB, Huber MR, Minev B. Immunotherapy and
prostate cancer. Cancer Treat Rev. 2003 Jun;29(3):199-209. Review. PubMed PMID:
12787714.


756: Kamrava M, Tsang KY, Madan RA, Kaushal A, Coleman CN, Gulley J. Long-term
survival and PSA control with radiation and immunotherapy for node positive
prostate cancer. Clin Dev Immunol. 2009;2009:363914. doi: 10.1155/2009/363914.
Epub 2010 Mar 8. PubMed PMID: 20224813; PubMed Central PMCID: PMC2834955.


757: Kaneno R, Shurin GV, Tourkova IL, Shurin MR. Chemomodulation of human
dendritic cell function by antineoplastic agents in low noncytotoxic
concentrations. J Transl Med. 2009 Jul 10;7:58. doi: 10.1186/1479-5876-7-58.
PubMed PMID: 19591684; PubMed Central PMCID: PMC2716306.


758: Kantoff P, Higano CS. Integration of immunotherapy into the management of
advanced prostate cancer. Urol Oncol. 2012 Sep-Oct;30(5 Suppl):S41-7. doi:
10.1016/j.urolonc.2012.06.002. Review. PubMed PMID: 23040162.


759: Kantoff PW, Mohler JL. New developments in the management of prostate
cancer. J Natl Compr Canc Netw. 2013 May;11(5 Suppl):653-7. Review. PubMed PMID: 
23704236.


760: Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. 
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in
castration-resistant prostate cancer. J Natl Cancer Inst. 2012 Jul
18;104(14):1107-9; author reply 1109-12. doi: 10.1093/jnci/djs279. PubMed PMID:
22825556.


761: Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M,
Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey
WR. Overall survival analysis of a phase II randomized controlled trial of a
Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant
prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi:
10.1200/JCO.2009.25.0597. Epub 2010 Jan 25. PubMed PMID: 20100959; PubMed Central
PMCID: PMC2834462.


762: Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH,
Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study 
Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate
cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
PubMed PMID: 20818862.


763: Kao SC, Hovey E, Marx G. Second-line therapy for castrate-resistant prostate
cancer: a literature review. Asia Pac J Clin Oncol. 2011 Sep;7(3):212-23. doi:
10.1111/j.1743-7563.2011.01421.x. Review. PubMed PMID: 21884433.


764: Karaguzhin SG, Merinov DS, Martov AG. [One-stage transurethral resection of 
the urinary bladder and the prostate in patients with superficial cancer of the
urinary bladder combined with benign prostatic hyperplasia]. Urologiia. 2005
Sep-Oct;(5):17-21. Russian. PubMed PMID: 16281833.


765: Karan D. Prostate immunotherapy: should all guns be aimed at the
prostate-specific antigen? Immunotherapy. 2013 Sep;5(9):907-10. doi:
10.2217/imt.13.83. Review. PubMed PMID: 23998723.


766: Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB. Cancer
immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol. 2012
May 29;9(7):376-85. doi: 10.1038/nrurol.2012.106. Review. PubMed PMID: 22641164.


767: Karan D, Van Veldhuizen P. Combination immunotherapy with prostate GVAX and 
ipilimumab: safety and toxicity. Immunotherapy. 2012 Jun;4(6):577-80. doi:
10.2217/imt.12.53. PubMed PMID: 22788125.


768: Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.
Dual antigen target-based immunotherapy for prostate cancer eliminates the growth
of established tumors in mice. Immunotherapy. 2011 Jun;3(6):735-46. doi:
10.2217/imt.11.59. PubMed PMID: 21668311.


769: Karan D, Thrasher JB, Lubaroff D. Prostate cancer: genes, environment,
immunity and the use of immunotherapy. Prostate Cancer Prostatic Dis.
2008;11(3):230-6. doi: 10.1038/pcan.2008.3. Epub 2008 Feb 19. Review. PubMed
PMID: 18283297.


770: Karkada M, Berinstein NL, Mansour M. Therapeutic vaccines and cancer: focus 
on DPX-0907. Biologics. 2014 Feb 10;8:27-38. doi: 10.2147/BTT.S55196. eCollection
2014. Review. PubMed PMID: 24596453; PubMed Central PMCID: PMC3930480.


771: Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr Pharm
Des. 2006;12(7):807-17. Review. PubMed PMID: 16515497.


772: Karr JF, Kantor JA, Hand PH, Eggensperger DL, Schlom J. The presence of
prostate-specific antigen-related genes in primates and the expression of
recombinant human prostate-specific antigen in a transfected murine cell line.
Cancer Res. 1995 Jun 1;55(11):2455-62. PubMed PMID: 7538903.


773: Kashyap V, Bonavida B. Role of YY1 in the pathogenesis of prostate cancer
and correlation with bioinformatic data sets of gene expression. Genes Cancer.
2014 Mar;5(3-4):71-83. Review. PubMed PMID: 25053986; PubMed Central PMCID:
PMC4091534.


774: Katari UL, Keirnan JM, Worth AC, Hodges SE, Leen AM, Fisher WE, Vera JF.
Engineered T cells for pancreatic cancer treatment. HPB (Oxford). 2011
Sep;13(9):643-50. doi: 10.1111/j.1477-2574.2011.00344.x. Epub 2011 Jul 20. PubMed
PMID: 21843265; PubMed Central PMCID: PMC3183449.


775: Kato H, Koshida K, Yokoyama K, Mizokami A, Namiki M. Potential benefits of
combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for
prostate cancer: experimental study. Int J Urol. 2002 Oct;9(10):567-76. PubMed
PMID: 12445236.


776: Kato T, Ueda Y, Kinoh H, Yoneyama Y, Matsunaga A, Komaru A, Harada Y, Suzuki
H, Komiya A, Shibata S, Hasegawa M, Hayashi H, Ichikawa T, Yonemitsu Y. RIG-I
helicase-independent pathway in sendai virus-activated dendritic cells is
critical for preventing lung metastasis of AT6.3 prostate cancer. Neoplasia. 2010
Nov;12(11):906-14. PubMed PMID: 21076616; PubMed Central PMCID: PMC2978913.


777: Katoh H, Qin ZS, Liu R, Wang L, Li W, Li X, Wu L, Du Z, Lyons R, Liu CG, Liu
X, Dou Y, Zheng P, Liu Y. FOXP3 orchestrates H4K16 acetylation and H3K4
trimethylation for activation of multiple genes by recruiting MOF and causing
displacement of PLU-1. Mol Cell. 2011 Dec 9;44(5):770-84. doi:
10.1016/j.molcel.2011.10.012. PubMed PMID: 22152480; PubMed Central PMCID:
PMC3243051.


778: Katoh H, Zheng P, Liu Y. Signalling through FOXP3 as an X-linked tumor
suppressor. Int J Biochem Cell Biol. 2010 Nov;42(11):1784-7. doi:
10.1016/j.biocel.2010.07.015. Epub 2010 Aug 1. Review. PubMed PMID: 20678582;
PubMed Central PMCID: PMC2950213.


779: Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.
Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody
for the immunotherapy of prostate cancer. Anticancer Res. 2000
May-Jun;20(3A):1551-5. PubMed PMID: 10928069.


780: Kausch I, Ardelt P, Böhle A, Ratliff TL. Immune gene therapy in urology.
Curr Urol Rep. 2002 Feb;3(1):82-9. Review. PubMed PMID: 12084224.


781: Kaushik A. Leuvectin Vical Inc. Curr Opin Investig Drugs. 2001
Jul;2(7):976-81. Review. PubMed PMID: 11757801.


782: Kawai K, Tani K, Asano S, Akaza H. Ex vivo gene therapy using
granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines. Mol
Urol. 2000 Summer;4(2):43-6. Review. PubMed PMID: 12006240.


783: Kawakami Y, Haas GP, Lotze MT. Expansion of tumor-infiltrating lymphocytes
from human tumors using the T-cell growth factors interleukin-2 and
interleukin-4. J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):336-47. PubMed
PMID: 8280717.


784: Kawakita M, Yoshida O, Ratliff TL. [Poxvirus vectors for gene transfer].
Hinyokika Kiyo. 1997 Nov;43(11):835-8. Japanese. PubMed PMID: 9436032.


785: Kawakita M, Rao GS, Ritchey JK, Ornstein DK, Hudson MA, Tartaglia J,
Paoletti E, Humphrey PA, Harmon TJ, Ratliff TL. Effect of canarypox virus
(ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl
Cancer Inst. 1997 Mar 19;89(6):428-36. PubMed PMID: 9091644.


786: Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for
castration-resistant prostate cancer. A systematic review and meta-analysis. Arch
Med Sci. 2012 Nov 9;8(5):767-75. doi: 10.5114/aoms.2012.31610. Epub 2012 Oct 8.
PubMed PMID: 23185184; PubMed Central PMCID: PMC3506233.


787: Keizman D, Maimon N, Gottfried M. [Metastatic hormone refractory prostate
cancer: new treatment horizon]. Harefuah. 2012 Sep;151(9):545-9, 555, 554.
Review. Hebrew. PubMed PMID: 23367751.


788: Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM.
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate
cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate. 2009
Jan 1;69(1):92-104. doi: 10.1002/pros.20856. PubMed PMID: 18942092; PubMed
Central PMCID: PMC2597150.


789: Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJ, Vuckovic S, Hart DN.
Prostate specific antigen inhibits immune responses in vitro: a potential role in
prostate cancer. J Urol. 2002 Aug;168(2):741-7. PubMed PMID: 12131362.


790: Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in
older patients. Drugs Aging. 2012 Nov;29(11):871-83. doi:
10.1007/s40266-012-0021-4. Review. PubMed PMID: 23135826.


791: Kessler M, Jay N, Molle R, Guillemin F. Excess risk of cancer in renal
transplant patients. Transpl Int. 2006 Nov;19(11):908-14. PubMed PMID: 17018126.


792: Khan A, Shergill I, Arya M, Barua JM, Kaisary AV. Radiommunotherapy and
prostate cancer: a promising new therapy in the management of metastatic disease.
BJU Int. 2006 Jul;98(1):8-9. PubMed PMID: 16831137.


793: Khatri A, Russell PJ. Targeted, gene-directed enzyme prodrug therapies to
tackle diversity and aggression of late stage prostate cancer. Discov Med. 2007
Feb;7(37):39-45. Review. PubMed PMID: 17343804.


794: Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M.
Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers 
(Basel). 2012 Feb 22;4(1):193-217. doi: 10.3390/cancers4010193. PubMed PMID:
24213236; PubMed Central PMCID: PMC3712678.


795: Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
Advances in specific immunotherapy for prostate cancer. Eur Urol. 2008
Apr;53(4):694-708. Epub 2007 Nov 26. Review. PubMed PMID: 18061335.


796: Kiessling A, Stevanovic S, Füssel S, Weigle B, Rieger MA, Temme A, Rieber
EP, Schmitz M. Identification of an HLA-A*0201-restricted T-cell epitope derived 
from the prostate cancer-associated protein prostein. Br J Cancer. 2004 Mar
8;90(5):1034-40. PubMed PMID: 14997204; PubMed Central PMCID: PMC2410218.


797: Kiessling A, Füssel S, Schmitz M, Stevanovic S, Meye A, Weigle B, Klenk U,
Wirth MP, Rieber EP. Identification of an HLA-A*0201-restricted T-cell epitope
derived from the prostate cancer-associated protein trp-p8. Prostate. 2003 Sep
1;56(4):270-9. PubMed PMID: 12858355.


798: Kiessling A, Schmitz M, Stevanovic S, Weigle B, Hölig K, Füssel M, Füssel S,
Meye A, Wirth MP, Rieber EP. Prostate stem cell antigen: Identification of
immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer
patients. Int J Cancer. 2002 Dec 1;102(4):390-7. PubMed PMID: 12402309.


799: Kikkawa K, Fujii R, Kuramoto T, Mori T, Inagaki T, Kohjimoto Y, Iwahashi M, 
Yamaue H, Hara I. Dendritic cells with transduced survivin gene induce specific
cytotoxic T lymphocytes in human urologic cancer cell lines. Urology. 2009
Jul;74(1):222-8. doi: 10.1016/j.urology.2008.12.045. Epub 2009 Mar 13. PubMed
PMID: 19285711.


800: Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, Zhou Q, Dubrovska A,
Biroc SL, Marsden R, Pinstaff J, Smider VV, Schultz PG. Bispecific small
molecule-antibody conjugate targeting prostate cancer. Proc Natl Acad Sci U S A. 
2013 Oct 29;110(44):17796-801. doi: 10.1073/pnas.1316026110. Epub 2013 Oct 14.
PubMed PMID: 24127589; PubMed Central PMCID: PMC3816437.


801: Kim DS. Cancer vaccines in the immunotherapy era: rational approach. Hum
Vaccin Immunother. 2013 Sep;9(9):2017-8. doi: 10.4161/hv.25556. Epub 2013 Jul 3. 
PubMed PMID: 23831824; PubMed Central PMCID: PMC3906373.


802: Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. TroVax, a recombinant
modified vaccinia Ankara virus encoding 5T4: lessons learned and future
development. Hum Vaccin. 2010 Oct;6(10):784-91. Epub 2010 Oct 1. Review. PubMed
PMID: 20975327.


803: Kim JJ, Rajagopalan K, Hussain B, Williams BH, Kulkarni P, Mooney SM. CETN1 
is a cancer testis antigen with expression in prostate and pancreatic cancers.
Biomark Res. 2013 Jun 13;1(1):22. doi: 10.1186/2050-7771-1-22. PubMed PMID:
24252580; PubMed Central PMCID: PMC4177615.


804: Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson 
DM, Weiner DB. Induction of immune responses and safety profiles in rhesus
macaques immunized with a DNA vaccine expressing human prostate specific antigen.
Oncogene. 2001 Jul 27;20(33):4497-506. PubMed PMID: 11494145.


805: Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, Chattergoon
MA, Dang K, Patel M, Ahn L, Boyer JD, Chalian AA, Schoemaker H, Kieber-Emmons T, 
Agadjanyan MA, Weiner DB. Molecular and immunological analysis of genetic
prostate specific antigen (PSA) vaccine. Oncogene. 1998 Dec 17;17(24):3125-35.
Erratum in: Oncogene 1999 Apr 8;18(14):2411. Shoemaker H [corrected to Schoemaker
H]. PubMed PMID: 9872328.


806: Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic cancer vaccines in
prostate cancer: the quest for intermediate markers of response. Cancers (Basel).
2012 Nov 22;4(4):1229-46. doi: 10.3390/cancers4041229. PubMed PMID: 24213505;
PubMed Central PMCID: PMC3712729.


807: Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opin
Biol Ther. 2012 Apr;12(4):463-78. doi: 10.1517/14712598.2012.668516. Review.
PubMed PMID: 22413824; PubMed Central PMCID: PMC3482162.


808: Kim SJ, Kim SI. Current treatment strategies for castration-resistant
prostate cancer. Korean J Urol. 2011 Mar;52(3):157-65. doi:
10.4111/kju.2011.52.3.157. Epub 2011 Mar 18. PubMed PMID: 21461278; PubMed
Central PMCID: PMC3065126.


809: Kimura Y, Inoue K, Abe M, Nearman J, Baranowska-Kortylewicz J. PDGFRbeta and
HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental
prostate cancer. Cancer Biol Ther. 2007 Nov;6(11):1763-72. Epub 2007 Aug 12.
PubMed PMID: 17986854.


810: Kinahan TJ, McLoughlin MG, Manson AD. Radical prostatectomy for localized
prostatic carcinoma in the renal transplant patient. J Urol. 1991
Jul;146(1):104-7. PubMed PMID: 2056566.


811: Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old 
LJ, Wang RF. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate
cancer. Clin Cancer Res. 2007 Dec 1;13(23):6947-58. PubMed PMID: 18056169.


812: Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas 
GP. Expression of prostate-specific membrane antigen in normal and malignant
human tissues. World J Surg. 2006 Apr;30(4):628-36. PubMed PMID: 16555021.


813: Kinoshita Y, Kuratsukuri K, Newman N, Rovito PM, Kaumaya PT, Wang CY, Haas
GP. Targeting epitopes in prostate-specific membrane antigen for antibody therapy
of prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(4):359-63. PubMed PMID:
16172607.


814: Kipp RT, McNeel DG. Immunotherapy for prostate cancer - recent progress in
clinical trials. Clin Adv Hematol Oncol. 2007 Jun;5(6):465-74, 477-9. Review.
PubMed PMID: 17679921.


815: Kirman I, Kalantarov GF, Lobel LI, Hibshoosh H, Estabrook A, Canfield R,
Trakht I. Isolation of native human monoclonal autoantibodies to breast cancer.
Hybrid Hybridomics. 2002 Dec;21(6):405-14. PubMed PMID: 12573104.


816: Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, Arredouani MS.
Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc
Natl Acad Sci U S A. 2014 Jul 8;111(27):9887-92. doi: 10.1073/pnas.1402468111.
Epub 2014 Jun 23. PubMed PMID: 24958858; PubMed Central PMCID: PMC4103356.


817: Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Immunization with a peptide
containing MHC class I and II epitopes derived from the tumor antigen SIM2
induces an effective CD4 and CD8 T-cell response. PLoS One. 2014 Apr
1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014. PubMed PMID: 
24690990; PubMed Central PMCID: PMC3972205.


818: Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Development of a peptide-based
vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. Cancer Immunol
Immunother. 2013 Dec;62(12):1831-40. doi: 10.1007/s00262-013-1482-y. Epub 2013
Oct 23. PubMed PMID: 24149465; PubMed Central PMCID: PMC3864132.


819: Kittai A, Meshikhes M, Aragon-Ching JB. Ipilimumab: a potential immunologic 
agent in the treatment of metastatic castration-resistant prostate cancer. Cancer
Biol Ther. 2014 Oct;15(10):1299-300. doi: 10.4161/cbt.29928. Epub 2014 Jul 21.
PubMed PMID: 25046606; PubMed Central PMCID: PMC4130722.


820: Klyushnenkova EN, Riabov VB, Kouiavskaia DV, Wietsma A, Zhan M, Alexander
RB. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential 
for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse
model of prostate cancer. Prostate. 2014 Oct;74(14):1423-32. doi:
10.1002/pros.22858. Epub 2014 Aug 11. PubMed PMID: 25111463.


821: Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander 
RB, Jarvis MA. A cytomegalovirus-based vaccine expressing a single tumor-specific
CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer. J
Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50. PubMed PMID:
22576344; PubMed Central PMCID: PMC3366429.


822: Klyushnenkova EN, Alexander RB. CD4 T-Cell-mediated immune response to
prostatic proteins in HLA-DRB1*1503 transgenic mice and identification of a novel
HLA-DRB1*1503-restricted T-cell epitope from human prostatic acid phosphatase.
Prostate. 2011 May;71(6):561-6. doi: 10.1002/pros.21271. Epub 2010 Sep 30. PubMed
PMID: 20886538.


823: Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB.
Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic
acid phosphatase. Prostate. 2007 Jul 1;67(10):1019-28. PubMed PMID: 17455230.


824: Klyushnenkova EN, Link J, Oberle WT, Kodak J, Rich C, Vandenbark AA,
Alexander RB. Identification of HLA-DRB1*1501-restricted T-cell epitopes from
prostate-specific antigen. Clin Cancer Res. 2005 Apr 15;11(8):2853-61. PubMed
PMID: 15837732.


825: Klyushnenkova EN, Ponniah S, Rodriguez A, Kodak J, Mann DL, Langerman A,
Nishimura MI, Alexander RB. CD4 and CD8 T-lymphocyte recognition of prostate
specific antigen in granulomatous prostatitis. J Immunother. 2004
Mar-Apr;27(2):136-46. PubMed PMID: 14770085.


826: Knutson KL. Technology evaluation: DCVax, Northwest Biotherapeutics. Curr
Opin Mol Ther. 2002 Aug;4(4):403-7. PubMed PMID: 12222879.


827: Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T,
Gillies SD. Safety, pharmacokinetics, and biological pharmacodynamics of the
immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with
prostate cancer. J Immunother. 2004 May-Jun;27(3):232-9. PubMed PMID: 15076141.


828: Kobayashi H, Azumi M, Kimura Y, Sato K, Aoki N, Kimura S, Honma M, Iizuka H,
Tateno M, Celis E. Focal adhesion kinase as an immunotherapeutic target. Cancer
Immunol Immunother. 2009 Jun;58(6):931-40. doi: 10.1007/s00262-008-0608-0. Epub
2008 Oct 22. PubMed PMID: 18941742; PubMed Central PMCID: PMC2664392.


829: Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi
M, Kakizaki H, Tateno M, Celis E. Recognition of prostate and melanoma tumor
cells by six-transmembrane epithelial antigen of prostate-specific helper T
lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res. 
2007 Jun 1;67(11):5498-504. PubMed PMID: 17545632.


830: Kobayashi H, Nagato T, Oikawa K, Sato K, Kimura S, Aoki N, Omiya R, Tateno
M, Celis E. Recognition of prostate and breast tumor cells by helper T
lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
Clin Cancer Res. 2005 May 15;11(10):3869-78. PubMed PMID: 15897588; PubMed
Central PMCID: PMC1594816.


831: Kobayashi H, Omiya R, Sodey B, Yanai M, Oikawa K, Sato K, Kimura S, Senju S,
Nishimura Y, Tateno M, Celis E. Identification of naturally processed helper
T-cell epitopes from prostate-specific membrane antigen using peptide-based in
vitro stimulation. Clin Cancer Res. 2003 Nov 1;9(14):5386-93. PubMed PMID:
14614024.


832: Kobayashi K, Noguchi M, Itoh K, Harada M. Identification of a
prostate-specific membrane antigen-derived peptide capable of eliciting both
cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Cancer Sci. 2003 Jul;94(7):622-7. PubMed PMID: 12841872.


833: Kocheril SV, Grignon DJ, Wang CY, Maughan RL, Montecillo EJ, Talati B,
Tekyi-Mensah S, Pontes Je, Hillman GG. Responsiveness of human prostate carcinoma
bone tumors to interleukin-2 therapy in a mouse xenograft tumor model. Cancer
Detect Prev. 1999;23(5):408-16. PubMed PMID: 10468893.


834: Kogan Y, Halevi-Tobias K, Elishmereni M, Vuk-Pavlović S, Agur Z.
Reconsidering the paradigm of cancer immunotherapy by computationally aided
real-time personalization. Cancer Res. 2012 May 1;72(9):2218-27. doi:
10.1158/0008-5472.CAN-11-4166. Epub 2012 Mar 15. PubMed PMID: 22422938.


835: Koh MB, Suck G. Cell therapy: promise fulfilled? Biologicals. 2012
May;40(3):214-7. doi: 10.1016/j.biologicals.2011.12.002. Epub 2012 Mar 8. Review.
PubMed PMID: 22405888.


836: Koh YT, Gray A, Higgins SA, Hubby B, Kast WM. Androgen ablation augments
prostate cancer vaccine immunogenicity only when applied after immunization.
Prostate. 2009 May 1;69(6):571-84. doi: 10.1002/pros.20906. PubMed PMID:
19143030; PubMed Central PMCID: PMC2732563.


837: Kohaar I, Porter-Gill P, Lenz P, Fu YP, Mumy A, Tang W, Apolo AB, Rothman N,
Baris D, Schned AR, Ylaya K, Schwenn M, Johnson A, Jones M, Kida M, Silverman DT,
Hewitt SM, Moore LE, Prokunina-Olsson L. Genetic variant as a selection marker
for anti-prostate stem cell antigen immunotherapy of bladder cancer. J Natl
Cancer Inst. 2013 Jan 2;105(1):69-73. doi: 10.1093/jnci/djs458. Epub 2012 Dec 23.
PubMed PMID: 23266392; PubMed Central PMCID: PMC3536639.


838: Kohli M, Tindall DJ. New developments in the medical management of prostate 
cancer. Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442. Review.
PubMed PMID: 20042563; PubMed Central PMCID: PMC2800284.


839: Komaru A, Ueda Y, Furuya A, Tanaka S, Yoshida K, Kato T, Kinoh H, Harada Y, 
Suzuki H, Inoue M, Hasegawa M, Ichikawa T, Yonemitsu Y. Sustained and NK/CD4+ T
cell-dependent efficient prevention of lung metastasis induced by dendritic cells
harboring recombinant Sendai virus. J Immunol. 2009 Oct 1;183(7):4211-9. doi:
10.4049/jimmunol.0803845. Epub 2009 Sep 4. PubMed PMID: 19734206.


840: Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A,
Doi A, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T. Gene
expression profiles in peripheral blood as a biomarker in cancer patients
receiving peptide vaccination. Cancer. 2012 Jun 15;118(12):3208-21. doi:
10.1002/cncr.26636. Epub 2011 Nov 9. PubMed PMID: 22071976.


841: Komatsu N, Terasaki Y, Moriya F, Suekane S, Noguchi M, Todo S, Itoh K,
Shichijo S. A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes
restricted to the HLA-A24 allele in prostate cancer patients. Exp Ther Med. 2010 
Sep;1(5):833-839. Epub 2010 Jul 20. PubMed PMID: 22993607; PubMed Central PMCID: 
PMC3445947.


842: Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrauch MR, Liebig T,
Shimabukuro-Vornhagen A, Kochanek M, Draube A, von Bergwelt-Baildon MS.
CD40-activated B cells can be generated in high number and purity in cancer
patients: analysis of immunogenicity and homing potential. Clin Exp Immunol. 2009
Feb;155(2):249-56. doi: 10.1111/j.1365-2249.2008.03820.x. Epub 2008 Nov 24.
Review. PubMed PMID: 19040609; PubMed Central PMCID: PMC2675256.


843: Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A,
Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K. Zoledronate facilitates
large-scale ex vivo expansion of functional gammadelta T cells from cancer
patients for use in adoptive immunotherapy. Cytotherapy. 2008;10(8):842-56. doi: 
10.1080/14653240802419328. PubMed PMID: 19016372.


844: Kong HY, Byun J. Emerging roles of human prostatic Acid phosphatase. Biomol 
Ther (Seoul). 2013 Jan;21(1):10-20. doi: 10.4062/biomolther.2012.095. Review.
PubMed PMID: 24009853; PubMed Central PMCID: PMC3762301.


845: Konishi S, Hamacher K, Vallabhajosula S, Kothari P, Bastidas D, Bander N,
Goldsmith S. Determination of immunoreactive fraction of radiolabeled monoclonal 
antibodies: what is an appropriate method? Cancer Biother Radiopharm. 2004
Dec;19(6):706-15. PubMed PMID: 15665617.


846: Korn K, Reil H, Ensser A, Knöll A. No evidence of XMRV infection in
immunocompromised patients and HIV-positive individuals from Germany. Infection. 
2012 Apr;40(2):181-4. doi: 10.1007/s15010-012-0249-2. Epub 2012 Feb 21. PubMed
PMID: 22350961.


847: Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM,
Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A, Vile R. 
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries
cures established tumors. Nat Med. 2011 Jun 19;17(7):854-9. doi: 10.1038/nm.2390.
Erratum in: Nat Med. 2012 Sep;18(9):1445. PubMed PMID: 21685898; PubMed Central
PMCID: PMC3918897.


848: Kottke T, Sanchez-Perez L, Diaz RM, Thompson J, Chong H, Harrington K,
Calderwood SK, Pulido J, Georgopoulos N, Selby P, Melcher A, Vile R. Induction of
hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic
prostate cancer. Cancer Res. 2007 Dec 15;67(24):11970-9. PubMed PMID: 18089828.


849: Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, 
Alexander RB. Vaccination with agonist peptide PSA: 154-163 (155L) derived from
prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 
154-163 but failed to induce the reactivity against tumor targets expressing PSA:
a phase 2 study in patients with recurrent prostate cancer. J Immunother. 2009
Jul-Aug;32(6):655-66. doi: 10.1097/CJI.0b013e3181a80e0d. PubMed PMID: 19483644;
PubMed Central PMCID: PMC2758610.


850: Koupparis A, Casey RG, Robinson M, Gleave ME. Novel targeted agents on the
horizon for castration-resistant prostate cancer. Future Oncol. 2010
Dec;6(12):1883-95. doi: 10.2217/fon.10.145. Review. Erratum in: Future Oncol.
2011 Jun;7(6):802. Casey, Rowan [corrected to Casey, Rowan G]. PubMed PMID:
21142862.


851: Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic
behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984
Aug;44(8):3522-9. PubMed PMID: 6744277.


852: Krege S, Giani G, Meyer R, Otto T, Rübben H. A randomized multicenter trial 
of adjuvant therapy in superficial bladder cancer: transurethral resection only
versus transurethral resection plus mitomycin C versus transurethral resection
plus bacillus Calmette-Guerin. Participating Clinics. J Urol. 1996
Sep;156(3):962-6. PubMed PMID: 8709374.


853: Krejci KG, Markiewicz MA, Kwon ED. Immunotherapy for urological
malignancies. J Urol. 2004 Feb;171(2 Pt 1):870-6. Review. PubMed PMID: 14713844.


854: Krewet JA, Ren W, Huang XF, Chen SY, Shah MR. Anti-tumor immune responses
following neoadjuvant immunotherapy with a recombinant adenovirus expressing
HSP72 to rodent tumors. Cancer Immunol Immunother. 2005 Oct;54(10):988-98. Epub
2005 May 12. PubMed PMID: 15889253.


855: Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC,
Leshchinsky T, DeNardo SJ. Apoptosis-related gene and protein expression in human
lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1
radioimmunotherapy. Cancer Biother Radiopharm. 2001 Jun;16(3):213-25. PubMed
PMID: 11471486.


856: Kronik N, Kogan Y, Elishmereni M, Halevi-Tobias K, Vuk-Pavlović S, Agur Z.
Predicting outcomes of prostate cancer immunotherapy by personalized mathematical
models. PLoS One. 2010 Dec 8;5(12):e15482. doi: 10.1371/journal.pone.0015482.
PubMed PMID: 21151630; PubMed Central PMCID: PMC2999571.


857: Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M. Immunization
with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering 
PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine. 2011 Feb 
4;29(7):1504-13. doi: 10.1016/j.vaccine.2010.12.016. Epub 2010 Dec 21. PubMed
PMID: 21182993.


858: Kuan CT, Wikstrand CJ, Bigner DD. EGFRvIII as a promising target for
antibody-based brain tumor therapy. Brain Tumor Pathol. 2000;17(2):71-8. Review. 
PubMed PMID: 11210174.


859: Kuang Y, Weng X, Liu X, Zhu H, Chen Z, Jiang B, Chen H. Anti-tumor immune
response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL
recombinant adenoviruses. Cancer Lett. 2010 Jul 28;293(2):254-62. doi:
10.1016/j.canlet.2010.01.011. Epub 2010 Feb 9. PubMed PMID: 20149524.


860: Kuchiike D, Uto Y, Mukai H, Ishiyama N, Abe C, Tanaka D, Kawai T, Kubo K,
Mette M, Inui T, Endo Y, Hori H. Degalactosylated/desialylated human serum
containing GcMAF induces macrophage phagocytic activity and in vivo antitumor
activity. Anticancer Res. 2013 Jul;33(7):2881-5. PubMed PMID: 23780974.


861: Kudrin A, Hanna MG Jr. Overview of the cancer vaccine field: are we moving
forward? Hum Vaccin Immunother. 2012 Aug;8(8):1135-40. doi: 10.4161/hv.20474.
Epub 2012 Aug 1. Review. PubMed PMID: 22854670; PubMed Central PMCID: PMC3551888.


862: Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A,
Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Köllermann MW, Pantel K,
Riethmüller G. Heterogeneous expression of MAGE-A genes in occult disseminated
tumor cells: a novel multimarker reverse transcription-polymerase chain reaction 
for diagnosis of micrometastatic disease. Cancer Res. 2002 Jan 1;62(1):251-61.
PubMed PMID: 11782385.


863: Kundig TM, Renner Ch, Knuth A. [Cancer immunotherapy--current status]. Ther 
Umsch. 2006 Apr;63(4):262-6. Review. German. PubMed PMID: 16689457.


864: Kuratsukuri K, Sone T, Wang CY, Nishisaka N, Jones RF, Haas GP. Inhibition
of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination
with either full-length or the C-terminal end of PSMA. Int J Cancer. 2002 Nov
20;102(3):244-9. PubMed PMID: 12397643.


865: Kuratsukuri K, Wang CY, Sone T, Nishisaka N, Jones RF, Haas GP. Induction of
antibodies against prostate-specific membrane antigen (PSMA) by vaccination with 
a PSMA DNA vector. Eur Urol. 2002 Jul;42(1):67-73. PubMed PMID: 12121733.


866: Kuratsukuri K, Nishisaka N, Jones RF, Wang CY, Haas GP. Clinical trials of
immunotherapy for advanced prostate cancer. Urol Oncol. 2000 Nov 1;5(6):265-273. 
PubMed PMID: 11008095.


867: Kurtz DM, Gambhir SS. Tracking cellular and immune therapies in cancer. Adv 
Cancer Res. 2014;124:257-96. doi: 10.1016/B978-0-12-411638-2.00008-2. PubMed
PMID: 25287692.


868: Kuslak SL, Van Dyke T. Advances in Prostate Cancer Research--AACR Special
Conference In Cancer Research. IDrugs. 2009 Mar;12(3):159-62. PubMed PMID:
19333894.


869: Kwek SS, Cha E, Fong L. Unmasking the immune recognition of prostate cancer 
with CTLA4 blockade. Nat Rev Cancer. 2012 Mar 1;12(4):289-97. doi:
10.1038/nrc3223. PubMed PMID: 22378189; PubMed Central PMCID: PMC3433280.


870: Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB.
Elimination of residual metastatic prostate cancer after surgery and adjunctive
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc
Natl Acad Sci U S A. 1999 Dec 21;96(26):15074-9. PubMed PMID: 10611340; PubMed
Central PMCID: PMC24775.


871: Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg
MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for
immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul
22;94(15):8099-103. PubMed PMID: 9223321; PubMed Central PMCID: PMC21563.


872: Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA
transfected dendritic cells. Cancer Immunol Immunother. 2006 Nov;55(11):1432-42. 
Epub 2006 Apr 13. Review. PubMed PMID: 16612595.


873: Kübler H, Miller K. [New therapy concepts for castration-resistant prostate 
cancer: between hormone manipulation, targeted therapy and chemotherapy]. Urologe
A. 2013 Nov;52(11):1517-8, 1520-1, 1524-6 passim. doi: 10.1007/s00120-013-3247-9.
Review. German. PubMed PMID: 24166056.


874: Kübler H, Gschwend JE. [Active immunotherapy of urologic malignancies and
tumor-mediated immunosuppression]. Urologe A. 2008 Sep;47(9):1122-7. doi:
10.1007/s00120-008-1822-2. Review. German. PubMed PMID: 18704362.


875: Labarthe MC, Theocharous P, Russell N, Todryk S, Bangma C, Thraves P,
Dalgleish AG, Whelan MA. A novel murine model of allogeneic vaccination against
prostate cancer. Cancer Immunol Immunother. 2008 Apr;57(4):453-65. Epub 2007 Sep 
6. PubMed PMID: 17805533.


876: Laber DA, Khan MI, Kloecker GH, Schonard C, Taft BS, Salvador C. A phase I
study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer
Biol Ther. 2007 Jun;6(6):840-5. Epub 2007 Mar 5. PubMed PMID: 17582215.


877: Lacher MD, Provenzano M. Cancer T cell immunotherapy with bispecific
antibodies and chimeric antigen receptors. Recent Pat Anticancer Drug Discov.
2013 Sep;8(3):239-54. Review. PubMed PMID: 23688207.


878: Ladd A, Walfield A, Tsong YY, Thau R. Active immunization against LHRH alone
or combined with LHRH-analogue treatment impedes growth of androgen-dependent
prostatic carcinoma. Am J Reprod Immunol. 1995 Sep;34(3):200-6. PubMed PMID:
8561879.


879: Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell
carcinoma 2005: new frontiers in staging, prognostication and targeted molecular 
therapy. J Urol. 2005 Jun;173(6):1853-62. Review. PubMed PMID: 15879764.


880: Lam MG, de Klerk JM, van Rijk PP. 186Re-HEDP for metastatic bone pain in
breast cancer patients. Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S162-70. 
Epub 2004 Apr 29. Review. PubMed PMID: 15118846.


881: Lamm DL, Riggs DR. Enhanced immunocompetence by garlic: role in bladder
cancer and other malignancies. J Nutr. 2001 Mar;131(3s):1067S-70S. Review. PubMed
PMID: 11238818.


882: Lammert A, Schneider HJ, Bergmann T, Benck U, Krämer BK, Gärtner R, Metzner 
C, Schöfl C, Berking C. Hypophysitis caused by ipilimumab in cancer patients:
hormone replacement or immunosuppressive therapy. Exp Clin Endocrinol Diabetes.
2013 Nov;121(10):581-7. doi: 10.1055/s-0033-1355337. Epub 2013 Oct 11. PubMed
PMID: 24122241.


883: Lange PH. PROSTASCINT scan for staging prostate cancer. Urology. 2001
Mar;57(3):402-6. PubMed PMID: 11248606.


884: Lange PH, Winfield HN. Biological markers in urologic cancer. Cancer. 1987
Aug 1;60(3 Suppl):464-72. Review. PubMed PMID: 3036331.


885: Lange PH, Hakala TR, Fraley EE. Immunobiology of genitourinary tumors.
Urology. 1973 Nov;2(5):485-92. Review. PubMed PMID: 4358375.


886: Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV
infection and solid-organ transplantation among elderly adults. Int J Cancer.
2010 Apr 1;126(7):1724-31. doi: 10.1002/ijc.24931. PubMed PMID: 19810102; PubMed 
Central PMCID: PMC2818159.


887: Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C,
Silva-Santos B. Protective role of the inflammatory CCR2/CCL2 chemokine pathway
through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J
Immunol. 2013 Jun 15;190(12):6673-80. doi: 10.4049/jimmunol.1300434. Epub 2013
May 17. PubMed PMID: 23686489.


888: Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM,
Spencer DM. Enhanced activation of human dendritic cells by inducible CD40 and
Toll-like receptor-4 ligation. Cancer Res. 2007 Nov 1;67(21):10528-37. PubMed
PMID: 17974997.


889: Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer 
J. 2011 Sep-Oct;17(5):359-71. doi: 10.1097/PPO.0b013e3182325e63. Review. PubMed
PMID: 21952287; PubMed Central PMCID: PMC3207353.


890: Lasalvia-Prisco E, Goldschmidt P, Galmarini F, Cucchi S, Vázquez J,
Aghazarian M, Lasalvia-Galante E, Golomar W, Gordon W. Addition of an induction
regimen of antiangiogenesis and antitumor immunity to standard chemotherapy
improves survival in advanced malignancies. Med Oncol. 2012 Dec;29(5):3626-33.
doi: 10.1007/s12032-012-0301-1. Epub 2012 Jul 19. PubMed PMID: 22810591; PubMed
Central PMCID: PMC3505507.


891: Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr
Opin Oncol. 2010 May;22(3):263-7. doi: 10.1097/CCO.0b013e3283380939. PubMed PMID:
20177381.


892: Lauer RC, Friend SC, Rietz C, Pasqualini R, Arap W. Drug design strategies
for the treatment of prostate cancer. Expert Opin Drug Discov. 2014 Nov 4:1-10.
[Epub ahead of print] PubMed PMID: 25366417.


893: Le DT, Jaffee EM. Next-generation cancer vaccine approaches: integrating
lessons learned from current successes with promising biotechnologic advances. J 
Natl Compr Canc Netw. 2013 Jul;11(7):766-72. Review. PubMed PMID: 23847215;
PubMed Central PMCID: PMC4115809.


894: Lechevallier E, Cormier L, Barrou B, Benoit G, Bensadoun H, Boudjema K,
Descottes JL, Doré B, Guy L, Malavaud B, Martin X, Petit J, Salomon L. Prostate
cancer in renal transplant recipients. Transplant Proc. 2002 Mar;34(2):722.
PubMed PMID: 12009678.


895: Lee D. Autologous dendritic cells pulsed with prostatic acid phosphatase
(APC8015) for patients with hormone-refractory prostate cancer with a Gleason
score <or= 7. Clin Prostate Cancer. 2003 Sep;2(2):81-3. PubMed PMID: 15040867.


896: Lee D. New treatment modalities for hormone-resistant prostate cancer. Clin 
Prostate Cancer. 2002 Dec;1(3):139-41. Review. PubMed PMID: 15046687.


897: Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS,
Tagawa ST, Shariat SF. Novel therapeutics for the management of
castration-resistant prostate cancer (CRPC). BJU Int. 2012 Apr;109(7):968-85.
doi: 10.1111/j.1464-410X.2011.10643.x. Epub 2011 Oct 28. Review. PubMed PMID:
22035221.


898: Lee IH, An S, Yu MK, Kwon HK, Im SH, Jon S. Targeted chemoimmunotherapy
using drug-loaded aptamer-dendrimer bioconjugates. J Control Release. 2011 Nov
7;155(3):435-41. doi: 10.1016/j.jconrel.2011.05.025. Epub 2011 May 27. PubMed
PMID: 21641946.


899: Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, Stone NN, Droller
MJ, Stock RG. Putative protein markers in the sera of men with prostatic
neoplasms. BJU Int. 2003 Aug;92(3):223-5. PubMed PMID: 12887471.


900: Leinonen J, Niemelä P, Lövgren J, Bocchi L, Pettersson K, Nevanlinna H,
Stenman UH. Characterization of monoclonal antibodies against prostate specific
antigen produced by genetic immunization. J Immunol Methods. 2004
Jun;289(1-2):157-67. PubMed PMID: 15251421.


901: Lemke CD, Graham JB, Lubaroff DM, Salem AK. Development of an MHC class I
L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T 
cells in the mouse. Prostate Cancer Prostatic Dis. 2011 Jun;14(2):118-21. doi:
10.1038/pcan.2010.57. Epub 2011 Jan 25. PubMed PMID: 21263453; PubMed Central
PMCID: PMC3094480.


902: Leo S, Accettura C, Lorusso V. Castration-resistant prostate cancer:
targeted therapies. Chemotherapy. 2011;57(2):115-27. doi: 10.1159/000323581. Epub
2011 Mar 24. Review. PubMed PMID: 21430379.


903: Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. Carbonic anhydrase
IX and the future of molecular markers in renal cell carcinoma. BJU Int. 2005
Aug;96(3):281-5. PubMed PMID: 16042714.


904: Leung K. (89)Zr-Desferrioxamine B-7E11 anti-prostate-specific membrane
antigen monoclonal antibody. 2011 Nov 22 [updated 2012 Feb 23]. Molecular Imaging
and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center
for Biotechnology Information (US); 2004-2013. Available from
http://www.ncbi.nlm.nih.gov/books/NBK84305/
PubMed PMID: 22379638.


905: Leung K. DiD-Labeled anti-EpCAM-directed NK-92-scFv(MOC31) zeta cells. 2009 
Aug 28 [updated 2009 Sep 30]. Molecular Imaging and Contrast Agent Database
(MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information 
(US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK23559/
PubMed PMID: 20641757.


906: Leung K. (111)In-Capromab pendetide . 2005 Oct 05 [updated 2008 May 24].
Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): 
National Center for Biotechnology Information (US); 2004-2013. Available from
http://www.ncbi.nlm.nih.gov/books/NBK23237/
PubMed PMID: 20641439.


907: Levin I, Klein T, Kuperman O, Segal S, Shapira J, Gal R, Hart Y, Klein B.
The expression of HLA class I antigen in prostate cancer in relation to tumor
differentiation and patient survival. Cancer Detect Prev. 1994;18(6):443-5.
PubMed PMID: 7867017.


908: Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK. Memory and cellular 
immunity induced by a DNA vaccine encoding self antigen TPD52 administered with
soluble GM-CSF. Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi:
10.1007/s00262-009-0659-x. Epub 2009 Jan 24. PubMed PMID: 19169682.


909: Li H, Ma W. Intracellular delivery of tumor antigenic peptides in
biodegradable-polymer adjuvant for enhancing cancer immunotherapy. Curr Med Chem.
2014;21(21):2357-66. PubMed PMID: 25030301.


910: Li H, Cao MY, Lee Y, Benatar T, Lee V, Feng N, Gu X, Liu P, Jin H, Wang M,
Der S, Lightfoot J, Wright JA, Young AH. Virulizin, a novel immunotherapy agent, 
stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo. Int
Immunopharmacol. 2007 Oct;7(10):1350-9. Epub 2007 Jun 26. PubMed PMID: 17673150.


911: Li H, Cao MY, Lee Y, Lee V, Feng N, Benatar T, Jin H, Wang M, Der S, Wright 
JA, Young AH. Virulizin, a novel immunotherapy agent, activates NK cells through 
induction of IL-12 expression in macrophages. Cancer Immunol Immunother. 2005
Nov;54(11):1115-26. Epub 2005 May 13. PubMed PMID: 15891881.


912: Li J, Sun Y, Jia T, Zhang R, Zhang K, Wang L. Messenger RNA vaccine based on
recombinant MS2 virus-like particles against prostate cancer. Int J Cancer. 2014 
Apr 1;134(7):1683-94. doi: 10.1002/ijc.28482. Epub 2013 Oct 8. Erratum in: Int J 
Cancer. 2014 Oct 1;135(7):E5. PubMed PMID: 24105486.


913: Li M, Sun Y, Feng Y, Wu Q, Huang N, Wang B. [Construction and immunological 
study of recombinant hBD-2/PSMA chimeric protein eukaryotic expressive plasmid]. 
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2005 Apr;22(2):283-7. Chinese. PubMed
PMID: 15884536.


914: Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.
Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen
gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Immunol Lett. 2007 Nov 15;113(2):90-8. Epub 2007 Aug 29. PubMed PMID: 17913245.


915: Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.
Potent systemic antitumor immunity induced by vaccination with
chemotactic-prostate tumor associated antigen gene-modified tumor cell and
blockade of B7-H1. J Clin Immunol. 2007 Jan;27(1):117-30. Epub 2006 Dec 16.
PubMed PMID: 17180470.


916: Li QX, Liu G, Zhang X. Fusogenic oncolytic herpes simplex viruses as a
potent and personalized cancer vaccine. Curr Pharm Biotechnol. 2012
Jul;13(9):1773-85. Review. PubMed PMID: 21740353.


917: Li S, Hu X, Cui S, He D. Novel centrosome protein, TCC52, is a cancer-testis
antigen. Cancer Sci. 2008 Nov;99(11):2274-9. doi:
10.1111/j.1349-7006.2008.00937.x. Epub 2008 Oct 14. PubMed PMID: 18957058.


918: Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y. Identification of a tumor
suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate 
cancers. Cancer Res. 2011 Mar 15;71(6):2162-71. doi:
10.1158/0008-5472.CAN-10-3268. Epub 2011 Jan 28. PubMed PMID: 21278236; PubMed
Central PMCID: PMC3070402.


919: Li Y, Cozzi PJ. MUC1 is a promising therapeutic target for prostate cancer
therapy. Curr Cancer Drug Targets. 2007 May;7(3):259-71. Review. PubMed PMID:
17504123.


920: Li Y, Abbas Rizvi SM, Blair nee Brown JM, Cozzi PJ, Qu CF, Ow KT, Tam PN,
Perkins AC, Russell PJ, Allen BJ. Antigenic expression of human metastatic
prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with
213Bi-conjugates. Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):896-908. PubMed 
PMID: 15465208.


921: Li Y, Cozzi PJ, Qu CF, Zhang DY, Abbas Rizvi SM, Raja C, Allen BJ.
Cytotoxicity of human prostate cancer cell lines in vitro and induction of
apoptosis using 213Bi-Herceptin alpha-conjugate. Cancer Lett. 2004 Mar
18;205(2):161-71. PubMed PMID: 15036648.


922: Li Y, Russell PJ, Allen BJ. Targeted alpha-therapy for control of
micrometastatic prostate cancer. Expert Rev Anticancer Ther. 2004
Jun;4(3):459-68. Review. PubMed PMID: 15161444.


923: Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ. In vitro and preclinical
targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody
against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis.
2002;5(1):36-46. PubMed PMID: 15195129.


924: Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp
Hematol Oncol. 2013 Dec 10;2(1):33. doi: 10.1186/2162-3619-2-33. PubMed PMID:
24326015; PubMed Central PMCID: PMC4176488.


925: Lin AM, Small EJ. Prostate cancer update: 2006. Curr Opin Oncol. 2007
May;19(3):229-33. Review. PubMed PMID: 17414641.


926: Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using
prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006
Sep-Oct;24(5):434-41. Review. PubMed PMID: 16962496.


927: Linch SN, Redmond WL. Combined OX40 ligation plus CTLA-4 blockade: More than
the sum of its parts. Oncoimmunology. 2014 Mar 17;3:e28245. eCollection 2014.
PubMed PMID: 25050194; PubMed Central PMCID: PMC4091104.


928: Link KA, Balasubramaniam S, Sharma A, Comstock CE, Godoy-Tundidor S, Powers 
N, Cao KH, Haelens A, Claessens F, Revelo MP, Knudsen KE. Targeting the BAF57
SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor
activity. Cancer Res. 2008 Jun 15;68(12):4551-8. doi:
10.1158/0008-5472.CAN-07-6392. PubMed PMID: 18559499; PubMed Central PMCID:
PMC2862487.


929: Lipinski KS, Pelech S, Mountain A, Irvine AS, Kraaij R, Bangma CH, Mills KH,
Todryk SM. Nitroreductase-based therapy of prostate cancer, enhanced by raising
expression of heat shock protein 70, acts through increased anti-tumour immunity.
Cancer Immunol Immunother. 2006 Mar;55(3):347-54. Epub 2005 Jun 17. PubMed PMID: 
16075195.


930: Lissoni P, Fumagalli L, Brivio F, Rovelli F, Messina G, Di Fede G, Colciago 
M, Brera G. Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery 
in the medical oncology. J Biol Regul Homeost Agents. 2006 Jan-Jun;20(1-2):29-35.
PubMed PMID: 18088552.


931: Litwin MS, Fine JT, Dorey F, Figlin RA, Belldegrun AS. Health related
quality of life outcomes in patients treated for metastatic kidney cancer: a
pilot study. J Urol. 1997 May;157(5):1608-12. PubMed PMID: 9112487.


932: Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Recombinant
full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med
(Berl). 2007 Oct;85(10):1113-23. Epub 2007 Jun 7. PubMed PMID: 17554518.


933: Liu G, Lu S, Wang X, Page ST, Higano CS, Plymate SR, Greenberg NM, Sun S, Li
Z, Wu JD. Perturbation of NK cell peripheral homeostasis accelerates prostate
carcinoma metastasis. J Clin Invest. 2013 Oct 1;123(10):4410-22. doi:
10.1172/JCI69369. Epub 2013 Sep 9. PubMed PMID: 24018560; PubMed Central PMCID:
PMC3784540.


934: Liu G, Dou S, Pretorius PH, Liu X, Rusckowski M, Hnatowich DJ. Pretargeting 
CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur
J Nucl Med Mol Imaging. 2008 Feb;35(2):272-80. Epub 2007 Oct 2. PubMed PMID:
17909792; PubMed Central PMCID: PMC2259287.


935: Liu JJ, Zhang J. Sequencing systemic therapies in metastatic
castration-resistant prostate cancer. Cancer Control. 2013 Jul;20(3):181-7.
Review. PubMed PMID: 23811702.


936: Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA.
Identification of rat prostatic steroid-binding protein as a target antigen of
experimental autoimmune prostatitis: implications for prostate cancer therapy. J 
Immunol. 1997 Jul 1;159(1):472-80. PubMed PMID: 9200488.


937: Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P.
Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A. 2004 Oct
5;101 Suppl 2:14567-71. Epub 2004 Aug 27. Review. PubMed PMID: 15333750; PubMed
Central PMCID: PMC521989.


938: Liu T, Toriyabe Y, Berkman CE. Purification of prostate-specific membrane
antigen using conformational epitope-specific antibody-affinity chromatography.
Protein Expr Purif. 2006 Oct;49(2):251-5. Epub 2006 May 22. PubMed PMID:
16815035.


939: Liu T, Meredith RF, Saleh MN, Wheeler RH, Khazaeli MB, Plott WE, Schlom J,
LoBuglio AF. Correlation of toxicity with treatment parameters for 131I-CC49
radioimmunotherapy in three phase II clinical trials. Cancer Biother Radiopharm. 
1997 Apr;12(2):79-87. PubMed PMID: 10851451.


940: Liu WM, Dalgleish AG. The potential beneficial effects of drugs on the
immune response to vaccination. Semin Oncol. 2012 Jun;39(3):340-7. doi:
10.1053/j.seminoncol.2012.02.012. Review. PubMed PMID: 22595056.


941: Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, Giercksky KE, 
Axcrona K. Is the clinical malignant phenotype of prostate cancer a result of a
highly proliferative immune-evasive B7-H3-expressing cell population? Int J Urol.
2012 Aug;19(8):749-56. doi: 10.1111/j.1442-2042.2012.03017.x. Epub 2012 Apr 4.
PubMed PMID: 22487487.


942: Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD. Protective
immunosurveillance and therapeutic antitumor activity of gammadelta T cells
demonstrated in a mouse model of prostate cancer. J Immunol. 2008 May
1;180(9):6044-53. PubMed PMID: 18424725.


943: Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD. Ex vivo expanded human
Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against
human prostate cancer cells in vitro. J Urol. 2005 May;173(5):1552-6. PubMed
PMID: 15821484.


944: Lo-Man R, Vichier-Guerre S, Perraut R, Dériaud E, Huteau V, BenMohamed L,
Diop OM, Livingston PO, Bay S, Leclerc C. A fully synthetic therapeutic vaccine
candidate targeting carcinoma-associated Tn carbohydrate antigen induces
tumor-specific antibodies in nonhuman primates. Cancer Res. 2004 Jul
15;64(14):4987-94. PubMed PMID: 15256473.


945: Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA,
Yan L, Pienta KJ. Targeting CCL2 with systemic delivery of neutralizing
antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007 Oct
1;67(19):9417-24. PubMed PMID: 17909051.


946: Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer
Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
Systemic therapy in men with metastatic castration-resistant prostate cancer: a
systematic review. Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi:
10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review. PubMed PMID: 23587782.


947: Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based 
immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.
Cancer Res. 2000 Feb 15;60(4):829-33. PubMed PMID: 10706088.


948: Lodge PA, Childs RA, Monahan SJ, McLean JG, Sehgal A, Boynton AL, Salgaller 
ML, Murphy GP. Expression and purification of prostate-specific membrane antigen 
in the baculovirus expression system and recognition by prostate-specific
membrane antigen-specific T cells. J Immunother. 1999 Jul;22(4):346-55. PubMed
PMID: 10404436.


949: Loening S, Lubaroff D. Cryosurgery and immunotherapy for prostatic cancer.
Urol Clin North Am. 1984 May;11(2):327-36. Review. PubMed PMID: 6203207.


950: Logothetis CJ. Treatment of castrate-resistant prostate cancer. J Urol. 2013
Aug;190(2):439-40. doi: 10.1016/j.juro.2013.05.041. Epub 2013 May 21. PubMed
PMID: 23707438.


951: Longo DL. New therapies for castration-resistant prostate cancer. N Engl J
Med. 2010 Jul 29;363(5):479-81. doi: 10.1056/NEJMe1006300. PubMed PMID: 20818868.


952: Lopez-Barcons LA. Serially heterotransplanted human prostate tumours as an
experimental model. J Cell Mol Med. 2010 Jun;14(6B):1385-95. doi:
10.1111/j.1582-4934.2009.00957.x. Epub 2009 Oct 29. Review. PubMed PMID:
19874422.


953: Lou DY, Fong L. Neoadjuvant therapy for localized prostate cancer: Examining
mechanism of action and efficacy within the tumor. Urol Oncol. 2014 Feb 1. pii:
S1078-1439(13)00500-0. doi: 10.1016/j.urolonc.2013.12.001. [Epub ahead of print] 
Review. PubMed PMID: 24495446.


954: Loughlin KR. Immunotherapy: a new paradigm for androgen-refractory prostate 
cancer. Urol Oncol. 2008 Nov-Dec;26(6):575. doi: 10.1016/j.urolonc.2008.08.005.
PubMed PMID: 18996313.


955: Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, 
Agadjanyan MG. Antitumor efficacy of DNA vaccination to the epigenetically acting
tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell
Biochem. 2006 Aug 1;98(5):1037-43. PubMed PMID: 16741971.


956: Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, 
Ottensmeier CH. DNA vaccination with electroporation induces increased antibody
responses in patients with prostate cancer. Hum Gene Ther. 2009
Nov;20(11):1269-78. doi: 10.1089/hum.2009.067. PubMed PMID: 19619001.


957: Lu J, Zhang Q, Liang CM, Xia SJ, Zhong CP, Wang DW. Antitumor immunity by a 
dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on 
murine prostate cancer. Asian J Androl. 2008 Nov;10(6):883-9. doi:
10.1111/j.1745-7262.2008.00431.x. PubMed PMID: 18958352.


958: Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T
lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 2002 Oct
15;62(20):5807-12. PubMed PMID: 12384542.


959: Lu L, Yan H, Shyam-Sundar V, Janowitz T. Cross-sectional and longitudinal
analysis of cancer vaccination trials registered on the US Clinical Trials
Database demonstrates paucity of immunological trial endpoints and decline in
registration since 2008. Drug Des Devel Ther. 2014 Sep 27;8:1539-53. doi:
10.2147/DDDT.S65963. eCollection 2014. PubMed PMID: 25302014; PubMed Central
PMCID: PMC4189706.


960: Lu SX, Takach EJ, Solomon M, Zhu Q, Law SJ, Hsieh FY. Mass spectral analyses
of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated
anti-PSMA antibody for prostate cancer therapy. J Pharm Sci. 2005
Apr;94(4):788-97. PubMed PMID: 15729708.


961: Lu Y, Mekoo DJ, Ouyang K, Hu X, Liu Y, Lin M, Jin L, Cao R, Li T, Zhang Y,
Fan H, Liu J. Strong humoral response elicited by a DNA vaccine targeting
gastrin-releasing peptide with optimized adjuvants inhibits murine prostate
carcinoma growth in vivo. Endocr Relat Cancer. 2009 Dec;16(4):1171-84. doi:
10.1677/ERC-09-0058. Epub 2009 Jul 31. PubMed PMID: 19648182.


962: Lu Y, Ouyang K, Fang J, Zhang H, Wu G, Ma Y, Zhang Y, Hu X, Jin L, Cao R,
Fan H, Li T, Liu J. Improved efficacy of DNA vaccination against prostate
carcinoma by boosting with recombinant protein vaccine and by introduction of a
novel adjuvant epitope. Vaccine. 2009 Aug 27;27(39):5411-8. doi:
10.1016/j.vaccine.2009.06.089. Epub 2009 Jul 17. PubMed PMID: 19616501.


963: Lu Y. Viral based gene therapy for prostate cancer. Curr Gene Ther. 2001
Jul;1(2):183-200. Review. PubMed PMID: 12108954.


964: Lubaroff DM, Vaena D, Brown JA, Zehr P, Griffith KC, Brown E, Eastman J,
Nepple K, Kattula A, Williams RD. Vaccine immunotherapy for prostate cancer: from
mice to men. Immunol Res. 2014 Aug;59(1-3):229-35. doi:
10.1007/s12026-014-8531-2. PubMed PMID: 24847764.


965: Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev
Vaccines. 2012 Jul;11(7):857-68. doi: 10.1586/erv.12.54. Review. PubMed PMID:
22913261.


966: Lubaroff DM, Karan D. CpG oligonucleotide as an adjuvant for the treatment
of prostate cancer. Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74. doi:
10.1016/j.addr.2008.12.005. Epub 2009 Jan 7. Review. PubMed PMID: 19166887.


967: Lugnani F, Simone G, Biava PM, Ablin RJ. The role of neuroendocrine cells in
prostate cancer: a comprehensive review of current literature and subsequent
rationale to broaden and integrate current treatment modalities. Curr Med Chem.
2014;21(9):1082-92. Review. PubMed PMID: 24304274.


968: Lum HE, Miller M, Davol PA, Grabert RC, Davis JB, Lum LG. Preclinical
studies comparing different bispecific antibodies for redirecting T cell
cytotoxicity to extracellular antigens on prostate carcinomas. Anticancer Res.
2005 Jan-Feb;25(1A):43-52. PubMed PMID: 15816517.


969: Lum LG, Fok H, Sievers R, Abedi M, Quesenberry PJ, Lee RJ. Targeting of
Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured
myocardium. Blood Cells Mol Dis. 2004 Jan-Feb;32(1):82-7. PubMed PMID: 14757418.


970: Lum LG, Rathore R, Quesenberry PJ, Elfenbein GJ. Future prospects for
patient care utilizing autologous lymphoid and hematopoietic stem cells. Med
Health R I. 2003 Aug;86(8):247-8. Review. PubMed PMID: 14582220.


971: Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-Patiño J,
Andersen RS, Pisa P. A modified epitope identified for generation and monitoring 
of PSA-specific T cells in patients on early phases of PSA-based
immunotherapeutic protocols. Vaccine. 2009 Mar 4;27(10):1557-65. doi:
10.1016/j.vaccine.2009.01.011. Epub 2009 Jan 24. PubMed PMID: 19171173.


972: Lundqvist A, Palmborg A, Bidla G, Whelan M, Pandha H, Pisa P. Allogeneic
tumor-dendritic cell fusion vaccines for generation of broad prostate cancer
T-cell responses. Med Oncol. 2004;21(2):155-65. PubMed PMID: 15299188.


973: Lundqvist A, Choudhury A, Nagata T, Andersson T, Quinn G, Fong T, Maitland
N, Pettersson S, Paulie S, Pisa P. Recombinant adenovirus vector activates and
protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther.
2002 Sep 1;13(13):1541-9. PubMed PMID: 12228009.


974: Lü C, Williams AK, Chalasani V, Martínez CH, Chin J. Immunotherapy for
metastatic prostate cancer: where are we at with sipuleucel-T? Expert Opin Biol
Ther. 2011 Jan;11(1):99-108. doi: 10.1517/14712598.2011.538677. Epub 2010 Nov 17.
Review. PubMed PMID: 21080858.


975: Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation anti-prostate
specific membrane antigen designer T cells for prostate cancer immunotherapy.
Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749. PubMed PMID: 24174378.


976: Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate
specific membrane antigen designer T cells for prostate cancer therapy. Prostate.
2004 Sep 15;61(1):12-25. PubMed PMID: 15287090.


977: Mabjeesh NJ, Zhong H, Simons JW. Gene therapy of prostate cancer: current
and future directions. Endocr Relat Cancer. 2002 Jun;9(2):115-39. Review. PubMed 
PMID: 12121835.


978: Macfarlane RJ, Chi KN. Research in castration-resistant prostate cancer:
what does the future hold? Curr Oncol. 2010 Sep;17 Suppl 2:S80-6. PubMed PMID:
20882138; PubMed Central PMCID: PMC2935715.


979: Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A,
Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L. Preventive and
therapeutic vaccination with PAP-3, a novel human prostate cancer peptide,
inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother.
2007 Feb;56(2):217-26. Epub 2006 Jun 1. PubMed PMID: 16738849.


980: Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz 
I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L. Human CTL 
epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of
prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res. 2005 Jul 
15;65(14):6435-42. PubMed PMID: 16024648.


981: Machlenkin A, Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH,
Vadai E, Tzehoval E, Eisenbach L. Combined dendritic cell cryotherapy of tumor
induces systemic antimetastatic immunity. Clin Cancer Res. 2005 Jul
1;11(13):4955-61. PubMed PMID: 16000595.


982: Madan RA, Heery CR, Gulley JL. Poxviral-based vaccine elicits immunologic
responses in prostate cancer patients. Oncoimmunology. 2014 Apr 29;3:e28611.
eCollection 2014. PubMed PMID: 25097802; PubMed Central PMCID: PMC4091323.


983: Madan RA, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate
cancer: understanding current and future treatment strategies. Cancer J. 2013
Jan-Feb;19(1):50-8. doi: 10.1097/PPO.0b013e31828160a9. PubMed PMID: 23337757;
PubMed Central PMCID: PMC3556901.


984: Madan RA, Arlen PM. Recent advances revolutionize treatment of metastatic
prostate cancer. Future Oncol. 2013 Aug;9(8):1133-44. doi: 10.2217/fon.13.65.
Review. PubMed PMID: 23902245.


985: Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM,
Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in
metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012
Feb 10. PubMed PMID: 22326924.


986: Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of
TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012 Jun;39(3):296-304.
doi: 10.1053/j.seminoncol.2012.02.010. Review. PubMed PMID: 22595052; PubMed
Central PMCID: PMC3398615.


987: Madan RA, Schwaab T, Gulley JL. Strategies for optimizing the clinical
impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J
Natl Compr Canc Netw. 2012 Dec 1;10(12):1505-12. PubMed PMID: 23221788.


988: Madan RA, Gulley JL. Therapeutic cancer vaccine fulfills the promise of
immunotherapy in prostate cancer. Immunotherapy. 2011 Jan;3(1):27-31. doi:
10.2217/imt.10.77. PubMed PMID: 21174555; PubMed Central PMCID: PMC3474245.


989: Madan RA, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in
metastatic castration-resistant prostate cancer: principles in clinical trial
design. Expert Opin Biol Ther. 2010 Jan;10(1):19-28. doi:
10.1517/14712590903321421. PubMed PMID: 19857185.


990: Madan RA, Gulley JL. The current and emerging role of immunotherapy in
prostate cancer. Clin Genitourin Cancer. 2010 Dec 1;8(1):10-6. doi:
10.3816/CGC.2010.n.002. Review. PubMed PMID: 21208850; PubMed Central PMCID:
PMC3447981.


991: Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a
vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig
Drugs. 2009 Jul;18(7):1001-11. doi: 10.1517/13543780902997928. Review. PubMed
PMID: 19548854; PubMed Central PMCID: PMC3449276.


992: Maffezzini M, Simonato A, Fortis C. Salvage immunotherapy with subcutaneous 
recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3
prostate carcinoma failing second-line hormonal treatment. Prostate. 1996
May;28(5):282-6. PubMed PMID: 8610053.


993: Mahadevan M, Liu Y, You C, Luo R, You H, Mehta JL, Hermonat PL. Generation
of robust cytotoxic T lymphocytes against prostate specific antigen by
transduction of dendritic cells using protein and recombinant adeno-associated
virus. Cancer Immunol Immunother. 2007 Oct;56(10):1615-24. Epub 2007 Mar 14.
PubMed PMID: 17356843.


994: Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte
cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28
receptor. Nat Biotechnol. 2002 Jan;20(1):70-5. PubMed PMID: 11753365.


995: Maia CJ, Socorro S, Schmitt F, Santos CR. STEAP1 is over-expressed in breast
cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat
mammary gland. Endocrine. 2008 Aug-Dec;34(1-3):108-16. doi:
10.1007/s12020-008-9113-7. Epub 2008 Oct 29. PubMed PMID: 18958632.


996: Maitland NJ, Bryce SD, Stower MJ, Collins AT. Prostate cancer stem cells: a 
target for new therapies. Ernst Schering Found Symp Proc. 2006;(5):155-79.
Review. PubMed PMID: 17939301.


997: Makarova N, Zhao C, Zhang Y, Bhosle S, Suppiah S, Rhea JM, Kozyr N, Arnold
RS, Ly H, Molinaro RJ, Parslow TG, Hunter E, Liotta D, Petros J, Blackwell JL.
Antibody responses against xenotropic murine leukemia virus-related virus
envelope in a murine model. PLoS One. 2011 Apr 6;6(4):e18272. doi:
10.1371/journal.pone.0018272. Erratum in: PLoS One. 2011;6(5).
doi:10.1371/annotation/913fdc1e-877e-4c70-ac20-761d2d72400d. PubMed PMID:
21494670; PubMed Central PMCID: PMC3071813.


998: Makinde AY, John-Aryankalayil M, Palayoor ST, Cerna D, Coleman CN. Radiation
survivors: understanding and exploiting the phenotype following fractionated
radiation therapy. Mol Cancer Res. 2013 Jan;11(1):5-12. doi:
10.1158/1541-7786.MCR-12-0492. Epub 2012 Nov 21. Review. PubMed PMID: 23175523;
PubMed Central PMCID: PMC3552079.


999: Malara AE, Fedele C, Aloj L, Arra C, Laccetti P, D'Alessio G, De Lorenzo C. 
Effects of a human compact anti-ErbB2 antibody on prostate cancer. Oncol Rep.
2012 Jul;28(1):297-302. doi: 10.3892/or.2012.1760. Epub 2012 Apr 10. PubMed PMID:
22505344.


1000: Mallett CL, McFadden C, Chen Y, Foster PJ. Migration of iron-labeled KHYG-1
natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic
resonance imaging. Cytotherapy. 2012 Jul;14(6):743-51. doi:
10.3109/14653249.2012.667874. Epub 2012 Mar 23. PubMed PMID: 22443465.


1001: Maloney E, Hwang JH. Emerging HIFU applications in cancer therapy. Int J
Hyperthermia. 2014 Nov 4:1-8. [Epub ahead of print] PubMed PMID: 25367011.


1002: Mandl SJ, Rountree RB, Dela Cruz TB, Foy SP, Cote JJ, Gordon EJ, Trent E,
Delcayre A, Franzusoff A. Elucidating immunologic mechanisms of PROSTVAC cancer
immunotherapy. J Immunother Cancer. 2014 Oct 14;2(1):34. doi:
10.1186/s40425-014-0034-0. eCollection 2014. PubMed PMID: 25328681; PubMed
Central PMCID: PMC4201731.


1003: Mansi L, Thiery-Vuillemin A, Kalbacher E, Nguyen T, Maurina T, Nallet J,
Kim S, Borg C, Kleinclauss F, Pivot X, Adotevi O. [Immunotherapy: an emerging
strategies against prostate castration resistant cancer]. Bull Cancer. 2012
Jul;99 Suppl 1:S57-65. doi: 10.1684/bdc.2012.1564. Review. French. PubMed PMID:
22516539.


1004: Mantia-Smaldone GM, Chu CS. A review of dendritic cell therapy for cancer: 
progress and challenges. BioDrugs. 2013 Oct;27(5):453-68. doi:
10.1007/s40259-013-0030-9. Review. PubMed PMID: 23592406.


1005: Maraj BH, Aldersley MA, Markham AF. Prostate-specific membrane antigen
expression in the duodenum: implications in coeliac disease and immunotherapy for
prostate cancer. Lancet. 1998 May 23;351(9115):1559-60. PubMed PMID: 10326547.


1006: Maraj BH, Whelan P, Markham AF. Prostate-specific membrane antigen. Br J
Urol. 1998 Apr;81(4):523-8. Review. PubMed PMID: 9598621.


1007: Maricque BB, Eickhoff JC, McNeel DG. Antibody responses to
prostate-associated antigens in patients with prostatitis and prostate cancer.
Prostate. 2011 Feb 1;71(2):134-46. doi: 10.1002/pros.21229. PubMed PMID:
20632317; PubMed Central PMCID: PMC2978272.


1008: Markiewicz MA, Kast WM. Advances in immunotherapy for prostate cancer. Adv 
Cancer Res. 2003;87:159-94. Review. PubMed PMID: 12641276.


1009: Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, Parmiani G,
Rivoltini L. Vaccination therapy in prostate cancer. Cancer Immunol Immunother.
2007 Apr;56(4):429-45. Epub 2006 Oct 10. Review. PubMed PMID: 17031640.


1010: Marshall DJ, Rudnick KA, Lu J, Snyder LA. Cloning and sequencing of the
cynomolgus monkey prostate specific antigen cDNA. J Med Primatol. 2006
Feb;35(1):12-7. PubMed PMID: 16430490.


1011: Marshall DJ, San Mateo LR, Rudnick KA, McCarthy SG, Harris MC, McCauley C, 
Schantz A, Geng D, Cawood P, Snyder LA. Induction of Th1-type immunity and tumor 
protection with a prostate-specific antigen DNA vaccine. Cancer Immunol
Immunother. 2005 Nov;54(11):1082-94. Epub 2005 Jul 27. PubMed PMID: 16047142.


1012: Martínez-Piñeiro JA, Ruíz F, Hidalgo L, Muntañola P. [Cryo-immunological
response in prostatic cancer]. Actas Urol Esp. 1978 Jan-Feb;2(1):23-32. Spanish. 
PubMed PMID: 665346.


1013: Massard C, Fizazi K. Targeting continued androgen receptor signaling in
prostate cancer. Clin Cancer Res. 2011 Jun 15;17(12):3876-83. doi:
10.1158/1078-0432.CCR-10-2815. Review. PubMed PMID: 21680543.


1014: Matharoo-Ball B, Ball G, Rees R. Clinical proteomics: discovery of cancer
biomarkers using mass spectrometry and bioinformatics approaches--a prostate
cancer perspective. Vaccine. 2007 Sep 27;25 Suppl 2:B110-21. Review. PubMed PMID:
17916461.


1015: Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J
Gastroenterol. 2014 Feb 21;20(7):1657-66. doi: 10.3748/wjg.v20.i7.1657. Review.
PubMed PMID: 24587645; PubMed Central PMCID: PMC3930966.


1016: Matsueda S, Wang M, Weng J, Li Y, Yin B, Zou J, Li Q, Zhao W, Peng W,
Legras X, Loo C, Wang RF, Wang HY. Identification of prostate-specific G-protein 
coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer
immunotherapy. PLoS One. 2012;7(9):e45756. doi: 10.1371/journal.pone.0045756.
Epub 2012 Sep 20. PubMed PMID: 23029225; PubMed Central PMCID: PMC3447865.


1017: Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M.
Identification of new prostate stem cell antigen-derived peptides immunogenic in 
HLA-A2(+) patients with hormone-refractory prostate cancer. Cancer Immunol
Immunother. 2004 Jun;53(6):479-89. Epub 2003 Nov 21. PubMed PMID: 14634796.


1018: Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, Harada M. A
prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate
cancer patients. Prostate. 2004 Aug 1;60(3):205-13. PubMed PMID: 15176050.


1019: Matsumura S, Demaria S. Up-regulation of the pro-inflammatory chemokine
CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res.
2010 Apr;173(4):418-25. doi: 10.1667/RR1860.1. PubMed PMID: 20334513; PubMed
Central PMCID: PMC2857712.


1020: Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy pretreatment
sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated
cytotoxicity. Int J Cancer. 2006 Oct 1;119(7):1630-7. PubMed PMID: 16646079.


1021: Mattes MJ. Determination of antibody immunoreactive fraction. Cancer
Biother Radiopharm. 2004 Dec;19(6):667-8. PubMed PMID: 15665614.


1022: Maurer T, Pournaras C, Aguilar-Pimentel JA, Thalgott M, Horn T, Heck M,
Heit A, Kuebler H, Gschwend JE, Nawroth R. Immunostimulatory CpG-DNA and
PSA-peptide vaccination elicits profound cytotoxic T cell responses. Urol Oncol. 
2013 Oct;31(7):1395-401. doi: 10.1016/j.urolonc.2011.09.002. Epub 2011 Oct 7.
PubMed PMID: 21982682.


1023: Mauri G, Chiodoni C, Parenza M, Arioli I, Tripodo C, Colombo MP.
Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from
orthotopic prostate cancer. Cancer Immunol Immunother. 2013 Dec;62(12):1811-9.
doi: 10.1007/s00262-013-1486-7. Epub 2013 Oct 18. PubMed PMID: 24136641.


1024: May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate cancer
immunotherapy. Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi:
10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23. PubMed PMID: 21700764; PubMed
Central PMCID: PMC3263933.


1025: McArdle SE, Pockley AG, Gibson GR, Rees RC. Prostate cancer: Important
steps and considerations in the design of therapeutic vaccines. Oncoimmunology.
2014 Feb 14;3:e28049. eCollection 2014. PubMed PMID: 25340006; PubMed Central
PMCID: PMC4203569.


1026: McArdle SE, Ali SA, Li G, Mian S, Rees RC. Phenotypic and functional
differences of dendritic cells generated under different in vitro conditions.
Methods Mol Med. 2003;81:359-75. PubMed PMID: 12725131.


1027: McCarthy BA, Reddi AS, Coakley KM, Nguyen SM, Nayal RR, Javdan M, Paul S,
Ende N. Administration of human umbilical cord blood cells produces
interleukin-10 (IL-10) in IL-10 deficient mice without immunosuppression. Curr
Stem Cell Res Ther. 2010 Mar;5(1):13-6. PubMed PMID: 19951257.


1028: McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini
V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted
atomic nanogenerators. Science. 2001 Nov 16;294(5546):1537-40. PubMed PMID:
11711678.


1029: McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud 
AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander 
NH, Cordon-Cardo C, Scheinberg DA. An alpha-particle emitting antibody
([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000 Nov
1;60(21):6095-100. PubMed PMID: 11085533.


1030: McKarney I. Sipuleucel-T (Provenge): active cellular immunotherapy for
advanced prostate cancer. Issues Emerg Health Technol. 2007 Sep;(101):1-4. PubMed
PMID: 17763575.


1031: McKay RR, Choueiri TK, Taplin ME. Rationale for and review of neoadjuvant
therapy prior to radical prostatectomy for patients with high-risk prostate
cancer. Drugs. 2013 Sep;73(13):1417-30. doi: 10.1007/s40265-013-0107-2. Review.
PubMed PMID: 23943203; PubMed Central PMCID: PMC4127573.


1032: McKinnon C. Gene therapy and immunotherapy. IDrugs. 1999 Jul;2(7):620-3.
PubMed PMID: 16127624.


1033: McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, 
DeVries T, Sheikh NA, Dreicer R. A transient increase in eosinophils is
associated with prolonged survival in men with metastatic castration-resistant
prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014
Oct;2(10):988-99. doi: 10.1158/2326-6066.CIR-14-0073. Epub 2014 Sep 4. PubMed
PMID: 25189164; PubMed Central PMCID: PMC4185225.


1034: McNeel DG, Becker JT, Johnson LE, Olson BM. DNA Vaccines for Prostate
Cancer. Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263. PubMed PMID: 24587772;
PubMed Central PMCID: PMC3935480.


1035: McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL,
Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and
immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in
patients with stage D0 prostate cancer. J Clin Oncol. 2009 Sep 1;27(25):4047-54. 
doi: 10.1200/JCO.2008.19.9968. Epub 2009 Jul 27. PubMed PMID: 19636017; PubMed
Central PMCID: PMC2734418.


1036: McNeel DG. Prostate cancer immunotherapy. Curr Opin Urol. 2007
May;17(3):175-81. Review. PubMed PMID: 17414515.


1037: McNeel DG. Cellular immunotherapies for prostate cancer. Biomed
Pharmacother. 2007 Jul;61(6):315-22. Epub 2007 Jan 26. Review. PubMed PMID:
17306498.


1038: McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. Immunol
Lett. 2005 Jan 15;96(1):3-9. Review. PubMed PMID: 15585302.


1039: Meadors JL, Cui Y, Chen QR, Song YK, Khan J, Merlino G, Tsokos M, Orentas
RJ, Mackall CL. Murine rhabdomyosarcoma is immunogenic and responsive to
T-cell-based immunotherapy. Pediatr Blood Cancer. 2011 Dec 1;57(6):921-9. doi:
10.1002/pbc.23048. Epub 2011 Apr 1. PubMed PMID: 21462302.


1040: Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL. Recovery of
zeta-chain expression and changes in spontaneous IL-10 production after PSA-based
vaccines in patients with prostate cancer. Br J Cancer. 2002 Jan 21;86(2):168-78.
PubMed PMID: 11870501; PubMed Central PMCID: PMC2375179.


1041: Meidenbauer N, Andreesen R, Mackensen A. Dendritic cells for specific
cancer immunotherapy. Biol Chem. 2001 Apr;382(4):507-20. Review. PubMed PMID:
11405216.


1042: Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of
PSA-reactive effector cells after vaccination with a PSA-based vaccine in
patients with prostate cancer. Prostate. 2000 May 1;43(2):88-100. PubMed PMID:
10754524.


1043: Meier R, Golovko D, Tavri S, Henning TD, Knopp C, Piontek G, Rudelius M,
Heinrich P, Wels WS, Daldrup-Link H. Depicting adoptive immunotherapy for
prostate cancer in an animal model with magnetic resonance imaging. Magn Reson
Med. 2011 Mar;65(3):756-63. doi: 10.1002/mrm.22652. Epub 2010 Oct 6. PubMed PMID:
20928869.


1044: Meisel A, Stenner F. [New drug treatment possibilities in castration
resistant prostate carcinoma]. Praxis (Bern 1994). 2012 Sep 5;101(18):1143-9;
quiz 1150-1. doi: 10.1024/1661-8157/a001052. Review. German. PubMed PMID:
22945814.


1045: Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S,
Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H. Therapeutic
vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014
Sep;11(9):509-24. doi: 10.1038/nrclinonc.2014.111. Epub 2014 Jul 8. Review.
PubMed PMID: 25001465.


1046: Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 
2011 Dec 21;480(7378):480-9. doi: 10.1038/nature10673. Review. PubMed PMID:
22193102; PubMed Central PMCID: PMC3967235.


1047: Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La
Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N,
Stassi G, Dieli F, Hayday AC. In vivo manipulation of Vgamma9Vdelta2 T cells with
zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast
cancer patients. Clin Exp Immunol. 2010 Aug;161(2):290-7. doi:
10.1111/j.1365-2249.2010.04167.x. Epub 2010 May 10. PubMed PMID: 20491785; PubMed
Central PMCID: PMC2909411.


1048: Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM,
Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. T cell infiltration 
of the prostate induced by androgen withdrawal in patients with prostate cancer. 
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70. PubMed PMID: 11734652;
PubMed Central PMCID: PMC64722.


1049: Meredith RF, Khazaeli MB, Macey DJ, Grizzle WE, Mayo M, Schlom J, Russell
CD, LoBuglio AF. Phase II study of interferon-enhanced 131I-labeled high affinity
CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
Clin Cancer Res. 1999 Oct;5(10 Suppl):3254s-3258s. PubMed PMID: 10541372.


1050: Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH,
Schlom J, Russell CD, Liu T, LoBuglio AF. Treatment of metastatic prostate
carcinoma with radiolabeled antibody CC49. J Nucl Med. 1994 Jun;35(6):1017-22.
PubMed PMID: 8195861.


1051: Merrin C, Han T, Klein E, Wajsman Z, Murphy GP. Immunotherapy of prostatic 
carcinoma with bacillus Calmette-Guerin. Cancer Chemother Rep. 1975
Jan-Feb;59(1):157-63. PubMed PMID: 1093665.


1052: Merrin C, Han T, Klein E, Murphy GP. Immunotherapy of prostatic cancer with
Bacillus Calmette-Guérin and purified protein derivative. Preliminary results.
Urology. 1973 Dec;2(6):651-4. PubMed PMID: 4766022.


1053: Messing E, deKernion JB. Adjuvant therapy for genitourinary cancer. Surg
Clin North Am. 1981 Dec;61(6):1331-46. PubMed PMID: 7198295.


1054: Meye A, Bilkenroth U, Schmidt U, Füssel S, Robel K, Melchior AM, Blümke K, 
Pinkert D, Bartel F, Linne C, Taubert H, Wirth MP. Isolation and enrichment of
urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS
protocol. Int J Oncol. 2002 Sep;21(3):521-30. PubMed PMID: 12168095.


1055: Michael A, Relph K, Annels N, Pandha H. Prostate cancer vaccines. Expert
Rev Vaccines. 2013 Mar;12(3):253-62. doi: 10.1586/erv.13.27. Review. PubMed PMID:
23496665.


1056: Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty
P, Leader D, Whelan M, Pandha H. Delayed disease progression after allogeneic
cell vaccination in hormone-resistant prostate cancer and correlation with
immunologic variables. Clin Cancer Res. 2005 Jun 15;11(12):4469-78. PubMed PMID: 
15958632.


1057: Michaelson MD, Smith MR. Genitourinary malignancies. Cancer Chemother Biol 
Response Modif. 2003;21:547-64. Review. PubMed PMID: 15338763.


1058: Miers L, Lamborn K, Yuan A, Richman C, Natarajan A, DeNardo S, DeNardo G.
Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies
increase tumor-cumulated activity in epithelial cancers? Clin Cancer Res. 2005
Oct 1;11(19 Pt 2):7158s-7163s. PubMed PMID: 16203816.


1059: Mihalyo MA, Hagymasi AT, Slaiby AM, Nevius EE, Adler AJ. Dendritic cells
program non-immunogenic prostate-specific T cell responses beginning at early
stages of prostate tumorigenesis. Prostate. 2007 Apr 1;67(5):536-46. PubMed PMID:
17221844; PubMed Central PMCID: PMC2846359.


1060: Mikulski SM, Billing R, Terasaki PI. Inhibition of effector cell function
in human antibody-dependent cellular cytotoxicity by sera from cancer patients. J
Natl Cancer Inst. 1977 May;58(5):1485-7. PubMed PMID: 857035.


1061: Milano F, Krishnadath KK. Electroporation of dendritic cells with
autologous total RNA from tumor material. Methods Mol Biol. 2014;1139:87-95. doi:
10.1007/978-1-4939-0345-0_9. PubMed PMID: 24619673.


1062: Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel
MW. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for
radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother
Radiopharm. 2008 Oct;23(5):619-31. doi: 10.1089/cbr.2008.0493. PubMed PMID:
18999934; PubMed Central PMCID: PMC2586878.


1063: Miles AK, Rogers A, Li G, Seth R, Powe D, McArdle SE, McCulloch TA, Bishop 
MC, Rees RC. Identification of a novel prostate cancer-associated tumor antigen. 
Prostate. 2007 Feb 15;67(3):274-87. PubMed PMID: 17192878.


1064: Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer
Immunol Immunother. 2007 Jan;56(1):81-7. Epub 2005 Dec 16. Review. PubMed PMID:
16362411.


1065: Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, Pisa P. 
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate
cancer patients. J Immunol. 2006 Nov 15;177(10):7398-405. PubMed PMID: 17082659.


1066: Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in a phase 1
trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J
Immunother. 2005 Jul-Aug;28(4):389-95. PubMed PMID: 16000958.


1067: Min HJ, Lee Y, Zhao XF, Park YK, Lee MK, Lee JW, Kim S. TMPRSS4 upregulates
uPA gene expression through JNK signaling activation to induce cancer cell
invasion. Cell Signal. 2014 Feb;26(2):398-408. doi:
10.1016/j.cellsig.2013.08.002. Epub 2013 Aug 24. PubMed PMID: 23978400.


1068: Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K,
Harada M. Identification of SART3-derived peptides having the potential to induce
cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3
supertype alleles. Cancer Immunol Immunother. 2007 May;56(5):689-98. Epub 2006
Aug 26. PubMed PMID: 16937115.


1069: Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after
gene-based vaccination for immunotherapy-A: results from immunizations in
animals. Cancer Gene Ther. 2006 Apr;13(4):436-44. PubMed PMID: 16276349.


1070: Mincheff M, Zoubak S, Altankova I, Tchakarov S, Pogribnyy P, Makogonenko Y,
Botev C, Meryman HT. Depletion of CD25+ cells from human T-cell enriched fraction
eliminates immunodominance during priming with dendritic cells genetically
modified to express a secreted protein. Cancer Gene Ther. 2005 Feb;12(2):185-97. 
PubMed PMID: 15375382.


1071: Mincheff M, Zoubak S, Altankova I, Tchakarov S, Makogonenko Y, Botev C,
Ignatova I, Dimitrov R, Madarzhieva K, Hammett M, Pomakov Y, Meryman H,
Lissitchkov T. Human dendritic cells genetically engineered to express
cytosolically retained fragment of prostate-specific membrane antigen prime
cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther. 2003
Dec;10(12):907-17. PubMed PMID: 14712317.


1072: Mincheff M, Altankova I, Zoubak S, Tchakarov S, Botev C, Petrov S, Krusteva
E, Kurteva G, Kurtev P, Dimitrov V, Ilieva M, Georgiev G, Lissitchkov T,
Chernozemski I, Meryman HT. In vivo transfection and/or cross-priming of
dendritic cells following DNA and adenoviral immunizations for immunotherapy of
cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and
IFN-gamma lymphokine profile. Crit Rev Oncol Hematol. 2001
Jul-Aug;39(1-2):125-32. PubMed PMID: 11418309.


1073: Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I,
Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for
immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol. 2000
Aug;38(2):208-17. PubMed PMID: 10895014.


1074: Minev BR, Guo F, Gueorguieva I, Kaiser HE. Vaccines for immunotherapy of
breast cancer and prostate cancer: new developments and comparative aspects. In
Vivo. 2002 Nov-Dec;16(6):405-15. Review. PubMed PMID: 12494883.


1075: Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, Anderson
KS, Ruprecht RM. Overlapping synthetic peptides encoding TPD52 as breast cancer
vaccine in mice: prolonged survival. Vaccine. 2009 Mar 13;27(12):1825-33. doi:
10.1016/j.vaccine.2009.01.089. Epub 2009 Feb 6. PubMed PMID: 19201387.


1076: Mishra MV, Showalter TN. Pushing the limits of radiation therapy for
prostate cancer: where do we go next? Semin Oncol. 2013 Jun;40(3):297-307. doi:
10.1053/j.seminoncol.2013.04.005. Review. PubMed PMID: 23806495.


1077: Miyahira AK, Kissick HT, Bishop JL, Takeda DY, Barbieri CE, Simons JW,
Pienta KJ, Soule HR. Beyond immune checkpoint blockade: New approaches to
targeting host-tumor interactions in prostate cancer: Report from the 2014
Coffey-Holden prostate cancer Academy meeting. Prostate. 2014 Oct 30. doi:
10.1002/pros.22920. [Epub ahead of print] PubMed PMID: 25358693.


1078: Miyahira AK, Simons JW, Soule HR. The 20th Annual Prostate Cancer
Foundation Scientific Retreat report. Prostate. 2014 Jun;74(8):811-9. doi:
10.1002/pros.22808. Epub 2014 Apr 9. PubMed PMID: 24719035.


1079: Miyashita H, Troncoso P, Babaian RJ. BCG-induced granulomatous prostatitis:
a comparative ultrasound and pathologic study. Urology. 1992 Apr;39(4):364-7.
PubMed PMID: 1557848.


1080: Miyazawa T. Endogenous retroviruses as potential hazards for vaccines.
Biologicals. 2010 May;38(3):371-6. doi: 10.1016/j.biologicals.2010.03.003. Epub
2010 Apr 8. Review. PubMed PMID: 20378372.


1081: Moake JL, Landry PR, Oren ME, Sayer BL, Heffner LT. Transient peripheral
plasmacytosis. Am J Clin Pathol. 1974 Jul;62(1):8-15. PubMed PMID: 4209544.


1082: Moccia F, Tognoni E, Boccaccio P. Acquired factor VIII inhibitor associated
with prostatic cancer: successful treatment with steroid and immunosuppressive
therapy. Ann Ital Med Int. 2000 Apr-Jun;15(2):172-6. PubMed PMID: 10920509.


1083: Mohebtash M, Gulley JL, Madan RA, Ferrara T, Arlen PM. Cancer vaccines:
current directions and perspectives in prostate cancer. Curr Opin Mol Ther. 2009 
Feb;11(1):31-6. Review. PubMed PMID: 19169957; PubMed Central PMCID: PMC3488286.


1084: Mohebtash M, Madan RA, Gulley JL, Arlen PM. Therapeutic prostate cancer
vaccines: a review of the latest developments. Curr Opin Investig Drugs. 2008
Dec;9(12):1296-301. Review. PubMed PMID: 19037836; PubMed Central PMCID:
PMC3487159.


1085: Mohler JL. Concept and viability of androgen annihilation for advanced
prostate cancer. Cancer. 2014 Sep 1;120(17):2628-37. doi: 10.1002/cncr.28675.
Epub 2014 Apr 25. Review. PubMed PMID: 24771515; PubMed Central PMCID:
PMC4140964.


1086: Mohler JL. 2007 Annual Meeting of the Society of Urologic Oncology and the 
Society of Basic Urologic Research: Introduction. Urol Oncol. 2009
Jan-Feb;27(1):34-5. doi: 10.1016/j.urolonc.2008.07.035. PubMed PMID: 19111795.


1087: Mohsenzadegan M, Madjd Z, Asgari M, Abolhasani M, Shekarabi M, Taeb J,
Shariftabrizi A. Reduced expression of NGEP is associated with high-grade
prostate cancers: a tissue microarray analysis. Cancer Immunol Immunother. 2013
Oct;62(10):1609-18. doi: 10.1007/s00262-013-1463-1. Epub 2013 Aug 17. PubMed
PMID: 23955683.


1088: Molinié V, Longchampt E, Ouazana D, Lebret T. [Bladder tumors and molecular
markers. Current status and perspectives]. Ann Pathol. 2003 Sep;23(4):306-31.
Review. French. PubMed PMID: 14597895.


1089: Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW,
Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar 
KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; 
National Comprehensive Cancer Network. Bladder cancer. J Natl Compr Canc Netw.
2009 Jan;7(1):8-39. PubMed PMID: 19176203.


1090: Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB. Interleukin-2
transfected prostate cancer cells generate a local antitumor effect in vivo.
Prostate. 1994 May;24(5):244-51. PubMed PMID: 8170837.


1091: Moon C, Park JC, Chae YK, Yun JH, Kim S. Current status of experimental
therapeutics for prostate cancer. Cancer Lett. 2008 Aug 8;266(2):116-34. doi:
10.1016/j.canlet.2008.02.065. Epub 2008 Apr 28. Review. PubMed PMID: 18440696.


1092: Mooney D, Paluri R, Mehta A, Goyal J, Sonpavde G. Update in systemic
therapy of urologic malignancies. Postgrad Med. 2014 Jan;126(1):44-54. doi:
10.3810/pgm.2014.01.2724. Review. PubMed PMID: 24393751.


1093: Morales A, Nickel JC, Downey J, Clark J, van der Linden I. Immunotherapy of
an experimental adenocarcinoma of the prostate. J Urol. 1995 May;153(5):1706-10. 
PubMed PMID: 7715015.


1094: Moreaux J, Kassambara A, Hose D, Klein B. STEAP1 is overexpressed in
cancers: a promising therapeutic target. Biochem Biophys Res Commun. 2012 Dec
14;429(3-4):148-55. doi: 10.1016/j.bbrc.2012.10.123. Epub 2012 Nov 6. PubMed
PMID: 23142226.


1095: Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M,
Abken H, Rieber EP, Temme A. Targeting of tumor cells expressing the prostate
stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 2007 Jul
1;67(10):1121-31. PubMed PMID: 17492652.


1096: Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, Kubo M,
Nakamura M, Inaba S, Yamaguchi K, Tanaka M, Katano M. Dendritic cell-based
combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and
activated T cells for cancer patients: rationale, current progress, and
perspectives. Hum Cell. 2003 Dec;16(4):175-82. Review. PubMed PMID: 15147037.


1097: Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A,
Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A,
Curley T, Finn R, O'donoghue JA, Livingston P, Larson S, Scher HI. Pilot trial of
unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody
J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005 Oct
15;11(20):7454-61. PubMed PMID: 16243819.


1098: Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI. Targeting osseous 
metastases: rationale and development of radio-immunotherapy for prostate cancer.
Curr Urol Rep. 2005 May;6(3):163-70. Review. PubMed PMID: 15869719.


1099: Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI. Targeting osseous 
metastases: rationale and development of radio-immunotherapy for prostate cancer.
Curr Oncol Rep. 2004 May;6(3):222-9. Review. PubMed PMID: 15066234.


1100: Morris MJ, Scher HI. Novel therapies for the treatment of prostate cancer: 
current clinical trials and development strategies. Surg Oncol. 2002
Jun;11(1-2):13-23. Review. PubMed PMID: 12031864.


1101: Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of
prostate carcinoma. Cancer. 2000 Sep 15;89(6):1329-48. Review. PubMed PMID:
11002230.


1102: Morse MA, Lyerly HK. Clinical applications of dendritic cell vaccines. Curr
Opin Mol Ther. 2000 Feb;2(1):20-8. Review. PubMed PMID: 11249649.


1103: Mosca PJ, Clay TM, Kim Lyerly H, Morse MA. Current status of dendritic cell
immunotherapy of malignancies. Int Rev Immunol. 2003 May-Aug;22(3-4):255-81.
Review. PubMed PMID: 12745642.


1104: Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD.
Inflamm Bowel Dis. 2009 Sep;15(9):1399-409. doi: 10.1002/ibd.20944. Review.
PubMed PMID: 19591135.


1105: Mossoba ME, Walia JS, Rasaiah VI, Buxhoeveden N, Head R, Ying C, Foley JE, 
Bramson JL, Fowler DH, Medin JA. Tumor protection following vaccination with low 
doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther.
2008 Mar;16(3):607-17. doi: 10.1038/sj.mt.6300390. Epub 2008 Jan 8. PubMed PMID: 
18180774.


1106: Moul JW. Putting Provenge in perspective. Oncology (Williston Park). 2011
Mar;25(3):255, 258. Review. PubMed PMID: 21548468.


1107: Mouraviev V, Mariados N, Albala D, Concepcion RS, Shore ND, Sims RB,
Emberton M, Pieczonka CM. The Rationale for Optimal Combination Therapy With
Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. Rev Urol.
2014;16(3):122-30. Review. PubMed PMID: 25337042; PubMed Central PMCID:
PMC4191632.


1108: Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H,
Waehre H, Raabe N, Gaudernack G. Immunotherapy with allotumour mRNA-transfected
dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer. 2005
Oct 3;93(7):749-56. PubMed PMID: 16136047; PubMed Central PMCID: PMC2361645.


1109: Mu LJ, Gaudernack G, Saebøe-Larssen S, Hammerstad H, Tierens A, Kvalheim G.
A protocol for generation of clinical grade mRNA-transfected monocyte-derived
dendritic cells for cancer vaccines. Scand J Immunol. 2003 Nov;58(5):578-86.
PubMed PMID: 14629630.


1110: Mueller M, Reichardt W, Koerner J, Groettrup M. Coencapsulation of tumor
lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of
prostate carcinoma in TRAMP mice. J Control Release. 2012 Aug 20;162(1):159-66.
doi: 10.1016/j.jconrel.2012.06.015. Epub 2012 Jun 15. PubMed PMID: 22709589.


1111: Muir G, Rajbabu K, Callen C, Fabre JW. Preliminary evidence that the
allogeneic response might trigger antitumour immunity in patients with advanced
prostate cancer. BJU Int. 2006 Nov;98(5):989-95. Epub 2006 Jul 28. PubMed PMID:
16879440.


1112: Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal 
B, Longenecker BM, Gendler SJ. Mucin 1-specific immunotherapy in a mouse model of
spontaneous breast cancer. J Immunother. 2003 Jan-Feb;26(1):47-62. PubMed PMID:
12514429.


1113: Mukherji D, El Dika I, Temraz S, Haidar M, Shamseddine A. Evolving
treatment approaches for the management of metastatic castration-resistant
prostate cancer - role of radium-223. Ther Clin Risk Manag. 2014 May
23;10:373-80. doi: 10.2147/TCRM.S45667. eCollection 2014. Review. PubMed PMID:
24920911; PubMed Central PMCID: PMC4043797.


1114: Mukherji D, Pezaro CJ, Shamseddine A, De Bono JS. New treatment
developments applied to elderly patients with advanced prostate cancer. Cancer
Treat Rev. 2013 Oct;39(6):578-83. doi: 10.1016/j.ctrv.2012.12.004. Epub 2013 Jan 
3. Review. PubMed PMID: 23290885.


1115: Mukherji D, Temraz S, Wehbe D, Shamseddine A. Angiogenesis and
anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol. 2013
Aug;87(2):122-31. doi: 10.1016/j.critrevonc.2013.01.002. Epub 2013 Jan 29.
Review. PubMed PMID: 23375349.


1116: Mukherji D, Eichholz A, De Bono JS. Management of metastatic
castration-resistant prostate cancer: recent advances. Drugs. 2012 May
28;72(8):1011-28. doi: 10.2165/11633360-000000000-00000. Review. PubMed PMID:
22621691.


1117: Mukhopadhaya A, Mendecki J, Dong X, Liu L, Kalnicki S, Garg M, Alfieri A,
Guha C. Localized hyperthermia combined with intratumoral dendritic cells induces
systemic antitumor immunity. Cancer Res. 2007 Aug 15;67(16):7798-806. PubMed
PMID: 17699785.


1118: Muller R. Managed care considerations. A new era of advanced prostate
cancer management. Manag Care. 2011 Sep;20(9 Suppl 5):5. PubMed PMID: 22043721.


1119: Multanen MT, Lindell OI. Radical prostatectomy for localized prostatic
carcinoma in a renal transplant patient. Scand J Urol Nephrol. 1998
May;32(3):221-2. PubMed PMID: 9689704.


1120: Murakami T, Sunada Y. Plasmid DNA gene therapy by electroporation:
principles and recent advances. Curr Gene Ther. 2011 Dec;11(6):447-56. Review.
PubMed PMID: 22023474.


1121: Murav'ev VB, Al'tvaĭn IE. [The immunotherapy of prostatic cancer]. Urol
Nefrol (Mosk). 1997 Jul-Aug;(4):46-8. Review. Russian. PubMed PMID: 9381625.


1122: Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial:
T-cell therapy for prostate cancer using autologous dendritic cells pulsed with
HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate.
1996 Dec;29(6):371-80. PubMed PMID: 8977634.


1123: Murphy GP, Snow P, Simmons SJ, Tjoa BA, Rogers MK, Brandt J, Healy CG,
Bolton WE, Rodbold D. Use of artificial neural networks in evaluating prognostic 
factors determining the response to dendritic cells pulsed with PSMA peptides in 
prostate cancer patients. Prostate. 2000 Jan;42(1):67-72. PubMed PMID: 10579800.


1124: Murray JL. Monoclonal antibody treatment of solid tumors: a coming of age. 
Semin Oncol. 2000 Dec;27(6 Suppl 11):64-70; discussion 92-100. Review. PubMed
PMID: 11236030.


1125: Musselli C, Livingston PO, Ragupathi G. Keyhole limpet hemocyanin conjugate
vaccines against cancer: the Memorial Sloan Kettering experience. J Cancer Res
Clin Oncol. 2001 Oct;127 Suppl 2:R20-6. PubMed PMID: 11768620.


1126: Nabhan C, Parsons B, Touloukian EZ, Stadler WM. Novel approaches and future
directions in castration-resistant prostate cancer. Ann Oncol. 2011
Sep;22(9):1948-57. doi: 10.1093/annonc/mdq639. Epub 2011 Jan 20. PubMed PMID:
21252057.


1127: Nabhan C. Sipuleucel-T immunotherapy for castration-resistant prostate
cancer. N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968. doi:
10.1056/NEJMc1009982#SA2. PubMed PMID: 21067391.


1128: Nagata M, Takita M, Kishi Y, Kodama Y, Matsumura T, Murashige N, Homma Y,
Kami M. Cancer articles in weekly magazines: useful media to deliver cancer
information to the public? Jpn J Clin Oncol. 2013 Apr;43(4):426-30. doi:
10.1093/jjco/hyt004. Epub 2013 Jan 30. PubMed PMID: 23365111.


1129: Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg
J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against
unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic
cells. Nat Med. 2000 Sep;6(9):1011-7. PubMed PMID: 10973321.


1130: Naitoh J, Witte O, Belldegrun A. The University of California, Los
Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and
epithelial cell biology: bringing together basic scientists and clinicians in the
fight against advanced prostate cancer. Cancer Res. 1998 Jul 1;58(13):2895-900.
PubMed PMID: 9661908.


1131: Nakagawa S, Massie B, Hawley RG. Tetracycline-regulatable adenovirus
vectors: pharmacologic properties and clinical potential. Eur J Pharm Sci. 2001
Apr;13(1):53-60. Review. PubMed PMID: 11292568.


1132: Nakanishi H, Mizutani Y, Kawauchi A, Ukimura O, Shiraishi T, Hatano M,
Mizuno M, Yoshida J, Miki T. Significant antitumoral activity of cationic
multilamellar liposomes containing human IFN-beta gene against human renal cell
carcinoma. Clin Cancer Res. 2003 Mar;9(3):1129-35. PubMed PMID: 12631618.


1133: Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, 
Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa
K. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod
Pathol. 2006 Jun;19(6):804-14. PubMed PMID: 16547468.


1134: Nambirajan T, Woolsey S, Mahendra V, O'Rourke D, Walsh IK, Kernohan RM.
Squamous cell carcinoma of the bladder and prostatic urethra in a post renal
transplant patient. Ulster Med J. 2003 Nov;72(2):121-2. PubMed PMID: 14696826;
PubMed Central PMCID: PMC2475424.


1135: Naoe M, Ogawa Y, Takeshita K, Morita J, Shichijo T, Fuji K, Fukagai T,
Iwamoto S, Terao S. Zoledronate stimulates gamma delta T cells in prostate cancer
patients. Oncol Res. 2010;18(10):493-501. PubMed PMID: 20681408.


1136: Naoe M, Marumoto Y, Ishizaki R, Ogawa Y, Nakagami Y, Yoshida H. Correlation
between major histocompatibility complex class I molecules and CD8+ T lymphocytes
in prostate, and quantification of CD8 and interferon-gamma mRNA in prostate
tissue specimens. BJU Int. 2002 Nov;90(7):748-53. PubMed PMID: 12410760.


1137: Narmala SK, Boulmay BC. PSA flare after initiation of abiraterone acetate. 
J Community Support Oncol. 2014 May;12(5):191-2. PubMed PMID: 24971430.


1138: Nasu Y, Sasaki K, Kumon H, Kaku H, Watanabe M. [Suicide gene and immuno
gene therapy for prostate cancer]. Nihon Rinsho. 2011 Jun;69 Suppl 5:554-8.
Review. Japanese. PubMed PMID: 22208043.


1139: Nasu Y, Abarzua F, Kumon H. [Prostate cancer gene therapy]. Nihon Rinsho.
2005 Dec;63 Suppl 12:544-7. Review. Japanese. PubMed PMID: 16416850.


1140: Navarre RJ Jr, Loening SA, Platz C, Narayana A, Culp DA. Nephrogenic
adenoma: a report of 9 cases and review of the literature. J Urol. 1982
Apr;127(4):775-9. PubMed PMID: 7040700.


1141: Naz RK, Shiley B. Prophylactic vaccines for prevention of prostate cancer. 
Front Biosci (Schol Ed). 2012 Jan 1;4:932-40. Review. PubMed PMID: 22202100.


1142: Neel HB 3rd. Cryosurgery for the treatment of cancer. Laryngoscope. 1980
Aug;90(8 Pt 2):1-48. PubMed PMID: 6995752.


1143: Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG.
Partially circumventing peripheral tolerance for oncogene-specific prostate
cancer immunotherapy. Prostate. 2008 May 15;68(7):715-27. doi:
10.1002/pros.20689. PubMed PMID: 18302222.


1144: Neidhardt-Berard EM, Berard F, Banchereau J, Palucka AK. Dendritic cells
loaded with killed breast cancer cells induce differentiation of tumor-specific
cytotoxic T lymphocytes. Breast Cancer Res. 2004;6(4):R322-8. Epub 2004 Apr 30.
PubMed PMID: 15217499; PubMed Central PMCID: PMC468631.


1145: Nelson PS. Identifying immunotherapeutic targets for prostate carcinoma
through the analysis of gene expression profiles. Ann N Y Acad Sci. 2002
Dec;975:232-46. Review. PubMed PMID: 12538168.


1146: Nelson WG, Simons JW. New approaches to adjuvant therapy for patients with 
adverse histopathologic findings following radical prostatectomy. Urol Clin North
Am. 1996 Nov;23(4):685-96. Review. PubMed PMID: 8948421.


1147: Nemunaitis J. Cancer targeting vaccines: surrogate measures of activity.
Hum Vaccin Immunother. 2013 Jan;9(1):213-8. doi: 10.4161/hv.22091. PubMed PMID:
23442594; PubMed Central PMCID: PMC3667941.


1148: Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D,
Bishop D, Rennie PS, Gleave M, Blood P, Pai H, Ludgate C, Nelson BH. Standard
treatments induce antigen-specific immune responses in prostate cancer. Clin
Cancer Res. 2007 Mar 1;13(5):1493-502. PubMed PMID: 17332294.


1149: Newsom-Davis TE, Wang D, Steinman L, Chen PF, Wang LX, Simon AK, Screaton
GR. Enhanced immune recognition of cryptic glycan markers in human tumors. Cancer
Res. 2009 Mar 1;69(5):2018-25. doi: 10.1158/0008-5472.CAN-08-3589. Epub 2009 Feb 
17. PubMed PMID: 19223535; PubMed Central PMCID: PMC2657676.


1150: Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2
ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis
of prostate cancer cells in the presence of mitochondrial activation:
sensitization by overexpression of second mitochondria-derived activator of
caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther.
2002 Oct;1(12):1051-8. PubMed PMID: 12481428.


1151: Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with
Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate
cancer cells: role of XIAP in resistance. Prostate. 2002 Dec 1;53(4):286-99.
PubMed PMID: 12430140.


1152: Ng L, Heck W, Lavsa S, Crowther D, Atkinson B, Xiao L, Araujo J. The lack
of predictors for rapid progression in prostate cancer patients receiving
sipuleucel-T. Cancers (Basel). 2013 May 6;5(2):511-8. doi:
10.3390/cancers5020511. PubMed PMID: 24216988; PubMed Central PMCID: PMC3730335.


1153: Nguyen MC, Tu GH, Koprivnikar KE, Gonzalez-Edick M, Jooss KU, Harding TC.
Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients
treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunol
Immunother. 2010 Sep;59(9):1313-23. doi: 10.1007/s00262-010-0858-5. Epub 2010 May
25. PubMed PMID: 20499060.


1154: Nicodemus CF, Wang L, Lucas J, Varghese B, Berek JS. Toll-like receptor-3
as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol. 
2010 Jun;202(6):608.e1-8. doi: 10.1016/j.ajog.2009.12.001. Epub 2010 Jan 18.
PubMed PMID: 20080226.


1155: Nicolet CM, Siegel DH, Surfus JE, Sondel PM. TAG-72-reactive antibody CC49 
recognizes molecules expressed by hematopoietic cell lines. Tumour Biol.
1997;18(6):356-66. PubMed PMID: 9372869.


1156: Nishinaka Y, Ravindranath MH, Irie RF. Development of a human monoclonal
antibody to ganglioside G(M2) with potential for cancer treatment. Cancer Res.
1996 Dec 15;56(24):5666-71. PubMed PMID: 8971173.


1157: Nishio S, Horii A, Morikawa Y, Kawakita J, Nishijima T, Kishimoto T,
Maekawa M. Studies of the nonspecific cellular immune response in patients with
urinary bladder carcinoma. II. Immunodepressive effect of sera from bladder
carcinoma. Invest Urol. 1979 Mar;16(5):342-5. PubMed PMID: 429128.


1158: Niu Y, Terasaki Y, Komatsu N, Noguchi M, Shichijo S, Itoh K. Identification
of peptides applicable as vaccines for HLA-A26-positive cancer patients. Cancer
Sci. 2009 Nov;100(11):2167-74. doi: 10.1111/j.1349-7006.2009.01298.x. Epub 2009
Jul 23. PubMed PMID: 19689476.


1159: Noe CA, Barry PP. Healthy aging: guidelines for cancer screening and
immunizations. Geriatrics. 1996 Jan;51(1):75-7, 81-3. PubMed PMID: 8543201.


1160: Noguchi M, Moriya F, Suekane S, Ohnishi R, Matsueda S, Sasada T, Yamada A, 
Itoh K. A phase II trial of personalized peptide vaccination in
castration-resistant prostate cancer patients: prolongation of prostate-specific 
antigen doubling time. BMC Cancer. 2013 Dec 30;13:613. doi:
10.1186/1471-2407-13-613. PubMed PMID: 24373380; PubMed Central PMCID:
PMC3882108.


1161: Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S,
Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K,
Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K. Assessment of
immunological biomarkers in patients with advanced cancer treated by personalized
peptide vaccination. Cancer Biol Ther. 2010 Dec 15;10(12):1266-79. Epub 2010 Dec 
15. PubMed PMID: 20935522.


1162: Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M,
Suekane S, Itoh K, Matsuoka K. Combination therapy of personalized peptide
vaccination and low-dose estramustine phosphate for metastatic hormone refractory
prostate cancer patients: an analysis of prognostic factors in the treatment.
Oncol Res. 2007;16(7):341-9. PubMed PMID: 17518272.


1163: Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M,
Suekane S, Matsuoka K. Immunological evaluation of individualized peptide
vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate.
2005 Apr 1;63(1):1-12. PubMed PMID: 15378520.


1164: Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri 
K, Yamada A, Noda S. Immunological monitoring during combination of
patient-oriented peptide vaccination and estramustine phosphate in patients with 
metastatic hormone refractory prostate cancer. Prostate. 2004 Jun 15;60(1):32-45.
PubMed PMID: 15129427.


1165: Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh
K, Noda S. Induction of cellular and humoral immune responses to tumor cells and 
peptides in HLA-A24 positive hormone-refractory prostate cancer patients by
peptide vaccination. Prostate. 2003 Sep 15;57(1):80-92. PubMed PMID: 12886526.


1166: Norström MM, Rådestad E, Stikvoort A, Egevad L, Bergqvist M, Henningsohn L,
Mattsson J, Levitsky V, Uhlin M. Novel method to characterize immune cells from
human prostate tissue. Prostate. 2014 Oct;74(14):1391-9. doi: 10.1002/pros.22854.
Epub 2014 Aug 11. PubMed PMID: 25111297.


1167: Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, 
Palucka KA. Dendritic cells capture killed tumor cells and present their antigens
to elicit tumor-specific immune responses. J Immunol. 2000 Oct 1;165(7):3797-803.
PubMed PMID: 11034385.


1168: Novak A, Binnington B, Ngan B, Chadwick K, Fleshner N, Lingwood CA.
Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce 
their immunodetection in human cancer biopsies. Glycobiology. 2013
Nov;23(11):1230-9. doi: 10.1093/glycob/cwt059. Epub 2013 Jul 31. PubMed PMID:
23906628.


1169: Nowak M, Schmidt-Wolf IG. Natural killer T cells subsets in cancer,
functional defects in prostate cancer and implications for immunotherapy. Cancers
(Basel). 2011 Sep 20;3(3):3661-75. doi: 10.3390/cancers3033661. PubMed PMID:
24212972; PubMed Central PMCID: PMC3759215.


1170: Nseyo UO, Lamm DL. Immunotherapy of bladder cancer. Semin Surg Oncol. 1997 
Sep-Oct;13(5):342-9. Review. PubMed PMID: 9259090.


1171: Nseyo UO, Lamm DL. Therapy of superficial bladder cancer. Semin Oncol. 1996
Oct;23(5):598-604. Review. PubMed PMID: 8893870.


1172: O'Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R, Ryan C, Priest 
K, Bromelow KV, Palmer RD, Tuckwell N, Kennard DA, Souberbielle BE. A randomized 
phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in
patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br
J Cancer. 2000 Oct;83(7):853-7. PubMed PMID: 10970684; PubMed Central PMCID:
PMC2374669.


1173: O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL,
Meyers FJ. Combined modality radioimmunotherapy for human prostate cancer
xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate. 2002 Jan
1;50(1):27-37. PubMed PMID: 11757033.


1174: O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, Griffith IJ,
Goldstein DS, Kukis DL, Martinez GS, Mirick GR, DeNardo GL, Meyers FJ.
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate
cancer. Clin Cancer Res. 2001 Jun;7(6):1561-8. PubMed PMID: 11410491.


1175: O'Donnell RT, DeNardo SJ, DeNardo GL, Miers L, Lamborn KR, Kukis DL, Meyers
FJ. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for 
PC3-tumored mice. Prostate. 2000 Aug 1;44(3):187-92. PubMed PMID: 10906734.


1176: O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, Meyers 
FJ. L6 monoclonal antibody binds prostate cancer. Prostate. 1998 Oct
1;37(2):91-7. PubMed PMID: 9759703.


1177: O'Neill DW. Dendritic cells and T cells in immunotherapy. J Drugs Dermatol.
2010 Nov;9(11):1383-92. Review. PubMed PMID: 21061761.


1178: Oates RD, Stilmant MM, Freedlund MC, Siroky MB. Granulomatous prostatitis
following bacillus Calmette-Guerin immunotherapy of bladder cancer. J Urol. 1988 
Oct;140(4):751-4. PubMed PMID: 3418796.


1179: Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Identification of 
polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides
immunogenic in HLA-A24+ prostate cancer patients. Prostate. 2004 Sep
1;60(4):273-81. PubMed PMID: 15264237.


1180: Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology--analysis of host 
and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011 Aug
9;8(12):711-9. doi: 10.1038/nrclinonc.2011.122. Review. PubMed PMID: 21826083;
PubMed Central PMCID: PMC3227751.


1181: Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L,
Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ. Novel options for the
treatment of castration-resistant prostate cancer. World J Urol. 2012
Aug;30(4):495-503. doi: 10.1007/s00345-011-0796-7. Epub 2011 Nov 20. Review.
PubMed PMID: 22101903.


1182: Oikawa T, Kawai K, Ishiwata I, Ohno T, Akaza H. Induction of potent
antitumour natural-killer cells from peripheral blood of patients with advanced
prostate cancer. BJU Int. 2003 Dec;92(9):1009-15. PubMed PMID: 14632866.


1183: Ojemuyiwa MA, Madan RA, Dahut WL. Tyrosine kinase inhibitors in the
treatment of prostate cancer: taking the next step in clinical development.
Expert Opin Emerg Drugs. 2014 Dec;19(4):459-70. doi:
10.1517/14728214.2014.969239. Epub 2014 Oct 25. PubMed PMID: 25345821.


1184: Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I,
Fujiki F, Nakajima H, Yamamoto Y, Shibata S, Nakamura M, Hasegawa K, Takagi S,
Fukuda I, Hoshikawa T, Murakami Y, Mori M, Inoue M, Naka T, Tomonaga T, Shimizu
Y, Nakagawa M, Hasegawa J, Nezu R, Inohara H, Izumoto S, Nonomura N, Yoshimine T,
Okumura M, Morii E, Maeda H, Nishida S, Hosen N, Tsuboi A, Oka Y, Sugiyama H. The
translation elongation factor eEF2 is a novel tumor‑associated antigen
overexpressed in various types of cancers. Int J Oncol. 2014 May;44(5):1461-9.
doi: 10.3892/ijo.2014.2318. Epub 2014 Mar 4. PubMed PMID: 24589652; PubMed
Central PMCID: PMC4027928.


1185: Okada T, Akada M, Fujita T, Iwata T, Goto Y, Kido K, Okada T, Matsuzaki Y, 
Kobayashi K, Matsuno S, Sunamura M, Kawakami Y. A novel cancer testis antigen
that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin
Cancer Res. 2006 Jan 1;12(1):191-7. PubMed PMID: 16397042.


1186: Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE,
Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy
using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother.
2007 May-Jun;30(4):396-405. PubMed PMID: 17457214.


1187: Oliver RT. Circumcision and/or vaccination against human papillomavirus in 
the male to prevent infection with human immunodeficiency virus: an early
surrogate endpoint for the later prevention of penile, prostate, anal and oral
cancer? BJU Int. 2009 Sep;104(6):753-5. doi: 10.1111/j.1464-410X.2009.08596.x.
Epub 2009 May 7. PubMed PMID: 19426185.


1188: Oliver RT, Williams G, Paris AM, Blandy JP. Intermittent androgen
deprivation after PSA-complete response as a strategy to reduce induction of
hormone-resistant prostate cancer. Urology. 1997 Jan;49(1):79-82. PubMed PMID:
9000190.


1189: Oliver RT. New directions with hormone therapy in prostate cancer: possible
benefit from blocking prolactin and use of hormone treatment intermittently in
combination with immunotherapy. Eur J Cancer. 1995 Jun;31A(6):859-60. PubMed
PMID: 7646910.


1190: Oliver RT, Gallagher CJ. Intermittent endocrine therapy and its potential
for chemoprevention of prostate cancer. Cancer Surv. 1995;23:191-207. Review.
PubMed PMID: 7621458.


1191: Oliver RT, Joseph JV, Gallagher CJ. Castration-induced lymphocytosis in
prostate cancer: possible evidence for gonad/thymus endocrine interaction in man.
Urol Int. 1995;54(4):226-9. PubMed PMID: 7610506.


1192: Olson BM, Johnson LE, McNeel DG. The androgen receptor: a biologically
relevant vaccine target for the treatment of prostate cancer. Cancer Immunol
Immunother. 2013 Mar;62(3):585-96. doi: 10.1007/s00262-012-1363-9. Epub 2012 Oct 
30. PubMed PMID: 23108626; PubMed Central PMCID: PMC3577997.


1193: Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG.
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by
CTLA-4 or IL-35 blockade. J Immunol. 2012 Dec 15;189(12):5590-601. doi:
10.4049/jimmunol.1201744. Epub 2012 Nov 14. PubMed PMID: 23152566; PubMed Central
PMCID: PMC3735346.


1194: Olson BM, McNeel DG. Sipuleucel-T: immunotherapy for advanced prostate
cancer. Open Access J Urol. 2011 May 3;3:49-60. doi: 10.2147/OAJU.S13069. Review.
PubMed PMID: 24198636; PubMed Central PMCID: PMC3818937.


1195: Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG.
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer
Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub
2010 Feb 6. PubMed PMID: 20140431; PubMed Central PMCID: PMC3038205.


1196: Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies
targeting prostate-specific membrane antigen. Rev Recent Clin Trials. 2007
Sep;2(3):182-90. Review. PubMed PMID: 18474004.


1197: Olurinde MO, Shen CH, Drake A, Bai A, Chen J. Persistence of
tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent. Cell
Mol Immunol. 2011 Sep;8(5):415-23. doi: 10.1038/cmi.2011.18. Epub 2011 Jun 13.
PubMed PMID: 21666707; PubMed Central PMCID: PMC3381361.


1198: Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Golmakani 
N. Production of a novel camel single-domain antibody specific for the type III
mutant EGFR. Tumour Biol. 2004 Sep-Dec;25(5-6):296-305. PubMed PMID: 15627895.


1199: Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics
in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol. 2014
Feb;6(1):3-14. doi: 10.1177/1756287213509677. Review. PubMed PMID: 24489604;
PubMed Central PMCID: PMC3891292.


1200: Omlin A, de Bono JS. Therapeutic options for advanced prostate cancer: 2011
update. Curr Urol Rep. 2012 Apr;13(2):170-8. doi: 10.1007/s11934-012-0239-z.
Review. PubMed PMID: 22373838.


1201: Oosterlinck W, Decaestecker K. Current strategies in the treatment of
non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2012
Aug;12(8):1097-106. doi: 10.1586/era.12.87. Review. PubMed PMID: 23030228.


1202: Orange DE, Jegathesan M, Blachère NE, Frank MO, Scher HI, Albert ML,
Darnell RB. Effective antigen cross-presentation by prostate cancer patients'
dendritic cells: implications for prostate cancer immunotherapy. Prostate Cancer 
Prostatic Dis. 2004;7(1):63-72. PubMed PMID: 14999241.


1203: Otto T, Rübben H. [Carcinoma in situ of the urinary bladder--definition and
status of treatment]. Urologe A. 1991 May;30(3):163-6. Review. German. PubMed
PMID: 1871934.


1204: Oudard S. Progress in emerging therapies for advanced prostate cancer.
Cancer Treat Rev. 2013 May;39(3):275-89. doi: 10.1016/j.ctrv.2012.09.005. Epub
2012 Oct 26. Review. PubMed PMID: 23107383.


1205: Ouzaid I, Ravery V, Pouessel D, Culine S. [Novel agents for the therapy of 
castration-resistant prostate cancer: overview of pivotal studies and new
strategies to come]. Prog Urol. 2013 Jan;23(1):1-7. doi:
10.1016/j.purol.2012.07.007. Epub 2012 Aug 13. Review. French. PubMed PMID:
23287477.


1206: Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll 
MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia
virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell
destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S
A. 1999 Mar 16;96(6):2982-7. PubMed PMID: 10077623; PubMed Central PMCID:
PMC15881.


1207: Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL,
Baranova AV, Kozlov AP, Schlom J. The human T-box mesodermal transcription factor
Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin
Cancer Res. 2007 Apr 15;13(8):2471-8. PubMed PMID: 17438107.


1208: Palena C, Zhu M, Schlom J, Tsang KY. Human B cells that hyperexpress a
triad of costimulatory molecules via avipox-vector infection: an alternative
source of efficient antigen-presenting cells. Blood. 2004 Jul 1;104(1):192-9.
Epub 2004 Mar 9. PubMed PMID: 15010371.


1209: Paller CJ, Antonarakis ES. Sipuleucel-T for the treatment of metastatic
prostate cancer: promise and challenges. Hum Vaccin Immunother. 2012
Apr;8(4):509-19. doi: 10.4161/hv.18860. Epub 2012 Apr 1. Review. PubMed PMID:
22336881.


1210: Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio 
H. Female gender and carcinoma in situ in the prostatic urethra are prognostic
factors for recurrence, progression, and disease-specific mortality in T1G3
bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2012
Jul;62(1):118-25. doi: 10.1016/j.eururo.2011.10.029. Epub 2011 Oct 25. PubMed
PMID: 22101115.


1211: Palou J, Xavier B, Laguna P, Montlleó M, Vicente J. In situ transitional
cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy
without previous transurethral resection of the prostate. Urology. 1996
Apr;47(4):482-4. PubMed PMID: 8638354.


1212: Pan MH, Gao DW, Feng J, He J, Seo Y, Tedesco J, Wolodzko JG, Hasegawa BH,
Franc BL. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to
prostate-specific membrane antigen in xenograft model of prostate cancer and
potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11
radioimmunotherapy. Mol Imaging Biol. 2009 May-Jun;11(3):159-66. doi:
10.1007/s11307-008-0185-9. Epub 2008 Nov 25. PubMed PMID: 19034582; PubMed
Central PMCID: PMC2841328.


1213: Pandey JP, Namboodiri AM, Kistner-Griffin E. IgG and FcγR genotypes and
humoral immunity to mucin 1 in prostate cancer. Hum Immunol. 2013
Aug;74(8):1030-3. doi: 10.1016/j.humimm.2013.04.008. Epub 2013 Apr 22. PubMed
PMID: 23619475.


1214: Pandha H, Eaton J, Greenhalgh R, Soars D, Dalgleish A. Immunotherapy of
murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex
viral thymidine kinase/ganciclovir suicide gene therapy. Cancer Gene Ther. 2005
Jun;12(6):572-8. PubMed PMID: 15803141.


1215: Pandha HS, Cook D, Greenhalgh R, Dalgleish A. Immunotherapy of murine
prostate cancer using whole tumour cells killed ex vivo by cytosine
deaminase/5-fluorocytosine suicide-gene therapy. BJU Int. 2005 Jun;95(9):1336-43.
PubMed PMID: 15892827.


1216: Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C,
Dalgleish AG. Dendritic cell immunotherapy for urological cancers using
cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int.
2004 Aug;94(3):412-8. PubMed PMID: 15291878.


1217: Pandhi N, DeVoe JE, Schumacher JR, Bartels C, Thorpe CT, Thorpe JM, Smith
MA. Number of first-contact access components required to improve preventive
service receipt in primary care homes. J Gen Intern Med. 2012 Jun;27(6):677-84.
doi: 10.1007/s11606-011-1955-7. Epub 2012 Jan 4. PubMed PMID: 22215269; PubMed
Central PMCID: PMC3358386.


1218: Pandhi N, DeVoe JE, Schumacher JR, Bartels C, Thorpe CT, Thorpe JM, Smith
MA. Preventive service gains from first contact access in the primary care home. 
J Am Board Fam Med. 2011 Jul-Aug;24(4):351-9. doi: 10.3122/jabfm.2011.04.100254. 
PubMed PMID: 21737759; PubMed Central PMCID: PMC3137250.


1219: Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, 
Scher HI, Larson SM, Divgi CR. Antibody mass escalation study in patients with
castration-resistant prostate cancer using 111In-J591: lesion detectability and
dosimetric projections for 90Y radioimmunotherapy. J Nucl Med. 2008
Jul;49(7):1066-74. doi: 10.2967/jnumed.107.049502. Epub 2008 Jun 13. PubMed PMID:
18552139; PubMed Central PMCID: PMC2766795.


1220: Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagalà C, Astone A, Landolfi 
R, Barone C. The immune response to tumors as a tool toward immunotherapy. Clin
Dev Immunol. 2011;2011:894704. doi: 10.1155/2011/894704. Epub 2011 Dec 5. Review.
PubMed PMID: 22190975; PubMed Central PMCID: PMC3235449.


1221: Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed
capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer
immunotherapy. Immunol Cell Biol. 2014 Feb;92(2):116-23. doi:
10.1038/icb.2013.74. Epub 2013 Nov 12. PubMed PMID: 24217810.


1222: Pang J, Gao X, Liu X, Wang K, Zhang Y, Feng L, Zhan H. Enhanced antitumor
effects by the coculture of allotumor RNA-pulsed dendritic cells with autologous 
cytokine-induced killer cells on hormone-refractory prostate cancer. Cancer
Invest. 2007;25(7):527-34. PubMed PMID: 17952744.


1223: Pang X, Tashiro K, Eguchi R, Komatsu N, Sasada T, Itoh K, Kuhara S.
Haptoglobin proved a prognostic biomarker in peripheral blood of patients with
personalized peptide vaccinations for advanced castration-resistant prostate
cancer. Biosci Biotechnol Biochem. 2013;77(4):766-70. Epub 2013 Apr 7. PubMed
PMID: 23563546.


1224: Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME,
Belldegrun AS, Figlin RA. Phase I trial of antigen-specific gene therapy using a 
recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients
with advanced prostate cancer. J Immunother. 2004 May-Jun;27(3):240-53. PubMed
PMID: 15076142.


1225: Paolino A. Immunotherapy holds promise for HRPC. Lancet Oncol. 2007
Aug;8(8):676. PubMed PMID: 17726784.


1226: Papatsoris AG, Karamouzis MV, Papavassiliou AG. Novel biological agents for
the treatment of hormone-refractory prostate cancer (HRPC). Curr Med Chem.
2005;12(3):277-96. Review. PubMed PMID: 15723619.


1227: Papatsoris AG, Papavassiliou AG. Prostate cancer: horizons in the
development of novel anti-cancer strategies. Curr Med Chem Anticancer Agents.
2001 May;1(1):47-70. Review. PubMed PMID: 12678770.


1228: Papetti M, Herman IM. Controlling tumor-derived and vascular endothelial
cell growth: role of the 4Ff2 cell surface antigen. Am J Pathol. 2001
Jul;159(1):165-78. Erratum in: Am J Pathol 2001 Nov;159(5):1975. PubMed PMID:
11438464; PubMed Central PMCID: PMC1850433.


1229: Parente-Pereira AC, Burnet J, Ellison D, Foster J, Davies DM, van der
Stegen S, Burbridge S, Chiapero-Stanke L, Wilkie S, Mather S, Maher J.
Trafficking of CAR-engineered human T cells following regional or systemic
adoptive transfer in SCID beige mice. J Clin Immunol. 2011 Aug;31(4):710-8. doi: 
10.1007/s10875-011-9532-8. Epub 2011 Apr 20. PubMed PMID: 21505816.


1230: Parker C. A near miss for prostate cancer immunotherapy. Lancet Oncol. 2014
Jun;15(7):669-71. doi: 10.1016/S1470-2045(14)70220-7. Epub 2014 May 13. PubMed
PMID: 24831980.


1231: Parkinson RJ, Mian S, Bishop MC, Gray T, Li G, McArdle SE, Ali S, Rees RC. 
Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate
vector system for gene delivery/expression of GM-CSF in human prostate cancer
therapy. Prostate. 2003 Jun 15;56(1):65-73. PubMed PMID: 12746848.


1232: Parmigiani RB, Bettoni F, Grosso DM, Lopes A, Cunha IW, Soares FA, Carvalho
AL, Fonseca F, Camargo AA. Antibodies against the cancer-testis antigen CTSP-1
are frequently found in prostate cancer patients and are an independent
prognostic factor for biochemical-recurrence. Int J Cancer. 2008 May
15;122(10):2385-90. doi: 10.1002/ijc.23369. PubMed PMID: 18214856.


1233: Parmigiani RB, Bettoni F, Vibranovski MD, Lopes MH, Martins WK, Cunha IW,
Soares FA, Simpson AJ, de Souza SJ, Camargo AA. Characterization of a
cancer/testis (CT) antigen gene family capable of eliciting humoral response in
cancer patients. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18066-71. Epub
2006 Nov 17. PubMed PMID: 17114284; PubMed Central PMCID: PMC1838707.


1234: Parnes HL, Brawley OW, Minasian LM, Ford LG. Phase III prostate cancer
chemoprevention trials. Recent Results Cancer Res. 2014;202:73-7. doi:
10.1007/978-3-642-45195-9_9. PubMed PMID: 24531780.


1235: Parra S, Pinochet R, Vargas R, Sepúlveda C, Miranda D, Puente J. [Natural
killer cytolytic activity in renal and prostatic cancer]. Rev Med Chil. 1994
Jun;122(6):630-7. Spanish. PubMed PMID: 7732206.


1236: Parry R, Schneider D, Hudson D, Parkes D, Xuan JA, Newton A, Toy P, Lin R, 
Harkins R, Alicke B, Biroc S, Kretschmer PJ, Halks-Miller M, Klocker H, Zhu Y,
Larsen B, Cobb RR, Bringmann P, Roth G, Lewis JS, Dinter H, Parry G.
Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based 
radiotherapy of prostate cancer. Cancer Res. 2005 Sep 15;65(18):8397-405. PubMed 
PMID: 16166318.


1237: Pastor F, Kolonias D, McNamara JO 2nd, Gilboa E. Targeting 4-1BB
costimulation to disseminated tumor lesions with bi-specific oligonucleotide
aptamers. Mol Ther. 2011 Oct;19(10):1878-86. doi: 10.1038/mt.2011.145. Epub 2011 
Aug 9. PubMed PMID: 21829171; PubMed Central PMCID: PMC3188744.


1238: Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic,
androgen-independent prostate cancer. Ann Pharmacother. 2008 Jan;42(1):91-8. Epub
2007 Dec 19. Review. PubMed PMID: 18094343.


1239: Paukstadt W. [Molecular biology methods in cancer medicine: options beyond 
steel instrument, ray and chemotherapy]. MMW Fortschr Med. 2004 Nov
18;146(47):12, 14. German. PubMed PMID: 15624648.


1240: Pavlenko M, Leder C, Moreno S, Levitsky V, Pisa P. Priming of CD8+ T-cell
responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice.
Vaccine. 2007 Aug 21;25(34):6341-7. Epub 2007 Jun 29. PubMed PMID: 17628235.


1241: Pavlenko M, Leder C, Roos AK, Levitsky V, Pisa P. Identification of an
immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate. 2005 Jun
15;64(1):50-9. PubMed PMID: 15651071.


1242: Pavlenko M, Roos AK, Leder C, Hansson LO, Kiessling R, Levitskaya E, Pisa
P. Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated
by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol
Immunother. 2004 Dec;53(12):1085-92. PubMed PMID: 15696608.


1243: Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman 
B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P. A
phase I trial of DNA vaccination with a plasmid expressing prostate-specific
antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004
Aug 16;91(4):688-94. PubMed PMID: 15280930; PubMed Central PMCID: PMC2364780.


1244: Pedro Silva IE, Osorio Acosta V, Farfán Chávez FA. [Cystic adenoid
carcinoma of the prostate. Report of two cases]. Arch Esp Urol. 2006
Oct;59(8):823-5. Spanish. PubMed PMID: 17153506.


1245: Pei Z, Li H, Guo Y, Jin Y, Lin D. Sodium selenite inhibits the expression
of VEGF, TGFbeta(1) and IL-6 induced by LPS in human PC3 cells via TLR4-NF-(K)B
signaling blockage. Int Immunopharmacol. 2010 Jan;10(1):50-6. doi:
10.1016/j.intimp.2009.09.020. Epub 2009 Oct 5. PubMed PMID: 19811770.


1246: Pentinga SE, Bruining HG, Gerritsen WR, van den Eertwegh AJ, Rustemeyer T. 
A case of delayed-type hypersensitivity to subcutaneously administered drugs
during anticancer immunotherapy. Br J Dermatol. 2009 May;160(5):1132-4. doi:
10.1111/j.1365-2133.2009.09087.x. Epub 2009 Mar 9. PubMed PMID: 19292712.


1247: Peppercorn J, Armstrong A, Zaas DW, George D. Rationing in urologic
oncology: lessons from sipuleucel-T for advanced prostate cancer. Urol Oncol.
2013 Oct;31(7):1079-84. doi: 10.1016/j.urolonc.2011.12.022. Epub 2012 Feb 4.
PubMed PMID: 22305627.


1248: Perambakam S, Xie H, Edassery S, Peace DJ. Long-term follow-up of HLA-A2+
patients with high-risk, hormone-sensitive prostate cancer vaccinated with the
prostate specific antigen peptide homologue (PSA146-154). Clin Dev Immunol.
2010;2010:473453. doi: 10.1155/2010/473453. Epub 2011 Jan 5. PubMed PMID:
21253471; PubMed Central PMCID: PMC3022181.


1249: Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, 
Mahmud D, Nunez R, Sosman JA, Peace DJ. Induction of specific T cell immunity in 
patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer
Immunol Immunother. 2006 Sep;55(9):1033-42. Epub 2005 Nov 10. PubMed PMID:
16283303.


1250: Perambakam S, Xue BH, Sosman JA, Peace DJ. Induction of Tc2 cells with
specificity for prostate-specific antigen from patients with hormone-refractory
prostate cancer. Cancer Immunol Immunother. 2002 Jul;51(5):263-70. Epub 2002 Apr 
24. PubMed PMID: 12070713.


1251: Perez CA, Santos ES, Raez LE. Active immunotherapy for non-small-cell lung 
cancer: moving toward a reality. Expert Rev Anticancer Ther. 2011
Oct;11(10):1599-605. doi: 10.1586/era.11.155. Review. PubMed PMID: 21999133.


1252: Perez SA, Anastasopoulou EA, Papamichail M, Baxevanis CN. AE37 peptide
vaccination in prostate cancer: identification of biomarkers in the context of
prognosis and prediction. Cancer Immunol Immunother. 2014 Nov;63(11):1141-50.
doi: 10.1007/s00262-014-1582-3. Epub 2014 Jul 23. PubMed PMID: 25052849.


1253: Perez SA, Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H,
Papamichail M, Baxevanis CN. AE37 peptide vaccination in prostate cancer: a
4-year immunological assessment updates on a phase I trial. Cancer Immunol
Immunother. 2013 Oct;62(10):1599-608. doi: 10.1007/s00262-013-1461-3. Epub 2013
Aug 10. PubMed PMID: 23934022.


1254: Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K,
Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E, Baxevanis CN. Results
from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid
peptide vaccine in patients with prostate cancer. Clin Cancer Res. 2010 Jul
1;16(13):3495-506. doi: 10.1158/1078-0432.CCR-10-0085. Epub 2010 May 13. PubMed
PMID: 20466887.


1255: Perico ME, Mezzanzanica D, Luison E, Alberti P, Panza L, Russo G, Canevari 
S. Development of a new vaccine formulation that enhances the immunogenicity of
tumor-associated antigen CaMBr1. Cancer Immunol Immunother. 2000
Aug;49(6):296-304. PubMed PMID: 10946811.


1256: Perry MJ, Hroulda D, Dalgleish AG. Prospects for vaccination in prostate
cancer. Drugs Aging. 2000 May;16(5):321-7. Review. PubMed PMID: 10917069.


1257: Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate 
tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting
cells pulsed with prostatic acid phosphatase peptide. Prostate. 1998 Jul
1;36(2):129-38. PubMed PMID: 9655265.


1258: Peskin SR. Immunotherapy for advanced prostate cancer: a novel treatment
option to improve survival. Manag Care. 2011 Sep;20(9 Suppl 5):3-4, 6-11. PubMed 
PMID: 22046617.


1259: Petrizzo A, Tagliamonte M, Tornesello M, Buonaguro FM, Buonaguro L. Systems
vaccinology for cancer vaccine development. Expert Rev Vaccines. 2014
Jun;13(6):711-9. doi: 10.1586/14760584.2014.913484. Epub 2014 Apr 28. PubMed
PMID: 24766452.


1260: Petrovich Z, Baert L, Bagshaw MA, Brady LW, Elgamal A, Goethuys H, Heilman 
HP, Kirkels WJ, Lieskovsky G, Perez CA, Van Poppel H, Williams RD. Adenocarcinoma
of the prostate: innovations in management. Am J Clin Oncol. 1997
Apr;20(2):111-9. Review. PubMed PMID: 9124181.


1261: Petrylak D. Successive therapies may extend survival in AIPC. Interview by 
Alice Goodman. RN. 2007 Mar;70(3):1-2. PubMed PMID: 17405359.


1262: Petrányi Á. [The treatment of castration-resistant prostate cancer]. Magy
Onkol. 2012 Dec;56(4):219-28. doi: MagyOnkol.2012.56.4.219. Epub 2012 Oct 3.
Review. Hungarian. PubMed PMID: 23236591.


1263: Pezaro C, Omlin A, Lorente D, de Bono J. Management of patients with
castration-resistant disease. Hematol Oncol Clin North Am. 2013
Dec;27(6):1243-60, ix. doi: 10.1016/j.hoc.2013.08.008. Epub 2013 Sep 20. Review. 
PubMed PMID: 24188261.


1264: Pienta KJ, Walia G, Simons JW, Soule HR. Beyond the androgen receptor: new 
approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck
Prostate Cancer Meeting. Prostate. 2014 Feb;74(3):314-20. doi:
10.1002/pros.22753. PubMed PMID: 24249419.


1265: Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I,
Kanety H, Ramon J, Eshhar Z. Adoptive immunotherapy of prostate cancer bone
lesions using redirected effector lymphocytes. J Clin Invest. 2004
Dec;114(12):1774-81. PubMed PMID: 15599402; PubMed Central PMCID: PMC535069.


1266: Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, 
Ramon J, Eshhar Z. Immuno-gene therapy of established prostate tumors using
chimeric receptor-redirected human lymphocytes. Cancer Res. 2003 May
15;63(10):2470-6. PubMed PMID: 12750268.


1267: Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI.
Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res.
2003 Dec 15;9(17):6523-33. PubMed PMID: 14695157.


1268: Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, 
Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola V,
Viza D. A preliminary report on the use of transfer factor for treating stage D3 
hormone-unresponsive metastatic prostate cancer. Biotherapy. 1996;9(1-3):123-32. 
PubMed PMID: 8993770.


1269: Plosker GL. Sipuleucel-T: in metastatic castration-resistant prostate
cancer. Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000.
Review. PubMed PMID: 21175243.


1270: Pollard M, Luckert PH. Immunotherapy by BCG against prostate
adenocarcinomas in anatomical compartments. Anticancer Res. 1994
Nov-Dec;14(6B):2691-4. PubMed PMID: 7872703.


1271: Pollard M, Chang CF, Luckert PH. Investigations on prostatic
adenocarcinomas in rats. Oncology. 1977;34(3):129-32. PubMed PMID: 917442.


1272: Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in
autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate. 2000 Jun
15;44(1):49-54. PubMed PMID: 10861757.


1273: Pontes JE, Choe B, Rose N, Pierce JM Jr. Indirect immunofluorescence for
identification of prostatic epithelial cells. J Urol. 1977 Apr;117(4):459-63.
PubMed PMID: 321808.


1274: Porfyris O, Kalomoiris P. Current role of immunotherapy for the treatment
of prostate cancer. J BUON. 2013 Oct-Dec;18(4):809-17. Review. PubMed PMID:
24344002.


1275: Pracht M, Herrera F, Tawadros T, Berthold D. [Immunotherapy: a therapeutic 
revolution against prostate cancer?]. Rev Med Suisse. 2013 May 22;9(387):1070-5. 
French. PubMed PMID: 23757912.


1276: Prehn RT, Berd D. Whipsaw cancer treatments: the role of hormesis in
endocrine and immune therapies. Semin Oncol. 2006 Dec;33(6):708-10. Review.
PubMed PMID: 17145351.


1277: Preise D, Scherz A, Salomon Y. Antitumor immunity promoted by vascular
occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP).
Photochem Photobiol Sci. 2011 May;10(5):681-8. doi: 10.1039/c0pp00315h. Epub 2011
Jan 24. Review. PubMed PMID: 21258718.


1278: Prejean JD, Griswold DP, Weisburger JH. Transplantation of allogeneic
tumors in rats and mice treated with azathioprine, prednisone and antilymphocyte 
serum. Proc Soc Exp Biol Med. 1972 Apr;139(4):1425-8. PubMed PMID: 4336832.


1279: Prell RA, Gearin L, Simmons A, Vanroey M, Jooss K. The anti-tumor efficacy 
of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel
administration. Cancer Immunol Immunother. 2006 Oct;55(10):1285-93. Epub 2006 Jan
12. PubMed PMID: 16408214.


1280: Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI,
Goldstein NI. The biologic effects of C225, a chimeric monoclonal antibody to the
EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996
Nov;19(6):419-27. PubMed PMID: 9041461.


1281: Price N. Highlights from the 29th European Society for Medical Oncology
Congress: Vienna, Austria, October 29 through November 2, 2004. Clin Prostate
Cancer. 2004 Dec;3(3):136-40. PubMed PMID: 15636678.


1282: Prikler L, Scandella E, Men Y, Engeler DS, Diener PA, Gillessen S, Ludewig 
B, Schmid HP. [Adaptive immunotherapy of the advanced prostate cancer - cancer
testis antigen (CTA) as possible target antigens]. Aktuelle Urol. 2004
Aug;35(4):326-30. German. PubMed PMID: 15459874.


1283: Prinz J, Kraushaar J, Rothauge CF. Late results of complementary specific
immunostimulation in metastatic prostate carcinoma. Urol Int. 1987;42(4):292-4.
PubMed PMID: 3672659.


1284: Proudfoot O, Pouniotis D, Sheng KC, Loveland BE, Pietersz GA. Dendritic
cell vaccination. Expert Rev Vaccines. 2007 Aug;6(4):617-33. Review. PubMed PMID:
17669014.


1285: Prout GR Jr. Status of the treatment of prostatic carcinoma--1964. Proc
Natl Cancer Conf. 1964;5:309. PubMed PMID: 5889426.


1286: Pulley MS, Nagendran V, Edwards JM, Dumonde DC. Intravenous, intralesional 
and endolymphatic administration of lymphokines in human cancer. Lymphokine Res. 
1986;5 Suppl 1:S157-63. PubMed PMID: 3784610.


1287: Pyo P, Louie B, Rajamahanty S, Choudhury M, Konno S. Possible
immunotherapeutic potentiation with D-fraction in prostate cancer cells. J
Hematol Oncol. 2008 Dec 4;1:25. doi: 10.1186/1756-8722-1-25. PubMed PMID:
19055833; PubMed Central PMCID: PMC2613393.


1288: Pályi I, Vincze B, Lovas S, Mezö I, Pató J, Kálnay A, Turi G, Gaál D,
Mihalik R, Péter I, Teplán I, Murphy RF. Gonadotropin-releasing hormone analogue 
conjugates with strong selective antitumor activity. Proc Natl Acad Sci U S A.
1999 Mar 2;96(5):2361-6. PubMed PMID: 10051647; PubMed Central PMCID: PMC26789.


1289: Qi SY, Wang M, Xu Y. [Changes of dendritic cells in prostate cancer and
dendritic cell-based immunotherapy]. Zhonghua Nan Ke Xue. 2007 May;13(5):453-6.
Review. Chinese. PubMed PMID: 17569266.


1290: Qian F, Odunsi K, Blatt LM, Scanlan MJ, Mannan M, Shah N, Montgomery J,
Haddad F, Taylor M. Tumor associated antigen recognition by autologous serum in
patients with breast cancer. Int J Mol Med. 2005 Jan;15(1):137-44. PubMed PMID:
15583840.


1291: Qian Y, Yao HP, Shen L, Cheng LF, Zhang LH. [Expression of B7-H4 in
prostate cancer and its clinical significance]. Zhejiang Da Xue Xue Bao Yi Xue
Ban. 2010 Jul;39(4):345-9. Chinese. PubMed PMID: 20731031.


1292: Qiu FM, Li ZP, Huang J. [Research progress of gammadelta T cell-based
immunotherapy]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010 Jul;39(4):424-9. Review.
Chinese. PubMed PMID: 20731045.


1293: Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing 
therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer
Ther. 2014 Jan;14(1):51-61. doi: 10.1586/14737140.2014.848065. Review. PubMed
PMID: 24224900.


1294: Quintero IB, Araujo CL, Pulkka AE, Wirkkala RS, Herrala AM, Eskelinen EL,
Jokitalo E, Hellström PA, Tuominen HJ, Hirvikoski PP, Vihko PT. Prostatic acid
phosphatase is not a prostate specific target. Cancer Res. 2007 Jul
15;67(14):6549-54. PubMed PMID: 17638863.


1295: Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume
and detect the presence of occult tumor metastases in vivo. Cancer Res. 2002 Apr 
15;62(8):2390-7. PubMed PMID: 11956102.


1296: Rabinovsky R, Uhr JW, Vitetta ES, Yefenof E. Cancer dormancy: lessons from 
a B cell lymphoma and adenocarcinoma of the prostate. Adv Cancer Res.
2007;97:189-202. Review. PubMed PMID: 17419946.


1297: Raff AB, Gray A, Kast WM. Prostate stem cell antigen: a prospective
therapeutic and diagnostic target. Cancer Lett. 2009 May 18;277(2):126-32. doi:
10.1016/j.canlet.2008.08.034. Epub 2008 Oct 5. Review. PubMed PMID: 18838214;
PubMed Central PMCID: PMC2680000.


1298: Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in
immunotherapy studies for prostate cancer. J Urol. 2004 Dec;172(6 Pt 2):2532-8.
Review. PubMed PMID: 15538202.


1299: Raja Gabaglia C, Diaz de Durana Y, Graham FL, Gauldie J, Sercarz EE,
Braciak TA. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus
vector treatment enhances natural killer cell-mediated killing of MHC class
I-negative LNCaP prostate tumors. Cancer Res. 2007 Mar 1;67(5):2290-7. PubMed
PMID: 17332360.


1300: Rajarubendra N, Lawrentschuk N, Bolton DM, Klotz L, Davis ID. Prostate
cancer immunology - an update for Urologists. BJU Int. 2011 Apr;107(7):1046-51.
doi: 10.1111/j.1464-410X.2010.09820.x. Epub 2010 Nov 10. Review. PubMed PMID:
21070575.


1301: Ramdass B, Duggal R, Minev B, Chowdhary A, Koka P. Functional role of solid
tumor stem cells in disease etiology and susceptibility to therapeutic
interventions. J Stem Cells. 2013;8(3-4):189-231. doi: jsc.2014.8.3/4.189.
Review. PubMed PMID: 24699025.


1302: Randlev B, Huang LC, Watatsu M, Marcus M, Lin A, Shih SJ. Validation of a
quantitative flow cytometer assay for monitoring HER-2/neu expression level in
cell-based cancer immunotherapy products. Biologicals. 2010 Mar;38(2):249-59.
doi: 10.1016/j.biologicals.2009.12.001. Epub 2010 Jan 15. PubMed PMID: 20080049.


1303: Rannikko A, Krogerus L, Nyberg M, Salmela K, Ruutu M. Rapid progression of 
small cell carcinoma in a renal transplant recipient. Int J Urol. 2006
Jun;13(6):817-9. PubMed PMID: 16834670.


1304: Rao MV, Ellimoottil C, Sondej T, Flanigan RC, Quek ML. Intravesical
bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for
high-grade non-muscle-invasive bladder cancer. Urol Oncol. 2013 Aug;31(6):857-61.
doi: 10.1016/j.urolonc.2011.07.005. Epub 2011 Aug 24. PubMed PMID: 21868262.


1305: Rao MV, Quek ML, Jayram G, Ellimoottil C, Sondej T, Hugen CM, Flanigan RC, 
Steinberg GD. Radical Cystectomy after BCG Immunotherapy for High-Risk
Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate
Radiotherapy. ISRN Urol. 2013 Jul 17;2013:405064. doi: 10.1155/2013/405064.
eCollection 2013. PubMed PMID: 23956880; PubMed Central PMCID: PMC3730135.


1306: Rascente M, Pisani F, Barletta A, D'Angelo M, Giammaria A, Parzanese I,
Rizza V, Iaria G, Famulari A. Malignancies after kidney transplantation.
Transplant Proc. 2005 Jul-Aug;37(6):2529-31. PubMed PMID: 16182735.


1307: Ratliff TL. Molecular research in cancer: future clinical applications.
Acta Urol Belg. 1996 May;64(2):53-5. PubMed PMID: 8701813.


1308: Rausch S, Schwentner C, Stenzl A, Bedke J. mRNA vaccine CV9103 and CV9104
for the treatment of prostate cancer. Hum Vaccin Immunother. 2014 Jul 7;10(11).
[Epub ahead of print] Review. PubMed PMID: 24999635.


1309: Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and
cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014 
May 14;2:14. doi: 10.1186/2051-1426-2-14. eCollection 2014. Review. PubMed PMID: 
24883190; PubMed Central PMCID: PMC4039332.


1310: Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Portoukalian J,
Brosman S, Morton DL. Gangliosides of organ-confined versus metastatic
androgen-receptor-negative prostate cancer. Biochem Biophys Res Commun. 2004 Nov 
5;324(1):154-65. PubMed PMID: 15464996.


1311: Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer
therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol.
2004;546:121-65. Review. PubMed PMID: 15584372.


1312: Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry
WT Jr, Mitchell DA, Fecci PE, Sampson JH, Dranoff G. An update on vaccine therapy
and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines.
2013 Jun;12(6):597-615. doi: 10.1586/erv.13.41. Review. PubMed PMID: 23750791;
PubMed Central PMCID: PMC3982399.


1313: Reddy GK, Gibson TB, Hutson T, Marianni S, Sartor O. Highlights from the
2005 American Society of Clinical Oncology Prostate Cancer Symposium, Orlando,
Florida. Clin Prostate Cancer. 2005 Mar;3(4):206-10. PubMed PMID: 15882475.


1314: Reddy GK, Tyagi P. Highlights from the 41st Annual Meeting of the American 
Society of Clinical Oncology, May 2005, and the 2005 American Society of Clinical
Oncology Prostate Cancer Symposium, February 2005, Orlando, Florida. Clin
Prostate Cancer. 2005 Jun;4(1):7-14. PubMed PMID: 15992456.


1315: Redmond WL, Gough MJ, Weinberg AD. Ligation of the OX40 co-stimulatory
receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J
Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348. PubMed PMID:
19672905; PubMed Central PMCID: PMC3509800.


1316: Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. Defects in
the acquisition of CD8 T cell effector function after priming with tumor or
soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol.
2007 Dec 1;179(11):7244-53. PubMed PMID: 18025166.


1317: Reichrath J, Nürnberg B. Solar UV-radiation, vitamin D and skin cancer
surveillance in organ transplant recipients (OTRs). Adv Exp Med Biol.
2008;624:203-14. doi: 10.1007/978-0-387-77574-6_16. Review. PubMed PMID:
18348458.


1318: Reimer TA, Anagnostopoulos I, Erdmann B, Lehmann I, Stein H, Daniel P,
Dörken B, Rehm A. Reevaluation of the 22-1-1 antibody and its putative antigen,
EBAG9/RCAS1, as a tumor marker. BMC Cancer. 2005 May 17;5:47. PubMed PMID:
15904507; PubMed Central PMCID: PMC1164403.


1319: Reiter MA, Pfitzenmaier J, Hohenfellner M, Haferkamp A. [Immunomodulatory
treatment approaches for prostate cancer]. Urologe A. 2009 Jul;48(7):755-63. doi:
10.1007/s00120-009-1984-6. Review. German. PubMed PMID: 19543879.


1320: Reiter WJ, Mock K. Radical prostatectomy for localized prostate cancer in a
liver transplant recipient. Urol Int. 2005;74(1):95-6. PubMed PMID: 15711119.


1321: Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, Ponnazhagan S.
Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a 
mouse prostate cancer lung metastasis model. Gene Ther. 2008 Nov;15(21):1446-53. 
doi: 10.1038/gt.2008.101. Epub 2008 Jul 3. PubMed PMID: 18596829; PubMed Central 
PMCID: PMC2766853.


1322: Ren H, Boulikas T, Lundstrom K, Söling A, Warnke PC, Rainov NG. Immunogene 
therapy of recurrent glioblastoma multiforme with a liposomally encapsulated
replication-incompetent Semliki forest virus vector carrying the human
interleukin-12 gene--a phase I/II clinical protocol. J Neurooncol. 2003
Aug-Sep;64(1-2):147-54. Erratum in: J Neurooncol. 2003 Nov;65(2):191. PubMed
PMID: 12952295.


1323: Ren J, Wang F, Wei G, Yang Y, Liu Y, Wei M, Huan Y, Larson AC, Zhang Z. MRl
of prostate cancer antigen expression for diagnosis and immunotherapy. PLoS One. 
2012;7(6):e38350. doi: 10.1371/journal.pone.0038350. Epub 2012 Jun 27. PubMed
PMID: 22761679; PubMed Central PMCID: PMC3384648.


1324: Ren JQ, Chen ZQ, Zheng L, Chen Q, Li H, Zhu HG. [Correlation study of
expression levels of prostate-specific membrane antigen and prostate-specific
antigen with Gleason score of prostate carcinoma]. Zhonghua Zhong Liu Za Zhi.
2004 Dec;26(12):735-8. Chinese. PubMed PMID: 15733392.


1325: Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G.
New perspectives in the therapy of castration resistant prostate cancer. Curr
Drug Targets. 2012 Dec;13(13):1676-86. Review. PubMed PMID: 23043326.


1326: Resnick MI, Grayhack JT. Treatment of stage IV carcinoma of the prostate.
Urol Clin North Am. 1975 Feb;2(1):141-61. Review. PubMed PMID: 1093057.


1327: Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J,
Rathore R, Liu PY, Lum LG. Anti-CD3 x anti-epidermal growth factor receptor
(EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive
cancers in vitro and in an animal model. Clin Cancer Res. 2006 Jan
1;12(1):183-90. PubMed PMID: 16397041.


1328: Reuter HJ. [Multifactorial immunological treatment of cancer in urology].
Helv Chir Acta. 1976 Jul;43(3):279-83. PubMed PMID: 947866.


1329: Reyes D, Salazar L, Espinoza E, Pereda C, Castellón E, Valdevenito R,
Huidobro C, Inés Becker M, Lladser A, López MN, Salazar-Onfray F. Tumour cell
lysate-loaded dendritic cell vaccine induces biochemical and memory immune
response in castration-resistant prostate cancer patients. Br J Cancer. 2013 Sep 
17;109(6):1488-97. doi: 10.1038/bjc.2013.494. Epub 2013 Aug 29. PubMed PMID:
23989944; PubMed Central PMCID: PMC3777003.


1330: Ribas A. Genetically modified dendritic cells for cancer immunotherapy.
Curr Gene Ther. 2005 Dec;5(6):619-28. Review. PubMed PMID: 16457651.


1331: Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano
JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR,
DeNardo GL. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel
in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody,
m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with
cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug
15;11(16):5920-7. PubMed PMID: 16115934.


1332: Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, 
Bellone M. Booster vaccinations against cancer are critical in prophylactic but
detrimental in therapeutic settings. Cancer Res. 2013 Jun 15;73(12):3545-54. doi:
10.1158/0008-5472.CAN-12-2449. Epub 2013 Mar 28. PubMed PMID: 23539449.


1333: Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest.
2003;21(6):873-86. PubMed PMID: 14735692.


1334: Riedmann EM. News studies: combining PROSTVAC with conventional cancer
therapy. Hum Vaccin Immunother. 2012 Jul;8(7):848-9. PubMed PMID: 23213665.


1335: Riedmann EM. Two years of Provenge. Hum Vaccin Immunother. 2012
Apr;8(4):505. doi: 10.4161/hv.20489. PubMed PMID: 22832253.


1336: Riether C, Schürch C, Ochsenbein AF. From "magic bullets" to specific
cancer immunotherapy. Swiss Med Wkly. 2013 Jan 23;143:w13734. doi:
10.4414/smw.2013.13734. Review. PubMed PMID: 23348718.


1337: Rigamonti N, Bellone M. Prostate cancer, tumor immunity and a renewed sense
of optimism in immunotherapy. Cancer Immunol Immunother. 2012 Apr;61(4):453-68.
doi: 10.1007/s00262-012-1216-6. Epub 2012 Feb 14. Review. PubMed PMID: 22331081.


1338: Riggs DR, Jackson B, Vona-Davis L, McFadden D. In vitro anticancer effects 
of a novel immunostimulant: keyhole limpet hemocyanin. J Surg Res. 2002
Dec;108(2):279-84. PubMed PMID: 12505053.


1339: Ringdén O. Immunotherapy by allogeneic stem cell transplantation. Adv
Cancer Res. 2007;97:25-60. Review. PubMed PMID: 17419940.


1340: Rini B. Recent clinical development of dendritic cell-based immunotherapy
for prostate cancer. Expert Opin Biol Ther. 2004 Nov;4(11):1729-34. Review.
PubMed PMID: 15500401.


1341: Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination
immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells
(provenge) plus bevacizumab in patients with serologic progression of prostate
cancer after definitive local therapy. Cancer. 2006 Jul 1;107(1):67-74. PubMed
PMID: 16736512.


1342: Rini BI, Small EJ. The potential for prostate cancer immunotherapy. Crit
Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S117-25. Review. Erratum in: Crit Rev
Oncol Hematol. 2012 Sep;83(3):452. PubMed PMID: 12850532.


1343: Rini BI, Small EJ. Prostate cancer update. Curr Opin Oncol. 2002
May;14(3):286-91. Review. PubMed PMID: 11981273.


1344: Rini BI, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep. 2001 
Sep;3(5):418-23. Review. PubMed PMID: 11489243.


1345: Risk M, Corman JM. The role of immunotherapy in prostate cancer: an
overview of current approaches in development. Rev Urol. 2009 Winter;11(1):16-27.
PubMed PMID: 19390671; PubMed Central PMCID: PMC2668837.


1346: Ristau BT, O'Keefe DS, Bacich DJ. The prostate-specific membrane antigen:
lessons and current clinical implications from 20 years of research. Urol Oncol. 
2014 Apr;32(3):272-9. doi: 10.1016/j.urolonc.2013.09.003. Epub 2013 Dec 8. PubMed
PMID: 24321253; PubMed Central PMCID: PMC3972351.


1347: Rizvi S, Allen B, Lee C, Bruchertseifer F, Apostolidis C, Morgenstern A,
Clarke R. Orthotopic administration of (213)Bi-bevacizumab inhibits progression
of PC3 xenografts in the prostate. Immunotherapy. 2012 May;4(5):549-54. doi:
10.2217/imt.12.42. PubMed PMID: 22642336.


1348: Robinson MR, Rigby CC, Pugh RC, Dumonde DC. Prostate carcinoma: intratumor 
BCG immunotherapy. Natl Cancer Inst Monogr. 1978 Dec;(49):351-3. PubMed PMID:
311894.


1349: Robinson MR, Rigby CC, Pugh RC, Dumonde DC. Adjuvant immunotherapy with
B.C.G. in carcinoma of the prostate. Br J Urol. 1977 Jun;49(3):221-6. PubMed
PMID: 912245.


1350: Robinson MR, Nakhla LS, Whitaker RH. A new concept in the management of
carcinoma of the prostate. Br J Urol. 1971 Dec;43(6):728-32. PubMed PMID:
5159575.


1351: Rodeberg DA, Erskine C, Celis E. In vitro induction of immune responses to 
shared tumor-associated antigens in rhabdomyosarcoma. J Pediatr Surg. 2007
Aug;42(8):1396-402. PubMed PMID: 17706503.


1352: Rodríguez Cordón M, Ferrer Albiach E, Ferrer Albiach C. [Current
multidisciplinary treatment of metastatic prostatic cancer]. Actas Urol Esp. 2003
Nov-Dec;27(10):767-81; discussion 781-2. Review. Spanish. PubMed PMID: 14735858.


1353: Rojan A, Funches R, Regan MM, Gulley JL, Bubley GJ. Dramatic and prolonged 
PSA response after retreatment with a PSA vaccine. Clin Genitourin Cancer. 2013
Sep;11(3):362-4. doi: 10.1016/j.clgc.2013.01.003. Epub 2013 Jun 20. PubMed PMID: 
23791437.


1354: Rojas-Martínez A, Manzanera AG, Sukin SW, Esteban-María J,
González-Guerrero JF, Gomez-Guerra L, Garza-Guajardo R, Flores-Gutiérrez JP,
Elizondo Riojas G, Delgado-Enciso I, Ortiz-López R, Aguilar LK, Butler EB,
Barrera-Saldaña HA, Aguilar-Cordova E. Intraprostatic distribution and long-term 
follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with
prostate cancer. Cancer Gene Ther. 2013 Nov;20(11):642-9. doi:
10.1038/cgt.2013.56. Epub 2013 Sep 20. PubMed PMID: 24052127; PubMed Central
PMCID: PMC3842423.


1355: Ronquist KG, Carlsson L, Ronquist G, Nilsson S, Larsson A.
Prostasome-derived proteins capable of eliciting an immune response in prostate
cancer patients. Int J Cancer. 2006 Aug 15;119(4):847-53. PubMed PMID: 16557587.


1356: Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific
CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate. 2005
Feb 15;62(3):217-23. PubMed PMID: 15389792.


1357: Roscilli G, Cappelletti M, De Vitis C, Ciliberto G, Di Napoli A, Ruco L,
Mancini R, Aurisicchio L. Circulating MMP11 and specific antibody immune response
in breast and prostate cancer patients. J Transl Med. 2014 Feb 24;12:54. doi:
10.1186/1479-5876-12-54. PubMed PMID: 24564996; PubMed Central PMCID: PMC3936832.


1358: Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, 
Donahue R, Gulley JL, Schlom J, Guadagni F. Effects of conventional therapeutic
interventions on the number and function of regulatory T cells. Oncoimmunology.
2013 Oct 1;2(10):e27025. PubMed PMID: 24353914; PubMed Central PMCID: PMC3862634.


1359: Ross JS, Gray KE, Webb IJ, Gray GS, Rolfe M, Schenkein DP, Nanus DM,
Millowsky MI, Bander NH. Antibody-based therapeutics: focus on prostate cancer.
Cancer Metastasis Rev. 2005 Dec;24(4):521-37. Review. PubMed PMID: 16408160.


1360: Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller 
GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard 
D, Rubin MA, Lasky LA, Koeppen H. Prostate stem cell antigen as therapy target:
tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002
May 1;62(9):2546-53. PubMed PMID: 11980648.


1361: Ross S, Spencer SD, Lasky LA, Koeppen H. Selective expression of murine
prostate stem cell antigen in fetal and adult tissues and the transgenic
adenocarcinoma of the mouse prostate model of prostate carcinogenesis. Am J
Pathol. 2001 Mar;158(3):809-16. PubMed PMID: 11238029; PubMed Central PMCID:
PMC1850373.


1362: Ross S, Liu V, Abulafia R, Hogan C, Osband M. Adoptive immunotherapy of
hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T
cells (autolymphocyte therapy): results from a pilot study. Biotechnol Ther.
1993;4(3-4):197-211. PubMed PMID: 7507387.


1363: Rothauge CF, Kraushaar J, Gutschank S. [Specific immunotherapy of prostate 
carcinoma]. Urol Int. 1983;38(2):84-90. German. PubMed PMID: 6845566.


1364: Rothauge CF, Kraushaar J, Gutschank J, Sedlacek HH. [Behavior of serum acid
phosphatases following specific immunotherapy of metastasizing prostatic
carcinoma]. Med Welt. 1981 Jan 9;32(2):50-3. German. PubMed PMID: 7207127.


1365: Rothauge CF, Kraushaar J, Gutschank S, Weidner W, Krause W. [Behavior of
phosphatases and carcino-embryonal antigens in serum following specific
immunotherapy of metastasizing prostatic cancers]. Helv Chir Acta. 1981
Aug;48(3-4):453-8. German. PubMed PMID: 7287484.


1366: Rothschild J, Thompson IM 3rd, Concepcion RS, Shore ND. Infusion therapy
and implantables for the urologist. Urol Clin North Am. 2013 Nov;40(4):591-8.
doi: 10.1016/j.ucl.2013.07.014. Review. PubMed PMID: 24182978.


1367: Rothschild S, Zippelius A. [Cancer immunotherapy - novel perspectives].
Ther Umsch. 2012 Oct;69(10):559-63. doi: 10.1024/0040-5930/a000330. German.
PubMed PMID: 23026880.


1368: Rotow J, Gameiro SR, Madan RA, Gulley JL, Schlom J, Hodge JW. Vaccines as
monotherapy and in combination therapy for prostate cancer. Clin Transl Sci. 2010
Jun;3(3):116-22. doi: 10.1111/j.1752-8062.2010.00186.x. PubMed PMID: 20590682;
PubMed Central PMCID: PMC2914613.


1369: Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo K, Do L, Lombardo JR,
Schoonmaker PL, Brinkmann K, Dirmeier U, Laus R, Delcayre A. Exosome targeting of
tumor antigens expressed by cancer vaccines can improve antigen immunogenicity
and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44. doi:
10.1158/0008-5472.CAN-10-4076. Epub 2011 Jun 13. PubMed PMID: 21670078.


1370: Rousseau C, Kraeber-Bodéré F, Barbet J, Chatal JF. Pretargeted
radioimmunotherapy: clinically more efficient than conventional
radioimmunotherapy? Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1373-6. doi:
10.1007/s00259-013-2469-9. PubMed PMID: 23760632.


1371: Rove KO, Crawford ED. Evolution of treatment options for patients with CRPC
and bone metastases: bone-targeted agents that go beyond palliation of symptoms
to improve overall survival. Oncology (Williston Park). 2011 Dec;25(14):1362-70, 
1375-81, 1387. Review. PubMed PMID: 22329188.


1372: Rove KO, Flaig TW. A renaissance in the medical treatment of advanced
prostate cancer. Oncology (Williston Park). 2010 Dec;24(14):1308-13, 1318.
Review. PubMed PMID: 21294475.


1373: Rozková D, Tiserová H, Fucíková J, Last'ovicka J, Podrazil M, Ulcová H,
Budínský V, Prausová J, Linke Z, Minárik I, Sedivá A, Spísek R, Bartůnková J.
FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of
hormone-refractory metastatic prostate cancer. Clin Immunol. 2009
Apr;131(1):1-10. doi: 10.1016/j.clim.2009.01.001. Epub 2009 Feb 8. Review. PubMed
PMID: 19201656.


1374: Rubenstein M, Muchnik S, Chet M, Shaw MW, Dubin A, Guinan P. Efficacy of
immunopriming prior to isolation of tumor infiltrating lymphocytes for use in
adoptive immunotherapy. Immunopharmacol Immunotoxicol. 1990;12(4):583-94. PubMed 
PMID: 2151144.


1375: Ruoppolo M, Gozo M, Milesi R, Spina R, Fragapane G. [Urethral recurrence of
invasive carcinoma following BCG treatment for bladder Ca in situ]. Urologia.
2010 Oct-Dec;77 Suppl 17:72-7. Italian. PubMed PMID: 21308679.


1376: Ruutu M, Mikkola A, Pétas A. Treatment of prostate cancer--any news? Ann
Chir Gynaecol. 2001;90(1):5-9. Review. PubMed PMID: 11336371.


1377: Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Phase II 
study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for
prostate cancer: effect of extent of disease on outcome. J Urol. 2007
Dec;178(6):2372-6; discussion 2377. Epub 2007 Oct 22. PubMed PMID: 17936834.


1378: Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes
EE, Vogelzang NJ. CI-980 in advanced melanoma and hormone refractory prostate
cancer. Invest New Drugs. 2000 May;18(2):187-91. PubMed PMID: 10857996.


1379: Rydh A, Riklund-Ahlström K, Widmark A, Bergh A, Johansson L, Tavelin B,
Nilsson S, Stigbrand T, Damber JE, Hietala SO. Radioimmunotherapy of DU-145
tumours in nude mice--a pilot study with E4, a novel monoclonal antibody against 
prostate cancer. Acta Oncol. 1999;38(8):1075-9. PubMed PMID: 10665766.


1380: Rüttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, Fox BA, Weber
JS. Immunotherapy of cancer: key findings and commentary on the third Tegernsee
conference. Oncologist. 2010;15(1):112-8. doi: 10.1634/theoncologist.2009-0213.
Epub 2010 Jan 8. PubMed PMID: 20061401; PubMed Central PMCID: PMC3227889.


1381: Rüttinger D, Li R, Urba WJ, Fox BA, Hu HM. Regression of bone metastases
following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine
draining lymph node cells. Clin Exp Metastasis. 2004;21(4):305-12. PubMed PMID:
15554386.


1382: Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and
Hyde molecule? Clin Cancer Res. 2010 Jul 15;16(14):3533-8. doi:
10.1158/1078-0432.CCR-09-3169. Epub 2010 May 25. Review. PubMed PMID: 20501618;
PubMed Central PMCID: PMC2905486.


1383: Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A.
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the
survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S
A. 2001 Feb 27;98(5):2658-63. Epub 2001 Feb 13. PubMed PMID: 11226295; PubMed
Central PMCID: PMC30194.


1384: Saffran DC, Reiter RE, Jakobovits A, Witte ON. Target antigens for prostate
cancer immunotherapy. Cancer Metastasis Rev. 1999;18(4):437-49. Review. PubMed
PMID: 10855787.


1385: Sahlén G, Ahlander A, Frost A, Ronquist G, Norlén BJ, Nilsson BO.
Prostasomes are secreted from poorly differentiated cells of prostate cancer
metastases. Prostate. 2004 Nov 1;61(3):291-7. PubMed PMID: 15368476.


1386: Sai S, Sakakibara T, Takashi M, Sakata T, Miyake K. [Granulomatous
prostatitis after intravesical BCG immunotherapy of superficial bladder cancer: a
case report]. Hinyokika Kiyo. 1990 Aug;36(8):953-5. Japanese. PubMed PMID:
2239600.


1387: Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley 
AG, Durrant L, Metheringham R, Rees RC, McArdle SE. Novel prostate acid
phosphatase-based peptide vaccination strategy induces antigen-specific T-cell
responses and limits tumour growth in mice. Eur J Immunol. 2014
Apr;44(4):994-1004. doi: 10.1002/eji.201343863. Epub 2014 Mar 7. PubMed PMID:
24338683.


1388: Saika T, Kusaka N, Mouraviev V, Satoh T, Kumon H, Timme TL, Thompson TC.
Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12
gene therapy in a mouse prostate cancer model. Cancer Gene Ther. 2006 Jan
1;13(1):91-8. PubMed PMID: 16052232.


1389: Saika T, Satoh T, Kusaka N, Ebara S, Mouraviev VB, Timme TL, Thompson TC.
Route of administration influences the antitumor effects of bone marrow-derived
dendritic cells engineered to produce interleukin-12 in a metastatic mouse
prostate cancer model. Cancer Gene Ther. 2004 May;11(5):317-24. PubMed PMID:
15044961.


1390: Saintigny P, Chouahnia K, Charniot JC, Breau JL. [Cardiovascular toxicity
of some cancer agents (others than anthracyclines, fluoropyrimidines and
trastuzumab)]. Bull Cancer. 2004 Nov;91 Suppl 3:174-84. Review. French. PubMed
PMID: 15899625.


1391: Sakamoto S, Ryan AJ, Kyprianou N. Targeting vasculature in urologic tumors:
mechanistic and therapeutic significance. J Cell Biochem. 2008 Feb
15;103(3):691-708. Review. PubMed PMID: 17668426; PubMed Central PMCID:
PMC2274917.


1392: Salazar-Onfray F, Pereda C, Reyes D, López MN. TAPCells, the Chilean
dendritic cell vaccine against melanoma and prostate cancer. Biol Res.
2013;46(4):431-40. doi: 10.4067/S0716-97602013000400014. PubMed PMID: 24510145.


1393: Salgaller ML. American Association for Cancer Research: Clinical trials of 
immunotherapeutics and immunologic monitoring. April 1-5, 2000, San Francisco,
CA, USA. Expert Opin Investig Drugs. 2000 Jun;9(6):1413-7. PubMed PMID: 11203450.


1394: Salgaller ML. Prostate cancer immunotherapy at the dawn of the new
millennium. Expert Opin Investig Drugs. 2000 Jun;9(6):1217-29. Review. PubMed
PMID: 11060738.


1395: Salgaller ML, Thurnher M, Bartsch G, Boynton AL, Murphy GP. Report from the
International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop 
on the use of dendritic cells in cancer clinical trials. Cancer. 1999 Dec
15;86(12):2674-83. PubMed PMID: 10594863.


1396: Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM,
Rogers M, Boynton AL, Murphy GP. Report of immune monitoring of prostate cancer
patients undergoing T-cell therapy using dendritic cells pulsed with
HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
Prostate. 1998 May;35(2):144-51. PubMed PMID: 9568678.


1397: Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP.
Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol.
1998;18(1-2):109-19. PubMed PMID: 9419453.


1398: Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, Rooney CM,
Leen AM, Brenner MK, Vera JF. Combining T-cell immunotherapy and anti-androgen
therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013
Jun;16(2):123-31, S1. doi: 10.1038/pcan.2012.49. Epub 2013 Jan 8. PubMed PMID:
23295316; PubMed Central PMCID: PMC3883310.


1399: Sanda MG. Biological principles and clinical development of prostate cancer
gene therapy. Semin Urol Oncol. 1997 Feb;15(1):43-55. Review. PubMed PMID:
9050139.


1400: Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons
JW. Molecular characterization of defective antigen processing in human prostate 
cancer. J Natl Cancer Inst. 1995 Feb 15;87(4):280-5. PubMed PMID: 7707419; PubMed
Central PMCID: PMC2104544.


1401: Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff
G, Pardoll DM, Mulligan RC, Simons JW. Demonstration of a rational strategy for
human prostate cancer gene therapy. J Urol. 1994 Mar;151(3):622-8. PubMed PMID:
8308972.


1402: Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K,
Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den
Eertwegh AJ, Gerritsen WR, de Gruijl TD. T cell profiling reveals high CD4+CTLA-4
+ T cell frequency as dominant predictor for survival after prostate
GVAX/ipilimumab treatment. Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi:
10.1007/s00262-012-1330-5. Epub 2012 Aug 10. PubMed PMID: 22878899.


1403: Santolaria T, Robard M, Léger A, Catros V, Bonneville M, Scotet E. Repeated
systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells
efficiently control tumor development in vivo. J Immunol. 2013 Aug
15;191(4):1993-2000. doi: 10.4049/jimmunol.1300255. Epub 2013 Jul 8. PubMed PMID:
23836057.


1404: Sarosdy MF. Oral bropirimine immunotherapy of rodent prostate cancer. Eur
Urol. 1997;31 Suppl 1:5-9. PubMed PMID: 9076480.


1405: Sartor O, Michels RM, Massard C, de Bono JS. Novel therapeutic strategies
for metastatic prostate cancer in the post-docetaxel setting. Oncologist.
2011;16(11):1487-97. doi: 10.1634/theoncologist.2010-0412. Epub 2011 Nov 2.
Review. PubMed PMID: 22048000; PubMed Central PMCID: PMC3233282.


1406: Sasada T, Noguchi M, Yamada A, Itoh K. Personalized peptide vaccination: a 
novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother. 2012
Sep;8(9):1309-13. doi: 10.4161/hv.20988. Epub 2012 Aug 16. PubMed PMID: 22894962;
PubMed Central PMCID: PMC3579913.


1407: Satoh T, Irie A, Egawa S, Baba S. In situ gene therapy for prostate cancer.
Curr Gene Ther. 2005 Feb;5(1):111-9. Review. PubMed PMID: 15638715.


1408: Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G, Wang J, Mouraviev V,
Cao G, Fattah el MA, Thompson TC. Macrophages transduced with an adenoviral
vector expressing interleukin 12 suppress tumor growth and metastasis in a
preclinical metastatic prostate cancer model. Cancer Res. 2003 Nov
15;63(22):7853-60. PubMed PMID: 14633713.


1409: Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N,
Mouraviev V, Thompson TC. Adenoviral vector-mediated mRTVP-1 gene therapy for
prostate cancer. Hum Gene Ther. 2003 Jan 20;14(2):91-101. PubMed PMID: 12614561.


1410: Satthaporn S, Eremin O. Dendritic cells (II): Role and therapeutic
implications in cancer. J R Coll Surg Edinb. 2001 Jun;46(3):159-67. Review.
PubMed PMID: 11478013.


1411: Satyam A, Singh P, Badjatia N, Seth A, Sharma A. A disproportion of TH1/TH2
cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol
Oncol. 2011 Jan-Feb;29(1):58-65. doi: 10.1016/j.urolonc.2009.06.002. Epub 2009
Oct 17. PubMed PMID: 19837616.


1412: Savage PA, Leventhal DS, Malchow S. Shaping the repertoire of
tumor-infiltrating effector and regulatory T cells. Immunol Rev. 2014
May;259(1):245-58. doi: 10.1111/imr.12166. Review. PubMed PMID: 24712470; PubMed 
Central PMCID: PMC4122093.


1413: Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K,
Jungbluth AA, Allison JP. Recognition of a ubiquitous self antigen by prostate
cancer-infiltrating CD8+ T lymphocytes. Science. 2008 Jan 11;319(5860):215-20.
doi: 10.1126/science.1148886. PubMed PMID: 18187659.


1414: Scardino A, Correale P, Firat H, Pellegrini M, Kosmatopoulos K, Opolon P,
Alves P, Zurbriggen R, Glück R, Lemonnier FA, Francini G, Cusi MG. In vivo study 
of the GC90/IRIV vaccine for immune response and autoimmunity into a novel
humanised transgenic mouse. Br J Cancer. 2003 Jul 7;89(1):199-205. PubMed PMID:
12838324; PubMed Central PMCID: PMC2394210.


1415: Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW,
Debucquoy A, Haustermans K, McBride WH. T-cell responses to survivin in cancer
patients undergoing radiation therapy. Clin Cancer Res. 2008 Aug
1;14(15):4883-90. doi: 10.1158/1078-0432.CCR-07-4462. PubMed PMID: 18676762;
PubMed Central PMCID: PMC2748652.


1416: Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.
Lower baseline prostate-specific antigen is associated with a greater overall
survival benefit from sipuleucel-T in the Immunotherapy for Prostate
Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013 Jun;81(6):1297-302. doi:
10.1016/j.urology.2013.01.061. Epub 2013 Apr 9. PubMed PMID: 23582482.


1417: Schellhammer PF, Hershberg RM. Immunotherapy with autologous antigen
presenting cells for the treatment of androgen independent prostate cancer. World
J Urol. 2005 Feb;23(1):47-9. Epub 2005 Jan 13. PubMed PMID: 15647927.


1418: Schellhammer PF, Ladaga LE, Moriarty RP. Intravesical bacillus
Calmette-Guerin for the treatment of superficial transitional cell carcinoma of
the prostatic urethra in association with carcinoma of the bladder. J Urol. 1995 
Jan;153(1):53-6. PubMed PMID: 7966790.


1419: Schenk EA. Words of wisdom. Re: overall survival analysis of a phase II
randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in
metastatic castration-resistant prostate cancer. Eur Urol. 2010 Oct;58(4):632-3. 
PubMed PMID: 20848748.


1420: Schenkman E, Lamm DL. Superficial bladder cancer therapy.
ScientificWorldJournal. 2004 Jun 28;4 Suppl 1:387-99. Review. PubMed PMID:
15349563.


1421: Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM. Therapeutic
alternatives for hormone-refractory prostatic cancer. Semin Urol. 1992
Feb;10(1):55-64. Review. PubMed PMID: 1373515.


1422: Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri
C, Coussens LM, Balkwill FR. B regulatory cells and the tumor-promoting actions
of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A. 2011 Jun
28;108(26):10662-7. doi: 10.1073/pnas.1100994108. Epub 2011 Jun 13. PubMed PMID: 
21670304; PubMed Central PMCID: PMC3127875.


1423: Schirrmacher V, Bihari AS, Stücker W, Sprenger T. Long-term remission of
prostate cancer with extensive bone metastases upon immuno- and virotherapy: A
case report. Oncol Lett. 2014 Dec;8(6):2403-2406. Epub 2014 Oct 6. PubMed PMID:
25364402; PubMed Central PMCID: PMC4214463.


1424: Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B,
Madan RA, Heery CR, Gulley JL. Therapeutic cancer vaccines. Adv Cancer Res.
2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. PubMed PMID: 24889529.


1425: Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy.
Exp Biol Med (Maywood). 2008 May;233(5):522-34. doi: 10.3181/0708-MR-226. Epub
2008 Mar 28. Review. PubMed PMID: 18375829.


1426: Schlom J, Gulley JL, Arlen PM. Role of vaccine therapy in cancer: biology
and practice. Curr Oncol. 2007 Dec;14(6):238-45. PubMed PMID: 18080016; PubMed
Central PMCID: PMC2133100.


1427: Schmid HP, Gregorin J, Altwein JE. Growth hormone inhibitors in prostate
cancer: a systematic analysis. Urol Int. 2008;81(1):17-22. doi:
10.1159/000137635. Epub 2008 Jul 16. PubMed PMID: 18645266.


1428: Schmidt JD. The patient, disease status, and treatment options for prostate
cancer: stages D1 and D2. Prostate. 1983;4(5):493-501. PubMed PMID: 6351040.


1429: Schmudde M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, Moretta L,
Bröker BM. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic
effects of natural killer cells. Cancer Lett. 2008 Dec 8;272(1):110-21. doi:
10.1016/j.canlet.2008.06.027. Epub 2008 Aug 20. Erratum in: Cancer Lett. 2009 Feb
8;274(1):167. PubMed PMID: 18718708.


1430: Schreiber H, Rowley DA. Cancer. Quo vadis, specificity? Science. 2008 Jan
11;319(5860):164-5. doi: 10.1126/science.1153713. PubMed PMID: 18187644.


1431: Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, Yu
H, Müller-Newen G, Jove R. Loss of androgen receptor expression promotes a
stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 
2014 Feb 15;74(4):1227-37. doi: 10.1158/0008-5472.CAN-13-0594. Epub 2013 Oct 31. 
PubMed PMID: 24177177.


1432: Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF,
Chen SY. Identification of MHC class II-restricted T-cell epitopes in
prostate-specific membrane antigen. Clin Cancer Res. 2003 Aug 15;9(9):3260-71.
PubMed PMID: 12960111.


1433: Schroten C, Scheffer R, Boon L, de Ridder CM, Bangma CH, Kraaij R. Tumor
protection by IL-7 secreting whole cell vaccine is merely mediated by
NK1.1-positive cells. J Immunother. 2012 Feb-Mar;35(2):125-30. doi:
10.1097/CJI.0b013e318242514b. PubMed PMID: 22306900.


1434: Schulze H, Sommerfeld HJ. [Immunotherapy of prostate cancer]. Urologe A.
1993 Sep;32(5):382-9. Review. German. PubMed PMID: 8212423.


1435: Schwaab T, Ernstoff MS. Therapeutic vaccines in renal cell carcinoma.
Therapy. 2011 Jul;4(8):369-377. PubMed PMID: 21869865; PubMed Central PMCID:
PMC3159492.


1436: Schwaab T, Pili R. Provenge: combating prostate cancer with a vengeance?
Expert Rev Vaccines. 2011 Aug;10(8):1113-4. doi: 10.1586/erv.11.85. PubMed PMID: 
21854304.


1437: Schwaab T, Lewis LD, Cole BF, Deo Y, Fanger MW, Wallace P, Guyre PM,
Kaufman PA, Heaney JA, Schned AR, Harris RD, Ernstoff MS. Phase I pilot trial of 
the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients
whose prostate cancer overexpresses HER-2/neu. J Immunother. 2001
Jan-Feb;24(1):79-87. PubMed PMID: 11211151.


1438: Schwarze S, Rangnekar VM. Targeting plasma membrane GRP78 for cancer growth
inhibition. Cancer Biol Ther. 2010 Jan;9(2):153-5. Epub 2010 Jan 26. PubMed PMID:
20026905.


1439: Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent
developments and future challenges. Cancer Metastasis Rev. 2014
Sep;33(2-3):641-55. doi: 10.1007/s10555-013-9479-8. PubMed PMID: 24477411; PubMed
Central PMCID: PMC4116461.


1440: Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed
strategies for the treatment of prostate cancer: a new era of hormonal therapies 
is born. Ther Adv Urol. 2012 Aug;4(4):167-78. doi: 10.1177/1756287212452196.
PubMed PMID: 22852027; PubMed Central PMCID: PMC3398601.


1441: Schwemmer B. Natural killer T cells in patients with prostatic carcinoma.
Urol Int. 2003;71(2):146-9. PubMed PMID: 12890950.


1442: Schwemmer B, Lehmer A, Hofmann R, Braun J. Natural killer cell activity in 
patients with prostatic carcinoma and its in vivo boosting with bacillus
Calmette-Guérin. Urol Int. 1984;39(6):321-6. PubMed PMID: 6523641.


1443: Schülke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM,
Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC. The
homodimer of prostate-specific membrane antigen is a functional target for cancer
therapy. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12590-5. PubMed PMID:
14583590; PubMed Central PMCID: PMC240662.


1444: Scott AM. Radioimmunotherapy of prostate cancer: does tumor size matter? J 
Clin Oncol. 2005 Jul 20;23(21):4567-9. Epub 2005 Apr 18. PubMed PMID: 15837975.


1445: See D, Mason S, Roshan R. Increased tumor necrosis factor alpha (TNF-alpha)
and natural killer cell (NK) function using an integrative approach in late stage
cancers. Immunol Invest. 2002 May;31(2):137-53. PubMed PMID: 12148949.


1446: Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel
A, Hofstaedter F, Hartmann A. Association of HLA class I antigen abnormalities
with disease progression and early recurrence in prostate cancer. Cancer Immunol 
Immunother. 2010 Apr;59(4):529-40. doi: 10.1007/s00262-009-0769-5. Epub 2009 Oct 
7. PubMed PMID: 19820934; PubMed Central PMCID: PMC3426221.


1447: Sengeløv L, Klarskov OP, Karlsson S. [Treatment of hormonal refractory
metastatic prostate cancer]. Ugeskr Laeger. 2007 May 14;169(20):1905-7. Danish.
PubMed PMID: 17553368.


1448: Seow SW, Cai S, Rahmat JN, Bay BH, Lee YK, Chan YH, Mahendran R.
Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic
bladder tumors. Cancer Sci. 2010 Mar;101(3):751-8. doi:
10.1111/j.1349-7006.2009.01426.x. Epub 2009 Nov 6. PubMed PMID: 20015287.


1449: Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human
prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate.
2009 Nov 1;69(15):1694-703. doi: 10.1002/pros.21020. PubMed PMID: 19670224;
PubMed Central PMCID: PMC2782577.


1450: Shafer-Weaver K, Anderson M, Malyguine A, Hurwitz AA. T cell tolerance to
tumors and cancer immunotherapy. Adv Exp Med Biol. 2007;601:357-68. Review.
PubMed PMID: 17713024.


1451: Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM,
Hurwitz AA. Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic
tumors are induced to become suppressor cells. J Immunol. 2009 Oct
15;183(8):4848-52. doi: 10.4049/jimmunol.0900848. PubMed PMID: 19801511.


1452: Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord
WG, Greenberg NM, Hurwitz AA. Immunity to murine prostatic tumors: continuous
provision of T-cell help prevents CD8 T-cell tolerance and activates
tumor-infiltrating dendritic cells. Cancer Res. 2009 Aug 1;69(15):6256-64. doi:
10.1158/0008-5472.CAN-08-4516. Epub 2009 Jul 21. PubMed PMID: 19622771; PubMed
Central PMCID: PMC2732120.


1453: Shah AH, Lee C. TGF-beta-based immunotherapy for cancer: breaching the
tumor firewall. Prostate. 2000 Oct 1;45(2):167-72. Review. PubMed PMID: 11027416.


1454: Shah J, Khaksar SJ, Sooriakumaran P. Management of prostate cancer. Part 3:
metastatic disease. Expert Rev Anticancer Ther. 2006 May;6(5):813-21. Review.
PubMed PMID: 16759171.


1455: Shah KV, Palma LD, Murphy GP. The occurrence of SV40-Neutralizing
antibodies in sera of patients with genitourinary carcinoma. J Surg Oncol.
1971;3(4):443-50. PubMed PMID: 4329010.


1456: Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P.
Development of a Listeria monocytogenes based vaccine against prostate cancer.
Cancer Immunol Immunother. 2008 Sep;57(9):1301-13. doi:
10.1007/s00262-008-0463-z. Epub 2008 Feb 14. PubMed PMID: 18273616.


1457: Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Wernert
N. Identification of immunity-related genes in prostate cancer and potential role
of the ETS family of transcription factors in their regulation. Int J Mol Med.
2011 Nov;28(5):799-807. doi: 10.3892/ijmm.2011.771. Epub 2011 Aug 10. PubMed
PMID: 21833467.


1458: Shan L. Biotinylated anti-Tn MLS128 monoclonal
antibody-(125)I-streptavidin. 2009 Jul 21 [updated 2009 Sep 17]. Molecular
Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National
Center for Biotechnology Information (US); 2004-2013. Available from
http://www.ncbi.nlm.nih.gov/books/NBK23686/
PubMed PMID: 20641881.


1459: Shan L. Biotinylated anti-Tn MLS128 monoclonal
antibody-streptavidin-(111)In-DTPA-biotin. 2009 Jul 21 [updated 2009 Sep 17].
Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): 
National Center for Biotechnology Information (US); 2004-2013. Available from
http://www.ncbi.nlm.nih.gov/books/NBK23544/
PubMed PMID: 20641742.


1460: Shankar G, Fourrier MS, Grevenkamp MA, Lodge PA. Validation of the COSTIM
bioassay for dendritic cell potency. J Pharm Biomed Anal. 2004 Oct
29;36(2):285-94. PubMed PMID: 15496321.


1461: Shanmugam A, Suriano R, Goswami N, Chaudhuri D, Ashok BT, Rajoria S, George
AL, Mittelman A, Tiwari RK. Identification of peptide mimotopes of gp96 using
single-chain antibody library. Cell Stress Chaperones. 2011 Mar;16(2):225-34.
doi: 10.1007/s12192-010-0234-6. Epub 2010 Oct 16. PubMed PMID: 20953748; PubMed
Central PMCID: PMC3059791.


1462: Shao N, Wang Y, Jiang WY, Qiao D, Zhang SG, Wu Y, Zhang XX, Wang JL, Ding
Y, Feng NH. Immunotherapy and endothelin receptor antagonists for treatment of
castration-resistant prostate cancer. Int J Cancer. 2013 Oct 1;133(7):1743-50.
doi: 10.1002/ijc.28162. Epub 2013 Apr 8. PubMed PMID: 23504603.


1463: Shapiro D, Tareen B. Current and emerging treatments in the management of
castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012
Jul;12(7):951-64. doi: 10.1586/era.12.59. Review. PubMed PMID: 22845410.


1464: Shariat SF, Sadeghi F, Slawin KM. Vaccine-based immunotherapy for prostate 
cancer. Rev Urol. 2000 Fall;2(4):222-7. PubMed PMID: 16985756; PubMed Central
PMCID: PMC1476116.


1465: Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy
agents with survival benefit: recent successes and next steps. Nat Rev Cancer.
2011 Oct 24;11(11):805-12. doi: 10.1038/nrc3153. Review. PubMed PMID: 22020206;
PubMed Central PMCID: PMC3426440.


1466: Sharma S, Dominguez AL, Lustgarten J. Aging affect the anti-tumor potential
of dendritic cell vaccination, but it can be overcome by co-stimulation with
anti-OX40 or anti-4-1BB. Exp Gerontol. 2006 Jan;41(1):78-84. Epub 2005 Nov 14.
PubMed PMID: 16289924.


1467: Shaw MW, Ablin RJ, Guinan PD, Bhatti RA. Effect of transfer factor on
tumor-associated immunity and tumor growth of the Dunning R-3327G rat prostate
adenocarcinoma. Am J Reprod Immunol Microbiol. 1985 Jul;8(3):80-3. PubMed PMID:
4025670.


1468: Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY,
Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL. Sipuleucel-T immune
parameters correlate with survival: an analysis of the randomized phase 3
clinical trials in men with castration-resistant prostate cancer. Cancer Immunol 
Immunother. 2013 Jan;62(1):137-47. doi: 10.1007/s00262-012-1317-2. Epub 2012 Aug 
3. PubMed PMID: 22865266; PubMed Central PMCID: PMC3541926.


1469: Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell 
activation. Cancer Immunol Immunother. 2008 Sep;57(9):1381-90. doi:
10.1007/s00262-008-0474-9. Epub 2008 Feb 23. PubMed PMID: 18297282.


1470: Sheikhi A, Saadati K, Salmani R, Yahaghi N, Sheikhi A, Siemens DR. In vitro
modulation of natural killer activity of human peripheral blood mononuclear cells
against prostate tumor cell line. Immunopharmacol Immunotoxicol. 2011
Dec;33(4):700-8. doi: 10.3109/08923973.2011.561437. Epub 2011 Mar 22. PubMed
PMID: 21425925.


1471: Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG. Intravesical
gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic 
review. BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. 
Review. PubMed PMID: 22313502.


1472: Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical
Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev.
2000;(4):CD001986. Review. PubMed PMID: 11034738.


1473: Shen L, Sundstedt A, Ciesielski MJ, Miles KM, Celander M, Adelaiye R,
Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker RA, Abrams SI,
Eriksson H, Leanderson T, Olson A, Pili R. Tasquinimod modulates suppressive
myeloid cells and enhances cancer immunotherapies in murine models. Cancer
Immunol Res. 2014 Nov 4. pii: canimm.0036.2014. [Epub ahead of print] PubMed
PMID: 25370534.


1474: Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P,
Shrikant P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor
entinostat suppresses regulatory T cells and enhances immunotherapies in renal
and prostate cancer models. PLoS One. 2012;7(1):e30815. doi:
10.1371/journal.pone.0030815. Epub 2012 Jan 27. PubMed PMID: 22303460; PubMed
Central PMCID: PMC3267747.


1475: Shen S, Meredith RF, Duan J, Brezovich I, Khazaeli MB, LoBuglio AF.
Comparison of methods for predicting myelotoxicity for non-marrow targeting
I-131-antibody therapy. Cancer Biother Radiopharm. 2003 Apr;18(2):209-15. PubMed 
PMID: 12804046.


1476: Sheryka E, Wheeler MA, Hausladen DA, Weiss RM. Urinary interleukin-8 levels
are elevated in subjects with transitional cell carcinoma. Urology. 2003
Jul;62(1):162-6. PubMed PMID: 12837459.


1477: Shi FF, Gunn GR, Snyder LA, Goletz TJ. Intradermal vaccination of MUC1
transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary
metastases. Vaccine. 2007 Apr 30;25(17):3338-46. Epub 2007 Jan 22. PubMed PMID:
17292519.


1478: Shih J, Rahman M, Luong QT, Lomeli SH, Riss J, Prins RM, Gure AO, Zeng G.
Dominant B-cell epitopes from cancer/stem cell antigen SOX2 recognized by serum
samples from cancer patients. Am J Clin Exp Immunol. 2014 Aug 15;3(2):84-90.
eCollection 2014. PubMed PMID: 25143868; PubMed Central PMCID: PMC4138131.


1479: Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM. In vitro and in vivo
reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer
Res. 1995 Dec 1;55(23 Suppl):5857s-5863s. PubMed PMID: 7493360.


1480: Shiota M, Yokomizo A, Fujimoto N, Kuruma H, Naito S. Castration-resistant
prostate cancer: novel therapeutics pre- or post- taxane administration. Curr
Cancer Drug Targets. 2013 May;13(4):444-59. Review. PubMed PMID: 23517595.


1481: Shojaeian J, Jeddi-Tehrani M, Dokouhaki P, Mahmoudi AR, Ghods R, Bozorgmehr
M, Nikoo S, Bayat AA, Akhondi MM, Ostadkarampour M, Rezania S, Zarnani AH. Mutual
helper effect in copulsing of dendritic cells with 2 antigens: a novel approach
for improvement of dendritic-based vaccine efficacy against tumors and infectious
diseases simultaneously. J Immunother. 2009 May;32(4):325-32. doi:
10.1097/CJI.0b013e31819aa31e. PubMed PMID: 19342973.


1482: Shore N, Mason M, de Reijke TM. New developments in castrate-resistant
prostate cancer. BJU Int. 2012 Jun;109 Suppl 6:22-32. doi:
10.1111/j.1464-410X.2012.11217.x. Review. PubMed PMID: 22672122.


1483: Shore ND. PROSTVAC® targeted immunotherapy candidate for prostate cancer.
Immunotherapy. 2014 Mar;6(3):235-47. doi: 10.2217/imt.13.176. PubMed PMID:
24762070.


1484: Shore ND, Concepcion R, Barocas DA. A urologic oncology roundtable
discussion: the role of disease monitoring in treatment decision-making for
patients with metastatic castration-resistant prostate cancer. Hosp Pract (1995).
2013 Oct-Nov;41(4):78-80. doi: 10.3810/hp.2013.10.1083. PubMed PMID: 24145592.


1485: Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C,
Finkelstein SE, Fishman MN. Building on sipuleucel-T for immunologic treatment of
castration-resistant prostate cancer. Cancer Control. 2013 Jan;20(1):7-16.
Review. PubMed PMID: 23302902.


1486: Shore ND. Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 
2011, Barcelona, Spain. Immunotherapy. 2011 Aug;3(8):931-2. doi:
10.2217/imt.11.90. PubMed PMID: 21843080.


1487: Shu Y, Sun D. [Prostate stem cell antigen and related cancers]. Zhonghua
Nan Ke Xue. 2004 May;10(5):382-4. Review. Chinese. PubMed PMID: 15190837.


1488: Shukla SK, Limouris GS, Cusumano R, Acconcia A, Cipriani C, Atzei G, Argirò
G, Boemi S. Advanced prostate cancer diagnosis and therapy with gallium-67 and
yttrium-90, respectively. Anticancer Res. 1997 May-Jun;17(3B):1731-4. PubMed
PMID: 9179226.


1489: Siddiqui K, Klotz LH. Emerging drugs for prostate cancer. Expert Opin Emerg
Drugs. 2009 Sep;14(3):455-70. doi: 10.1517/14728210903142147. Review. PubMed
PMID: 19650748.


1490: Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, Pross H, Graham CH. 
Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role
of nitric oxide. Cancer Res. 2008 Jun 15;68(12):4746-53. doi:
10.1158/0008-5472.CAN-08-0054. PubMed PMID: 18559521.


1491: Siemens DR, Elzey BD, Lubaroff DM, Bohlken C, Jensen RJ, Swanson AK,
Ratliff TL. Cutting edge: restoration of the ability to generate CTL in mice
immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol. 
2001 Jan 15;166(2):731-5. PubMed PMID: 11145643.


1492: Siemens DR, Austin JC, Hedican SP, Tartaglia J, Ratliff TL. Viral vector
delivery in solid-state vehicles: gene expression in a murine prostate cancer
model. J Natl Cancer Inst. 2000 Mar 1;92(5):403-12. PubMed PMID: 10699070.


1493: Sikora K, Pandha H. Gene therapy for prostate cancer. Br J Urol. 1997
Apr;79 Suppl 2:64-8. Review. PubMed PMID: 9126072.


1494: Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE,
Bishop MC. Anti-GnRH antibodies can induce castrate levels of testosterone in
patients with advanced prostate cancer. Br J Cancer. 2000 Aug;83(4):443-6. PubMed
PMID: 10945488; PubMed Central PMCID: PMC2374644.


1495: Simoens S. Pharmaco-economic aspects of sipuleucel-T. Hum Vaccin
Immunother. 2012 Apr;8(4):506-8. doi: 10.4161/hv.18334. Epub 2012 Feb 16. Review.
PubMed PMID: 22336882.


1496: Simone CB 2nd, Hahn SM. What's in a Label? Radioimmunotherapy for
metastatic prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):4908-10. doi:
10.1158/1078-0432.CCR-13-1540. Epub 2013 Aug 7. PubMed PMID: 23926229.


1497: Simone G, Papalia R, Leonardo C, Sacco R, Damiano R, Guaglianone S,
Forastiere E, Gallucci M. Prostatic capsule and seminal vesicle-sparing
cystectomy: improved functional results, inferior oncologic outcome. Urology.
2008 Jul;72(1):162-6. doi: 10.1016/j.urology.2007.11.077. Epub 2008 Apr 18.
PubMed PMID: 18372008.


1498: Simons JW. Prostate Cancer Immunotherapy: Beyond Immunity to Curability.
Cancer Immunol Res. 2014 Nov;2(11):1034-1043. Review. PubMed PMID: 25367978.


1499: Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating
factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for 
prostate cancer. Urol Oncol. 2006 Sep-Oct;24(5):419-24. Review. PubMed PMID:
16962494.


1500: Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift
SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG. Phase I/II trial of an
allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer
Res. 2006 Jun 1;12(11 Pt 1):3394-401. PubMed PMID: 16740763.


1501: Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE,
Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG,
Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG.
Induction of immunity to prostate cancer antigens: results of a clinical trial of
vaccination with irradiated autologous prostate tumor cells engineered to secrete
granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Cancer Res. 1999 Oct 15;59(20):5160-8. PubMed PMID: 10537292.


1502: Simons JW, Mikhak B. Ex-vivo gene therapy using cytokine-transduced tumor
vaccines: molecular and clinical pharmacology. Semin Oncol. 1998
Dec;25(6):661-76. Review. PubMed PMID: 9865681.


1503: Sims RB. Development of sipuleucel-T: autologous cellular immunotherapy for
the treatment of metastatic castrate resistant prostate cancer. Vaccine. 2012 Jun
19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.
PubMed PMID: 22122856.


1504: Sims RB. Sipuleucel-T: autologous cellular immunotherapy for men with
asymptomatic or minimally symptomatic metastatic castrate resistant prostate
cancer. J Cancer. 2011;2:357-9. Epub 2011 Jun 15. PubMed PMID: 21716715; PubMed
Central PMCID: PMC3119403.


1505: Singh BH, Gulley JL. Therapeutic vaccines as a promising treatment modality
against prostate cancer: rationale and recent advances. Ther Adv Vaccines. 2014
Sep;2(5):137-48. doi: 10.1177/2051013614539478. Review. PubMed PMID: 25177493;
PubMed Central PMCID: PMC4144263.


1506: Singh BH, Gulley JL. Immunotherapy and therapeutic vaccines in prostate
cancer: an update on current strategies and clinical implications. Asian J
Androl. 2014 May-Jun;16(3):364-71. doi: 10.4103/1008-682X.122585. PubMed PMID:
24435055; PubMed Central PMCID: PMC4023361.


1507: Singh Jaggi J, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C,
McDevitt MR, Nolan D, Mittal V, Benezra R, Scheinberg DA. Selective
alpha-particle mediated depletion of tumor vasculature with vascular
normalization. PLoS One. 2007 Mar 7;2(3):e267. PubMed PMID: 17342201; PubMed
Central PMCID: PMC1801076.


1508: Sinha AA, Fernandes ET, Ewing SL, Wilson MJ. Prediction of immune
surveillance responsive metastatic prostate cancer in pelvic lymph node and
emergence of surveillance unresponsive/resistant metastatic cells. Anticancer
Res. 2013 Sep;33(9):3635-43. PubMed PMID: 24023290.


1509: Sinnathamby G, Zerfass J, Hafner J, Block P, Nickens Z, Hobeika A, Secord
AA, Lyerly HK, Morse MA, Philip R. ADAM metallopeptidase domain 17 (ADAM17) is
naturally processed through major histocompatibility complex (MHC) class I
molecules and is a potential immunotherapeutic target in breast, ovarian and
prostate cancers. Clin Exp Immunol. 2011 Mar;163(3):324-32. doi:
10.1111/j.1365-2249.2010.04298.x. Epub 2010 Dec 22. PubMed PMID: 21175594; PubMed
Central PMCID: PMC3048615.


1510: Sissom JF, Eigenbrodt ML, Porter JC. Anti-growth action on mouse mammary
and prostate glands of a monoclonal antibody to prolactin receptor. Am J Pathol. 
1988 Dec;133(3):589-95. PubMed PMID: 2462356; PubMed Central PMCID: PMC1880813.


1511: Sithambaram D, Palanivelu S, Subramanian K, Sahoo S, Verma RS. Specific
targeting of Ep-CAM in various carcinomas by novel monoclonal antibodies.
Hybridoma (Larchmt). 2011 Dec;30(6):511-8. doi: 10.1089/hyb.2011.0069. PubMed
PMID: 22149275.


1512: Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune
modulation by melanoma and ovarian tumor cells through expression of the
immunosuppressive molecule CD200. Cancer Immunol Immunother. 2008
Jul;57(7):987-96. PubMed PMID: 18060403.


1513: Siva AC, Kirkland RE, Lin B, Maruyama T, McWhirter J, Yantiri-Wernimont F, 
Bowdish KS, Xin H. Selection of anti-cancer antibodies from combinatorial
libraries by whole-cell panning and stringent subtraction with human blood cells.
J Immunol Methods. 2008 Jan 31;330(1-2):109-19. Epub 2007 Dec 17. PubMed PMID:
18096183.


1514: Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E,
Schlom J, Hand PH. A CDR-grafted (humanized) domain-deleted antitumor antibody.
Cancer Biother Radiopharm. 1997 Oct;12(5):305-16. PubMed PMID: 10851481.


1515: Slovin S. Chemotherapy and immunotherapy combination in advanced prostate
cancer. Clin Adv Hematol Oncol. 2012 Feb;10(2):90-100. Review. PubMed PMID:
22402350.


1516: Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher
HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination
with radiotherapy in metastatic castration-resistant prostate cancer: results
from an open-label, multicenter phase I/II study. Ann Oncol. 2013
Jul;24(7):1813-21. doi: 10.1093/annonc/mdt107. Epub 2013 Mar 27. PubMed PMID:
23535954; PubMed Central PMCID: PMC3707423.


1517: Slovin SF. Targeting castration-resistant prostate cancer with monoclonal
antibodies and constructs. Immunotherapy. 2013 Dec;5(12):1347-55. doi:
10.2217/imt.13.140. Review. PubMed PMID: 24283845.


1518: Slovin SF. A clinical trials outcome paradox: should survival prevail in
the absence of clinical benefit? Immunotherapy. 2010 Mar;2(2):155-8. doi:
10.2217/imt.10.5. PubMed PMID: 20635924.


1519: Slovin SF. Tribulations or triumphs in prostate cancer immunotherapy: on
the road to victory? Expert Rev Anticancer Ther. 2008 Mar;8(3):465-74. doi:
10.1586/14737140.8.3.465. Review. PubMed PMID: 18366293.


1520: Slovin SF. Pitfalls or promise in prostate cancer immunotherapy-which is
winning? Cancer J. 2008 Jan-Feb;14(1):26-34. doi: 10.1097/PPO.0b013e318161bffa.
Review. PubMed PMID: 18303480.


1521: Slovin SF. Emerging role of immunotherapy in the management of prostate
cancer. Oncology (Williston Park). 2007 Mar;21(3):326-33; discussion 334, 338,
346-8. Review. PubMed PMID: 17447437.


1522: Slovin SF. Prostate cancer vaccines: maximizing a suboptimal immune
response for improved outcome. Clin Adv Hematol Oncol. 2007 Dec;5(12):972-80.
Review. PubMed PMID: 18277959.


1523: Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly
WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI. A polyvalent vaccine
for high-risk prostate patients: "are more antigens better?". Cancer Immunol
Immunother. 2007 Dec;56(12):1921-30. Epub 2007 Jul 10. PubMed PMID: 17619878.


1524: Slovin SF. Immunologic targeting: how to channel a minimal response for
maximal outcome. Curr Opin Urol. 2006 May;16(3):179-85. Review. PubMed PMID:
16679856.


1525: Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS,
Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI. A
bivalent conjugate vaccine in the treatment of biochemically relapsed prostate
cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines
given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR
QS-21. Vaccine. 2005 May 2;23(24):3114-22. PubMed PMID: 15837210.


1526: Slovin SF. Targeting novel antigens for prostate cancer treatment: focus on
prostate-specific membrane antigen. Expert Opin Ther Targets. 2005
Jun;9(3):561-70. Review. PubMed PMID: 15948673; PubMed Central PMCID: PMC1855285.


1527: Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D,
Danishefsky S, Livingston P, Scher HI. Thomsen-Friedenreich (TF) antigen as a
target for prostate cancer vaccine: clinical trial results with TF cluster
(c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed
prostate cancer. Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb
22. PubMed PMID: 15726361.


1528: Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD,
Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI. Fully synthetic
carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical
trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate
vaccine. J Clin Oncol. 2003 Dec 1;21(23):4292-8. PubMed PMID: 14645418.


1529: Slovin SF. Vaccines as treatment strategies for relapsed prostate cancer:
approaches for induction of immunity. Hematol Oncol Clin North Am. 2001
Jun;15(3):477-96. Review. PubMed PMID: 11525292.


1530: Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M,
Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO,
Danishefsky SJ, Scher HI. Carbohydrate vaccines in cancer: immunogenicity of a
fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci U S
A. 1999 May 11;96(10):5710-5. PubMed PMID: 10318949; PubMed Central PMCID:
PMC21925.


1531: Slovin SF, Scher HI, Divgi CR, Reuter V, Sgouros G, Moore M, Weingard K,
Pettengall R, Imbriaco M, El-Shirbiny A, Finn R, Bronstein J, Brett C, Milenic D,
Dnistrian A, Shapiro L, Schlom J, Larson SM. Interferon-gamma and monoclonal
antibody 131I-labeled CC49: outcomes in patients with androgen-independent
prostate cancer. Clin Cancer Res. 1998 Mar;4(3):643-51. PubMed PMID: 9533532.


1532: Slovin SF, Livingston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, Mendelsohn
J, Scher HI. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering
Cancer Center approach. Semin Oncol. 1996 Dec;23(6 Suppl 14):41-8. Review. PubMed
PMID: 8996585.


1533: Slovin SR. Toward maximizing immunotherapy in metastatic
castration-resistant prostate cancer - rationale for combinatorial approaches
using chemotherapy. Front Oncol. 2012 May 30;2:43. doi: 10.3389/fonc.2012.00043. 
eCollection 2012. PubMed PMID: 22662316; PubMed Central PMCID: PMC3362835.


1534: Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP.
Time to disease-related pain and first opioid use in patients with metastatic
castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer
Prostatic Dis. 2014 Sep;17(3):259-64. doi: 10.1038/pcan.2014.21. Epub 2014 Jun
24. PubMed PMID: 24957547; PubMed Central PMCID: PMC4160816.


1535: Small EJ, Fong L. Developing immunotherapy as legitimate therapy for
patients with prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1085-7. doi:
10.1200/JCO.2009.26.3483. Epub 2010 Jan 25. PubMed PMID: 20100956.


1536: Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG,
Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW. Granulocyte
macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy
for hormone-refractory prostate cancer. Clin Cancer Res. 2007 Jul
1;13(13):3883-91. PubMed PMID: 17606721.


1537: Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH,
Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of
immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic,
asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul
1;24(19):3089-94. PubMed PMID: 16809734.


1538: Small EJ. Monoclonal antibody therapy for prostate cancer: finally a
reality? J Clin Oncol. 2004 Jul 1;22(13):2515-6. Epub 2004 Jun 1. PubMed PMID:
15173211.


1539: Small EJ, Reese DM. New treatment strategies in advanced prostate cancer.
Radiol Clin North Am. 2000 Jan;38(1):203-11, ix-x. Review. PubMed PMID: 10664673.


1540: Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH.
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic
cells. J Clin Oncol. 2000 Dec 1;18(23):3894-903. PubMed PMID: 11099318.


1541: Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2
elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother. 2011
Oct;34(8):569-80. doi: 10.1097/CJI.0b013e31822b5b1d. PubMed PMID: 21904219;
PubMed Central PMCID: PMC3175298.


1542: Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic
targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer 
Res. 2011 Nov 1;71(21):6785-95. doi: 10.1158/0008-5472.CAN-11-2127. Epub 2011 Aug
31. PubMed PMID: 21880588.


1543: Smith MR, Nelson JB. Future therapies in hormone-refractory prostate
cancer. Urology. 2005 May;65(5 Suppl):9-16; discussion 17. Review. PubMed PMID:
15885273.


1544: Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol
Imaging. 2004 Dec;48(4):297-304. Review. PubMed PMID: 15640793.


1545: Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12:
mechanisms of innate immunity that are model and dose dependent. J Immunol. 2000 
Sep 1;165(5):2665-70. PubMed PMID: 10946296.


1546: Snyder A, Tepper JE, Slovin SF. Perspectives on immunotherapy in prostate
cancer and solid tumors: where is the future? Semin Oncol. 2013 Jun;40(3):347-60.
doi: 10.1053/j.seminoncol.2013.04.009. Review. PubMed PMID: 23806499.


1547: Sokoloff MH, Nardin A, Solga MD, Lindorfer MA, Sutherland WM, Bankovich AJ,
Zhau HE, Chung LW, Taylor RP. Targeting of cancer cells with monoclonal
antibodies specific for C3b(i). Cancer Immunol Immunother. 2000
Dec;49(10):551-62. PubMed PMID: 11129326.


1548: Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun
AS. In vitro modulation of tumor progression-associated properties of hormone
refractory prostate carcinoma cell lines by cytokines. Cancer. 1996 May
1;77(9):1862-72. PubMed PMID: 8646686.


1549: Soliman H. Immunotherapy strategies in the treatment of breast cancer.
Cancer Control. 2013 Jan;20(1):17-21. Review. PubMed PMID: 23302903.


1550: Soloway MS. Follow up of patients receiving treatment for superficial
bladder cancer with mitomycin C and BCG. Prog Clin Biol Res. 1990;350:71-9.
PubMed PMID: 2117289.


1551: Soloway MS. Diagnosis and management of superficial bladder cancer. Semin
Surg Oncol. 1989;5(4):247-54. Review. PubMed PMID: 2549605.


1552: Somers KD, Brown RR, Holterman DA, Yousefieh N, Glass WF, Wright GL Jr,
Schellhammer PF, Qian J, Ciavarra RP. Orthotopic treatment model of prostate
cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand
immunotherapy. Int J Cancer. 2003 Dec 10;107(5):773-80. PubMed PMID: 14566827.


1553: Sommariva ML, Sandri SD, Guerrer CS. [Treatment of acute iatrogenic
cystitis secondary to bladder chemo-immuno-instillation or pelvic radiotherapy]. 
Urologia. 2010 Jul-Sep;77(3):187-92. Italian. PubMed PMID: 20931548.


1554: Song EY, Abbas Rizvi SM, Qu CF, Raja C, Brechbiel MW, Morgenstern A,
Apostolidis C, Allen BJ. Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in
preclinical targeted alpha therapy for cancer. Cancer Biol Ther. 2007
Jun;6(6):898-904. Epub 2007 Mar 5. PubMed PMID: 17582216.


1555: Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C,
Morgenstern A, Sgouros G. Radioimmunotherapy of breast cancer metastases with
alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 
2009 Dec 1;69(23):8941-8. doi: 10.1158/0008-5472.CAN-09-1828. Epub 2009 Nov 17.
PubMed PMID: 19920193; PubMed Central PMCID: PMC2789180.


1556: Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann
MM, Wheeler TM, Gee AP, Wang RF, Hayes TG. HLA-restricted NY-ESO-1 peptide
immunotherapy for metastatic castration resistant prostate cancer. Invest New
Drugs. 2014 Apr;32(2):235-42. doi: 10.1007/s10637-013-9960-9. Epub 2013 Apr 23.
PubMed PMID: 23609828; PubMed Central PMCID: PMC4100683.


1557: Sonpavde G, Kantoff PW. Immunotherapy for castration-resistant prostate
cancer. Urol Clin North Am. 2012 Nov;39(4):465-81. doi:
10.1016/j.ucl.2012.07.004. Review. PubMed PMID: 23084524.


1558: Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND. The
role of sipuleucel-T in therapy for castration-resistant prostate cancer: a
critical analysis of the literature. Eur Urol. 2012 Apr;61(4):639-47. doi:
10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24. Review. PubMed PMID: 22036643.


1559: Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Recent advances in
immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2011
Aug;11(8):997-1009. doi: 10.1517/14712598.2011.575357. Epub 2011 Jun 15. Review. 
PubMed PMID: 21675925.


1560: Sonpavde G, Slawin KM, Spencer DM, Levitt JM. Emerging vaccine therapy
approaches for prostate cancer. Rev Urol. 2010 Winter;12(1):25-34. PubMed PMID:
20428291; PubMed Central PMCID: PMC2859139.


1561: Sonpavde G, Spencer DM, Slawin KM. Vaccine therapy for prostate cancer.
Urol Oncol. 2007 Nov-Dec;25(6):451-9. Review. PubMed PMID: 18047951.


1562: Sood AK. PDEF and PDEF-induced proteins as candidate tumor antigens for T
cell and antibody-mediated immunotherapy of breast cancer. Immunol Res. 2010
Mar;46(1-3):206-15. doi: 10.1007/s12026-009-8129-2. Review. PubMed PMID:
19763888.


1563: Sorrentino C, Musiani P, Pompa P, Cipollone G, Di Carlo E. Androgen
deprivation boosts prostatic infiltration of cytotoxic and regulatory T
lymphocytes and has no effect on disease-free survival in prostate cancer
patients. Clin Cancer Res. 2011 Mar 15;17(6):1571-81. doi:
10.1158/1078-0432.CCR-10-2804. Epub 2010 Dec 15. PubMed PMID: 21159885.


1564: Sotiropoulou G, Kono M, Anisowicz A, Stenman G, Tsuji S, Sager R.
Identification and functional characterization of a human GalNAc
[alpha]2,6-sialyltransferase with altered expression in breast cancer. Mol Med.
2002 Jan;8(1):42-55. PubMed PMID: 11984005; PubMed Central PMCID: PMC2039932.


1565: Sotiropoulou PA, Perez SA, Iliopoulou EG, Missitzis I, Voelter V, Echner H,
Baxevanis CN, Papamichail M. Cytotoxic T-cell precursor frequencies to HER-2
(369-377) in patients with HER-2/neu-positive epithelial tumours. Br J Cancer.
2003 Sep 15;89(6):1055-61. PubMed PMID: 12966425; PubMed Central PMCID:
PMC2376937.


1566: Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB,
Papamichail M, Baxevanis CN. Natural CD8+ T-cell responses against MHC class I
epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors. Cancer
Immunol Immunother. 2003 Dec;52(12):771-9. Epub 2003 Sep 10. PubMed PMID:
13680193.


1567: Sowery RD, So AI, Gleave ME. Therapeutic options in advanced prostate
cancer: present and future. Curr Urol Rep. 2007 Jan;8(1):53-9. Review. PubMed
PMID: 17239317.


1568: Spicer J, Quatan N, Plunkett T, Pandha H. Cellular immunotherapy for
cancer: current concepts and clinical perspectives Monitoring immune responses
and clinical trials: part II. Clin Oncol (R Coll Radiol). 2004 Sep;16(6):395-404.
PubMed PMID: 15487131.


1569: Spies E, Reichardt W, Alvarez G, Groettrup M, Ohlschläger P. An artificial 
PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model
for prostate carcinoma. Mol Ther. 2012 Mar;20(3):555-64. doi:
10.1038/mt.2011.241. Epub 2011 Nov 15. PubMed PMID: 22086231; PubMed Central
PMCID: PMC3293618.


1570: Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor 
O, Saad F. Castration-resistant prostate cancer: from new pathophysiology to new 
treatment. Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008.
Epub 2013 Aug 11. Review. PubMed PMID: 23957948.


1571: Srinivasan R, Wolchok JD. Tumor antigens for cancer immunotherapy:
therapeutic potential of xenogeneic DNA vaccines. J Transl Med. 2004 Apr
16;2(1):12. PubMed PMID: 15090064; PubMed Central PMCID: PMC419720.


1572: Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol. 2006
Apr;18(2):201-5. Epub 2006 Feb 7. Review. PubMed PMID: 16464565.


1573: Stauffer Y, Theiler G, Sperisen P, Lebedev Y, Jongeneel CV. Digital
expression profiles of human endogenous retroviral families in normal and
cancerous tissues. Cancer Immun. 2004 Feb 11;4:2. PubMed PMID: 14871062.


1574: Stavridi F, Karapanagiotou EM, Syrigos KN. Targeted therapeutic approaches 
for hormone-refractory prostate cancer. Cancer Treat Rev. 2010 Apr;36(2):122-30. 
doi: 10.1016/j.ctrv.2009.06.001. Epub 2010 Jan 27. Review. PubMed PMID: 20106600.


1575: Steiner MS, Gingrich JR, Chauhan RD. Prostate cancer gene therapy. Surg
Oncol Clin N Am. 2002 Jul;11(3):607-20. Review. PubMed PMID: 12487058.


1576: Stephan MT, Stephan SB, Bak P, Chen J, Irvine DJ. Synapse-directed delivery
of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials. 2012
Aug;33(23):5776-87. doi: 10.1016/j.biomaterials.2012.04.029. Epub 2012 May 15.
PubMed PMID: 22594972; PubMed Central PMCID: PMC3395588.


1577: Sternberg CN, Petrylak DP, Madan RA, Parker C. Progress in the treatment of
advanced prostate cancer. Am Soc Clin Oncol Educ Book. 2014:117-31. doi:
10.14694/EdBook_AM.2014.34.117. PubMed PMID: 24857068.


1578: Sternberg CN. What's new in the treatment of advanced prostate cancer? Eur 
J Cancer. 2003 Jan;39(2):136-46. Review. PubMed PMID: 12509944.


1579: Stewart AB, Lwaleed BA, Douglas DA, Birch BR. Current drug therapy for
prostate cancer: an overview. Curr Med Chem Anticancer Agents. 2005
Nov;5(6):603-12. Review. PubMed PMID: 16305482.


1580: Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki
D, Boczkowski D, Gilboa E, Vieweg J. Telomerase mRNA-transfected dendritic cells 
stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with
metastatic prostate cancer. J Immunol. 2005 Mar 15;174(6):3798-807. PubMed PMID: 
15749921.


1581: Suckow MA, Wheeler J, Wolter WR, Sailes V, Yan M. Immunization with a
tissue vaccine enhances the effect of irradiation on prostate tumors. In Vivo.
2008 Mar-Apr;22(2):171-7. PubMed PMID: 18468400.


1582: Suckow MA, Wolter WR, Sailes VT. Inhibition of prostate cancer metastasis
by administration of a tissue vaccine. Clin Exp Metastasis. 2008;25(8):913-8.
doi: 10.1007/s10585-008-9213-z. Epub 2008 Sep 28. PubMed PMID: 18821060.


1583: Suckow MA, Rosen ED, Wolter WR, Sailes V, Jeffrey R, Tenniswood M.
Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue
vaccine. Cancer Immunol Immunother. 2007 Aug;56(8):1275-83. Epub 2007 Jan 23.
PubMed PMID: 17242926.


1584: Suckow MA, Wolter WR, Pollard M. Prevention of de novo prostate cancer by
immunization with tumor-derived vaccines. Cancer Immunol Immunother. 2005
Jun;54(6):571-6. Epub 2005 Feb 1. PubMed PMID: 15685450.


1585: Surolia I, Gulley J, Madan RA. Recent advances in the use of therapeutic
cancer vaccines in genitourinary malignancies. Expert Opin Biol Ther. 2014
Dec;14(12):1769-81. doi: 10.1517/14712598.2014.955010. Epub 2014 Sep 12. PubMed
PMID: 25212872.


1586: Suárez C, Morales-Barrera R, Ramos V, Núñez I, Valverde C, Planas J, Morote
J, Maldonado X, Carles J. Role of immunotherapy in castration-resistant prostate 
cancer (CRPC). BJU Int. 2014 Mar;113(3):367-75. doi: 10.1111/bju.12110. Epub 2013
Apr 12. Review. PubMed PMID: 23650874.


1587: Swindle PW, Tepes S, Clements J. DC therapy for prostate cancer.
Cytotherapy. 2004;6(2):164-71. PubMed PMID: 15203993.


1588: Symes JC, Siatskas C, Fowler DH, Medin JA. Retrovirally transduced murine T
lymphocytes expressing FasL mediate effective killing of prostate cancer cells.
Cancer Gene Ther. 2009 May;16(5):439-52. doi: 10.1038/cgt.2008.96. Epub 2008 Dec 
19. PubMed PMID: 19096446; PubMed Central PMCID: PMC2857530.


1589: Szmigielski S, Jeljaszewicz J, Pulverer G. Thermoimmunotherapy of advanced 
neoplasms. A concept and preliminary results. Biomed Pharmacother.
1987;41(3):132-8. PubMed PMID: 3607266.


1590: Sánchez-Martín D, Martínez-Torrecuadrada J, Teesalu T, Sugahara KN,
Alvarez-Cienfuegos A, Ximénez-Embún P, Fernández-Periáñez R, Martín MT,
Molina-Privado I, Ruppen-Cañás I, Blanco-Toribio A, Cañamero M, Cuesta AM, Compte
M, Kremer L, Bellas C, Alonso-Camino V, Guijarro-Muñoz I, Sanz L, Ruoslahti E,
Alvarez-Vallina L. Proteasome activator complex PA28 identified as an accessible 
target in prostate cancer by in vivo selection of human antibodies. Proc Natl
Acad Sci U S A. 2013 Aug 20;110(34):13791-6. doi: 10.1073/pnas.1300013110. Epub
2013 Aug 5. PubMed PMID: 23918357; PubMed Central PMCID: PMC3752212.


1591: Tabi Z, Spary LK, Coleman S, Clayton A, Mason MD, Staffurth J. Resistance
of CD45RA- T cells to apoptosis and functional impairment, and activation of
tumor-antigen specific T cells during radiation therapy of prostate cancer. J
Immunol. 2010 Jul 15;185(2):1330-9. doi: 10.4049/jimmunol.1000488. Epub 2010 Jun 
14. PubMed PMID: 20548027.


1592: Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich
D, Petrillo K, Parmar S, Nanus DM, Bander NH. Anti-prostate-specific membrane
antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010 Feb 15;116(4
Suppl):1075-83. doi: 10.1002/cncr.24795. PubMed PMID: 20127956; PubMed Central
PMCID: PMC2820151.


1593: Takahashi S, Kato K, Nakamura K, Nakano R, Kubota K, Hamada H. Neural cell 
adhesion molecule 2 as a target molecule for prostate and breast cancer gene
therapy. Cancer Sci. 2011 Apr;102(4):808-14. doi:
10.1111/j.1349-7006.2011.01855.x. Epub 2011 Feb 25. PubMed PMID: 21214674.


1594: Takaue Y, Tanosaki R, Tobisu K. [Peptide-pulsed dendritic cell therapy].
Nihon Rinsho. 2000 Jul;58 Suppl:295-8. Review. Japanese. PubMed PMID: 11022733.


1595: Takeda T, Nakamura K, Sato M, Takeda T, Tomimaru Y, Takeda H. [The effect
of immunotherapy and hyperthermia on patients with advanced or recurrent cancer -
analyses by cancer type and recurrence form]. Gan To Kagaku Ryoho. 2014
Oct;41(10):1261-3. Japanese. PubMed PMID: 25335711.


1596: Takeda T, Miyazawa K, Takeda T, Takeda H, Takeda Y. [Multidisciplinary
therapy for 984 cancer patients--hyperthermic immunotherapy]. Gan To Kagaku
Ryoho. 2010 Nov;37(12):2243-5. Japanese. PubMed PMID: 21224535.


1597: Talwar GP, Raina K, Gupta JC, Ray R, Wadhwa S, Ali MM. A recombinant
luteinising-hormone-releasing-hormone immunogen bioeffective in causing prostatic
atrophy. Vaccine. 2004 Sep 9;22(27-28):3713-21. PubMed PMID: 15315851.


1598: Talwar GP, Gupta R, Gupta SK, Malhotra R, Khanna R, Mitra DK, Sehgal S,
Minz R, Kumar A. A monoclonal antibody cytolytic to androgen independent DU145
and PC3 human prostatic carcinoma cells. Prostate. 2001 Feb 15;46(3):207-13.
PubMed PMID: 11170149.


1599: Talwar GP. Vaccines and passive immunological approaches for the control of
fertility and hormone-dependent cancers. Immunol Rev. 1999 Oct;171:173-92.
Review. PubMed PMID: 10582171.


1600: Talwar GP, Singh O, Pal R, Chatterjee N, Suri AK, Shaha C. Vaccines for
control of fertility. Indian J Exp Biol. 1992 Nov;30(11):947-50. Review. PubMed
PMID: 1293038.


1601: Talwar GP, Singh O, Pal R, Chatterjee N. Vaccines for control of fertility 
and hormone dependent cancers. Int J Immunopharmacol. 1992 Apr;14(3):511-4.
Review. PubMed PMID: 1618603.


1602: Tamura T, Chiba J. Production of antibodies against multipass membrane
proteins expressed in human tumor cells using dendritic cell immunization. J
Biomed Biotechnol. 2009;2009:673098. doi: 10.1155/2009/673098. Epub 2009 Apr 15. 
PubMed PMID: 19390695; PubMed Central PMCID: PMC2669292.


1603: Tan A, De La Peña H, Seifalian AM. The application of exosomes as a
nanoscale cancer vaccine. Int J Nanomedicine. 2010 Nov 10;5:889-900. doi:
10.2147/IJN.S13402. Review. PubMed PMID: 21116329; PubMed Central PMCID:
PMC2990382.


1604: Tan Z, Chen P, Schneider N, Glover S, Cui L, Torgue J, Rixe O, Spitz HB,
Dong Z. Significant systemic therapeutic effects of high-LET immunoradiation by
212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate
cancer in mice. Int J Oncol. 2012 Jun;40(6):1881-8. doi: 10.3892/ijo.2012.1357.
Epub 2012 Feb 6. PubMed PMID: 22322558.


1605: Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L,
Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, 
Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer
growth, metastasis and castration resistance. Nat Med. 2010 Dec;16(12):1414-20.
doi: 10.1038/nm.2236. Epub 2010 Nov 7. PubMed PMID: 21057494; PubMed Central
PMCID: PMC3088104.


1606: Tanaka T, Nakatani T. New therapeutic strategies for castration-resistant
prostate cancer. Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):373-83. doi:
10.2174/157489211796957793. Review. PubMed PMID: 21612574.


1607: Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor
targeting for cancer therapeutics. Expert Opin Ther Targets. 2011
Jan;15(1):31-51. doi: 10.1517/14728222.2011.538682. Review. PubMed PMID:
21142802; PubMed Central PMCID: PMC3016619.


1608: Taneja SS, Pang S, Cohan P, Belldegrun A. Gene therapy: principles and
potential. Cancer Surv. 1995;23:247-66. Review. PubMed PMID: 7542564.


1609: Tang S, Moore ML, Grayson JM, Dubey P. Increased CD8+ T-cell function
following castration and immunization is countered by parallel expansion of
regulatory T cells. Cancer Res. 2012 Apr 15;72(8):1975-85. doi:
10.1158/0008-5472.CAN-11-2499. Epub 2012 Feb 28. PubMed PMID: 22374980; PubMed
Central PMCID: PMC3690568.


1610: Tangney M, Ahmad S, Collins SA, O'Sullivan GC. Gene therapy for prostate
cancer. Postgrad Med. 2010 May;122(3):166-80. doi: 10.3810/pgm.2010.05.2154.
PubMed PMID: 20463426.


1611: Tanimoto T, Hori A, Kami M. Sipuleucel-T immunotherapy for
castration-resistant prostate cancer. N Engl J Med. 2010 Nov 11;363(20):1966;
author reply 1967-8. doi: 10.1056/NEJMc1009982#SA1. PubMed PMID: 21067392.


1612: Taplin ME, Berry WR, Casey AM, Aslo A. A urologic oncology roundtable
discussion: issues to consider in choosing treatment for metastatic
castration-resistant prostate cancer. Hosp Pract (1995). 2013 Oct-Nov;41(4):81-2.
doi: 10.3810/hp.2013.10.1084. PubMed PMID: 24145593.


1613: Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate
cancer. Oncologist. 2006 May;11(5):451-62. Review. PubMed PMID: 16720845.


1614: Tartour E, Sandoval F, Bonnefoy JY, Fridman WH. [Cancer immunotherapy:
recent breakthroughs and perspectives]. Med Sci (Paris). 2011 Oct;27(10):833-41. 
doi: 10.1051/medsci/20112710011. Epub 2011 Oct 21. Review. French. PubMed PMID:
22027420.


1615: Tasch J, Gong M, Sadelain M, Heston WD. A unique folate hydrolase,
prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev
Immunol. 2001;21(1-3):249-61. Review. PubMed PMID: 11642607.


1616: Tavri S, Jha P, Meier R, Henning TD, Müller T, Hostetter D, Knopp C,
Johansson M, Reinhart V, Boddington S, Sista A, Wels WS, Daldrup-Link HE. Optical
imaging of cellular immunotherapy against prostate cancer. Mol Imaging. 2009
Jan-Feb;8(1):15-26. PubMed PMID: 19344572.


1617: Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M. Chemopreventive
potential of curcumin in prostate cancer. Genes Nutr. 2010 Mar;5(1):61-74. doi:
10.1007/s12263-009-0152-3. Epub 2009 Oct 6. PubMed PMID: 19806380; PubMed Central
PMCID: PMC2820199.


1618: Tenuta A, Klotz L, Parker JL. Clinical trial risk in castration-resistant
prostate cancer: immunotherapies show promise. BJU Int. 2014 May;113(5b):E82-9.
doi: 10.1111/bju.12309. Epub 2013 Dec 2. PubMed PMID: 24053150.


1619: Terasaki Y, Shichijo S, Niu Y, Komatsu N, Noguchi M, Todo S, Itoh K. An
HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs
restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother. 2009
Nov;58(11):1877-85. doi: 10.1007/s00262-009-0699-2. Epub 2009 Mar 28. PubMed
PMID: 19330328.


1620: Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Identification and
characterization of a human agonist cytotoxic T-lymphocyte epitope of human
prostate-specific antigen. Clin Cancer Res. 2002 Jan;8(1):41-53. PubMed PMID:
11801539.


1621: Terunuma H. Autologous Immune Enhancement Therapy for Cancer - Our
experience since 2004. J Stem Cells Regen Med. 2012 Nov 26;8(3):205-6.
eCollection 2012. PubMed PMID: 24693200.


1622: Tewari AK, George DJ. Novel chemotherapies in development for management of
castration-resistant prostate cancer. Curr Opin Urol. 2013 May;23(3):220-9. doi: 
10.1097/MOU.0b013e32835f7da2. Review. PubMed PMID: 23511791.


1623: Thakur A, Vaishampayan U, Lum LG. Immunotherapy and immune evasion in
prostate cancer. Cancers (Basel). 2013 May 24;5(2):569-90. doi:
10.3390/cancers5020569. PubMed PMID: 24216992; PubMed Central PMCID: PMC3730318.


1624: Tham SM, Ng KH, Pook SH, Esuvaranathan K, Mahendran R. Tumor and
microenvironment modification during progression of murine orthotopic bladder
cancer. Clin Dev Immunol. 2011;2011:865684. doi: 10.1155/2011/865684. Epub 2011
Oct 13. PubMed PMID: 22013484; PubMed Central PMCID: PMC3195679.


1625: Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI. 
Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012 Apr
18;4(2):420-41. doi: 10.3390/cancers4020420. PubMed PMID: 24213318; PubMed
Central PMCID: PMC3712699.


1626: Thara E, Dorff TB, Pinski JK, Quinn DI. Vaccine therapy with sipuleucel-T
(Provenge) for prostate cancer. Maturitas. 2011 Aug;69(4):296-303. doi:
10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review. PubMed PMID: 21621934.


1627: Thau R. Anti-LHRH and anti-pituitary gonadotropin vaccines: their
development and clinical applications. Scand J Immunol Suppl. 1992;11:127-30.
PubMed PMID: 1514027.


1628: Theurillat JP, Zürrer-Härdi U, Varga Z, Barghorn A, Saller E, Frei C, Storz
M, Behnke S, Seifert B, Fehr M, Fink D, Rageth C, Linsenmeier C, Pestalozzi B,
Chen YT, Knuth A, Jäger D, Moch H. Distinct expression patterns of the
immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their
malignant counterparts. Int J Cancer. 2008 Apr 1;122(7):1585-91. PubMed PMID:
18041742.


1629: Thomas-Kaskel AK, Veelken H. Dendritic-cell vaccination for prostate
cancer. Immunotherapy. 2009 Jan;1(1):63-72. doi: 10.2217/1750743X.1.1.63. Review.
PubMed PMID: 20635974.


1630: Thomas-Kaskel AK, Veelken H. [Active immunotherapy of prostate cancer with 
a focus on dendritic cells]. Actas Urol Esp. 2007 Jun;31(6):668-79. Review.
Spanish. PubMed PMID: 17896564.


1631: Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H. Immunotherapy
with dendritic cells for prostate cancer. Int J Cancer. 2007 Aug 1;121(3):467-73.
Review. PubMed PMID: 17514654.


1632: Thompson JF, Shaw HM, Stretch JR, McCarthy WH, Milton GW. The Sydney
Melanoma Unit--a multidisciplinary melanoma treatment center. Surg Clin North Am.
2003 Apr;83(2):431-51. Review. PubMed PMID: 12744618.


1633: Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in
urologic malignancies. Immunotherapy. 2009 Jan;1(1):129-39. doi:
10.2217/1750743X.1.1.129. PubMed PMID: 20445772; PubMed Central PMCID:
PMC2864044.


1634: Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4
(CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol. 2006
Sep-Oct;24(5):442-7. Review. PubMed PMID: 16962497; PubMed Central PMCID:
PMC1976273.


1635: Thomsen RW, Farkas DK, Friis S, Sværke C, Ording AG, Nørgaard M, Sørensen
HT. Endocarditis and risk of cancer: a Danish nationwide cohort study. Am J Med. 
2013 Jan;126(1):58-67. doi: 10.1016/j.amjmed.2012.07.026. PubMed PMID: 23260503.


1636: Thong YH, Vincent MM, Hensen SA, Fuccillo DA, Rola-Pleszczynski M, Bellanti
JA. Depressed specific cell-mediated immunity to Herpes simplex virus type 1 in
patients with recurrent herpes labialis. Infect Immun. 1975 Jul;12(1):76-80.
PubMed PMID: 166930; PubMed Central PMCID: PMC415247.


1637: Thundimadathil J. Cancer treatment using peptides: current therapies and
future prospects. J Amino Acids. 2012;2012:967347. doi: 10.1155/2012/967347. Epub
2012 Dec 20. PubMed PMID: 23316341; PubMed Central PMCID: PMC3539351.


1638: Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ,
Kadmon D, Thompson TC. Therapeutic targets for metastatic prostate cancer. Curr
Drug Targets. 2003 Apr;4(3):251-61. Review. PubMed PMID: 12643475.


1639: Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G. Presentation of 
prostate tumor antigens by dendritic cells stimulates T-cell proliferation and
cytotoxicity. Prostate. 1996 Jan;28(1):65-9. PubMed PMID: 8545283.


1640: Tjoa B, Erickson S, Barren R 3rd, Ragde H, Kenny G, Boynton A, Murphy G. In
vitro propagated dendritic cells from prostate cancer patients as a component of 
prostate cancer immunotherapy. Prostate. 1995 Aug;27(2):63-9. PubMed PMID:
7638084.


1641: Tjoa BA, Murphy GP. Development of dendritic-cell based prostate cancer
vaccine. Immunol Lett. 2000 Sep 15;74(1):87-93. Review. PubMed PMID: 10996633.


1642: Tjoa BA, Murphy GP. Progress in active specific immunotherapy of prostate
cancer. Semin Surg Oncol. 2000 Jan-Feb;18(1):80-7. Review. PubMed PMID: 10617899.


1643: Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP. Dendritic
cell-based immunotherapy for prostate cancer. CA Cancer J Clin. 1999
Mar-Apr;49(2):117-28, 65. PubMed PMID: 11198886.


1644: Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ,
Boynton AL, Murphy GP. Follow-up evaluation of a phase II prostate cancer vaccine
trial. Prostate. 1999 Jul 1;40(2):125-9. PubMed PMID: 10386473.


1645: Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC,
Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of prostate cancer
patients infused with autologous dendritic cells pulsed with PSMA peptides.
Prostate. 1997 Sep 1;32(4):272-8. PubMed PMID: 9288186.


1646: Tjoa BA, Erickson SJ, Bowes VA, Salgaller ML, Lodge PA, McLean JG, Ragde H,
Kenny GM, Boynton AL, Murphy GP. Cancer immunotherapy for prostate cancer. Can J 
Urol. 1997 Jun;4(2 Supp 1):79-82. PubMed PMID: 12735843.


1647: Tjota A, Lee MT, Isaacs JT, Kadohama N, Lee CL. Murine monoclonal
antibodies reactive with a variety of androgen independent Dunning rat prostate
adenocarcinoma sublines also reactive with human prostate adenocarcinoma. J Urol.
1991 Jul;146(1):205-12. PubMed PMID: 2056591.


1648: Tjota A, Zhang YQ, Piedmonte MR, Lee CL. Adoptive immunotherapy using
lymphokine-activated killer cells and recombinant interleukin-2 in preventing and
treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate
tumor. J Urol. 1991 Jul;146(1):177-83. PubMed PMID: 2056587.


1649: Todorova K, Zoubak S, Mincheff M, Kyurkchiev S. Biochemical nature and
mapping of PSMA epitopes recognized by human antibodies induced after
immunization with gene-based vaccines. Anticancer Res. 2005
Nov-Dec;25(6C):4727-32. PubMed PMID: 16334167.


1650: Todorova K, Ignatova I, Tchakarov S, Altankova I, Zoubak S, Kyurkchiev S,
Mincheff M. Humoral immune response in prostate cancer patients after
immunization with gene-based vaccines that encode for a protein that is
proteasomally degraded. Cancer Immun. 2005 Jan 11;5:1. PubMed PMID: 15641767.


1651: Todryk SM, Eaton J, Birchall L, Greenhalgh R, Soars D, Dalgleish AG,
Melcher AA, Pandha HS. Heated tumour cells of autologous and allogeneic origin
elicit anti-tumour immunity. Cancer Immunol Immunother. 2004 Apr;53(4):323-30.
Epub 2003 Nov 28. PubMed PMID: 14648067.


1652: Tomasini P, Khobta N, Greillier L, Barlesi F. Ipilimumab: its potential in 
non-small cell lung cancer. Ther Adv Med Oncol. 2012 Mar;4(2):43-50. doi:
10.1177/1758834011431718. PubMed PMID: 22423263; PubMed Central PMCID:
PMC3296082.


1653: Tomblyn MB, Katin MJ, Wallner PE. The new golden era for
radioimmunotherapy: not just for lymphomas anymore. Cancer Control. 2013
Jan;20(1):60-71. Review. PubMed PMID: 23302908.


1654: Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA. Immunotherapy 
for gastrointestinal malignancies. Cancer Control. 2013 Jan;20(1):32-42. Review. 
PubMed PMID: 23302905.


1655: Toren PJ, Gleave ME. Evolving landscape and novel treatments in metastatic 
castrate-resistant prostate cancer. Asian J Androl. 2013 May;15(3):342-9. doi:
10.1038/aja.2013.38. Epub 2013 Apr 15. Review. PubMed PMID: 23584378; PubMed
Central PMCID: PMC3739642.


1656: Totterman TH, Loskog A, Essand M. The immunotherapy of prostate and bladder
cancer. BJU Int. 2005 Oct;96(5):728-35. PubMed PMID: 16144528.


1657: Toungouz M, Quinet C, Thille E, Fourez S, Pradier O, Delville JP, Velu T,
Lambermont M. Generation of immature autologous clinical grade dendritic cells
for vaccination of cancer patients. Cytotherapy. 1999;1(6):447-53. doi:
10.1080/0032472031000141304. PubMed PMID: 20426545.


1658: Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology,
genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev
Clin Oncol. 2013 May;10(5):289-301. doi: 10.1038/nrclinonc.2013.41. Epub 2013 Mar
26. Review. PubMed PMID: 23529000.


1659: Traynor K. Cellular immunotherapy licensed for advanced prostate cancer. Am
J Health Syst Pharm. 2010 Jun 1;67(11):862. doi: 10.2146/news100039. PubMed PMID:
20484204.


1660: Triemer HL, Pearson TC, Odom KL, Larsen CP. Analysis of a single-center
experience with mycophenolate mofetil based immunosuppression in renal
transplantation. Clin Transplant. 2000 Aug;14(4 Pt 2):413-20. PubMed PMID:
10946781.


1661: Triozzi PL, Achberger S, Aldrich W, Elson P, Garcia J, Dreicer R.
Differential immunologic and microRNA effects of 2 dosing regimens of recombinant
human granulocyte/macrophage colony stimulating factor. J Immunother. 2012
Sep;35(7):587-94. doi: 10.1097/CJI.0b013e31826b20b6. PubMed PMID: 22892455.


1662: Tritsch GL, Murphy GP. Adenosine deaminase specific activity in normal,
benign hypertrophied and neoplastic human prostate tissue. Eur Urol.
1980;6(4):229-31. PubMed PMID: 6156073.


1663: Troy A, Davidson P, Atkinson C, Hart D. The contribution of dendritic cells
to immune responses against urological cancers. Urol Oncol. 1998
Jan-Feb;4(1):17-23. PubMed PMID: 21227165.


1664: Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J,
Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK. A phase I
trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk
localized prostate cancer. Cancer Gene Ther. 2003 Oct;10(10):755-63. PubMed PMID:
14502228.


1665: Tsagozis P, Eriksson F, Pisa P. Zoledronic acid modulates antitumoral
responses of prostate cancer-tumor associated macrophages. Cancer Immunol
Immunother. 2008 Oct;57(10):1451-9. doi: 10.1007/s00262-008-0482-9. Epub 2008 Feb
23. PubMed PMID: 18297280.


1666: Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK. Metabolic and toxicological
considerations of newly approved prostate cancer drugs. Expert Opin Drug Metab
Toxicol. 2013 Jul;9(7):835-46. doi: 10.1517/17425255.2013.789019. Epub 2013 Apr
12. Review. PubMed PMID: 23581700.


1667: Tse BW, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ. From
bench to bedside: immunotherapy for prostate cancer. Biomed Res Int.
2014;2014:981434. doi: 10.1155/2014/981434. Epub 2014 Sep 4. PubMed PMID:
25276838; PubMed Central PMCID: PMC4168152.


1668: Tse BW, Russell PJ, Lochner M, Förster I, Power CA. IL-18 inhibits growth
of murine orthotopic prostate carcinomas via both adaptive and innate immune
mechanisms. PLoS One. 2011;6(9):e24241. doi: 10.1371/journal.pone.0024241. Epub
2011 Sep 15. PubMed PMID: 21935389; PubMed Central PMCID: PMC3174151.


1669: Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG.
Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a
mouse model of prostate cancer. Cancer Immunol Immunother. 2008
Sep;57(9):1357-65. doi: 10.1007/s00262-008-0471-z. Epub 2008 Feb 12. PubMed PMID:
18265979.


1670: Tsukamoto S, Miyanaga N, Kawai K, Akaza H. [Evidence-based medicine for
urological cancer chemotherapy]. Gan To Kagaku Ryoho. 2000 Feb;27(2):183-91.
Review. Japanese. PubMed PMID: 10700888.


1671: Tucker JA, Jochems C, Gulley JL, Schlom J, Tsang KY. Immunotherapy:
shifting the balance of cell-mediated immunity and suppression in human prostate 
cancer. Cancers (Basel). 2012 Dec 11;4(4):1333-48. doi: 10.3390/cancers4041333.
PubMed PMID: 24213509; PubMed Central PMCID: PMC3712722.


1672: Tuma RS. Immunotherapies in clinical trials: do they demand different
evaluation tools? J Natl Cancer Inst. 2011 May 18;103(10):780-1. doi:
10.1093/jnci/djr184. Epub 2011 May 6. PubMed PMID: 21551417.


1673: Tuma RS. Business barriers slowing the pace of cancer immunotherapy
research and development. J Natl Cancer Inst. 2007 Nov 7;99(21):1570-3. Epub 2007
Oct 30. Erratum in: J Natl Cancer Inst. 2008 Jan 2;100(1):10. PubMed PMID:
17971521.


1674: Turkeri L, Onol FF, Ozyurek M. Tumor specific cytotoxicity and telomerase
down-regulation in prostate cancer by autologous dendritic cells loaded with
whole tumor cell antigens. Urol Oncol. 2010 May-Jun;28(3):290-5. doi:
10.1016/j.urolonc.2009.01.029. Epub 2009 Apr 11. PubMed PMID: 19362861.


1675: Turkstra JA, van der Staay FJ, Stockhofe-Zurwieden N, Woelders H, Meloen
RH, Schuurman T. Pharmacological and toxicological assessment of a potential GnRH
vaccine in young-adult male pigs. Vaccine. 2011 May 12;29(21):3791-801. doi:
10.1016/j.vaccine.2011.03.023. Epub 2011 Mar 23. PubMed PMID: 21439319.


1676: Tykodi SS, Thompson JA. Development of modified vaccinia Ankara-5T4 as
specific immunotherapy for advanced human cancer. Expert Opin Biol Ther. 2008
Dec;8(12):1947-53. doi: 10.1517/14712590802567298 . Review. PubMed PMID:
18990081; PubMed Central PMCID: PMC2592504.


1677: Téllez-Avila FI, García-Osogobio SM. [The carcinoembryonic antigen: apropos
of an old friend]. Rev Invest Clin. 2005 Nov-Dec;57(6):814-9. Review. Spanish.
PubMed PMID: 16708907.


1678: Uemura H, Fujimoto K, Mine T, Uejima S, de Velasco MA, Hirao Y, Komatsu N, 
Yamada A, Itoh K. Immunological evaluation of personalized peptide vaccination
monotherapy in patients with castration-resistant prostate cancer. Cancer Sci.
2010 Mar;101(3):601-8. doi: 10.1111/j.1349-7006.2009.01459.x. Epub 2009 Dec 7.
PubMed PMID: 20128819.


1679: Uemura H. [Tumor inhibitory factors in urologic malignancies]. Hinyokika
Kiyo. 2008 Jan;54(1):49-52. Review. Japanese. PubMed PMID: 18260361.


1680: Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y,
Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth
AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E. T cell immunomonitoring
and tumor responses in patients immunized with a complex of cholesterol-bearing
hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 2007 Apr 19;7:9.
PubMed PMID: 17441676; PubMed Central PMCID: PMC2935756.


1681: Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F,
Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P,
Bronte V. Autoimmune B-cell lymphopenia after successful adoptive therapy with
telomerase-specific T lymphocytes. Blood. 2010 Feb 18;115(7):1374-84. doi:
10.1182/blood-2009-07-233270. Epub 2009 Nov 10. PubMed PMID: 19903903.


1682: Uhlman MA, Bing MT, Lubaroff DM. Prostate cancer vaccines in combination
with additional treatment modalities. Immunol Res. 2014 Aug;59(1-3):236-42. doi: 
10.1007/s12026-014-8532-1. PubMed PMID: 24838261.


1683: Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat
Rev Cancer. 2012 Dec;12(12):835-48. doi: 10.1038/nrc3397. Epub 2012 Nov 15.
Review. PubMed PMID: 23151603.


1684: Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small
EJ. Treatment of biochemical recurrence of prostate cancer with
granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular 
immunotherapy. J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi:
10.1016/j.juro.2008.07.048. Epub 2008 Sep 17. PubMed PMID: 18801509.


1685: Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A,
Bonavida B. Chemosensitization of human prostate carcinoma cell lines to
anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res. 1997
Jun;3(6):963-72. PubMed PMID: 9815772.


1686: Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon
J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic
cell-based interventions for cancer therapy. Oncoimmunology. 2013 Oct
1;2(10):e25771. Epub 2013 Jul 29. Review. PubMed PMID: 24286020; PubMed Central
PMCID: PMC3841205.


1687: Vaishampayan U. Therapeutic options and multifaceted treatment paradigms in
metastatic castrate-resistant prostate cancer. Curr Opin Oncol. 2014
May;26(3):265-73. doi: 10.1097/CCO.0000000000000066. Review. PubMed PMID:
24626129; PubMed Central PMCID: PMC4238025.


1688: Vaishampayan U, Hussain M. Update in systemic therapy of prostate cancer:
improvement in quality and duration of life. Expert Rev Anticancer Ther. 2008
Feb;8(2):269-81. doi: 10.1586/14737140.8.2.269. Review. PubMed PMID: 18279067.


1689: Valdespino V, Tsagozis P, Pisa P. Current perspectives in the treatment of 
advanced prostate cancer. Med Oncol. 2007;24(3):273-86. Review. PubMed PMID:
17873302.


1690: Valdés Olmos RA, Hoefnagel CA, Bais E, Boot H, Taal B, de Kraker J, Vote
PA. [Therapeutic advances of nuclear medicine in oncology]. Rev Esp Med Nucl.
2001 Dec;20(7):547-57. Review. Spanish. PubMed PMID: 11709141.


1691: Valenzuela AA, Archibald CW, Fleming B, Ong L, O'Donnell B, Crompton J J,
Selva D, McNab AA, Sullivan TJ. Orbital metastasis: clinical features, management
and outcome. Orbit. 2009;28(2-3):153-9. PubMed PMID: 19839900.


1692: Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander
NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591
monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin
Cancer Res. 2005 Oct 1;11(19 Pt 2):7195s-7200s. PubMed PMID: 16203821.


1693: Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S,
Milowski MI, Nanus DM, Bander NH. Prediction of myelotoxicity based on bone
marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and
177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J 
Nucl Med. 2005 May;46(5):850-8. PubMed PMID: 15872360.


1694: Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH.
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal
antibodies specific to prostate specific membrane antigen (PSMA): studies in nude
mice. Prostate. 2004 Feb 1;58(2):145-55. PubMed PMID: 14716739.


1695: Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R.
Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61. PubMed PMID: 11777265.


1696: Van Allen EM, Pomerantz M. Moving toward personalized medicine in
castration-resistant prostate cancer. Urol Clin North Am. 2012 Nov;39(4):483-90. 
doi: 10.1016/j.ucl.2012.07.005. Epub 2012 Aug 27. Review. PubMed PMID: 23084525.


1697: van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van
Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM,
Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen
WR. Combined immunotherapy with granulocyte-macrophage colony-stimulating
factor-transduced allogeneic prostate cancer cells and ipilimumab in patients
with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation
trial. Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4.
Epub 2012 Feb 10. PubMed PMID: 22326922.


1698: Van Lint S, Thielemans K, Breckpot K. mRNA: delivering an antitumor
message? Immunotherapy. 2011 May;3(5):605-7. doi: 10.2217/imt.11.28. PubMed PMID:
21554090.


1699: van Moorselaar RJ, Voest EE. Angiogenesis in prostate cancer: its role in
disease progression and possible therapeutic approaches. Mol Cell Endocrinol.
2002 Nov 29;197(1-2):239-50. Review. PubMed PMID: 12431818.


1700: van Rij CM, Lütje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM,
McBride WJ, Rossi EA, Oyen WJ, Boerman OC. Pretargeted immuno-PET and
radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific
antibody. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1377-83. doi:
10.1007/s00259-013-2434-7. Epub 2013 May 15. PubMed PMID: 23674207.


1701: van Schalkwyk MC, Papa SE, Jeannon JP, Guerrero Urbano T, Spicer JF, Maher 
J. Design of a phase I clinical trial to evaluate intratumoral delivery of
ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent 
head and neck cancer. Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42. doi:
10.1089/humc.2013.144. PubMed PMID: 24099518.


1702: Vanaja DK, Grossmann ME, Celis E, Young CY. Tumor prevention and antitumor 
immunity with heat shock protein 70 induced by 15-deoxy-delta12,14-prostaglandin 
J2 in transgenic adenocarcinoma of mouse prostate cells. Cancer Res. 2000 Sep
1;60(17):4714-8. PubMed PMID: 10987274.


1703: Vander Weg MW, Howren MB, Cai X. Use of routine clinical preventive
services among daily smokers, non-daily smokers, former smokers, and
never-smokers. Nicotine Tob Res. 2012 Feb;14(2):123-30. doi: 10.1093/ntr/ntr141. 
Epub 2011 Dec 16. PubMed PMID: 22180595.


1704: VanOosten RL, Griffith TS. Activation of tumor-specific CD8+ T Cells after 
intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res. 
2007 Dec 15;67(24):11980-90. PubMed PMID: 18089829.


1705: Vaňhara P, Hampl A, Kozubík A, Souček K. Growth/differentiation factor-15: 
prostate cancer suppressor or promoter? Prostate Cancer Prostatic Dis. 2012
Dec;15(4):320-8. doi: 10.1038/pcan.2012.6. Epub 2012 Feb 28. Review. PubMed PMID:
22370725.


1706: Veggeberg S. Dendritic cells pick up the pace in trials. Mol Med Today.
1997 Dec;3(12):518-9. PubMed PMID: 9449120.


1707: Vennegoor C, Calafat J, Hageman P, van Buitenen F, Janssen H, Kolk A, Rümke
P. Biochemical characterization and cellular localization of a formalin-resistant
melanoma-associated antigen reacting with monoclonal antibody NKI/C-3. Int J
Cancer. 1985 Mar 15;35(3):287-95. PubMed PMID: 3882581.


1708: Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr, Vesely DL.
Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers.
Eur J Clin Invest. 2006 Nov;36(11):810-9. PubMed PMID: 17032349.


1709: Vexler A, Lidawi G, Loew V, Barnea I, Karaush V, Lev-Ari S, Shtabsky A,
Ben-Yosef R. Anti-ERBb4 targeted therapy combined with radiation therapy in
prostate cancer. Results of in vitro and in vivo studies. Cancer Biol Ther. 2008 
Jul;7(7):1090-4. Epub 2008 Apr 19. PubMed PMID: 18443429.


1710: Vieweg J. Immunotherapy for advanced prostate cancer. Rev Urol. 2007;9
Suppl 1:S29-38. PubMed PMID: 17387370; PubMed Central PMCID: PMC1831540.


1711: Vieweg J, Boczkowski D, Roberson KM, Edwards DW, Philip M, Philip R, Rudoll
T, Smith C, Robertson C, Gilboa E. Efficient gene transfer with adeno-associated 
virus-based plasmids complexed to cationic liposomes for gene therapy of human
prostate cancer. Cancer Res. 1995 Jun 1;55(11):2366-72. PubMed PMID: 7757988.


1712: Vieweg J, Gilboa E. Gene therapy approaches in urologic oncology. Surg
Oncol Clin N Am. 1995 Apr;4(2):203-18. Review. PubMed PMID: 7796281.


1713: Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B,
Gilboa E. Immunotherapy of prostate cancer in the Dunning rat model: use of
cytokine gene modified tumor vaccines. Cancer Res. 1994 Apr 1;54(7):1760-5.
PubMed PMID: 8137291.


1714: Vinals C, Gaulis S, Coche T. Using in silico transcriptomics to search for 
tumor-associated antigens for immunotherapy. Vaccine. 2001 Mar
21;19(17-19):2607-14. PubMed PMID: 11257399.


1715: Vittes GE, Harden EL, Ottensmeier CH, Rice J, Stevenson FK. DNA fusion gene
vaccines induce cytotoxic T-cell attack on naturally processed peptides of human 
prostate-specific membrane antigen. Eur J Immunol. 2011 Aug;41(8):2447-56. doi:
10.1002/eji.201141518. Epub 2011 Jul 4. PubMed PMID: 21604260.


1716: Vogt P, Frei U, Repp H, Bunzendahl H, Oldhafer K, Pichlmayr R. Malignant
tumours in renal transplant recipients receiving cyclosporin: survey of 598
first-kidney transplantations. Nephrol Dial Transplant. 1990;5(4):282-8. PubMed
PMID: 2113225.


1717: von Amsberg G, Stroelin P, Bokemeyer C, Steuber T. [Current treatment
concepts for castration resistant prostate cancer]. Dtsch Med Wochenschr. 2014
Oct;139(41):2086-90. doi: 10.1055/s-0034-1387276. Epub 2014 Sep 30. German.
PubMed PMID: 25268211.


1718: von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T,
Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, 
Wild PJ. MAGE-C2/CT10 protein expression is an independent predictor of
recurrence in prostate cancer. PLoS One. 2011;6(7):e21366. doi:
10.1371/journal.pone.0021366. Epub 2011 Jul 6. PubMed PMID: 21754986; PubMed
Central PMCID: PMC3130772.


1719: Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY,
Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM.
Vaccination of cancer patients against telomerase induces functional antitumor
CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 1;10(3):828-39. PubMed PMID:
14871958.


1720: Vuckovic S, Clark GJ, Hart DN. Growth factors, cytokines and dendritic cell
development. Curr Pharm Des. 2002;8(5):405-18. Review. PubMed PMID: 12069378.


1721: Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB.
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate. 2010
Mar 1;70(4):443-55. doi: 10.1002/pros.21078. PubMed PMID: 19902470; PubMed
Central PMCID: PMC2935631.


1722: Vuky J, Corman JM, Porter C, Olgac S, Auerbach E, Dahl K. Phase II trial of
neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in
patients with high-risk clinically localized prostate cancer. Oncologist. 2013
Jun;18(6):687-8. doi: 10.1634/theoncologist.2011-0234. Epub 2013 Jun 5. PubMed
PMID: 23740935; PubMed Central PMCID: PMC4063395.


1723: Wada S, Harris TJ, Tryggestad E, Yoshimura K, Zeng J, Yen HR, Getnet D,
Grosso JF, Bruno TC, De Marzo AM, Netto GJ, Pardoll DM, DeWeese TL, Wong J, Drake
CG. Combined treatment effects of radiation and immunotherapy: studies in an
autochthonous prostate cancer model. Int J Radiat Oncol Biol Phys. 2013 Nov
15;87(4):769-76. doi: 10.1016/j.ijrobp.2013.07.015. Epub 2013 Sep 21. PubMed
PMID: 24064321.


1724: Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, Goldberg MV, 
Bruno TC, Grosso JF, Durham N, Netto GJ, Pardoll DM, Drake CG. Sequencing CTLA-4 
blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013
Apr 4;11:89. doi: 10.1186/1479-5876-11-89. PubMed PMID: 23557194; PubMed Central 
PMCID: PMC3666941.


1725: Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF,
Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG. Cyclophosphamide 
augments antitumor immunity: studies in an autochthonous prostate cancer model.
Cancer Res. 2009 May 15;69(10):4309-18. doi: 10.1158/0008-5472.CAN-08-4102. Epub 
2009 May 12. PubMed PMID: 19435909; PubMed Central PMCID: PMC3084614.


1726: Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP,
Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. Dendritic cell-based
multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer
Immunol Immunother. 2006 Dec;55(12):1524-33. Epub 2006 Apr 13. PubMed PMID:
16612599.


1727: Waeckerle-Men Y, Allmen EU, von Moos R, Classon BJ, Scandella E, Schmid HP,
Ludewig B, Groettrup M, Gillessen S. Dendritic cells generated from patients with
androgen-independent prostate cancer are not impaired in migration and T-cell
stimulation. Prostate. 2005 Sep 1;64(4):323-31. PubMed PMID: 15754347.


1728: Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B,
Krishnan S, Chang JY, Cheung MR. Effect of combining anti-epidermal growth factor
receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep. 2008
May;19(5):1071-7. PubMed PMID: 18425360.


1729: Waisbren BA. Update on the treatment of cancer with multiple immunotherapy.
Cancer Biother Radiopharm. 1999 Feb;14(1):27-30. PubMed PMID: 10850284.


1730: Walker RD. New concepts in the treatment of genitourinary cancer in
childhood. Semin Surg Oncol. 1989;5(4):227-34. Review. PubMed PMID: 2672229.


1731: Wallace S, Charnsangavej C, Carrasco CH, Bechtel W. Infusion-embolization. 
Cancer. 1984 Dec 1;54(11 Suppl):2751-65. Review. PubMed PMID: 6093984.


1732: Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V. Construction and
characterization of an attenuated Listeria monocytogenes strain for clinical use 
in cancer immunotherapy. Clin Vaccine Immunol. 2009 Jan;16(1):96-103. doi:
10.1128/CVI.00274-08. Epub 2008 Nov 19. PubMed PMID: 19020110; PubMed Central
PMCID: PMC2620657.


1733: Waller EK. The role of sargramostim (rhGM-CSF) as immunotherapy.
Oncologist. 2007;12 Suppl 2:22-6. Review. PubMed PMID: 18039636.


1734: Waller EK, Ernstoff MS. Modulation of antitumor immune responses by
hematopoietic cytokines. Cancer. 2003 Apr 1;97(7):1797-809. Review. PubMed PMID: 
12655538.


1735: Wallerand H, Bernhard JC, Culine S, Ballanger P, Robert G, Reiter RE,
Ferrière JM, Ravaud A. Targeted therapies in non-muscle-invasive bladder cancer
according to the signaling pathways. Urol Oncol. 2011 Jan-Feb;29(1):4-11. doi:
10.1016/j.urolonc.2009.07.025. Epub 2009 Nov 13. Review. PubMed PMID: 19914099.


1736: Walshe R, James EL, MacDonald-Wicks L, Boyes AW, Zucca A, Girgis A,
Lecathelinais C. Socio-demographic and medical correlates of the use of
biologically based complementary and alternative medicines amongst recent
Australian cancer survivors. Prev Med. 2012 Jan;54(1):23-6. doi:
10.1016/j.ypmed.2011.10.020. Epub 2011 Nov 10. PubMed PMID: 22100734.


1737: Waltzer KB. Simple, sensible preventive measures for managed care settings.
Geriatrics. 1998 Oct;53(10):65-8, 75-7, 81; quiz 82. Review. PubMed PMID:
9791197.


1738: Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi 
G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen
H. Cancer biomarkers defined by autoantibody signatures to aberrant
O-glycopeptide epitopes. Cancer Res. 2010 Feb 15;70(4):1306-13. doi:
10.1158/0008-5472.CAN-09-2893. Epub 2010 Feb 2. PubMed PMID: 20124478.


1739: Wang CY, Walfield AM. Site-specific peptide vaccines for immunotherapy and 
immunization against chronic diseases, cancer, infectious diseases, and for
veterinary applications. Vaccine. 2005 Mar 18;23(17-18):2049-56. PubMed PMID:
15755569.


1740: Wang D, Dafik L, Nolley R, Huang W, Wolfinger RD, Wang LX, Peehl DM.
Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate
Cancer. Drug Dev Res. 2013 Mar;74(2):65-80. PubMed PMID: 25152555; PubMed Central
PMCID: PMC4139012.


1741: Wang FL, Qin WJ, Wen WH, Tian F, Song B, Zhang Q, Lee C, Zhong WD, Guo YL, 
Wang H. TGF-beta insensitive dendritic cells: an efficient vaccine for murine
prostate cancer. Cancer Immunol Immunother. 2007 Nov;56(11):1785-93. Epub 2007
May 1. PubMed PMID: 17473921.


1742: Wang H, Thompson TC. Gene-modified bone marrow cell therapy for prostate
cancer. Gene Ther. 2008 May;15(10):787-96. doi: 10.1038/gt.2008.37. Epub 2008 Apr
3. Review. PubMed PMID: 18385769.


1743: Wang HY, Lin WY, Chen MC, Lin T, Chao CH, Hsu FN, Lin E, Huang CY, Luo TY, 
Lin H. Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer
cell growth: a possible radioimmunotherapy to prostate carcinoma. Int J Radiat
Biol. 2013 May;89(5):346-55. doi: 10.3109/09553002.2013.762136. Epub 2013 Feb 27.
PubMed PMID: 23294030.


1744: Wang HY, Wang RF. Enhancing cancer immunotherapy by intracellular delivery 
of cell-penetrating peptides and stimulation of pattern-recognition receptor
signaling. Adv Immunol. 2012;114:151-76. doi: 10.1016/B978-0-12-396548-6.00006-8.
Review. PubMed PMID: 22449781; PubMed Central PMCID: PMC3760162.


1745: Wang K, Gao X, Pang J, Liu X, Cai Y, Zhang Y, Zhou J, Zhan H. Dendritic
cells transduced with a PSMA-encoding adenovirus and cocultured with autologous
cytokine-induced lymphocytes induce a specific and strong immune response against
prostate cancer cells. Urol Oncol. 2009 Jan-Feb;27(1):26-32. doi:
10.1016/j.urolonc.2007.09.003. Epub 2008 Jan 14. PubMed PMID: 18367124.


1746: Wang L, Liu R, Ribick M, Zheng P, Liu Y. FOXP3 as an X-linked tumor
suppressor. Discov Med. 2010 Oct;10(53):322-8. Review. PubMed PMID: 21034673.


1747: Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P,
Zuo T, Cooney KA, Liu Y, Zheng P. Somatic single hits inactivate the X-linked
tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009 Oct 6;16(4):336-46.
doi: 10.1016/j.ccr.2009.08.016. PubMed PMID: 19800578; PubMed Central PMCID:
PMC2758294.


1748: Wang M, Senger RS, Paredes C, Banik GG, Lin A, Papoutsakis ET.
Microarray-based gene expression analysis as a process characterization tool to
establish comparability of complex biological products: scale-up of a whole-cell 
immunotherapy product. Biotechnol Bioeng. 2009 Nov 1;104(4):796-808. doi:
10.1002/bit.22441. PubMed PMID: 19591186.


1749: Wang W, Mo ZN. [Advances in prostate-specific membrane antigen targeted
therapies for prostate cancer]. Zhonghua Nan Ke Xue. 2010 Jun;16(6):547-51.
Review. Chinese. PubMed PMID: 20608362.


1750: Wang X, Yin L, Rao P, Stein R, Harsch KM, Lee Z, Heston WD. Targeted
treatment of prostate cancer. J Cell Biochem. 2007 Oct 15;102(3):571-9. Review.
PubMed PMID: 17685433.


1751: Wang X, Zhao H, Xu Q, Jin W, Liu C, Zhang H, Huang Z, Zhang X, Zhang Y, Xin
D, Simpson AJ, Old LJ, Na Y, Zhao Y, Chen W. HPtaa database-potential target
genes for clinical diagnosis and immunotherapy of human carcinoma. Nucleic Acids 
Res. 2006 Jan 1;34(Database issue):D607-12. PubMed PMID: 16381942; PubMed Central
PMCID: PMC1347445.


1752: Wang Y, Harada M, Yano H, Ogasawara S, Tanaka M, Yamada A, Itoh K.
Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon
cancer patients. Oncol Rep. 2006 Feb;15(2):317-21. PubMed PMID: 16391848.


1753: Wang Y, Harada M, Yano H, Ogasawara S, Takedatsu H, Arima Y, Matsueda S,
Yamada A, Itoh K. Prostatic acid phosphatase as a target molecule in specific
immunotherapy for patients with nonprostate adenocarcinoma. J Immunother. 2005
Nov-Dec;28(6):535-41. PubMed PMID: 16224270.


1754: Wang Y, Xu M, Che M, Von Hofe E, Abbas A, Kallinteris NL, Lu X, Liss ZJ,
Forman JD, Hillman GG. Curative antitumor immune response is optimal with tumor
irradiation followed by genetic induction of major histocompatibility complex
class I and class II molecules and suppression of Ii protein. Hum Gene Ther. 2005
Feb;16(2):187-99. PubMed PMID: 15761259.


1755: Wang YS, Tsang YW, Chi CH, Chang CC, Chu RM, Chi KH. Synergistic anti-tumor
effect of combination radio- and immunotherapy by electro-gene therapy plus
intra-tumor injection of dendritic cells. Cancer Lett. 2008 Aug 8;266(2):275-85. 
doi: 10.1016/j.canlet.2008.02.063. Epub 2008 Apr 7. PubMed PMID: 18397820.


1756: Wang Z, Wang J, Li X, Xing L, Ding Y, Shi P, Zhang Y, Guo S, Shu X, Shan B.
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by
inhibiting WWP1, Smurf1 and Smurf2. Int J Oncol. 2014 Oct;45(4):1469-78. doi:
10.3892/ijo.2014.2545. Epub 2014 Jul 17. PubMed PMID: 25051198.


1757: Wang ZG, Williams LJ, Zhang XF, Zatorski A, Kudryashov V, Ragupathi G,
Spassova M, Bornmann W, Slovin SF, Scher HI, Livingston PO, Lloyd KO, Danishefsky
SJ. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet
hemocyanin vaccine: isolation, quantification, and characterization of immune
responses by using totally synthetic immobilized tumor antigens. Proc Natl Acad
Sci U S A. 2000 Mar 14;97(6):2719-24. PubMed PMID: 10716997; PubMed Central
PMCID: PMC15996.


1758: Wang-Johanning F, Frost AR, Jian B, Azerou R, Lu DW, Chen DT, Johanning GL.
Detecting the expression of human endogenous retrovirus E envelope transcripts in
human prostate adenocarcinoma. Cancer. 2003 Jul 1;98(1):187-97. PubMed PMID:
12833471.


1759: Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting
cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol
Ther. 2007 Dec;7(12):1893-902. Review. PubMed PMID: 18034654.


1760: Ward S, Copier J, Dalgleish A. Technical challenges facing therapeutic
cancer vaccines. Curr Opin Drug Discov Devel. 2008 Mar;11(2):168-77. Review.
PubMed PMID: 18283604.


1761: Ward-Kavanagh LK, Zhu J, Cooper TK, Schell TD. Whole-body irradiation
increases the magnitude and persistence of adoptively transferred T cells
associated with tumor regression in a mouse model of prostate cancer. Cancer
Immunol Res. 2014 Aug;2(8):777-88. doi: 10.1158/2326-6066.CIR-13-0164. Epub 2014 
May 6. PubMed PMID: 24801834; PubMed Central PMCID: PMC4125439.


1762: Watkins SK, Hurwitz AA. FOXO3: A master switch for regulating tolerance and
immunity in dendritic cells. Oncoimmunology. 2012 Mar 1;1(2):252-254. PubMed
PMID: 22720261; PubMed Central PMCID: PMC3376981.


1763: Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM,
Ambs S, Yagita H, Hurwitz AA. FOXO3 programs tumor-associated DCs to become
tolerogenic in human and murine prostate cancer. J Clin Invest. 2011
Apr;121(4):1361-72. doi: 10.1172/JCI44325. Epub 2011 Mar 23. PubMed PMID:
21436588; PubMed Central PMCID: PMC3069771.


1764: Webb KS, Liberman SN, Ware JL, Walther PJ. In vitro synergism between
hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of
prostate carcinoma. Cancer Immunol Immunother. 1986;21(2):100-6. PubMed PMID:
2418949.


1765: Webb KS, Ware JL, Parks SF, Walther PJ, Paulson DF. Evidence for a novel
hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a 
prostate-restricted antigen by the remaining antigen-combining site: potential
for immunotherapy. Cancer Treat Rep. 1985 Jun;69(6):663-72. PubMed PMID: 4040422.


1766: Webb KS, Ware JL, Parks SF, Briner WH, Paulson DF. Monoclonal antibodies to
different epitopes on a prostate tumor-associated antigen. Implications for
immunotherapy. Cancer Immunol Immunother. 1983;14(3):155-66. PubMed PMID:
6188529.


1767: Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL,
Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A. A phase 1 study of a
vaccine targeting preferentially expressed antigen in melanoma and
prostate-specific membrane antigen in patients with advanced solid tumors. J
Immunother. 2011 Sep;34(7):556-67. doi: 10.1097/CJI.0b013e3182280db1. PubMed
PMID: 21760528; PubMed Central PMCID: PMC3709852.


1768: Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology:
biology, therapeutics, and challenges. J Clin Oncol. 2005 Nov 10;23(32):8262-9.
Review. PubMed PMID: 16278482.


1769: Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG.
Tissue-specific expression of the human prostate-specific antigen gene in
transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci
U S A. 1997 Jun 10;94(12):6369-74. PubMed PMID: 9177224; PubMed Central PMCID:
PMC21056.


1770: Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK,
Looney RJ, Lord EM, Frelinger JG. Expression of human prostate-specific antigen
(PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific 
cytotoxic T lymphocytes. Cancer Immunol Immunother. 1996 Jul;42(6):362-8. PubMed 
PMID: 8830740.


1771: Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A,
Rieger MA, Meye A, Bachmann M, Wirth MP, Rieber EP. D-GPCR: a novel putative G
protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem
Biophys Res Commun. 2004 Sep 10;322(1):239-49. PubMed PMID: 15313197.


1772: Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH,
Navale L, Amado RG, Schwab G, Figlin RA. Dose and schedule study of panitumumab
monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008
Jan 15;14(2):502-8. doi: 10.1158/1078-0432.CCR-07-1509. PubMed PMID: 18223225.


1773: Weiss AT, von Deetzen MC, Hecht W, Reinacher M, Gruber AD. Molecular
characterization of the feline T-cell receptor γ alternate reading frame protein 
(TARP) ortholog. J Vet Sci. 2012 Dec;13(4):345-53. PubMed PMID: 23271175; PubMed 
Central PMCID: PMC3539119.


1774: Weissman RM, Coffey DS, Scott WW. Cell kinetic studies of prostatic cancer:
adjuvant therapy in animal models. Oncology. 1977;34(3):133-7. PubMed PMID:
917443.


1775: Wenner CA, Martzen MR, Lu H, Verneris MR, Wang H, Slaton JW.
Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor
immune response in an immunocompetent murine model of human prostate cancer. Int 
J Oncol. 2012 Apr;40(4):905-13. doi: 10.3892/ijo.2011.1292. Epub 2011 Dec 12.
PubMed PMID: 22159900; PubMed Central PMCID: PMC3584555.


1776: Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen
J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the
immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br 
J Cancer. 2006 Jan 16;94(1):128-35. PubMed PMID: 16404366; PubMed Central PMCID: 
PMC2361083.


1777: Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, Friess H, Büchler
MW, Reiter RE, Hines OJ. Prostate stem cell antigen is a putative target for
immunotherapy in pancreatic cancer. Pancreas. 2005 Aug;31(2):119-25. PubMed PMID:
16024997.


1778: Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T,
Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ.
Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in 
vivo after treatment with ligand agonists. J Immunol. 2008 Dec 1;181(11):7721-7. 
PubMed PMID: 19017961; PubMed Central PMCID: PMC3427921.


1779: Wesley JD, Whitmore J, Trager J, Sheikh N. An overview of sipuleucel-T:
autologous cellular immunotherapy for prostate cancer. Hum Vaccin Immunother.
2012 Apr;8(4):520-7. doi: 10.4161/hv.18769. Epub 2012 Feb 28. Review. PubMed
PMID: 22370520.


1780: Westdorp H, Sköld AE, Snijer BA, Franik S, Mulder SF, Major PP, Foley R,
Gerritsen WR, de Vries IJ. Immunotherapy for prostate cancer: lessons from
responses to tumor-associated antigens. Front Immunol. 2014 May 6;5:191. doi:
10.3389/fimmu.2014.00191. eCollection 2014. Review. PubMed PMID: 24834066; PubMed
Central PMCID: PMC4018526.


1781: Wheeler DL, Rangnekar VM, Schwarze SR. ErbB4 targeting approaches for
prostate cancer treatment. Cancer Biol Ther. 2008 Jul;7(7):1095-7. Epub 2008 Jun 
30. PubMed PMID: 18698169.


1782: White RL Jr, Amin A. Cancer immunotherapy. Surg Oncol Clin N Am. 2011
Jul;20(3):531-54, ix. doi: 10.1016/j.soc.2011.01.010. PubMed PMID: 21640920.


1783: Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S,
Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A,
Gouttefangeas C, Rammensee HG. Promiscuous survivin peptide induces robust CD4+
T-cell responses in the majority of vaccinated cancer patients. Int J Cancer.
2012 Jul 1;131(1):140-9. doi: 10.1002/ijc.26365. Epub 2011 Sep 14. PubMed PMID:
21858810.


1784: Wieckowski E, Chatta GS, Mailliard RM, Gooding W, Palucka K, Banchereau J, 
Kalinski P. Type-1 polarized dendritic cells loaded with apoptotic prostate
cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells 
and defined prostate cancer-specific epitopes. Prostate. 2011 Feb 1;71(2):125-33.
doi: 10.1002/pros.21228. Epub 2010 Aug 17. PubMed PMID: 20717900; PubMed Central 
PMCID: PMC2989344.


1785: Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira 
AC, Burbridge SE, Box C, Eccles SA, Maher J. Dual targeting of ErbB2 and MUC1 in 
breast cancer using chimeric antigen receptors engineered to provide
complementary signaling. J Clin Immunol. 2012 Oct;32(5):1059-70. doi:
10.1007/s10875-012-9689-9. Epub 2012 Apr 17. PubMed PMID: 22526592.


1786: Wilkie S, Burbridge SE, Chiapero-Stanke L, Pereira AC, Cleary S, van der
Stegen SJ, Spicer JF, Davies DM, Maher J. Selective expansion of chimeric antigen
receptor-targeted T-cells with potent effector function using interleukin-4. J
Biol Chem. 2010 Aug 13;285(33):25538-44. doi: 10.1074/jbc.M110.127951. Epub 2010 
Jun 18. PubMed PMID: 20562098; PubMed Central PMCID: PMC2919118.


1787: Wilkinson R, Woods K, D'Rozario R, Prue R, Vari F, Hardy MY, Dong Y,
Clements JA, Hart DN, Radford KJ. Human kallikrein 4 signal peptide induces
cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer
Immunol Immunother. 2012 Feb;61(2):169-79. doi: 10.1007/s00262-011-1095-2. Epub
2011 Aug 27. PubMed PMID: 21874303.


1788: Wilkinson R, Kassianos AJ, Swindle P, Hart DN, Radford KJ. Numerical and
functional assessment of blood dendritic cells in prostate cancer patients.
Prostate. 2006 Feb 1;66(2):180-92. PubMed PMID: 16173035.


1789: Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, Li XL, Rogers DL,
Korokhov N, Kovesdi I, Pereboev AV, Curiel DT, Mathis JM. Dendritic cell based
PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
PLoS One. 2012;7(10):e46981. doi: 10.1371/journal.pone.0046981. Epub 2012 Oct 8. 
PubMed PMID: 23056548; PubMed Central PMCID: PMC3466199.


1790: Williams G, Ghanadian R, Castro JE. The growth and viability of human
prostatic tissue maintained in immunosuppressed mice. Clin Oncol. 1978
Dec;4(4):347-51. PubMed PMID: 83214.


1791: Williams SB, Lay AH, Lau CS, Josephson DY, Wilson TG, Choueiri TK, Pal SK. 
New therapies for castrate-resistant prostate cancer. Expert Opin Pharmacother.
2011 Sep;12(13):2069-74. doi: 10.1517/14656566.2011.590133. Epub 2011 Jun 11.
Review. PubMed PMID: 21663529.


1792: Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF,
Federoff HJ, Lord EM, Frelinger JG. Dendritic cells transduced with HSV-1
amplicons expressing prostate-specific antigen generate antitumor immunity in
mice. Hum Gene Ther. 2001 Oct 10;12(15):1867-79. PubMed PMID: 11589829.


1793: Willis RA, Wei C, Turner MJ, Callahan BP, Pugh AE, Barth RK, Lord EM,
Frelinger JG. A transgenic strategy for analyzing the regulatory regions of the
human prostate-specific antigen gene: potential applications for the treatment of
prostate cancer (Review). Int J Mol Med. 1998 Feb;1(2):379-86. Review. PubMed
PMID: 9852240.


1794: Winter H, van den Engel NK, Rusan M, Schupp N, Poehlein CH, Hu HM, Hatz RA,
Urba WJ, Jauch KW, Fox BA, Rüttinger D. Active-specific immunotherapy for
non-small cell lung cancer. J Thorac Dis. 2011 Jun;3(2):105-14. doi:
10.3978/j.issn.2072-1439.2010.12.06. PubMed PMID: 22263073; PubMed Central PMCID:
PMC3256502.


1795: Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ,
Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a
novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y 
Acad Sci. 2013 Jul;1291:1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17. Review. 
PubMed PMID: 23772560; PubMed Central PMCID: PMC3910157.


1796: Wolchok JD, Gregor PD, Nordquist LT, Slovin SF, Scher HI. DNA vaccines: an 
active immunization strategy for prostate cancer. Semin Oncol. 2003
Oct;30(5):659-66. Review. PubMed PMID: 14571413.


1797: Wolf P, Alt K, Wetterauer D, Bühler P, Gierschner D, Katzenwadel A,
Wetterauer U, Elsässer-Beile U. Preclinical evaluation of a recombinant
anti-prostate specific membrane antigen single-chain immunotoxin against prostate
cancer. J Immunother. 2010 Apr;33(3):262-71. doi: 10.1097/CJI.0b013e3181c5495c.
PubMed PMID: 20445346.


1798: Wolf P, Alt K, Bühler P, Katzenwadel A, Wetterauer U, Tacke M,
Elsässer-Beile U. Anti-PSMA immunotoxin as novel treatment for prostate cancer?
High and specific antitumor activity on human prostate xenograft tumors in SCID
mice. Prostate. 2008 Feb 1;68(2):129-38. PubMed PMID: 18044731.


1799: Wolf P, Gierschner D, Bühler P, Wetterauer U, Elsässer-Beile U. A
recombinant PSMA-specific single-chain immunotoxin has potent and selective
toxicity against prostate cancer cells. Cancer Immunol Immunother. 2006
Nov;55(11):1367-73. Epub 2006 Mar 18. PubMed PMID: 16547705.


1800: Wolfraim LA, Takahara M, Viley AM, Shivakumar R, Nieda M, Maekawa R, Liu
LN, Peshwa MV. Clinical scale electroloading of mature dendritic cells with
melanoma whole tumor cell lysate is superior to conventional lysate co-incubation
in triggering robust in vitro expansion of functional antigen-specific CTL. Int
Immunopharmacol. 2013 Mar;15(3):488-97. doi: 10.1016/j.intimp.2013.01.009. Epub
2013 Feb 8. PubMed PMID: 23474736.


1801: Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan IA,
Shrivasta S, McLeod DG, Moul JW, Peoples GE. Preclinical testing of a
peptide-based, HER2/neu vaccine for prostate cancer. Int J Oncol. 2004
Dec;25(6):1769-80. PubMed PMID: 15547716.


1802: Wong JY, Wang J, Liu A, Odom-Maryon T, Shively JE, Raubitschek AA, Williams
LE. Evaluating changes in stable chromosomal translocation frequency in patients 
receiving radioimmunotherapy. Int J Radiat Oncol Biol Phys. 2000 Feb
1;46(3):599-607. PubMed PMID: 10701739.


1803: Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. The ubiquitin-like 
protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.
Cancer Immunol Immunother. 2012 May;61(5):689-700. doi:
10.1007/s00262-011-1129-9. Epub 2011 Nov 6. PubMed PMID: 22057675.


1804: Wright JC. Update in cancer chemotherapy: genitourinary tract cancer, Part 
1. J Natl Med Assoc. 1987 Dec;79(12):1249-58. Review. PubMed PMID: 3323538;
PubMed Central PMCID: PMC2625648.


1805: Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent
expression of the immunostimulatory MHC class I chain-related molecule is
counteracted by shedding in prostate cancer. J Clin Invest. 2004
Aug;114(4):560-8. PubMed PMID: 15314693; PubMed Central PMCID: PMC503776.


1806: Wu K, Meng JS, Baihetiya A, Wang YJ. [Clinical efficacy and relative
factors of dendritic cell-based tumor vaccination for prostate cancer: a
systematic review and meta-analysis]. Zhonghua Nan Ke Xue. 2013 Jun;19(6):545-50.
Review. Chinese. PubMed PMID: 23862236.


1807: Wu Y, Rosenberg JE, Taplin ME. Novel agents and new therapeutics in
castration-resistant prostate cancer. Curr Opin Oncol. 2011 May;23(3):290-6. doi:
10.1097/CCO.0b013e3283449400. Review. PubMed PMID: 21311328.


1808: Wu Z, Xu Y. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action 
through NK and CD8+ T cells proliferation and activation. J Mol Cell Biol. 2010
Aug;2(4):217-22. doi: 10.1093/jmcb/mjq012. PubMed PMID: 20671116.


1809: Xiao L, Joo KI, Lim M, Wang P. Dendritic cell-directed vaccination with a
lentivector encoding PSCA for prostate cancer in mice. PLoS One.
2012;7(11):e48866. doi: 10.1371/journal.pone.0048866. Epub 2012 Nov 6. PubMed
PMID: 23139820; PubMed Central PMCID: PMC3490948.


1810: Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Chen Y, Verstovsek S,
Wang H, Prchal J, Yang XF. An unconventional antigen translated by a novel
internal ribosome entry site elicits antitumor humoral immune reactions. J
Immunol. 2006 Oct 1;177(7):4907-16. PubMed PMID: 16982933; PubMed Central PMCID: 
PMC3902139.


1811: Xu M, Kallinteris NL, von Hofe E. CD4+ T-cell activation for immunotherapy 
of malignancies using Ii-Key/MHC class II epitope hybrid vaccines. Vaccine. 2012 
Apr 16;30(18):2805-10. doi: 10.1016/j.vaccine.2012.02.031. Epub 2012 Mar 3.
Review. PubMed PMID: 22386748.


1812: Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T
lymphocytes specific for prostate-specific antigen. Prostate. 1997 Feb
1;30(2):73-8. PubMed PMID: 9051144.


1813: Xue T, Xue XP, Huang QS, Wei L, Sun K, Xue T. Monoclonal antibodies against
human aspartyl (asparaginyl) beta-hydroxylase developed by DNA immunization.
Hybridoma (Larchmt). 2009 Aug;28(4):251-7. doi: 10.1089/hyb.2009.0017. PubMed
PMID: 19663697.


1814: Yabusaki M, Sato J, Kohyama A, Kojima T, Nobuoka D, Yoshikawa T, Sawada Y, 
Murakami K, Gohda K, Okegawa T, Nakamura M, Takamatsu K, Ito M, Kaneko K,
Nakatsura T. Detection and preliminary evaluation of circulating tumor cells in
the peripheral blood of patients with eight types of cancer using a
telomerase-specific adenovirus. Oncol Rep. 2014 Nov;32(5):1772-8. doi:
10.3892/or.2014.3436. Epub 2014 Aug 22. PubMed PMID: 25176113; PubMed Central
PMCID: PMC4203327.


1815: Yamamoto N, Suyama H, Yamamoto N. Immunotherapy for Prostate Cancer with Gc
Protein-Derived Macrophage-Activating Factor, GcMAF. Transl Oncol. 2008
Jul;1(2):65-72. PubMed PMID: 18633461; PubMed Central PMCID: PMC2510818.


1816: Yang X, Guo Z, Liu Y, Si T, Yu H, Li B, Tian W. Prostate stem cell antigen 
and cancer risk, mechanisms and therapeutic implications. Expert Rev Anticancer
Ther. 2014 Jan;14(1):31-7. doi: 10.1586/14737140.2014.845372. Epub 2013 Nov 26.
Review. PubMed PMID: 24308679.


1817: Yang XF, Mirkovic D, Zhang S, Zhang QE, Yan Y, Xiong Z, Yang F, Chen IH, Li
L, Wang H. Processing sites are different in the generation of
HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes.
Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):853-70. PubMed PMID: 17166407;
PubMed Central PMCID: PMC2888035.


1818: Yang XF, Wu CJ, Chen L, Alyea EP, Canning C, Kantoff P, Soiffer RJ, Dranoff
G, Ritz J. CML28 is a broadly immunogenic antigen, which is overexpressed in
tumor cells. Cancer Res. 2002 Oct 1;62(19):5517-22. PubMed PMID: 12359762.


1819: Yang XF, Wu CJ, McLaughlin S, Chillemi A, Wang KS, Canning C, Alyea EP,
Kantoff P, Soiffer RJ, Dranoff G, Ritz J. CML66, a broadly immunogenic tumor
antigen, elicits a humoral immune response associated with remission of chronic
myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7. PubMed
PMID: 11416219; PubMed Central PMCID: PMC34696.


1820: Yao A, Harada M, Matsueda S, Ishihara Y, Shomura H, Takao Y, Noguchi M,
Matsuoka K, Hara I, Kamidono S, Itoh K. New epitope peptides derived from
parathyroid hormone-related protein which have the capacity to induce prostate
cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
Prostate. 2005 Feb 15;62(3):233-42. PubMed PMID: 15389794.


1821: Yao A, Harada M, Matsueda S, Ishihara Y, Shomura H, Noguchi M, Matsuoka K, 
Hara I, Kamidono S, Itoh K. Identification of parathyroid hormone-related
protein-derived peptides immunogenic in human histocompatibility leukocyte
antigen-A24+ prostate cancer patients. Br J Cancer. 2004 Jul 19;91(2):287-96.
PubMed PMID: 15199397; PubMed Central PMCID: PMC2409818.


1822: Yao W, Peng Y, Du M, Luo J, Zong L. Preventative vaccine-loaded
mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance
immune responses and potent tumor immunity. Mol Pharm. 2013 Aug 5;10(8):2904-14. 
doi: 10.1021/mp4000053. Epub 2013 Jun 25. PubMed PMID: 23768205.


1823: Yedavelli SP, Guo L, Daou ME, Srivastava PK, Mittelman A, Tiwari RK.
Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in
an experimental prostate cancer model. Int J Mol Med. 1999 Sep;4(3):243-8. PubMed
PMID: 10425272.


1824: Yi H, Yu X, Guo C, Manjili MH, Repasky EA, Wang XY. Adoptive cell therapy
of prostate cancer using female mice-derived T cells that react with prostate
antigens. Cancer Immunol Immunother. 2011 Mar;60(3):349-60. doi:
10.1007/s00262-010-0939-5. Epub 2010 Nov 19. PubMed PMID: 21088965; PubMed
Central PMCID: PMC3042529.


1825: Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY.
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the
peripheral blood of patients with prostate cancer. Clin Cancer Res. 2008 Feb
15;14(4):1032-40. doi: 10.1158/1078-0432.CCR-07-2056. PubMed PMID: 18281535.


1826: Yokokawa J, Bera TK, Palena C, Cereda V, Remondo C, Gulley JL, Arlen PM,
Pastan I, Schlom J, Tsang KY. Identification of cytotoxic T-lymphocyte epitope(s)
and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int J
Cancer. 2007 Aug 1;121(3):595-605. PubMed PMID: 17397028.


1827: Yonemitsu Y, Ueda Y, Kinoh H, Hasegawa M. Immunostimulatory virotherapy
using recombinant Sendai virus as a new cancer therapeutic regimen. Front Biosci.
2008 May 1;13:4953-9. Review. PubMed PMID: 18508560.


1828: Yonemitsu Y, Ueda Y, Kinoh H, Hasegawa M. Immunostimulatory virotherapy
using recombinant Sendai virus as a new cancer therapeutic regimen. Front Biosci.
2008 Jan 1;13:1892-8. Review. PubMed PMID: 17981677.


1829: Yoo C, Do HA, Jeong IG, Park H, Hwang JJ, Hong JH, Cho JS, Choo MS, Ahn H, 
Kim CS. Efficacy of dendritic cells matured early with OK-432 (Picibanil),
prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory
prostate cancer cell line. J Korean Med Sci. 2010 Sep;25(9):1284-90. doi:
10.3346/jkms.2010.25.9.1284. Epub 2010 Aug 14. PubMed PMID: 20808670; PubMed
Central PMCID: PMC2923792.


1830: Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, Yanagimoto H,
Kawano K, Itoh K, Yamada A. Characteristics of severe adverse events after
peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncol
Rep. 2011 Jan;25(1):57-62. PubMed PMID: 21109957.


1831: Yoshida O, Oishi K, Arai Y, Mori H. [Prostatic cancer]. Gan To Kagaku
Ryoho. 1989 Dec;16(12):3704-11. Review. Japanese. PubMed PMID: 2688560.


1832: Yoshimura K, Uemura H. [Application of basic research to the treatment of
prostate cancer]. Nihon Rinsho. 2011 Jun;69 Suppl 5:19-24. Review. Japanese.
PubMed PMID: 22207935.


1833: Youlin K, Li Z, Xin G, Mingchao X, Xiuheng L, Xiaodong W. Enhanced function
of cytotoxic T lymphocytes induced by dendritic cells modified with truncated
PSMA and 4-1BBL. Hum Vaccin Immunother. 2013 Apr;9(4):766-72. doi:
10.4161/hv.23116. Epub 2013 Jan 7. PubMed PMID: 23295983; PubMed Central PMCID:
PMC3903894.


1834: Youlin K, Li Z, Xiaodong W, Xiuheng L, Hengchen Z. Combination
immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate
cancer. Clin Dev Immunol. 2012;2012:439235. doi: 10.1155/2012/439235. Epub 2012
Jan 23. PubMed PMID: 22312406; PubMed Central PMCID: PMC3270651.


1835: Young JG, Green NK, Mautner V, Searle PF, Young LS, James ND. Combining
gene and immunotherapy for prostate cancer. Prostate Cancer Prostatic Dis.
2008;11(2):187-93. Epub 2007 Aug 28. PubMed PMID: 17726452.


1836: Younger AR, Amria S, Jeffrey WA, Mahdy AE, Goldstein OG, Norris JS, Haque
A. HLA class II antigen presentation by prostate cancer cells. Prostate Cancer
Prostatic Dis. 2008;11(4):334-41. Epub 2007 Oct 16. PubMed PMID: 17938645.


1837: Yousefieh N, Hahto SM, Stephens AL, Ciavarra RP. Regulated expression of
CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis
in an orthotopic model of prostate cancer. Cancer Microenviron. 2009
Dec;2(1):59-67. doi: 10.1007/s12307-009-0021-z. Epub 2009 May 6. PubMed PMID:
19418243; PubMed Central PMCID: PMC2787929.


1838: Yu M, Huang C, Xiang M, Lai J, Yang H, Ma M, Tan D. [hARD1 antiserum
preparation and primary immunohistochemical analysis of hARD1 in tumor tissues]. 
Sheng Wu Gong Cheng Xue Bao. 2008 Jul;24(7):1155-61. Chinese. PubMed PMID:
18837388.


1839: Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann 
TA. Simultaneous inhibition of two regulatory T-cell subsets enhanced
Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A. 2012
Apr 17;109(16):6187-92. doi: 10.1073/pnas.1203479109. Epub 2012 Apr 2. PubMed
PMID: 22474386; PubMed Central PMCID: PMC3341063.


1840: Yu X, Guo C, Yi H, Qian J, Fisher PB, Subjeck JR, Wang XY. A
multifunctional chimeric chaperone serves as a novel immune modulator inducing
therapeutic antitumor immunity. Cancer Res. 2013 Apr 1;73(7):2093-103. doi:
10.1158/0008-5472.CAN-12-1740. Epub 2013 Jan 18. PubMed PMID: 23333935; PubMed
Central PMCID: PMC3618619.


1841: Yuriev E, Farrugia W, Scott AM, Ramsland PA. Three-dimensional structures
of carbohydrate determinants of Lewis system antigens: implications for effective
antibody targeting of cancer. Immunol Cell Biol. 2005 Dec;83(6):709-17. Review.
PubMed PMID: 16266323.


1842: Zamora S, Bhatti RA, Ablin RJ, Rao R, Baumgartner G, Guinan PD. In vitro
stimulation of tumor-associated immunity in prostatic cancer by levamisole. Cell 
Mol Biol Incl Cyto Enzymol. 1979;25(1):57-9. PubMed PMID: 574794.


1843: Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA,
Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human
prostate cancer and associated with disease spread and poor outcome. Proc Natl
Acad Sci U S A. 2007 Dec 4;104(49):19458-63. Epub 2007 Nov 27. PubMed PMID:
18042703; PubMed Central PMCID: PMC2148311.


1844: Zarour L, Alumkal J. Emerging therapies in castrate-resistant prostate
cancer. Curr Urol Rep. 2010 May;11(3):152-8. doi: 10.1007/s11934-010-0104-x.
Review. PubMed PMID: 20425621; PubMed Central PMCID: PMC3682789.


1845: Zell S, Geis N, Rutz R, Schultz S, Giese T, Kirschfink M. Down-regulation
of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides
(S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol. 2007
Dec;150(3):576-84. Epub 2007 Sep 28. PubMed PMID: 17903221; PubMed Central PMCID:
PMC2219364.


1846: Zelle-Rieser C, Barsoum AL, Sallusto F, Ramoner R, Rohrer JW, Höltl L,
Bartsch G, Coggin JH JR, Thurnher M. Expression and immunogenicity of oncofetal
antigen-immature laminin receptor in human renal cell carcinoma. J Urol. 2001
May;165(5):1705-9. PubMed PMID: 11342960.


1847: Zhang HZ, Jiang ZM, Guo MY, Zheng L. [Electron microscopic examination on
50 cases of prostatic needle biopsies]. Zhonghua Bing Li Xue Za Zhi. 2010
Sep;39(9):587-90. Chinese. PubMed PMID: 21092584.


1848: Zhang KQ, Yang F, Ye J, Jiang M, Liu Y, Jin FS, Wu YZ. A novel DNA/peptide 
combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and
suppresses tumor growth in experimental prostate cancer. Urology. 2012
Jun;79(6):1410.e7-13. doi: 10.1016/j.urology.2012.02.011. Epub 2012 Apr 17.
PubMed PMID: 22513035.


1849: Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg
NM, Kuzel T, Meagher R, Guo Y, Lee C. Blockade of transforming growth
factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor 
immune response cycle. Mol Cancer Ther. 2006 Jul;5(7):1733-43. PubMed PMID:
16891459.


1850: Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg
NM, Liu V, Guo Y, Lee C. Adoptive transfer of tumor-reactive transforming growth 
factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate
cancer. Cancer Res. 2005 Mar 1;65(5):1761-9. PubMed PMID: 15753372.


1851: Zhang RX, Li A, Liu B, Wang L, Xin J, Ren K, Qiao JT, Berman BM, Lao L.
Electroacupuncture attenuates bone-cancer-induced hyperalgesia and inhibits
spinal preprodynorphin expression in a rat model. Eur J Pain. 2008
Oct;12(7):870-8. doi: 10.1016/j.ejpain.2007.12.006. Epub 2008 Jan 24. PubMed
PMID: 18221900; PubMed Central PMCID: PMC3107701.


1852: Zhang S, Zeng G, Wilkes DS, Reed GE, McGarry RC, Eble JN, Cheng L.
Dendritic cells transfected with interleukin-12 and pulsed with tumor extract
inhibit growth of murine prostatic carcinoma in vivo. Prostate. 2003 Jun
1;55(4):292-8. PubMed PMID: 12712408.


1853: Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. Selection of
tumor antigens as targets for immune attack using immunohistochemistry: protein
antigens. Clin Cancer Res. 1998 Nov;4(11):2669-76. PubMed PMID: 9829729.


1854: Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO.
Expression of potential target antigens for immunotherapy on primary and
metastatic prostate cancers. Clin Cancer Res. 1998 Feb;4(2):295-302. PubMed PMID:
9516914.


1855: Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO,
Livingston PO. Selection of tumor antigens as targets for immune attack using
immunohistochemistry: II. Blood group-related antigens. Int J Cancer. 1997 Sep
26;73(1):50-6. PubMed PMID: 9334809.


1856: Zhang SY, Thara E, Quinn DI, Dorff TB. Blood cells and their use in active 
immunotherapy of prostate cancer. Hum Vaccin Immunother. 2012 Apr;8(4):528-33.
doi: 10.4161/hv.19188. Epub 2012 Feb 28. Review. PubMed PMID: 22370509.


1857: Zhang X, Shi X, Li J, Hu Z, Zhou D, Gao J, Tan W. A novel therapeutic
vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder
cancer. J Urol. 2012 Mar;187(3):1071-9. doi: 10.1016/j.juro.2011.10.126. Epub
2012 Jan 21. PubMed PMID: 22266013.


1858: Zhang X, Shi X, Li J, Hu Z, Guo F, Huang X, Zhang Z, Sun P, Jing Y, Gao J, 
Tan W. Novel immunotherapy for metastatic bladder cancer using vaccine of human
interleukin-2 surface-modified MB 49 cells. Urology. 2011
Sep;78(3):722.e1-722.e6. doi: 10.1016/j.urology.2011.04.044. Epub 2011 Jul 13.
PubMed PMID: 21741685.


1859: Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W. Vaccination with a 
DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific 
CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. J Gene Med.
2007 Aug;9(8):715-26. PubMed PMID: 17595048.


1860: Zhao H, Xi X, Cui L, He W. CDR3δ -grafted γ9δ2T cells mediate effective
antitumor reactivity. Cell Mol Immunol. 2012 Mar;9(2):147-54. doi:
10.1038/cmi.2011.28. Epub 2011 Sep 12. PubMed PMID: 21909128; PubMed Central
PMCID: PMC4002801.


1861: Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D. Toll-like receptors and prostate
cancer. Front Immunol. 2014 Jul 23;5:352. doi: 10.3389/fimmu.2014.00352.
eCollection 2014. Review. PubMed PMID: 25101092; PubMed Central PMCID:
PMC4107957.


1862: Zhao S, Yu EY. Castrate-resistant prostate cancer: postdocetaxel
management. Curr Opin Urol. 2013 May;23(3):201-7. doi:
10.1097/MOU.0b013e32835e2253. PubMed PMID: 23344012.


1863: Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P, Xuan JA, Sakamoto
C, Wada K, Schulze M, Müller-Tiemann B, Parry G, Dinter H. Targeting tomoregulin 
for radioimmunotherapy of prostate cancer. Cancer Res. 2005 Apr 1;65(7):2846-53. 
PubMed PMID: 15805286.


1864: Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N,
Navarro B, Ichim TE, Urquhart B, Min W. Silencing IDO in dendritic cells: a novel
approach to enhance cancer immunotherapy in a murine breast cancer model. Int J
Cancer. 2013 Feb 15;132(4):967-77. doi: 10.1002/ijc.27710. Epub 2012 Jul 20.
PubMed PMID: 22870862.


1865: Zhou G, Levitsky H. Towards curative cancer immunotherapy: overcoming
posttherapy tumor escape. Clin Dev Immunol. 2012;2012:124187. doi:
10.1155/2012/124187. Epub 2012 May 31. Review. PubMed PMID: 22778760; PubMed
Central PMCID: PMC3386616.


1866: Zhou P, Fang X, McNally BA, Yu P, Zhu M, Fu YX, Wang L, Liu Y, Zheng P.
Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in
mice with genetic predisposition. Proc Natl Acad Sci U S A. 2009 Oct
6;106(40):17134-9. doi: 10.1073/pnas.0905707106. Epub 2009 Sep 23. PubMed PMID:
19805094; PubMed Central PMCID: PMC2761305.


1867: Zhou P, Zheng X, Zhang H, Liu Y, Zheng P. B7 blockade alters the balance
between regulatory T cells and tumor-reactive T cells for immunotherapy of
cancer. Clin Cancer Res. 2009 Feb 1;15(3):960-70. doi:
10.1158/1078-0432.CCR-08-1611. PubMed PMID: 19188167; PubMed Central PMCID:
PMC2693886.


1868: Zhou SK, Chen WH, Shi ZD, Wang SP, Li L, Wen XF, Wang YM. Silencing the
expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 
prostate cancer cells in vitro. J Chin Med Assoc. 2014 Dec;77(12):630-6. doi:
10.1016/j.jcma.2014.03.008. Epub 2014 Sep 22. PubMed PMID: 25249301.


1869: Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY.
Enhanced activation of human T cells via avipox vector-mediated hyperexpression
of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 2001 
May 1;61(9):3725-34. PubMed PMID: 11325845.


1870: Zieger K, Jensen KM. Long-term risk of progression of carcinoma in situ of 
the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Scand J Urol Nephrol. 2011 Dec;45(6):411-8. doi: 10.3109/00365599.2011.599335.
Epub 2011 Jul 27. PubMed PMID: 21793636.


1871: Zimskind PD. Urology. Surg Gynecol Obstet. 1976 Feb;142(2):227-9. PubMed
PMID: 813316.


1872: Zippelius A, Knights A, Tinguely M, Jäger D, Renner C, Knuth A.
[Identification of tumor antigens: strategies and perspectives]. Dtsch Med
Wochenschr. 2006 Aug 18;131(33):1809-12. Review. German. PubMed PMID: 16902905.


1873: Zirbs M, Seifert F, Zink A, Ring J, Brockow K. A shortened docetaxel
desensitization protocol for use in special cases. J Eur Acad Dermatol Venereol. 
2012 Mar;26(3):391-3. doi: 10.1111/j.1468-3083.2011.04056.x. Epub 2011 Mar 24.
PubMed PMID: 22339786.


1874: Zisman A, Pantuck AJ, Belldegrun A. Gene and immune-based therapies for
genitourinary malignancies: current status and future prospects. Isr Med Assoc J.
2000 Jan;2(1):33-42. Review. PubMed PMID: 10892369.